# EDGAR Filing Document

**Accession Number:** 0001755672
**File Stem:** 0001755672-26-000004
**Filing Date:** 2026-2
**Character Count:** 733342
**Document Hash:** d2d1032f8f7bd5efa1445bc62152d103
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001755672-26-000004.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0001755672-26-000004

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 190

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Corteva, Inc.
- **CENTRAL INDEX KEY:** 0001755672
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE PRODUCTION - CROPS [0100]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 824979096
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38710
- **FILM NUMBER:** 26627721

**BUSINESS ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268
- **BUSINESS PHONE:** (833) 267-8382

**MAIL ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EIDP, Inc.
- **CENTRAL INDEX KEY:** 0000030554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTIC MATERIAL, SYNTH RESIN/RUBBER, CELLULOS (NO GLASS) [2820]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 510014090
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-00815
- **FILM NUMBER:** 26627722

**BUSINESS ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268
- **BUSINESS PHONE:** 8332678382

**MAIL ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DUPONT E I DE NEMOURS & CO
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? ctva-20251231

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**2025** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-K**

---

| | |
|:---|:---|
| (Mark One) | (Mark One) |
| ☒ | **ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the fiscal year ended December 31, 2025** 

---

| | |
|:---|:---|
| **OR** | **OR** |
| ☐ | **TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the transition period from _______ to _______**

**Commission File Number 001-38710** 

**Corteva, Inc.** 

(Exact Name of Registrant as Specified in Its Charter)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **Delaware** | **82-4979096** | **82-4979096** |
| (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | (I.R.S. Employer Identification No.) |
| **9330 Zionsville Road,** | **Indianapolis,** | **Indiana** | **46268** | **(833)** | **267-8382** |
| **1000 N. West Street, Suite 900,** | **Wilmington,** | **Delaware** | **19801** | **(833)** | **267-8382** |
| (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Registrant's Telephone Number, including area code) | (Registrant's Telephone Number, including area code) |

---

**Commission File Number 1-815** 

**EIDP, Inc.** 

(Exact Name of Registrant as Specified in Its Charter)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **Delaware** | **51-0014090** | **51-0014090** |
| (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | (I.R.S. Employer Identification No.) |
| **9330 Zionsville Road,** | **Indianapolis,** | **Indiana** | **46268** | **(833)** | **267-8382** |
| **1000 N. West Street, Suite 900,** | **Wilmington,** | **Delaware** | **19801** | **(833)** | **267-8382** |
| (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Registrant's Telephone Number, including area code) | (Registrant's Telephone Number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act for Corteva, Inc.:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | CTVA | New York Stock Exchange |

---

Securities registered pursuant to Section 12(b) of the Act for EIDP, Inc.:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| $3.50 Series Preferred Stock | CTAPrA | New York Stock Exchange |
| $4.50 Series Preferred Stock | CTAPrB | New York Stock Exchange |

---

**No securities are registered pursuant to Section 12(g) of the Act.**

_____________________________________________________

Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act).

Corteva, Inc. Yes ⌧ No □ <br> EIDP, Inc. Yes ⌧ No □

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Corteva, Inc. Yes □ No ⌧ <br> EIDP, Inc. Yes □ No ⌧

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Corteva, Inc. Yes ⌧ No □ <br> EIDP, Inc. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).

Corteva, Inc. Yes ⌧ No □ <br> EIDP, Inc. Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corteva, Inc. | Large Accelerated Filer | ⌧ | Accelerated Filer □ | Non-Accelerated Filer | □ | Smaller reporting company □ | Emerging growth company □ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EIDP, Inc. | Large Accelerated Filer | □ | Accelerated Filer □ | Non-Accelerated Filer | ⌧ | Smaller reporting company □ | Emerging growth company □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Corteva, Inc. □ <br> EIDP, Inc. □

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Corteva, Inc. Yes ⌧ No □ <br> EIDP, Inc. Yes ⌧ No □

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Corteva, Inc. □ <br> EIDP, Inc. □

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Corteva, Inc. □ <br> EIDP, Inc. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Corteva, Inc. Yes □ No ⌧ <br> EIDP, Inc. Yes □ No ⌧

The aggregate market value of voting stock of Corteva, Inc. held by non-affiliates of the registrant (excludes outstanding shares beneficially owned by directors and officers and treasury shares) as of June 30, 2025 was $50.6 billion.

As of February 5, 2026, 672,524,000 shares of Corteva, Inc.'s common stock, $0.01 par value, were outstanding.

As of February 5, 2026, all of EIDP, Inc.'s issued and outstanding common stock, comprised of 200 shares, $0.30 par value per share, is held by Corteva, Inc.

**EIDP, Inc. meets the conditions set forth in General Instruction I(1)(a), (b) and (d) of Form 10-K (as modified by a grant of no-action relief dated February 12, 2018) and is therefore filing this form with reduced disclosure format.**

**Documents Incorporated by Reference**

Information pertaining to certain Items in Part III of this report is incorporated herein by reference to portions of Corteva, Inc.'s definitive 2026 Annual Meeting Proxy Statement to be filed within 120 days after the end of the year covered by this Annual Report on Form 10-K, pursuant to Regulation 14A (the Proxy).

------

**Corteva, Inc.**

**Form 10-K**

**Table of Contents**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **[Explanatory Note](#i46860590cf424b89b8159966786b56bb_10)** | **[Explanatory Note](#i46860590cf424b89b8159966786b56bb_10)** | [2](#i46860590cf424b89b8159966786b56bb_10) |
| **[PART I](#i46860590cf424b89b8159966786b56bb_13)** |  |  |
| [Item 1.](#i46860590cf424b89b8159966786b56bb_16) | [Business](#i46860590cf424b89b8159966786b56bb_16) | [3](#i46860590cf424b89b8159966786b56bb_16) |
| [Item 1A.](#i46860590cf424b89b8159966786b56bb_19) | [Risk Factors](#i46860590cf424b89b8159966786b56bb_19) | [11](#i46860590cf424b89b8159966786b56bb_19) |
| [Item 1B.](#i46860590cf424b89b8159966786b56bb_22) | [Unresolved Staff Comments](#i46860590cf424b89b8159966786b56bb_22) | [24](#i46860590cf424b89b8159966786b56bb_22) |
| [Item 1C.](#i46860590cf424b89b8159966786b56bb_25) | [Cybersecurity](#i46860590cf424b89b8159966786b56bb_25) | [24](#i46860590cf424b89b8159966786b56bb_25) |
| [Item 2.](#i46860590cf424b89b8159966786b56bb_28) | [Properties](#i46860590cf424b89b8159966786b56bb_28) | [25](#i46860590cf424b89b8159966786b56bb_28) |
| [Item 3.](#i46860590cf424b89b8159966786b56bb_31) | [Legal Proceedings](#i46860590cf424b89b8159966786b56bb_31) | [25](#i46860590cf424b89b8159966786b56bb_31) |
| [Item 4.](#i46860590cf424b89b8159966786b56bb_34) | [Mine Safety Disclosures](#i46860590cf424b89b8159966786b56bb_34) | [27](#i46860590cf424b89b8159966786b56bb_34) |
| **[PART II](#i46860590cf424b89b8159966786b56bb_37)** |  |  |
| [Item 5.](#i46860590cf424b89b8159966786b56bb_40) | [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#i46860590cf424b89b8159966786b56bb_40) | [28](#i46860590cf424b89b8159966786b56bb_40) |
| [Item 6.](#i46860590cf424b89b8159966786b56bb_43) | [\[Reserved\]](#i46860590cf424b89b8159966786b56bb_43) | [29](#i46860590cf424b89b8159966786b56bb_43) |
| [Item 7.](#i46860590cf424b89b8159966786b56bb_46) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#i46860590cf424b89b8159966786b56bb_46) | [30](#i46860590cf424b89b8159966786b56bb_46) |
| [Item 7A.](#i46860590cf424b89b8159966786b56bb_85) | [Quantitative and Qualitative Disclosures About Market Risk](#i46860590cf424b89b8159966786b56bb_85) | [60](#i46860590cf424b89b8159966786b56bb_85) |
| [Item 8.](#i46860590cf424b89b8159966786b56bb_88) | [Financial Statements and Supplementary Data](#i46860590cf424b89b8159966786b56bb_88) | [61](#i46860590cf424b89b8159966786b56bb_88) |
| [Item 9.](#i46860590cf424b89b8159966786b56bb_91) | [Changes in and Disagreements With Accountants on Accounting and Financial Disclosure](#i46860590cf424b89b8159966786b56bb_91) | [61](#i46860590cf424b89b8159966786b56bb_91) |
| [Item 9A.](#i46860590cf424b89b8159966786b56bb_94) | [Controls and Procedures](#i46860590cf424b89b8159966786b56bb_94) | [62](#i46860590cf424b89b8159966786b56bb_94) |
| [Item 9B.](#i46860590cf424b89b8159966786b56bb_97) | [Other Information](#i46860590cf424b89b8159966786b56bb_97) | [63](#i46860590cf424b89b8159966786b56bb_97) |
| [Item 9C.](#i46860590cf424b89b8159966786b56bb_100) | [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#i46860590cf424b89b8159966786b56bb_100) | [63](#i46860590cf424b89b8159966786b56bb_100) |
| **[PART III](#i46860590cf424b89b8159966786b56bb_103)** |  |  |
| [Item 10.](#i46860590cf424b89b8159966786b56bb_106) | [Directors, Executive Officers and Corporate Governance](#i46860590cf424b89b8159966786b56bb_106) | [63](#i46860590cf424b89b8159966786b56bb_106) |
| [Item 11.](#i46860590cf424b89b8159966786b56bb_109) | [Executive Compensation](#i46860590cf424b89b8159966786b56bb_109) | [65](#i46860590cf424b89b8159966786b56bb_109) |
| [Item 12.](#i46860590cf424b89b8159966786b56bb_112) | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#i46860590cf424b89b8159966786b56bb_112) | [65](#i46860590cf424b89b8159966786b56bb_112) |
| [Item 13.](#i46860590cf424b89b8159966786b56bb_115) | [Certain Relationships and Related Transactions, and Director Independence](#i46860590cf424b89b8159966786b56bb_115) | [65](#i46860590cf424b89b8159966786b56bb_115) |
| [Item 14.](#i46860590cf424b89b8159966786b56bb_118) | [Principal Accountant Fees and Services](#i46860590cf424b89b8159966786b56bb_118) | [65](#i46860590cf424b89b8159966786b56bb_118) |
| **[PART IV](#i46860590cf424b89b8159966786b56bb_121)** |  |  |
| [Item 15.](#i46860590cf424b89b8159966786b56bb_124) | [Exhibits and Financial Statement Schedules](#i46860590cf424b89b8159966786b56bb_124) | [66](#i46860590cf424b89b8159966786b56bb_124) |
| [Item 16.](#i46860590cf424b89b8159966786b56bb_313) | [Form 10-K Summary](#i46860590cf424b89b8159966786b56bb_313) | F-[82](#i46860590cf424b89b8159966786b56bb_313) |
| **[SIGNATURES](#i46860590cf424b89b8159966786b56bb_130)** |  | [69](#i46860590cf424b89b8159966786b56bb_130) |
| **EIDP, Inc.[Financial Statements and Supplementary Data](#i46860590cf424b89b8159966786b56bb_268)** | **EIDP, Inc.[Financial Statements and Supplementary Data](#i46860590cf424b89b8159966786b56bb_268)** | F-[69](#i46860590cf424b89b8159966786b56bb_259) |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Explanatory Note**

This Annual Report on Form 10-K is a combined report being filed separately by Corteva, Inc. and EIDP, Inc. ("EIDP"). Corteva, Inc. owns all of the common equity interests in EIDP, and EIDP meets the conditions set forth in General Instruction I(1)(a), (b) and (d) of Form 10-K and is therefore filing its information within this Form 10-K with the reduced disclosure format. Each of Corteva, Inc. and EIDP is filing on its own behalf the information contained in this report that relates to itself, and neither company makes any representation as to information relating to the other company. Where information or an explanation is provided that is substantially the same for each company, such information or explanation has been combined in this report. Where information or an explanation is not substantially the same for each company, separate information and explanation has been provided. In addition, separate consolidated financial statements for each company, along with notes to the consolidated financial statements, are included in this report.

The primary differences between Corteva, Inc.'s and EIDP's financial statements relate to EIDP's Preferred Stock - $4.50 Series and EIDP's Preferred Stock - $3.50 Series; a related party loan between EIDP and Corteva, Inc. and the associated interest expense for EIDP through its repayment date in the fourth quarter of 2023; a Master In-House Banking Agreement between EIDP and Corteva, Inc., including certain consolidated subsidiaries, and the associated interest income for EIDP; EIDP dividends declared to Corteva, Inc. not yet paid; and the capital structure of Corteva, Inc. (See EIDP Note 1 - Basis of Presentation to EIDP's Consolidated Financial Statements, for additional information for above items). The separate EIDP financial statements and footnotes for areas that differ from Corteva, Inc., are included within this Annual Report on Form 10-K and begin on page F-73. Footnotes of EIDP that are identical to that of Corteva, Inc. are cross-referenced accordingly.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS**

Unless otherwise indicated or the context otherwise requires, references in this Annual Report on Form 10-K to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Corteva" or "the company" refers to Corteva, Inc. and its consolidated subsidiaries (including EIDP);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "EIDP" refers to EIDP, Inc. (formerly known as E. I. du Pont de Nemours and Company) and its consolidated subsidiaries or EIDP, Inc. excluding its consolidated subsidiaries, as the context may indicate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "DowDuPont" refers to DowDuPont Inc. and its subsidiaries prior to the Corteva Separation (as defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Historical Dow" refers to The Dow Chemical Company and its consolidated subsidiaries prior to the Internal Reorganization (as defined in Note 1 - Background and Basis of Presentation, to the Consolidated Financial Statements);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Historical DuPont" and "Historical EID" refers to EIDP prior to the Internal Reorganization;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Dow" refers to Dow Inc. after its separation from DowDuPont;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "DuPont" refers to DuPont de Nemours, Inc. after the Corteva Separation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Merger" refers to the all-stock merger of equals strategic combination between Historical Dow and Historical DuPont.

**Background** 

Corteva is a leading global provider of seed and crop protection solutions focused on the agriculture industry and contributing to a healthier, more secure and sustainable food supply. Corteva was incorporated in Delaware in March 2018 and maintains its business headquarters in Indianapolis, Indiana. With one of the broadest and most productive new product pipelines in the agriculture industry, Corteva is focused on progressing science-based innovations, which aim to deliver a wide range of improved agriculture products and services to its customers. The company leverages its rich heritage of scientific achievement to advance its robust innovation pipeline and continue to shape the future of responsible agriculture. New products are crucial to solving farmers' productivity challenges amid a growing global population while addressing natural resistance, evolving environmental and weather patterns, regulatory changes, safety requirements and competitive dynamics. The company's investments seek to generate returns through providing farmers with technology-based and solution-based product offerings to meet these evolving production needs. Meanwhile, through Corteva's unique routes to market, the company continues to work face-to-face with farmers around the world to understand their needs.

The company's broad portfolio of agriculture solutions fuels farmer productivity in approximately 110 countries. See Note 21 - Geographic Information, to the Consolidated Financial Statements, for details on the location of the company's sales and property.

Prior to March 31, 2019, Corteva, Inc. had engaged in no business operations and had no assets or liabilities of any kind, other than those incident to its formation by DowDuPont. As of April 1, 2019, DowDuPont, Dow, and Corteva, Inc entered into an agreement that sets forth, among other things, the effectuation of Corteva's separation from DowDuPont and the governance of certain aspects of the companies' ongoing relationships after the completion of their respective separations (the "Corteva Separation Agreement"). The separation of Corteva from DowDuPont was effectuated through a pro rata distribution (the "Corteva Distribution") of all of the then-issued and outstanding shares of common stock of Corteva, Inc. (the "Corteva Separation"). On June 1, 2019, Corteva, Inc. became an independent, publicly traded company trading on the New York Stock Exchange under the ticker symbol "CTVA." Prior to the Corteva Separation, EIDP was contributed to Corteva, Inc. resulting in Corteva, Inc. owning 100% of the outstanding common stock of EIDP. Shares of EIDP preferred stock, $3.50 Series and $4.50 Series, issued and outstanding immediately prior to the Corteva Separation, remained issued and outstanding and were unaffected by the Corteva Separation.

**Business Segments**

The company's operations are managed through two operating segments: Seed and Crop Protection. The Seed segment develops and supplies commercial seed combining superior germplasm with advanced traits to produce high yield potential for farmers around the world. The Crop Protection segment supplies products to protect crop yields against weeds, insects and disease, enabling farmers to achieve optimal results. On October 1, 2025, the company announced its intent to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies, in a transaction that is intended to be a tax-free spin-off for U.S. federal income tax purposes. Additional information with respect to business segment results is included in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, on page 39 of this report and Note 22 - Segment Information, to the Consolidated Financial Statements.

***Seed***

The Seed segment is a global leader in developing and supplying commercial seed combining advanced germplasm and traits that offer maximum yield potential for farmers around the world. The company's Seed segment is a leader in many key seed

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS,** *continued*

markets, including North America corn and soybeans, Europe corn and sunflower, as well as Brazil, India, South Africa and Argentina corn. The company offers seed and trait technologies that boost resilience to weather, pests, diseases, and herbicides used to manage weeds. Its digital solutions provide data-driven insights to help farmers optimize yield and profitability. As a separate company, the Seed business plans to grow through opportunities in gene editing, biofuels, hybrid wheat, expanded crop offerings, out-licensing, and mergers and acquisitions.

A summary of the Seed segment's net sales by major product line and geographic region (based on customer location) are as follows:

![9175](ctva-20251231_g1.jpg)![9177](ctva-20251231_g2.jpg)

*Products and Brands* 

The Seed segment's major brands and technologies, by key product line, are listed below:

---

| | |
|:---|:---|
| Seed Solutions Brands | Pioneer<sup>®</sup> seeds; Brevant<sup>®</sup> seeds; Dairyland Seed<sup>®</sup>; Hoegemeyer<sup>®</sup> hybrids; Nutech<sup>®</sup> seed; Seed Consultants<sup>®</sup>; AgVenture<sup>®</sup> brand; Cordius®, Licensing Division of Corteva Agriscience; DUO<sup>®</sup> hybrid corn; NEXSEM<sup>®</sup> corn; Nord<sup>TM</sup> semillas; PhytoGen<sup>®</sup> cottonseed; Pannar™ brand corn. |
| Seed Solutions Traits and Technologies | ENLIST® corn; ENLIST E3® soybeans; ENLIST® cotton; Enlist® weed control system; Herculex® Insect Protection; Herculex® XTRA Insect Protection; PowerCore® corn; PowerCore® Ultra corn; PowerCore® Enlist® corn; PowerCore® Ultra Enlist® corn; POWERCORE® trait technology family of products; Refuge Advanced® trait technology; SMARTSTAX® trait technology; NEXERA® canola trait; Omega-9 Oils; Optimum® AQUAmax® products; Pioneer® brand A-Series soybeans; Pioneer® brand Plenish® high oleic soybeans; ExpressSun® herbicide tolerant trait; Pioneer Protector® products for canola, sunflower and sorghum; Pioneer MAXIMUS® rapeseed hybrids; Qrome® corn; Clearfield® canola; PROPOUND® advanced canola meal; Vorceed® Enlist® products; Conkesta®; Conkesta E3® soybeans; WideStrike® Insect Protection; WideStrike® 3 Insect Protection; Inzen<sup>TM</sup> trait; BOLT® technology; STS® herbicide tolerant trait; CottonBest® program; Brevant® Protector products; Optimum® GLY herbicide tolerance trait Optimum® AcreMax® insect protection; Optimum® AcreMax® Leptra® insect protection; Optimum® AcreMax® Xtra insect protection; Optimum® AcreMax® XTreme insect protection; Bovalta® BMR products; Optimum® Intrasect® insect protection; Optimum® Leptra® insect protection. |
| Other | LumiGEN® seed treatments; Lumisena® fungicide seed treatment; Lumiposa® seed applied insecticide; Lumiscend® and Lumiscend® Pro fungicide seed treatments; Lumisure® insecticide seed treatment; Lumiflex™ fungicide seed treatment; Lumiante™ fungicide seed treatment; LumiTreo™ fungicide seed treatment; Dermacor™ X-100 seed treatment products; Vertisan® ST; Lumiderm® insecticide seed treatment; Lumivia™ CPL; Lumivia™ and Lumialza™ nematicide seed treatment. |

---

In connection with the validation of breeding plans and large-scale product development timelines focused on rapidly ramping up differentiated technology solutions, in 2019 the company began accelerating the ramp up of the Enlist E3® trait technology in the company's soybean portfolio mix across all brands, including the Pioneer<sup>®</sup> and Brevant® seed brand. In 2025,

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS,** *continued*

substantially all of the company's branded soybean portfolio offers the Enlist E3® trait, in proprietary Corteva germplasm. Enlist E3® technology has rapidly become the leading herbicide tolerance trait for soybeans in the United States. In Brazil, growth in adoption of Conkesta E3® soybean technology is being pursued through licensing.

*Distribution*

The Seed segment has a diverse worldwide network which markets and distributes the company's brands to customers, primarily through the company's multi-channel, multi-brand strategy, which includes four differentiated channels: Pioneer agency model, regional seed brands, retail, as well as third parties through licensing and distribution channels.

The Pioneer agency model is unique to Corteva and represents sales made directly to farmers primarily via independent sales representatives. Through this agency model, the company interacts directly with farmers at multiple points in the growing season, from prior to planting all the way through harvest. These regular interactions enable the company to provide the advice and service farmers need while giving the company real-time insights into the customers' future ordering decisions. The company's regional seed brands connect to customers through regional brand employees and farmer-dealer networks. Retail brands are offered through full-service retail storefronts which provide a one-stop shop for seed and chemistry solutions and may include sales to distributors, agricultural cooperatives, and dealers. Finally, Corteva out-licenses traits and germplasm to third parties.

*Key Raw Materials*

The key raw materials for the Seed segment include corn and soybean seeds. To produce high-quality seeds, the company contracts with third-party growers globally. Corteva focuses on production close to the customer to provide the seed product, which is suitable for that region and its weed, insect and disease challenges, weather, soil and other conditions. The company conditions and packages the seeds using its own plants and third-party contract production plants. By striking a balance between owning production facility assets directly and contracting with third-party growers, the company believes it is best able to maintain flexibility to react to demand changes unique to each geography while minimizing costs. The company seeks to collaborate with strategic seed growers and share its digital agronomy and product management knowledge with them. The company's third-party growers are an important part of its supply chain. Corteva provides them with rigorous training, planning tools and access to a system that tests and advances products matched to specific geographic needs.

The Seed segment's research and development ("R&D") and supply chain groups work seamlessly to select and maintain product characteristics that enhance the quality of its seed products and solutions. Corteva focuses on customer-driven innovation to deliver superior germplasm and trait technologies. With its large sets of digitized data and globally connected network, the company can manage its field operations efficiently and draw insights from data quickly and effectively. This allows the company's supply chain to react quickly to changing customer needs and provides the production team with tremendous amounts of data to analyze and incorporate into resource allocation decisions, as well as future R&D product advancement decisions. The company continues to invest in and build capabilities that drive value via data digitization and analytics that enable it to create an even more responsive and efficient answer to customer needs.

***Crop Protection***

The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that support overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment's crop protection solutions and digital solutions provide farmers tools to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The company is a leader in global herbicides, insecticides, nitrogen stabilizers, pasture and range management herbicides and biologicals and other nature-based products. As a separate company, the Crop Protection business plans to grow through its differentiated, sustainable product offerings, including biologicals, with a focus on operational excellence and disciplined mergers and acquisitions.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS,** *continued*

A summary of the Crop Protection segment's net sales by major product line and geographic region (based on customer location) are as follows:

![14069](ctva-20251231_g3.jpg)![14071](ctva-20251231_g4.jpg)

*Products and Brands* 

The Crop Protection segment's major brands and technologies, by key product line, are listed below:

---

| | |
|:---|:---|
| Insect and Nematode Management | JEMVELVA™; QALCOVA™; PYRAXALT™; ISOCLAST™; REKLEMEL™; CLOSER™; DELEGATE<sup>®</sup>; INTREPID<sup>®</sup>; EXALT®; PEXALON™; TRANSFORM™; VYDATE<sup>®</sup>; OPTIMUM<sup>®</sup>; SALIBRO™; RADIANT™; SENTRICON<sup>®</sup>; ENTRUST<sup>®</sup> SC; SUCCESS®; TRACER™; LANNATE®; EXPEDITION®; SPINTOR®; VETER |
| Disease Management | ZORVEC™; ADAVELT™; INATREQ™; FORCIVO™; APROACH® PRIMA; VESSARYA<sup>®</sup>; APROACH® PREMIUM; APROACH POWER<sup>®</sup>; VIOVAN<sup>®</sup>; TALENDO™; VERBEN<sup>®</sup>; EQUATION PRO<sup>®</sup>; EQUATION CONTACT<sup>®</sup>; CURZATE™; TANOS<sup>®</sup>; BIM® MAX; FONTELIS™; ACANTO® PLUS; GALILEO<sup>®</sup>; UNIVOQ® |
| Weed Control | ARYLEX<sup>®</sup>; ENLIST® weed control system; ENLIST ONE™; RINSKOR™; KERB<sup>®</sup>; QUELEX™; BELKAR®; PACTO®; LOYANT™; GRAZONNEXT® HL; PAXEO®; RESICORE® REV; SPIDER®; COACT®; DURACOR®; GAPPER®; ELEVORE®; FULTIME® NXT; KYBER® PRO; LINEAR®; TORDONULTRA®-S; VERDICT® ULTRA |
| Nitrogen Management | INSTINCT<sup>®</sup>; N-SERVE<sup>®</sup> Nitrogen Stabilizer |
| Biologicals | STIMULATE™; UTRISHA™ N; BlueN™; and STARTER™ |
| Other | LANDVisor™ |

---

*Key Raw Materials*

The key raw materials and supplies for the Crop Protection segment include chlorinated pyridines derivatives, specialty intermediates and technical grade active ingredients, chlorine, and seed treatments. Typically, the company purchases major raw materials through long-term contracts with multiple suppliers, which sometimes require minimum purchase commitments. Certain important raw materials are supplied by a few major suppliers. The company expects the markets for its raw materials to remain balanced. The company relies on contract manufacturers, both domestically and internationally, to produce certain inputs or key components for its product formulations. These inputs are sourced globally and the company generally formulates its products close to its end customers. Shifts in customer demand, reduced local availability of raw materials, and/or production capacity constraints may, at times, necessitate sourcing from an alternative geography. The company strives to maintain multiple high-quality supply sources for each input.

Corteva's supply chain strategy involves managing global supplies of active and intermediate ingredients sourced regionally with global best practices and oversight. Corteva's supply strategy includes a robust and flexible global footprint to meet future portfolio growth. The company's supply chain also provides competitive advantages including reducing time to meet customer requirements in regions while minimizing costs through the value chain.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS,** *continued*

**Seasonality**

Corteva's sales are generally strongest in the first half of the calendar year, which aligns with the planting and growing season in the northern hemisphere. The company typically generates about 60 percent of its sales in the first half of the calendar year, driven by northern hemisphere Seed and Crop Protection sales. The company generates about 40 percent of its sales in the second half of the calendar year, led by Seed sales in the southern hemisphere. The seasonality in sales impacts both the Seed and Crop Protection segments. The company's direct distribution channel, where products are shipped to farmers, is more affected by planting delays than its competitors. Generally speaking, unfavorable weather slows the planting season and can affect the company's quarterly results and sales mix. Severe unfavorable weather, however, can impact overall sales. Accounts receivable tends to be higher during the first half of the year, consistent with the peak sales period in the northern hemisphere, with cash collection focused in the fourth quarter.

**Human Capital Management**

Corteva aims to attract the best employees, and to retain those employees through offering career development and training opportunities while also prioritizing their safety and wellness in an inclusive and productive work environment. The company's strong employee base, along with its commitment to Corteva's core values, is a key element to the success of its business.

*Workforce Composition.* As of December 31, 2025, the company globally employs approximately 21,500 employees. In order to address regional specific customer needs within its global business, the company has a geographically diverse employee base with 47 percent, 21 percent, 20 percent, and 12 percent located in the North America, Latin America, EMEA, and Asia-Pacific regions, respectively.

Approximately 2 percent of the United States workforce is unionized and another 13 percent of our global workforce participate in works councils and collective bargaining arrangements outside the United States. In 2025, the company did not experience any work stoppages due to strike or lockouts.

*Safety.* Living safely is one of the company's core values by which the company manages its business. The company has implemented safety programs and management practices to promote a culture of safety to protect its employees, as well as the environment. This includes required trainings for employees, as well as specific qualifications and certifications for certain operational employees.

*Inclusion.* The company has a robust inclusion and belonging vision and strategy, based upon the belief that embracing individual differences benefits the company by creating a workforce with a greater variety of skills and perspectives as a result of their differentiated backgrounds and experiences. Specific inclusion and belonging initiatives are identified and tracked to create a culture of belonging that is designed to create an inclusive environment where the best talent is attracted, retained, and engaged. Critical to creating this environment are company-sponsored employee business resource groups ("BRGs") that support and promote certain mutual objectives of both the employee and the company, including community engagement and the professional development of employees. The BRGs are open to all employees and provide a voluntary space where employees can foster connections within a supportive environment. The company maintains nine global BRGs, each led by a member of the company's senior leadership: Disability Awareness Network; Global African Heritage Alliance; Global Indigenous Peoples Alliance; Growing Asian Impact Network; Latin Network; Pride; Professional Learning Acceleration Network; Veteran's Network; and Women's Inclusion Network.

The company monitors its recruitment and talent development processes, to prevent and detect inequities and potentially discriminatory practices that could negatively impact the creation of an inclusive culture and the retention of key talent for our leadership pipeline. The company reviews its inclusion and belonging efforts through periodic engagement surveys and other measures. The results of the company's efforts, along with its inclusion and belonging strategy, are reviewed periodically with the company's management, and through annual reviews of the company's leadership pipelines and inclusion and belonging programs with the People and Compensation Committee of the Board of Directors.

*Experienced Management.* The company believes its management team has the experience necessary to effectively execute its strategy and advance its product pipelines and technology. The company's chief executive officer and business presidents have an average of approximately 20 years of agriculture experience and are supported by an experienced and talented management team that is dedicated to maintaining and expanding its position as a global force in the agriculture industry.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS,** *continued*

**Intellectual Property**

Corteva considers its intellectual property estate, which includes patents, trade secrets, trademarks and copyrights, in the aggregate, to constitute a valuable asset of Corteva and actively seeks to secure intellectual property rights as part of an overall strategy to protect its investment in innovations and maximize the results of its research and development program. While the company believes that its intellectual property estate, taken as a whole, provides a competitive advantage in many of its businesses, no single patent, trademark, license or group of related patents or licenses is in itself essential to the company as a whole or to any of the company's segments.

Trade secrets are also an important element of the company's intellectual property. Many of the processes used to make Corteva products are kept as trade secrets which, from time to time, may be licensed to third parties. Corteva vigilantly protects its intellectual property. When the company discovers that its intellectual property has been unlawfully taken, it will take measures to mitigate any potential impact, which may include civil actions seeking redress, restitution and/or damages based on loss to the company and/or unjust enrichment, as well as reporting the matter to governmental authorities for investigation and potential criminal action, as appropriate.

*Patents & Trademarks.* Corteva continually applies for and obtains U.S. and foreign patents and has access to a large patent portfolio, both owned and licensed. Corteva's rights under these patents and licenses, as well as the products made and sold under them, are important to the company in the aggregate. The protection afforded by these patents varies based on country, scope of individual patent coverage, as well as the availability of legal remedies in each country. This significant patent estate may be leveraged to align with the company's strategic priorities within and across product lines. At December 31, 2025, the company owned about 5,900 U.S. patents and about 10,200 active patents outside of the U.S.

Remaining life of granted patents owned as of December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **Approximate U.S.** | **Approximate Other Countries** |
| Within 5 years | 1100 | 2500 |
| 6 to 10 years | 2100 | 5500 |
| 11 to 15 years | 1700 | 2000 |
| 16 to 20 years | 1000 | 200 |
| Total | 5900 | 10200 |

---

In addition to its owned patents, the company owns approximately 3,400 patent applications.

The company also owns or has licensed a substantial number of trade names, trademarks and trademark registrations in the United States and other countries, including approximately 11,900 registrations and 1,300 pending trademark applications in a number of jurisdictions.

In addition, the company holds multiple long-term biotechnology trait licenses from third parties in the normal course of business. Most corn hybrids and soybean varieties sold to customers contain biotechnology traits licensed from third parties under these long-term licenses.

**Competition**

The company competes with producers of seed germplasm, trait developers, and crop protection products on a global basis. The global market for products within the industry is highly competitive and the company believes competition has and will continue to intensify. Corteva competes based on germplasm and trait leadership, price, quality and cost competitiveness. The company's key competitors include BASF, Bayer, FMC, Syngenta and ChemChina, as well as companies trading in generic crop protection chemicals and regional seed companies.

**Environmental Matters** 

Information related to environmental matters is included in several areas of this report: (1) Environmental Proceedings beginning on page 26; (2) Management's Discussion and Analysis of Financial Condition and Results of Operations on pages 58-59; and (3) Note 2 - Summary of Significant Accounting Policies, and Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS,** *continued*

**Regulatory Considerations**

Our seed and crop protection products and operations are subject to certain approval procedures, manufacturing requirements and environmental protection laws and regulations in the jurisdictions in which we operate. We evaluate and test products throughout the research and development phases, and each new technology undergoes further rigorous scientific studies and tests to validate that the product can be used effectively and that use of the technology is safe for humans and animals and does not cause undue harm to the environment when used in accordance with the directions for use.

The regulatory approval processes and procedures globally are becoming increasingly more complex, which has resulted in additional testing needs, longer approval timelines that are difficult to predict, and higher development and maintenance costs. We continue to invest on an ongoing basis to keep dossiers current, respond to regulators and meet evolving regulatory standards required by global regulatory frameworks. Failure to comply with these regulations or future regulatory bans and requirements related to our products and their use may materially impact our financial performance.

*Regulation of Genetically Modified Organisms ("GMOs") and Gene Editing*

Genetically modified seed products are subject to regulatory approval processes and procedures. For example, in the United States, the Coordinated Framework for Regulation of Biotechnology governs genetically modified or gene edited organisms, using existing U.S. legislation and legal authorities on food, feed and environmental safety. Plant GMOs are regulated by the U.S. Department of Agriculture's (the "USDA") Animal and Plant Health Inspection Service (the "APHIS") under the Plant Protection Act. The APHIS assesses the trait to ensure that the trait will not pose a plant pest and is not a noxious weed. GMOs in food are regulated by the U.S. Food and Drug Administration (the "FDA") under the Federal Food, Drug, and Cosmetic Act (the "FFDCA"). The FDA ensures that the food is safe for food and feed. Pesticides and microorganisms containing GMOs are regulated by the U.S. Environmental Protection Agency (the "EPA") pursuant to the Federal Insecticide, Fungicide and Rodenticide Act (the "FIFRA") and the Toxic Substances Control Act. The EPA assesses the trait or the stack containing the traits to ensure that there is no unreasonable adverse effect to the environment.

Other countries also have rigorous approval processes, procedures, and scientific testing requirements for the cultivation or import of genetically modified seed products and gene editing technology. In the United States and other countries that have functioning regulatory systems, a rigorous scientific review is conducted by these agencies to demonstrate that genetically modified and gene edited products are as safe as traditionally bred, non-biotech/GMO counterparts for food, feed and the environment. Various countries in EMEA, Latin America, and Asia Pacific have banned GMOs entirely.

*Regulation of Crop Protection Products*

Globally, manufacturers of crop protection products, including herbicides, fungicides and insecticides are required to submit an application/dossier and obtain government regulatory approval prior to selling products in a particular country. In the United States, the EPA is responsible for registering and overseeing the approval and marketing of pesticides, pursuant to the FIFRA, the FFDCA and the Food Quality Protection Act. Also, the USDA and the FDA monitor levels of pesticide residue that is allowed on or in crops. Already registered pesticides are required to be re-registered every 15 years to ensure that those products continue to meet the rigorous safety standards set by the regulators. The EPA reevaluates pesticide tolerances at least every 10 years, taking into account ecological and human health risks, in addition to cumulative risks as a result of multiple routes and sources of exposure. For certain crop protection applications, we rely on the availability of data from the U.S. Department of Health and Human Services to address potential risks to human health.

Beginning in January 2022, before registering any new conventional pesticide active ingredient, the EPA evaluates the potential effects on listed species and their designated critical habitats under the Endangered Species Act (the "ESA"). The EPA also has initiated such evaluations for certain other active ingredients in response to existing or threatened litigation. Where the EPA determines that a pesticide in the registration and re-evaluation processes "may affect" a listed species, the EPA must consult with the U.S. Fish and Wildlife Service and the National Marine Fisheries Service. As part of its approval, registration, and reevaluation processes, the EPA may impose certain use restrictions on crop protection products under the ESA. When the U.S. Fish and Wildlife Service and the National Marine Fisheries Service add additional listed species, the EPA may initiate new ESA evaluations. Under the citizen suit provisions, the ESA also includes citizen suit provisions that allow the public to bring suit in court against federal agencies when they believe a listed species is not being adequately protected by the EPA. FIFRA contains similar provisions that allow the public to challenge an EPA's registration decision. These lawsuits may subject products to additional use limitations and labeling requirements and further studies, as well as result in registrations being revoked, in whole or in part.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1. BUSINESS,** *continued*

The company's European operations are subject to the European chemical regulation REACH ("Registration, Evaluation, Authorisation, and Restriction of Chemicals") and the CLP ("Classification, Labeling, and Packaging of Substances and Mixtures"). Other jurisdictions also have rigorous approval processes, procedures and scientific testing requirements for the approval of crop protection products. We continue to monitor legislative and regulatory developments related to pollution and other environmental health and safety matters.

**Available Information**

The company's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports are accessible on Corteva's website at http://investors.corteva.com by clicking on the section labeled "Financial Information", then on "SEC Filings." These reports are made available, without charge, as soon as is reasonably practicable after the company files or furnishes them electronically with the Securities and Exchange Commission. No portion of the company's website mentioned in this report, or the materials contained on it, have been made part of this annual report on Form 10-K or incorporated herein by reference, unless such incorporation is specifically mentioned herein.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS**

***Risks Related to Our Industry***

**Corteva may not be able to obtain or maintain the necessary regulatory approvals for some of its products, including its seed and crop protection products, which could restrict its ability to sell those products in some markets.**

Regulatory and legislative requirements affect the development, manufacture and distribution of Corteva's products, including the testing and planting of seeds containing Corteva's biotechnology traits and the import of crops grown from those seeds, and non-compliance can harm Corteva's sales and profitability.

Seed products incorporating biotechnology derived traits and crop protection products must be extensively tested for safety, efficacy and environmental impact before they can be registered for production, use, sale or commercialization in a given market. In certain jurisdictions, Corteva must periodically renew its approvals for both biotechnology and crop protection products, which typically require Corteva to demonstrate compliance with then-current standards which generally are more stringent since the prior registration. The regulatory approvals process is lengthy, costly, complex and in some markets unpredictable, with requirements that can vary by product, technology, industry and country. The regulatory approvals process for products that incorporate novel modes of action or new technologies can be particularly unpredictable and uncertain due to the then-current state of regulatory guidelines and objectives, as well as governmental policy considerations and non- governmental organization and other stakeholder considerations. The uncertainty and increased length of regulatory approvals may reduce Corteva's return on its research and development investments, and impede its ability to meet sales, profitability, or sustainability metrics.

Furthermore, the detection of biotechnology traits or chemical residues from a crop protection product not approved in the country in which Corteva sells or cultivates its product, or in a country to which Corteva imports its product, may affect Corteva's ability to supply or export its products, or even result in crop destruction, product recalls or trade disruption, which could result in lawsuits and termination of licenses related to biotechnology traits and raw material supply agreements. Delays in obtaining regulatory approvals to import, including those related to the importation of crops grown from seeds containing certain traits or treated with specific chemicals, may influence the rate of adoption of new products in globally traded crops.

Additionally, the regulatory environment may be impacted by the activities of non-governmental organizations and special interest groups and stakeholder reaction to actual or perceived impacts of new and existing technology, products or processes on safety, health and the environment. Obtaining and maintaining regulatory approvals requires submitting a significant amount of information and data, which may require participation from technology providers. Regulatory standards and trial procedures are continuously changing. In addition, Corteva has seen an increase in recent years in the number of lawsuits filed by those who identify themselves as public or environmental interest groups seeking to invalidate pesticide product registrations, including those for Enlist One<sup>®</sup>, and/or challenge the way federal or state governmental entities apply the rules and regulations governing pesticide produce use. The pace of change together with the lack of regulatory harmony could result in unintended noncompliance. Responding to these changes and meeting existing and new requirements may involve significant costs or capital expenditures or require changes in business practice that could result in reduced profitability. The failure to receive necessary permits or approvals, or the invalidation thereof, could have near- and long-term effects on Corteva's ability to produce and sell some current and future products.

**The successful development and commercialization of Corteva's pipeline products will be necessary for Corteva's growth.** 

Corteva uses advanced breeding technologies to produce hybrids and varieties with superior performance in farmers' fields and uses biotechnology to introduce traits that enhance specific characteristics of its crops. Corteva also uses advanced analytics, software tools, mobile communications and new planting and monitoring equipment to provide agronomic recommendations to growers. Additionally, Corteva conducts research into biological and chemical products to protect farmers' crops from pests and diseases and enhance plant productivity.

New product concepts may be abandoned for many reasons, including greater anticipated development costs, technical difficulties, lack of efficacy, regulatory obstacles or inability to market under regulatory frameworks, competition, inability to prove the original concept, lack of demand and the need to divert focus, from time to time, to other initiatives with perceived opportunities for better returns. The processes of active ingredient development or discovery, breeding, biotechnology trait discovery and development and trait integration are lengthy, and a very small percentage of the chemicals, genes and germplasm Corteva tests is selected for commercialization. Furthermore, the length of time and the risk associated with the

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

breeding and biotech pipelines are interlinked because both are required as a package for commercial success in markets where biotech traits are approved for growers, since seed hybrids and varieties could require modification to tolerate higher doses and/or new varieties of herbicides and pesticides as weeds and insects develop resistance. Commercial transitions to the company's new technologies can take several years to complete, and weed and insect resistance may develop faster than Corteva can respond with new technologies or enhancements to existing technologies. In countries where biotech traits are not approved for widespread use, Corteva's seed sales depend on the quality of its germplasm. Even when initial commercialization efforts have been promising, there are no guarantees that anticipated levels of product acceptability within Corteva's markets will be achieved or that higher quality products will not be developed by Corteva's competitors in the future.

Speed in discovering, developing, protecting and responding to new technologies, including artificial intelligence and new technology-based distribution channels that accelerate Corteva's product development timelines and could facilitate its ability to engage with customers and end users, and bringing related products to market is a significant competitive advantage. Commercial success frequently depends on being the first company to the market, and many of Corteva's competitors are also making considerable investments in similar new biotechnology products, improved germplasm products, biological and chemical products and agronomic recommendation products.

**The degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products and technologies can affect Corteva's sales and results of operations by affecting planting approvals, regulatory requirements and customer purchase decisions.**

Concerns and claims regarding the safe use of seeds with biotechnology traits and crop protection products in general, and their potential impact on health and the environment reflect a growing trend in societal demands for increasing levels of product safety and environmental protection. These include concerns and claims that increased use of crop protection products, drift, inversion, volatilization and the use of biotechnology traits meant to reduce the resistance of weeds or pests to control by crop protection products, could increase or accelerate such resistance and otherwise negatively impact health and the environment. These and other concerns could manifest themselves in delays or failures in obtaining or retaining regulatory approvals, delayed product launches, lack of market acceptance, product discontinuation, litigation, continued pressure for and adoption of more stringent regulatory intervention, termination of raw material supply agreements, legal claims, preferred purchases and stockholder proposals. These and other concerns could also influence public perceptions, the viability or continued sales of certain of Corteva's products, Corteva's reputation and the cost to comply with regulations. As a result, such concerns could have a material adverse effect on Corteva's business, results of operations, financial condition and cash flows.

**Corteva's business is subject to various competition and antitrust, rules and regulations around the world, and as the size of its business grows, scrutiny of its business by legislators and regulators in these areas may intensify.**

On December 6, 2025, President Trump issued an executive order titled "Addressing Security Risks from Price Fixing and Anti-Competitive Behavior in the Food Supply Chain." The order directs the U.S. Department of Justice ("DOJ") and the U.S. Federal Trade Commission ("FTC") to establish Food Supply Chain Security Task Forces focused on investigating anti-competitive conduct across food supply sectors, including seeds, and, critically, assessing whether control by foreign entities is increasing US food prices or creating national or economic security risks. While the ultimate impact of the executive order will depend on the actions ultimately resulting from the U.S. regulatory authorities, actions taken by such authorities may increase the regulation and regulatory costs associated with the agriculture industry in the future and restrict the company from pursuing certain growth opportunities, including mergers and acquisitions.

Scrutiny from regulators in the U.S. and abroad may intensify as Corteva's business presence grows or as industry concentration increases. This scrutiny and related investigations, even absent an enforcement action, may result in damage to a company's reputation, significant defense expense, as well as become a distraction to management. Antitrust and competition enforcement actions, including the current FTC and related state attorney general lawsuits pending against Corteva, may result in regulators imposing fines, penalties, or restrictions on a company's business practices in a manner that may significantly impact its results of operations.

**Changes in agricultural and related policies of governments and international organizations may prove unfavorable.**

In many markets there are various pressures to reduce government subsidies to farmers, which may inhibit the growth in these markets of products used in agriculture. In addition, government programs that provide financial support or create incentives for farmers, including those established by the U.S. Farm Bill, can be temporary in nature, or may be modified or discontinued.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

However, it is difficult to predict accurately whether, and if so when, such changes will occur. Corteva expects that the policies of governments and international organizations will continue to affect the planting choices made by growers as well as the income available to growers to purchase products used in agriculture and, accordingly, the operating results of the agriculture industry.

**The costs of complying with evolving regulatory requirements could negatively impact Corteva's business, results of operations and financial condition. Actual or alleged violations of environmental laws or permit requirements could result in restrictions or prohibitions on plant operations, substantial civil or criminal sanctions, as well as the assessment of strict liability and/or joint and several liability.**

Corteva is subject to extensive federal, state, local and foreign laws, regulations, rules and ordinances relating to pollution, protection of the environment, waste water discharges, the generation, storage, handling, transportation, treatment, disposal and remediation of hazardous substances and waste materials and the use of genetically modified seeds and crop protection active ingredients by growers.

Environmental and health and safety laws, regulations and standards, including those with respect to PFAS and other substances, expose Corteva to the risk of substantial costs and liabilities, including liabilities associated with Corteva's business and the discontinued and divested businesses and operations of EIDP. As is typical for businesses like Corteva's, soil and groundwater contamination has occurred in the past at certain sites and may be identified at other sites in the future. Disposal of waste from Corteva's business at off-site locations also exposes it to potential remediation costs. Consistent with past practice,

these sites continue to be monitored, investigated and remediated for soil and groundwater contamination, as applicable.

Costs and capital expenditures relating to environmental, health or safety matters are subject to evolving regulatory requirements and depend on the timing of the promulgation and enforcement of specific standards which impose the requirements. Moreover, changes in environmental regulations, including those related to climate change, could inhibit or interrupt Corteva's operations, or require modifications to its facilities in the future. Accordingly, environmental, health or safety regulatory matters could result in significant unanticipated costs or liabilities, which may be materially higher than Corteva's accruals.

**Climate change and unpredictable seasonal and weather factors could impact Corteva's sales and earnings.**

The agriculture industry is subject to seasonal and weather factors, which can vary unpredictably from period to period. Weather factors can affect the presence of disease and pests on a regional basis and, accordingly, can positively or adversely affect the demand for crop protection products, including the mix of products used or the level of returns. The weather also can affect supply chains and the quality, volume and cost of seed produced for sale as well as demand and product mix. Seed yields can be higher or lower than planned, which could lead to higher inventory and related write-offs. Climate change may increase the frequency or intensity of extreme weather such as storms, floods, heat waves, droughts and other events that could affect the quality, volume and cost of seed produced for sale as well as demand and product mix. Climate change may also affect the availability and suitability of arable land and contribute to unpredictable shifts in the average growing season, pest pressures and types of crops produced.

**Corteva participates in an industry that is highly competitive and has undergone consolidation, which could increase competitive pressures.**

Corteva currently faces significant competition in the markets in which it operates. In most segments of the market, the number of products available to the grower is steadily increasing as new products are introduced. At the same time, certain products are coming off patent and are thus available to generic manufacturers for production and commercialization. Upon the loss or expiration of patent protection for one of Corteva's products or of a product that Corteva licenses, or upon the "at- risk" launch (despite pending patent infringement litigation against the generic product) by a generic manufacturer of a generic version of one of Corteva's patented products or of a product that Corteva licenses, Corteva can lose a major portion of revenues for that product, which can have a material adverse effect on Corteva's business. Additionally, data analytic tools and web-based new direct purchase models offer increased transparency and comparability, which creates price pressures. Corteva cannot predict the pricing or promotional actions of its competitors. Aggressive marketing or pricing by Corteva's competitors could adversely affect Corteva's business, results of operations and financial condition. As a result, Corteva continues to face significant competitive challenges.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

**Recent funding and staff reductions, including at the EPA, the USDA, the FDA and the U.S. Department of Health and Human Services ("HHS"), could hinder our ability to receive timely regulatory approvals.**

Corteva's genetically modified seed products are subject to regulatory oversight under the Coordinated Framework for the Regulation of Biotechnology, which includes the regulatory authority of the USDA addressing plant safety, as well as the authority of the FDA for food and feed safety. Corteva's pesticidal crop protection products and certain biotechnology developed seed products that express pesticidal traits are also regulated by the EPA to verify that there is no unreasonable adverse effect to the environment. For Corteva's crop protection products, the EPA is responsible for registering and overseeing the approval and marketing of pesticides, while the USDA and the FDA monitor levels of pesticide residue permitted on or in crops. See "Part I – Item 1 – Business – Regulatory Considerations" of this report for more information on the regulation of our business.

Significant staff or funding reductions, along with any extended shutdown of the federal government, may significantly impact the timelines for reviewing our regulatory submissions and re-registrations. Longer-term structural changes at relevant federal agencies, including shifts in enforcement focus, review processes, evidentiary standards and resource allocation, may extend the time it takes to commercialize our products, thereby having a material adverse effect on our business, results of operations, and the value of our intellectual property.

**Corteva's sales to its customers may be adversely affected should a company successfully establish an intermediary platform for the sale of Corteva's products or otherwise position itself between Corteva and its customers.**

Corteva services customers in part through the Pioneer direct sales channel in key agricultural geographies, including the United States. In addition, Corteva supplements this approach with strong retail channels, including distributors, agricultural cooperatives and dealers, and with digital and data solutions that assist farmer decision-making with a view to optimize their product selection and maximize their yield and profitability. While Corteva expects its indirect channels will extend its reach and increase exposure of its products to other potential customers, including smaller farmers or farmers in less concentrated areas, there can be no assurance that Corteva will be successful in this regard. If a competitor were to successfully establish an intermediary platform for distribution of Corteva's products, it may disrupt Corteva's distribution model. In such a circumstance, Corteva's sales may be adversely affected.

***Risks Related to Our Operations***

**Our business, financial condition and results of operations could be materially affected by disruptions in the global economy caused by geopolitical and military conflicts.**

Military conflict or related geopolitical tensions and disputes including increased trade barriers or restrictions on global trade, could result in, among other things, cyberattacks, further supply disruptions, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business and supply chains. Such geopolitical instability and uncertainty has negatively impacted our ability to sell to, ship products to, collect payments from, and support customers in certain regions. Logistics restrictions, including closures of air space and shipping ports, the reduction of the availability of farmable land, and the destruction of facilities could further increase these adverse impacts and negatively impact demand for our products in impacted regions. The global economy was negatively impacted by the military conflict between Russia and Ukraine and we experienced shortages in materials, the inability to insure shipments, and increased costs for transportation, energy, and raw material and other inputs due in part to the negative impact of this conflict. Further escalation of the military conflict or related geopolitical tensions, including increased trade barriers or restrictions on global trade, could result in, among other things, cyberattacks, further supply disruptions, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business and supply chains.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

**Volatility in Corteva's input costs, which include raw materials and production costs, could have a significant impact on Corteva's business, results of operations and financial condition.**

Corteva's input costs are variable based on the costs associated with production or with raw materials Corteva uses. For example, Corteva's production costs vary, especially on a seasonal basis where changes in weather influence supply and demand. In addition, Corteva's manufacturing processes consume significant amounts of raw materials, the costs of which are subject to worldwide supply and demand as well as other factors beyond Corteva's control. Corteva refers to these costs collectively as input costs. Significant variations in input costs affect Corteva's operating results from period to period.

When possible, Corteva purchases raw materials through negotiated long-term contracts to minimize the impact of price fluctuations. Corteva also enters into over-the-counter and exchange traded derivative commodity instruments to hedge its exposure to price fluctuations on certain purchases. In addition, Corteva takes actions to offset the effects of higher input costs through selling price increases, productivity improvements and cost reduction programs. Success in offsetting higher input costs with price increases is largely influenced by competitive and economic conditions and could vary significantly depending on the market served. If Corteva is not able to fully offset the effects of higher input costs, it could have a significant impact on its financial results.

**Corteva's operations outside the United States are subject to risks and restrictions, which could negatively affect Corteva's business, results of operations and financial condition.**

Corteva's operations outside the United States are subject to risks and restrictions, including fluctuations in foreign currency exchange rates; inflation; exchange and price control regulations; corruption risks; competitive restrictions; changes in local political or economic conditions; import and trade restrictions; import or export licensing requirements and trade policy; and other potentially detrimental domestic and foreign governmental practices or policies affecting U.S. companies doing business abroad. In addition, Corteva's international operations are sometimes in countries with unstable governments, economic or fiscal challenges, military or political conflicts, local epidemics or pandemics, significant levels of crime and organized crime, or developing legal systems. This may increase the risk to the company's employees, subcontractors or other parties, and to other liabilities, such as property loss or damage to the company's products, and may affect Corteva's ability to safely operate in, or import into, or receive raw materials from these countries.

Additionally, Corteva's ability to export its products and its sales outside the United States has been, and may continue to be adversely affected by significant changes in trade, tax or other policies, including other countries retaliating by purchasing less from the United States and the imposition of their own trade restrictions and/or increased tariffs in response to substantial changes to U.S. tariff, trade and tax policies. Furthermore, significant changes in trade, tax, and other related policies or enforcement may pose business and financial risks, including raising the cost of manufacturing inputs and altering customer demands.

Although Corteva has operations throughout the world, Corteva's sales outside the United States in 2025 were principally to customers in Brazil, Eurozone countries, and Canada. Further, Corteva's largest currency exposures are the Brazilian real, Euro, Canadian dollar and Argentine peso. Inflation, market uncertainty or an economic downturn in these geographic areas could reduce demand for Corteva's products and result in decreased sales volume, which could have a negative impact on Corteva's results of operations. In addition, changes in exchange rates may affect Corteva's results of operations, financial condition and cash flows in future periods. Corteva actively manages currency exposures that are associated with net monetary asset positions and committed purchases.

**Corteva's business, results of operations and financial condition could be adversely affected by industrial espionage and other disruptions to its supply chain, information technology or network systems.**

Business and/or supply chain disruptions, plant and/or power outages and information technology system and/or network disruptions, regardless of cause including acts of sabotage, employee error or other actions, geopolitical activity, military conflict, local epidemics or pandemics, weather events and natural disasters could seriously harm Corteva's operations as well as the operations of its customers and suppliers. For example, a pandemic in locations where Corteva has significant operations, sales, or key suppliers could have a material adverse effect on Corteva's results of operations. In addition, terrorist attacks and natural disasters have increased stakeholder concerns about the security and safety of chemical production and distribution.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

Business and/or supply chain disruptions may also be caused by security breaches, which could include, for example, ransomware attacks and attacks on information technology and infrastructure by hackers, viruses, breaches due to employee error or actions or other disruptions. Corteva and/or its suppliers may fail to effectively prevent, detect and recover from these or other security breaches and, as a consequence, such breaches could result in misuse of Corteva's assets, business disruptions, loss of property including trade secrets and confidential business information, legal claims or proceedings, reporting errors, processing inefficiencies, negative media attention, loss of sales and interference with regulatory and data privacy compliance.

Like most major corporations, Corteva is the target of industrial espionage, including cyber-attacks, from time to time. Corteva has determined that these incidents have resulted, and could result in the future, in unauthorized parties gaining access to certain confidential business information. Although management does not believe that Corteva has experienced any material losses to date related to industrial espionage and security breaches, including cybersecurity incidents, there can be no assurance that Corteva will not suffer such losses in the future.

Corteva actively manages the risks within its control that could lead to business disruptions and security breaches. As these threats continue to evolve, particularly around cybersecurity and artificial intelligence, Corteva may be required to expend significant resources to enhance its control environment, processes, practices and other protective measures. Despite these efforts, such events could also have a material adverse effect on Corteva's business, financial condition, results of operations and reputation. Additionally, any losses from such an event may be excluded from, or in excess of the coverages provided by Corteva's insurance policies.

**Corteva's business, results of operations and financial condition could be adversely affected by environmental, litigation and other commitments and contingencies.**

As a result of Corteva's operations, including past operations and those related to divested businesses and discontinued operations of EIDP, Corteva incurs environmental operating costs for pollution abatement activities including waste collection and disposal, installation and maintenance of air pollution controls and wastewater treatment, emissions testing and monitoring and obtaining permits. Corteva also incurs environmental operating costs related to environmental related research and development activities including environmental field and treatment studies as well as toxicity and degradation testing to evaluate the environmental impact of products and raw materials. In addition, Corteva maintains and periodically reviews and adjusts its accruals for probable environmental remediation and restoration costs.

Corteva expects to continue to incur environmental operating costs since it will operate global manufacturing, product handling and distribution facilities that are subject to a broad array of environmental laws and regulations. These rules are subject to change by the implementing governmental agency, which Corteva monitors closely. Corteva's environmental policy requires that its operations fully meet or exceed legal and regulatory requirements. In addition, Corteva expects to continue certain voluntary programs, and could consider additional voluntary actions, to reduce air emissions, minimize the generation of hazardous waste, decrease the volume of water use and discharges, increase the efficiency of energy use and reduce the generation of persistent, bioaccumulative and toxic materials. Costs to comply with complex environmental laws and regulations, as well as internal voluntary programs and goals, are significant and Corteva expects these costs will continue to be significant for the foreseeable future. Over the long-term, such expenditures are subject to considerable uncertainty and could fluctuate significantly.

Corteva accrues for environmental matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. As remediation activities vary substantially in duration and cost from site to site, it is difficult to develop precise estimates of future site remediation costs. Corteva expects to base such estimates on several factors, including the complexity of the geology, the nature and extent of contamination, the type of remedy, the outcome of discussions with regulatory agencies and other Potentially Responsible Parties ("PRPs") at multi-party sites and the number of, and financial viability of, other PRPs. Considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may be materially higher than Corteva's accruals.

Corteva faces risks arising from various unasserted and asserted litigation matters arising out of the normal course of its current and former business operations, including intellectual property, commercial, product liability, environmental and antitrust lawsuits. Corteva has noted a trend in public and private suits being filed on behalf of states, counties, cities and utilities alleging harm to the general public and the environment, including waterways and watersheds. Claims alleging harm to the public and the environment may be brought against Corteva, notwithstanding years of scientific evidence and regulatory determinations supporting the safety of crop protection products. The litigation involving Monsanto's Roundup<sup>®</sup> non-selective

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

glyphosate containing weedkiller products has resulted in negative publicity and sentiment and may lead to similar suits with respect to glyphosate-containing products and/or other established crop protection products. Claims and allegations that Corteva's products or products that Corteva manufactures or markets on behalf of third parties are not safe could result in litigation, damage to Corteva's reputation and have a material adverse effect on Corteva's business. It is not possible to predict the outcome of these various proceedings and any potential impact on Corteva. An adverse outcome in any one or more of these matters may result in losses not fully covered by Corteva's insurance policies, and could be material to Corteva's financial results. Various factors or developments can lead to changes in current estimates of liabilities. Such factors and developments may include, but are not limited to, additional data, safety or risk assessments, as well as a final adverse judgment, significant settlement or changes in applicable law. A future adverse ruling or unfavorable development could result in future charges that could have a material adverse effect on Corteva.

The company, pursuant to the respective Separation Agreements, is entitled to cost sharing and indemnification from The Chemours Company ("Chemours"), Dow and DuPont, as applicable, for certain litigation, environmental, workers' compensation and other liabilities related to its historical operations. In connection with the recognition of liabilities related to these matters, Corteva records an indemnification asset when recovery is deemed probable. These estimates of recovery are subject to various factors and developments that could result in differences from future estimates or the actual recovery. As of December 31, 2025, the indemnification assets pursuant to the Chemours Separation Agreement and the Corteva Separation Agreement are in aggregate $242 million within accounts and notes receivable - net and $733 million within other assets in the company's Consolidated Balance Sheets. Any failure by, or inability to pay, these liabilities in line with the indemnification provisions of the Separation Agreements may have a material adverse effect on Corteva and its financial condition and results of operations.

In the ordinary course of business, Corteva may make certain commitments, including representations, warranties and indemnities relating to current and past operations, including those related to divested businesses and issue guarantees of third-party obligations. If Corteva were required to make payments as a result, they could exceed the amounts accrued, thereby adversely affecting Corteva's financial condition and results of operations.

**Corteva is dependent on its relationships or contracts with third parties with respect to certain of its raw materials or licenses and commercialization.**

Corteva is dependent on third parties in the research, development and commercialization of its products and enters into transactions including, but not limited to, supply agreements, licensing agreements, and manufacturing agreements in connection with Corteva's business. The majority of Corteva's corn hybrids and soybean varieties sold to customers contain biotechnology traits that Corteva licenses from third parties under long-term license agreements. If Corteva loses its rights under such licenses, it could negatively impact Corteva's ability to obtain future licenses on competitive terms, commercialize new products and generate sales from existing products. Corteva may elect to out-license its technology, including germplasm. There can be no guarantee that such out-licensing will not ultimately strengthen Corteva's competition thereby adversely impacting Corteva's results of operations.

While Corteva relies heavily on third parties for multiple aspects of its business and commercialization activities, Corteva does not control many aspects of such third parties' activities. Third parties may not complete activities on schedule or in accordance with Corteva's expectations. Failure by one or more of these third parties to meet their contractual or other obligations to Corteva or to comply with applicable laws or regulations, or any disruption in the relationship between Corteva and one or more of these third parties could delay or prevent the development, approval or commercialization of Corteva's products and could also result in non-compliance or reputational harm, all with potential negative implications for Corteva's business.

In addition, Corteva's agreements with third parties may obligate it to meet certain contractual or other obligations to third parties. For example, Corteva may be obligated to meet certain thresholds or abide by certain boundary conditions. If Corteva were to fail to meet such obligations to the third parties, its relationship with such third parties may be disrupted. Such a disruption could negatively impact certain of Corteva's licenses on which it depends, could cause reputational harm, and could negatively affect Corteva's business, results of operations and financial condition.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

**Corteva's customers may be unable to pay their debts to Corteva, which could adversely affect Corteva's results.**

Corteva offers its customers financing programs with credit terms generally less than one year from invoicing in alignment with the growing season. Due to these credit practices as well as the seasonality of Corteva's operations, Corteva may need to issue short-term debt at certain times of the year to fund its cash flow requirements. Corteva's customers may be exposed to a variety of conditions that could adversely affect their ability to pay their debts. For example, customers in economies experiencing an economic downturn or in a region experiencing adverse growing conditions may be unable to repay their obligations to Corteva, which could adversely affect Corteva's results.

**Failure to effectively manage acquisitions, divestitures, strategic investments, restructurings, cost savings initiatives and other portfolio actions may not have the results anticipated.**

From time-to-time, Corteva evaluates acquisition candidates that may strategically fit Corteva's business and/or growth objectives, along with making investments in strategic technologies through its Corteva Catalyst platform. If Corteva is unable to successfully integrate and develop acquired businesses, including its growth in biologicals, Corteva could fail to achieve expected increases in revenues and operating results, as well as anticipated investment returns, synergies and cost savings, which could have a material adverse effect on Corteva's financial results. Corteva continually reviews its portfolio of assets for contributions to its objectives and alignment with its strategy. However, Corteva may not be successful in separating underperforming or non-strategic assets and gains or losses on the divestiture of, or lost operating income from, such assets, may affect Corteva's earnings. Moreover, Corteva might incur asset impairment charges related to its investments and acquisitions, or divestitures that reduce its earnings. In addition, if the execution of these transactions, investments, or portfolio actions is not successful, it could adversely impact Corteva's financial condition, results of operations and cash flows.

**Corteva's liquidity, business, results of operations and financial condition could be impaired if it is unable to raise capital through the capital markets or short-term debt borrowings.**

Any limitation on Corteva's ability to raise money in the capital markets or through short-term debt borrowings could have a substantial negative effect on Corteva's liquidity. Corteva's ability to affordably access the capital markets and/or borrow short- term debt in amounts adequate to finance its activities could be impaired as a result of a variety of factors, including factors that are not specific to Corteva, such as a severe disruption of the financial markets and, in the case of debt securities or borrowings, interest rate fluctuations. Due to the seasonality of Corteva's business and the credit programs Corteva may offer its customers, net working capital investment and corresponding debt levels will fluctuate over the course of the year.

Corteva regularly extends credit to its customers to enable them to purchase seed or crop protection products at the beginning of the growing season. The customer receivables may be used as collateral for short-term financing programs. Any material adverse effect upon Corteva's ability to own or sell such customer receivables, including seasonal factors that may impact the amount of customer receivables Corteva owns, may materially impact Corteva's access to capital.

Corteva has additional agreements with financial institutions to establish programs that provide financing for select customers of Corteva's seed and crop protection products in the United States, Latin America, Europe and Asia. The programs are renewed on an annual basis. In most cases, Corteva guarantees the extension of such credit to such customers. If Corteva is unable to renew these agreements or access the debt markets to support customer financing, Corteva's sales may be negatively impacted, which could result in increased borrowing needs to fund working capital.

Corteva's earnings, operations and business, among other things, will impact its credit ratings, costs and availability of financing. There can be no assurance that Corteva or EIDP will maintain its current or prospective credit ratings. A decrease in the ratings assigned to Corteva or EIDP by the ratings agencies may negatively impact Corteva's liquidity, access to the debt capital markets and increase Corteva's cost of borrowing and the financing of its seasonal working capital.

**Increases in pension and other post-employment benefit plan funding obligations may adversely affect Corteva's results of operations, liquidity or financial condition.**

Through Corteva's ownership of EIDP, Corteva maintains the EIDP defined benefit pension and other post-employment benefit plans. For some of these plans, including EIDP's principal U.S. pension plan, Corteva continues as sponsor for the entire plan regardless of whether participants, including retirees, are or were associated with EIDP's agriculture business. Corteva uses many assumptions in calculating the expected future payment obligations under these plans. Significant adverse changes in

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

credit or market conditions could result in actual rates of returns on pension investments being lower than assumed. In 2026, Corteva expects to contribute approximately $40 million to its pension plans other than the principal U.S. pension plan, and approximately $100 million for its other post-employment benefit ("OPEB") plans. While there is no anticipated required contribution for 2026, Corteva expects to evaluate making discretionary contributions to the principal U.S. pension plan and/or may be required to make contributions in the future. These contributions could be significant and adversely affect Corteva's results of operations, liquidity and financial condition.

**Global or regional health pandemics or epidemics could negatively impact the company's business, financial condition and results of operations.**

Corteva's business, financial condition, and results of operations could be negatively impacted by human or animal pandemics or epidemics. The severity, magnitude and duration of the pandemics is uncertain, rapidly changing and difficult to predict. Future pandemics or epidemics and resulting illness, travel restrictions and workforce and operational disruptions could impact Corteva's global supply chain, its operations and its routes to market or those of its suppliers, co-manufacturers, or customers/distributors. These disruptions or the company's failure to effectively respond to them could increase product or distribution costs, alter the timing of recognizing manufacturing costs, or impact the delivery of products to customers or their ability to pay.

Government-pandemic or epidemic responses can significantly impact economic activity and markets around the world. Future outbreaks or pandemics could negatively impact customer demand and the company's business, financial condition, and results of operations in numerous ways, including but not limited to increased market volatility that impacts the company's hedging, financial forecasting, and liquidity, including its access to capital markets and delays or modifications to the company's strategic plans and productivity initiatives.

**Sentiment towards sustainability matters could adversely affect our stock price, results of operations, and access to capital.**

Corteva has established certain strategies, commitments and initiatives as part of its sustainability programs. Execution of these strategies and the achievements of Corteva's sustainability commitments are subject to certain risks and uncertainties, including regulatory action or inaction, changes in public or investor sentiment, and resource availability, many of which are out of its control. Failure to achieve its sustainability commitments within the expected timeframes and cost effectively could damage Corteva's reputation, customer and investor relationships, or its access to financing. Further, dissatisfaction with such a failure could cause stockholders to reduce their ownership holdings, all of which, in turn could adversely affect Corteva's business, financial condition, results of operations and cash flows and reduce its stock price.

***Risks Related to Our Intellectual Property***

**Enforcing Corteva's intellectual property rights, or defending against intellectual property claims asserted by others, could materially affect Corteva's business, results of operations and financial condition.**

Intellectual property rights, including patents, plant variety protection, trade secrets, confidential information, trademarks, trade names and other forms of trade dress, are important to Corteva's business. Corteva endeavors to protect its intellectual property rights in jurisdictions in which its products are produced or used and in jurisdictions into which its products are imported. However, Corteva may be unable to obtain protection for its intellectual property in key jurisdictions. Further, changes in government policies and regulations, including changes made in reaction to pressure from non-governmental organizations, or the public generally, could impact the extent of intellectual property protection afforded by such jurisdictions.

Competitors are increasingly challenging intellectual property positions and the outcomes to these challenges, including those with Inari, can be highly uncertain and negatively impact the value of Corteva's intellectual property and investment return on its research and development. Additionally, Corteva has been subject to claims that its products violate third party intellectual property rights. Defending such claims, even those without merit, is time-consuming and expensive. In addition, any such claim could result in Corteva's having to enter into, or continue, license agreements, develop non-infringing products or engage in litigation that could be costly. If challenges are resolved adversely, it could negatively impact Corteva's ability to obtain licenses on competitive terms, develop and commercialize new products, generate sales from existing products or reduce its reliance on licensed technologies.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

Corteva has designed and implemented internal controls to restrict use of, access to and distribution of its intellectual property. Despite these precautions, Corteva's intellectual property is vulnerable to infringement, misappropriation and other unauthorized access, including through employee or licensee error or actions, theft and cybersecurity incidents, and other security breaches. When unauthorized access and use or counterfeit products are discovered, Corteva may report such situations to governmental authorities for investigation, as appropriate, and takes measures to mitigate any potential impact. Protecting intellectual property related to biotechnology is particularly challenging because theft is difficult to detect and biotechnology can be self-replicating.

In addition, because of the rapid pace of technological change, the confidentiality of patent applications in some jurisdictions and/or the uncertainty in predicting the outcome of complex proceedings relating to ownership and the scope of patents relating to certain emerging technologies, competitors may be issued patents related to Corteva's business unexpectedly. These patents could reduce the value of Corteva's commercial or pipeline products or, to the extent they cover key technologies on which Corteva has relied, require Corteva to seek to obtain licenses (and Corteva cannot ensure it would be able to obtain such a license on acceptable terms) or cease using the technology, no matter how valuable to Corteva's business.

Legislation and jurisprudence on patent protection is evolving and changes in laws could affect Corteva's ability to obtain or maintain patent protection for, and otherwise enforce Corteva's patents related to, its products.

**Corteva's business may be adversely affected by the availability of counterfeit products.**

A counterfeit product is one that has been deliberately and fraudulently mislabeled as to its identity and source. A counterfeit Corteva product, therefore, is one manufactured by someone other than Corteva, but which appears to be the same as an authentic Corteva product. The prevalence of counterfeit products is a significant and growing industry-wide issue due to a variety of factors, including, but not limited to, the following: the widespread use of the Internet, which has greatly facilitated the ease by which counterfeit products can be advertised, purchased and delivered to individual consumers; the availability of sophisticated technology that makes it easier for counterfeiters to make counterfeit products; and the relatively modest risk of penalties faced by counterfeiters compared to the large profits that can be earned by them from the sale of counterfeit products. Further, laws against counterfeiting vary greatly from country to country, and the enforcement of existing laws varies greatly from jurisdiction to jurisdiction. For example, in some countries, counterfeiting is not a crime; in others, it may result in only minimal sanctions. In addition, those involved in the distribution of counterfeit products use complex transport routes to evade customs controls by disguising the true source of their products.

Corteva's global reputation makes its products prime targets for counterfeiting organizations. Counterfeit products pose a risk to consumer health and safety because of the conditions under which they are manufactured (often in unregulated, unlicensed, uninspected and unsanitary sites) as well as the lack of regulation of their contents. Failure to mitigate the threat of counterfeit products, which is exacerbated by the complexity of the supply chain, could adversely impact Corteva's business by, among other things, causing the loss of consumer confidence in Corteva's name and in the integrity of its products, potentially resulting in lost sales and an increased threat of litigation.

Corteva undertakes significant efforts to counteract the threats associated with counterfeit products, including, among other things, working with regulatory authorities and multinational coalitions to combat the counterfeiting of products and supporting efforts by law enforcement authorities to prosecute counterfeiters; assessing new and existing technologies to seek to make it more difficult for counterfeiters to copy Corteva's products and easier for consumers to distinguish authentic from counterfeit products; working diligently to raise public awareness about the dangers of counterfeit products; working collaboratively with wholesalers, customs offices and law enforcement agencies to increase inspection coverage, monitor distribution channels and improve surveillance of distributors; and working with other members of an international trade association of agrochemical companies to promote initiatives to combat counterfeiting activity. No assurance can be given, however, that Corteva's efforts and the efforts of others will be entirely successful, and the presence of counterfeit products may continue to increase.

**Restrictions under the intellectual property cross-license agreements limit Corteva's ability to develop and commercialize certain products and services and/or prosecute, maintain and enforce certain intellectual property.**

The company is dependent to a certain extent on DuPont and Dow to maintain and enforce certain of the intellectual property licensed under the Intellectual Property Cross-License Agreements. For example, DuPont and Dow are responsible for filing, prosecuting and maintaining (at their respective discretion) patents on trade secrets and know-how that they each respectively license to Corteva. They also have the first right to enforce their respective trade secrets and know-how licensed to Corteva. If

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

DuPont or Dow, as applicable, fails to fulfill its obligations or chooses to not enforce the licensed patents, trade secrets or know-how under the Intellectual Property Cross-License Agreements, the company may not be able to prevent competitors from making, using and selling competitive products and services.

In addition, Corteva's use of the intellectual property licensed to it under the Intellectual Property Cross-License Agreements is restricted to certain fields, which could limit Corteva's ability to develop and commercialize certain products and services. For example, the licenses granted to Corteva under the agreement will not extend to all fields of use that the company may decide to enter into in the future. These restrictions may make it more difficult, time consuming and/or expensive for Corteva to develop and commercialize certain new products and services, or may result in certain of its products or services being later to market than those of its competitors.

***Risks Related to the Corteva Separation***

**In connection with the Corteva Separation the company has assumed, and agreed to indemnify DuPont and Dow for, certain liabilities. If the company is required to make payments pursuant to these indemnities, the company may need to divert cash to meet those obligations and its financial results could be negatively impacted. In addition, DuPont and Dow have agreed to indemnify Corteva for certain liabilities. These indemnities may not be sufficient to insure the company against the full amount of liabilities it incurs, and DuPont and/or Dow, and/or their historical separated businesses, may not be able to satisfy their indemnification obligations in the future.**

Pursuant to the Separation Agreement, the Employee Matters Agreement and the Tax Matters Agreement with DuPont and Dow, the company agreed to assume, and indemnify DuPont and Dow for, certain liabilities for uncapped amounts, which may include, among other items, associated defense costs, settlement amounts and judgments, as discussed further in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, and Part I - Item 3 - Legal Proceedings. Payments pursuant to these indemnities may be significant and could negatively impact the company's business, particularly indemnities relating to certain litigation for Historical DuPont operations or its actions that could impact the tax-free nature of the Corteva Distribution. Third parties could also seek to hold the company responsible for any of the liabilities allocated to DuPont and Dow, including those related to DowDuPont's specialty products and/or materials science businesses, respectively, and those related to discontinued and/or divested businesses and operations of Historical Dow, which have been allocated to Dow. DuPont and/or Dow, as applicable, have agreed to indemnify Corteva for such liabilities, but such indemnities may not be sufficient to protect the company against the full amount of such liabilities. In addition, DuPont and/or Dow, as applicable, may not fully satisfy their indemnification obligations with respect to the liabilities the company incurs. Even if the company ultimately succeeds in recovering from DuPont and/or Dow, as applicable, any amounts for which the company is held liable, the company may be temporarily required to bear these losses itself.

Additionally, the company generally has assumed and is responsible for the payment of its share of (i) certain liabilities of DowDuPont relating to, arising out of or resulting from certain general corporate matters of DowDuPont, (ii) certain liabilities of Historical DuPont relating to, arising out of or resulting from general corporate matters of Historical DuPont and discontinued and/or divested businesses and operations of Historical DuPont, including its Performance Chemicals spin-off, Chemours, and (iii) certain separation expenses not otherwise allocated to DuPont or Dow (or allocated specifically to Corteva) pursuant to the Corteva Separation Agreement, and third parties could seek to hold Corteva responsible for DuPont's or Dow's share of any such liabilities. For more information, see Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, and Part I - Item 3 - Legal Proceedings. DuPont and/or Dow, as applicable, will indemnify Corteva for their share of any such liabilities; however, such indemnities may not be sufficient to protect Corteva against the full amount of such liabilities, and/or DuPont and/or Dow may not fully satisfy their respective indemnification obligations. In addition, even if the company ultimately succeeds in recovering from DuPont and/or Dow any amounts for which the company is held liable in excess of its agreed share, the company may be temporarily required to bear these losses itself and may not be able to fully insure itself to cover these risks.

Risks related to the satisfaction of these indemnification obligations and temporarily bearing losses may be increased if DuPont's electronics business spin-off, Qnity Electronics, Inc., or if other divested businesses of Historical DuPont (including Chemours) or Historical Dow do not or are unable to cover their liabilities or satisfy their indemnification obligations. Even if Corteva takes legal action to protect its rights with respect to such a transaction, these legal costs may be significant. Each of the above risks could materially affect the company's business, financial condition, results of operations and cash flows.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

**The Corteva Separation and related transactions may expose Corteva to potential liabilities arising out of state and federal fraudulent conveyance laws**

Although the company received a solvency opinion from an investment bank confirming that the company and DuPont were each adequately capitalized following the Corteva Distribution, the Separation could be challenged under various state and federal fraudulent conveyance laws. In connection with fraudulent conveyances or transfers are generally defined to include transfers made or obligations incurred with the actual intent to hinder, delay or defraud current or future creditors or transfers made or obligations incurred for less than reasonably equivalent value when the debtor was insolvent, or that rendered the debtor insolvent, inadequately capitalized or unable to pay its debts as they become due. Any unpaid creditor could claim that DuPont did not receive fair consideration or reasonably equivalent value in the Separation and Corteva Distribution, and that the Separation and Corteva Distribution left DuPont insolvent or with unreasonably small capital or that DuPont intended or believed it would incur debts beyond its ability to pay such debts as they matured. Additionally, under its indemnity provisions of the Separation Agreement, the company could find its liabilities increased as a result of a court concluding that Historical DuPont, Historical Dow or DowDuPont executed a fraudulent conveyance in connection with divestitures and spin-offs of any one of their historical operations, including Chemours. If a court were to agree with such a plaintiff, then such court could void the Separation and Distribution as a fraudulent transfer or impose substantial liabilities on Corteva, which could materially adversely affect its financial condition and results of operations. Among other things, the court could return some of Corteva's assets or shares of Corteva common stock to DuPont, provide DuPont with a claim for money damages against Corteva in an amount equal to the difference between the consideration received by DuPont and the fair market value of Corteva at the time of the Corteva Distribution, or require Corteva to fund liabilities of other companies involved in the Internal Reorganization for the benefit of creditors.

The Distribution is also subject to review under state corporate Distribution statutes. Under the Delaware General Corporation Law (the "DGCL"), a corporation may only pay dividends to its stockholders either (i) out of its surplus (net assets minus capital) or (ii) if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Although the Distribution was made out of DowDuPont's surplus and the company received an opinion that DowDuPont has adequate surplus under Delaware law to declare the dividend of Corteva common stock in connection with the Corteva Distribution, there can be no assurance that a court will not later determine that some or all of the Corteva Distribution was unlawful.

**The company is subject to continuing contingent tax-related liabilities of DowDuPont following the Distribution.**

There are several significant areas where the liabilities of DowDuPont may become Corteva's obligations either in whole or in part. For example, under the Code and the related rules and regulations, each corporation that was a member of DowDuPont's consolidated tax reporting group during any taxable period or portion of any taxable period ending on or before the effective time of the Distribution is jointly and severally liable for the U.S. federal income tax liability of the entire consolidated tax reporting group for such taxable period. Additionally, to the extent that any subsidiary of Corteva was included in the consolidated tax reporting group of either Historical DuPont or Historical Dow for any taxable period or portion of any taxable period ending on or before the effective date of the Merger, such subsidiary is jointly and severally liable for the U.S. federal income tax liability of the entire consolidated tax reporting group of Historical DuPont or Historical Dow, as applicable, for such taxable period. On April 1, 2019, the company entered into the Tax Matters Agreement with DuPont and Dow that allocates the responsibility for prior period consolidated taxes among Corteva, DuPont and Dow. If DuPont or Dow were unable or unwilling to pay any prior period taxes for which it is responsible, however, the company could be required to pay the entire amount of such taxes, and such amounts could be significant. Other provisions of federal, state, local, or foreign law may establish similar liability for other matters, including laws governing tax-qualified pension plans, as well as other contingent liabilities.

***Risks related to our Proposed Separation***

**Corteva is subject to risks related to its plans to separate its seed and crop protection businesses in a spin-off that will result in two standalone public companies, including that the proposed separation may not be completed on the contemplated timeline or at all and may not achieve the intended benefits.**

On October 1, 2025, Corteva announced its intent to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies, in a transaction that is intended to qualify as a tax-free spin-off for U.S. federal income tax purposes (the "Proposed Separation"). The Proposed Separation is subject to the satisfaction of a number of customary conditions,

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 1A. RISK FACTORS,** *continued*

including, among others, the filing and effectiveness of a Form 10 registration statement with the SEC, receipt of a tax opinion from external counsel to the effect that, among other things, the transaction will qualify as a tax-free spin-off, and final approval by Corteva's Board of Directors. The ultimate timing of the Proposed Separation will depend on the readiness of each business to operate as an independent public company and the finalization of appropriate capital structures for each. The failure to satisfy all of the required conditions for the Proposed Separation, as well as unanticipated developments, could delay, prevent or otherwise adversely affect the Proposed Separation. These potential developments, many of which are outside of Corteva's control, include, but are not limited to, disruptions in general or financial market conditions, material adverse changes in business or industry conditions, unanticipated costs, difficulties or delays in obtaining various regulatory and tax approvals or clearances, and stakeholder actions or challenges relating to the Proposed Separation or to other aspects of Corteva's business or strategy.

Executing the Proposed Separation will require significant time and attention from Corteva's senior management and employees, which could disrupt Corteva's ongoing business, negatively impact Corteva's relationships with employees, suppliers, customers, distributors, licensors and other stakeholders and adversely affect Corteva's financial results and results of operations. There can be no assurances that Corteva will be able to complete the Proposed Separation on the terms or on the timeline that was announced, if at all, or that the complexities, costs and dis-synergies associated with the Proposed Separation will not be significant or exceed expectations. Moreover, although Corteva expects to maintain an investment grade credit rating, a downgrade in Corteva's rating may lead to increased borrowing costs for Corteva. In addition, there may be increased borrowing costs associated with the re-allocation or taking on of new debt in connection with the Proposed Separation.

If the Proposed Separation is completed, Corteva may not be able to achieve the full strategic and financial benefits that are expected to result from the Proposed Separation. Following the Proposed Separation, the Seed and Crop Protection businesses will bear the full costs and responsibilities of operating a standalone public company and these dis-synergies may exceed expectations. Moreover, the Seed and Crop Protection businesses will each be smaller, less diversified enterprises, and as a result, the separated companies may be more exposed to industry-specific risks and changing market conditions than Corteva is today. The Proposed Separation also may prompt existing stockholders to divest holdings that no longer align with their investment objectives, potentially affecting the trading value of each company's common stock following the Proposed Separation. Further, there can be no assurance that the combined value of the common stock of the two companies will be equal to or greater than the value of Corteva's common stock had the Proposed Separation not occurred.

In addition, while it is expected that Corteva will receive a tax opinion from external counsel to the effect that, among other things, the Proposed Separation will qualify as a tax-free spin-off for U.S. federal income tax purposes, any such opinion is not binding on the U.S. Internal Revenue Service. Accordingly, the U.S. Internal Revenue Service may reach conclusions with respect to the Proposed Separation that are different from the conclusion reached in such opinion. If the Proposed Separation is ultimately determined to be taxable, either Corteva or Corteva's stockholders could incur significant income tax liabilities.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**ITEM 1B. UNRESOLVED STAFF COMMENTS**

None.

**ITEM 1C. CYBERSECURITY**

*Risk Management and Strategy.* The company's risk management programs for cybersecurity are integrated into the company's enterprise risk management and general compliance programs and processes.

Our cybersecurity program utilizes a layered, defense-in-depth strategy to identify and mitigate cybersecurity threats. The company's information security team is responsible for the day-to-day management of the company's global information security program, which includes defining policies and procedures to safeguard our information systems and data, conducting vulnerability, threat and third-party information security assessments, information security event management (i.e., responding to ransomware and other cyber-attacks, business continuity and recovery), evaluating external cyber intelligence, supporting industry cybersecurity efforts and working with governmental agencies. The global information security team also develops training for personnel (e.g., employees and contractors) with access to Corteva's system to support adherence to the company's policies and procedures, along with increasing awareness of cyber-related risk. The personnel training includes, but is not limited to, mandatory onboarding training, phishing simulations with automated remediation training, table-top incident response exercises, and educational intranet posting and email campaigns.

Our Enterprise Risk Management Committee, which includes the company's Chief Information Officer ("CIO") and Chief Information Security Officer ("CISO"), independently assesses and monitors the effectiveness of the company's cybersecurity risk management programs and strategies. The company's internal audit function also performs independent reviews and validation of the various programs, including policies and procedures as determined by their annual risk assessment.

The company leverages the U.S. Department of Commerce's National Institute of Standards and Technology ("NIST") Cybersecurity Framework ("Framework") as the foundation of its global information security program. The NIST Framework provides standards, guidelines, and practices for organizations to better manage and reduce cybersecurity risk and is designed to foster risk and cybersecurity management communications amongst both internal and external organizational stakeholders. The company's information security team works with independent, third-party consultants annually to assess the maturity of the company's cybersecurity program within the NIST Framework and to develop strategic areas of focus for the company's programs commensurate with the company's business objectives.

As part of the company's global information security program, we leverage both internal and external assessments and partnerships with industry leaders to help approach information security company-wide. Additionally, the company maintains a comprehensive program that defines standards for the planning, sourcing, management, and oversight of third-party relationships and third-party access to its system, facilities, and/or confidential or proprietary data.

Cybersecurity incidents may create risk to the company that may impact its reputation, financial performance, ability to operate safely or at all, and the value of its intellectual property. Like most major corporations, the company is the target of industrial espionage, including cyberattacks, from time to time. The company has determined that these incidents have resulted, and could result in the future, in unauthorized parties gaining access to certain confidential business information. However, to date, Corteva has not experienced any known cybersecurity incidents that have materially affected the company, including the company's results of operations and financial condition, changes in the competitive environment, business operations and strategy. Although management does not believe that Corteva has experienced any material losses to date related to cybersecurity incidents, there can be no assurance that Corteva will not suffer such losses in the future. For more information on potential risk related to cybersecurity incidents, including intellectual property theft and operational disruption, please see "Item 1A – Risk Factors" of this report.

*Governance.* The company's Audit Committee and Governance and Compliance Committee provide board oversight of company cybersecurity risks. The Audit Committee conducts a minimum of two cybersecurity program updates per year, including a review of capital spend, budget, and staffing, as well as quarterly reports on cybersecurity threats and key risk indicators related to the company's progress on risk mitigation activities. The Governance and Compliance Committee, as part of its oversight for the enterprise risk management program company-wide, reviews the company's oversight and governance structure related to company risks, including cybersecurity risks, remains appropriate and that risks are appropriately managed.

The company's CIO oversees the company's information technology programs and investments. The company's CISO reports to the CIO and oversees the company's information security programs. The company's CIO has over 30 years of information

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**ITEM 1C. CYBERSECURITY,** *continued*

technology experience, including 10 years in various information technology leadership roles. Our CIO holds a bachelor of science and master of science degrees in organizational communications as well as an M.B.A. in information technology. The company's CISO has over 30 years of experience in information security and is a Certified Information Security Manager<sup>®</sup> (CISM<sup>®</sup>), a Certified Data Privacy Solutions Engineer™ (CDPSE<sup>®</sup>), as well as being Certified in Risk and Information Systems Control<sup>®</sup> (CRISC<sup>®</sup>). Our CISO holds a bachelor of science degree in electric engineering as well as an M.B.A. in operations, technology.

Both the CIO and CISO regularly report to the Audit Committee, and Board, on the company's identification, prevention, detection, mitigation and remediation of cybersecurity risks and incidents. In 2025, the Board reviewed the company's cybersecurity program and maturity assessment, while the Audit Committee provided regular oversight of cybersecurity risks, with cybersecurity discussions and dashboard reviews of key performance indicators and risks at four committee meetings during the course of the year. With respect to specific incidents, the company leverages an incident response framework to elevate and evaluate specific incidents to the CIO and CISO, along with the company's senior leadership, including the finance and legal functions. In the event of a potentially material cybersecurity incident, the Audit Committee would be immediately notified and briefed.

**ITEM 2. PROPERTIES**

The company operates out of its headquarters in Indianapolis, Indiana. It also maintains a global business center in Johnston, Iowa, for its Seed business. Its manufacturing, processing, marketing and research and development facilities, as well as regional purchasing offices and distribution centers, are located throughout the world. The company has 95 production sites in the following geographic regions:

---

| | | | |
|:---|:---|:---|:---|
| | **Number of Sites** | **Number of Sites** | **Number of Sites** |
| | **Seed** | **Crop Protection** | **Total** |
| &nbsp;&nbsp;North America <sup>1</sup> | 38 | 7 | 45 |
| &nbsp;&nbsp;EMEA <sup>2</sup> | 12 | 9 | 21 |
| &nbsp;&nbsp;&nbsp;Latin America | 8 | 13 | 21 |
| &nbsp;&nbsp;&nbsp;Asia Pacific | 3 | 5 | 8 |
| Total | 61 | 34 | 95 |

---

<sup>1.</sup>&nbsp;&nbsp;&nbsp;&nbsp;North America consists of U.S. & Canada.

<sup>2.&nbsp;&nbsp;&nbsp;&nbsp;</sup>Europe, Middle East, and Africa ("EMEA").

The company's principal sites include facilities which, in the opinion of management, are suitable and adequate for their use and have sufficient capacity for the company's current needs and expected near-term growth. Properties are either owned by the company or leased, in such cases typically under a long-term lease. No title examination of the properties has been made for the purpose of this report and certain properties are shared with other tenants under long-term leases.

**ITEM 3. LEGAL PROCEEDINGS**

The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EIDP businesses unrelated to Corteva's current businesses but allocated to Corteva as part of the Corteva Separation from DuPont.

Often these proceedings raise complex factual and legal issues, which are subject to risks and uncertainties and which could require significant amounts of the senior leadership team's time. Litigation and other claims, along with regulatory proceedings, against the company could also materially adversely affect its operations, reputation, and/or result in the incurrence of unexpected expenses and liability. Even when the company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the company, including avoidance of future distraction and litigation defense cost, and its shareholders. Information regarding certain of these matters is set forth below and in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 3. LEGAL PROCEEDINGS,** *continued* 

**Litigation related to Corteva's current businesses**

*Inari Disputes*

On September 27, 2023, Corteva filed a lawsuit in Delaware federal court against Inari Agriculture, Inc. and Inari Agriculture. N.V. (collectively "Inari") asserting claims of Plant Variety Protection infringement, indirect patent infringement, breach of contract, and civil conversion. Corteva's lawsuit alleges Inari illegally obtained various varieties of seed technologies from a seed depository and illegally transported them abroad for the purpose of performing gene editing on the technologies and then filing a patent for such technologies. In August 2024, the court denied Inari's motion to dismiss the complaint. In September 2024, Corteva amended its complaint to include additional infringement claims with respect to soybean and corn technologies. In May 2025, the federal court dismissed Inari's claims of sham litigation, patent misuse, and state-based deceptive trade practices claims. This May 2025 order was amended to reinstate Inari's estoppel defense. The trial is expected to begin in the second half of 2026.

*Bayer Disputes*

Corteva resolved its outstanding litigation with Bayer. Further information with respect to these proceedings and their respective resolution is set forth under "Bayer Disputes" in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

*Other Matters*

Further information with respect to litigation matters related to Corteva's current business is set forth under "Federal Trade Commission Investigation" and "Lorsban® Lawsuits" in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

**Litigation related to legacy EIDP businesses unrelated to Corteva's current businesses**

As discussed below and in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, certain of the environmental proceedings and litigation allocated to Corteva as part of the Separation from DuPont relate to the legacy EIDP businesses, including their use of PFOA, which, for purposes of this report, means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs"). This PFOA litigation includes multiple natural resource damage lawsuits across the United States filed by municipalities and alleging PFOA contamination, as well as, lawsuits by four municipalities in the Netherlands alleging contamination of land and groundwater resulting from the emission of PFOA and GenX.

**Other Environmental Proceedings**

The company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The matters below involve the potential for $1 million or more in monetary fines and are included per Item 103(3)(c)(iii) of Regulation S-K of the Securities Exchange Act of 1934, as amended.

*Related to Corteva's current businesses*

*Nebraska Department of Environment and Energy, AltEn Facility*

The EPA and the Nebraska Department of Environment and Energy ("NDEE") are pursuing investigations, response and removal actions, litigation and enforcement action related to an ethanol plant located near Mead, Nebraska and owned and operated by AltEn LLC ("AltEn"). Corteva is one of six seed companies, who were customers of AltEn (collectively, the "Facility Response Group"), participating in the NDEE's Voluntary Cleanup Program to address certain interim remediation needs at the site. Further information with respect to these proceedings is set forth under "Nebraska Department of Environment and Energy, AltEn Facility" in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

*Bay Area Quality Management, Pittsburg Facility*

In December 2025, the Bay Area Quality Management District sent a notice to the company proposing a settlement for allegations of notices of violations from 2010 to 2023 relating to emissions, equipment leaks, monitoring inspections, recordkeeping, and training, at the company's Pittsburg, California facility.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part I**

**ITEM 3. LEGAL PROCEEDINGS,** *continued* 

*Related to legacy EIDP businesses unrelated to Corteva's current businesses*

*Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection*

In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC ("Denka") neoprene manufacturing facility in La Place, Louisiana. EIDP sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. In the spring of 2017, the EPA, the DOJ, the Louisiana Department of Environmental Quality, EIDP and Denka began discussions relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. In March 2025, the EPA and DOJ dismissed the action against Denka and EIDP. Following the dismissal, a private action mirroring the government's original claims was filed, as well as adding allegations of violations of the U.S. Resource Conservation and Recovery Act and U.S. Clean Water Act. Under the Separation Agreement, DuPont is defending and indemnifying the company in this matter.

*EPA CERCLA Claim*

In April 2024, the EPA also designated PFOA and PFAS as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA"). In November 2024, the EPA issued a letter to DuPont, EIDP and Corteva asserting CERCLA claims related to alleged PFAS contamination from six historical and present DuPont and Chemours sites and providing a demand for cleanup and restoration costs. In September 2025, the EPA announced its intent to retain the designation of PFOA and PFOS as CERCLA hazardous substances. Discussions among the parties are ongoing.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES**

**Market for Registrant's Common Equity and Related Stockholder Matters**

The company's common stock is listed on the New York Stock Exchange (symbol: CTVA). The number of record holders of common stock was approximately 56,000 at February 5, 2026.

During 2025 and 2024, the company paid four quarterly dividends on its common stock. The following table contains dividend information for each quarter during 2025 and 2024:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Fourth Quarter | $0.18 | $0.17 |
| Third Quarter | 0.18 | 0.17 |
| Second Quarter | 0.17 | 0.16 |
| First Quarter | 0.17 | 0.16 |
| Total | $0.70 | $0.66 |

---

See Part III, Item 11. Executive Compensation for information relating to the company's equity compensation plans.

**Issuer Purchases of Equity Securities**

The following table summarizes information with respect to the company's purchase of its common stock during the three months ended December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Month** | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of the Company's Publicly Announced Share Buyback Program**<sup>1</sup> | **Approximate Value of Shares that May Yet Be Purchased Under the Program**<sup>1</sup> <br>**(Dollars in millions)** |
| October 2025 | 1152982 | $62.88 | 1152982 | $2658 |
| November 2025 | 2421790 | 65.03 | 2421790 | 2500 |
| December 2025 | 1062131 | 65.88 | 1062131 | 2430 |
| Fourth quarter 2025 | 4636903 | $64.69 | 4636903 | $2430 |

---

1. On November 19, 2024, Corteva, Inc. announced that its Board of Directors authorized a $3 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES,** *continued*

**Stock Performance Graph**

The following graph illustrates the cumulative total return to Corteva stockholders since December 31, 2020. The chart compares the cumulative total return of Corteva's common stock with the S&P 500 Stock Index and the S&P 500 Chemicals Index.

![FY 2025 Stock Performance Graph.gif](ctva-20251231_g5.gif)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **12/31/2020** | **12/31/2021** | **12/31/2022** | **12/31/2023** | **12/31/2024** | **12/31/2025** |
| **Corteva** | $100 | $124 | $155 | $128 | $154 | $183 |
| **S&P 500 Index** | $100 | $129 | $105 | $133 | $166 | $196 |
| **S&P 500 Chemicals Index** | $100 | $126 | $112 | $124 | $124 | $122 |

---

The chart depicts a hypothetical $100 investment in each of Corteva common stock, the S&P 500 Index and the S&P 500 Chemicals Index as of the closing price on December 31, 2020 and illustrates the value of each investment over time (assuming the reinvestment of dividends) until December 31, 2025.

**ITEM 6. [RESERVED]**

Not applicable.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**CAUTIONARY STATEMENTS ABOUT FORWARD-LOOKING STATEMENTS** 

This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; the anticipated benefits, impacts, and timing of the Proposed Separation; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond the company's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the company's business, results of operations and financial condition. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of the company's products; (ii) failure to successfully develop and commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) effect of changes in agricultural and related policies of governments and international organizations; (vi) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vii) effect of climate change and unpredictable seasonal and weather factors; (viii) effect of competition in the company's industry; (ix) competitor's establishment of an intermediary platform for distribution of the company's products; (x) risks related to recent funding and staff reductions at U.S. government agencies; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in the company's input costs; (xiii) risks related to the company's global operations; (xiv) effect of industrial espionage and other disruptions to the company's supply chain, information technology or network systems; (xv) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the Corteva Separation; (xvi) impact of the company's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xvii) failure of the company's customers to pay their debts to the company, including customer financing programs; (xviii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xix) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to the company; (xx) increases in pension and other post-employment benefit plan funding obligations; (xxi) risks related to pandemics or epidemics; (xxii) capital markets sentiment towards sustainability matters; (xxiii) the company's intellectual property rights or defense against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) the company's dependence on intellectual property cross-license agreements; and (xxvi) risks related to Corteva's Separation from DowDuPont; and (xxvii) risks related to Corteva's Proposed Separation, including, but not limited to, whether the objectives of the proposed separation will be achieved; the terms, structure, benefits and costs of any action or transaction resulting from the proposed separation; the timing of any such separation or related action and whether any such separation will be consummated at all; the risk that the proposed separation could divert the attention and time of the company's management; the risk of any unexpected costs or expenses resulting from the proposed separation process or separation itself; and the risk of any litigation as a result of, or relating to, the Proposed Separation.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled "Risk Factors" (Part I, Item 1A of this Form 10-K).

**Overview**

The following is a summary of results from continuing operations for the year ended December 31, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** The company reported net sales of $17,401 million, an increase of 3 percent versus the year ended December 31, 2024, reflecting a 1 percent increase in price and a 3 percent increase in volume, partially offset by a 1 percent unfavorable currency impact.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cost of goods sold ("COGS") totaled $9,172 million, down from $9,529 million for the year ended December 31, 2024, primarily driven by ongoing cost and productivity actions, raw material deflation, lower commodity prices, and a reduction in net royalty expense, with a partial offset from higher volumes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Restructuring and asset related charges - net were $146 million, a decrease from $288 million for the year ended December 31, 2024. The charges for the year ended December 31, 2025 primarily relate to asset related charges, severance and related benefit costs, contract termination charges, and decommissioning and demolition costs associated with the Crop Protection Operations Strategy Restructuring Program.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Income from continuing operations after income taxes was $1,204 million, as compared to $863 million for the year ended December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA was $3,848 million, up from $3,376 million for the year ended December 31, 2024, primarily driven by volume growth, favorable Seed price and product mix, ongoing cost and productivity benefits and net royalty improvement, partially offset by continued investment in research and development, additional commissions and compensation expense, competitive Crop Protection pricing and unfavorable currency effects. See page 44 for further discussion of the company's Non-GAAP financial measures.

In addition to the financial highlights above, the following events occurred during the year ended December 31, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** The company returned approximately $1.5 billion to shareholders during the year ended December 31, 2025 under its previously announced share repurchase programs and through common stock dividends.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On July 29, 2025, the company's Board of Directors approved an approximately 6 percent increase in the quarterly common stock dividend from $0.17 per share to $0.18 per share.

**Priorities**

The company believes the following priorities will continue to create significant value for its customers and shareholders over the mid-term:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Focus on Execution*** – the company will focus on a value creation framework including: (1) the delivery of top tier technology in our prioritized core markets and crops with a continued focus on differentiation and yield advantage; (2) a continued move towards market share gains in Seed trait out-licensing market; (3) operational improvements focused on driving cost and productivity benefits; and (4) completing the intended separation into two industry-leading public companies in the second half of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Deliver Innovation to Farmers, Faster*** – Corteva aims to deliver greater value and productivity to growers through more differentiated and sustainably advantaged solutions, which in turn promise to strengthen global food security and help farmers address the impacts of climate change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Deploy capital with discipline*** – the company aims to prioritize investment, organic and inorganic growth, and returning cash to shareholders.

**Recent Developments**

On October 1, 2025, the company announced its intent to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies, in a transaction that is intended to be a tax-free spin-off for U.S. federal income tax purposes.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Analysis of Operations** 

***Crop Protection Operations Strategy Restructuring Program***

On November 5, 2023, management of the company approved a plan to further optimize its Crop Protection network of manufacturing and external partners (the "Crop Protection Operations Strategy Restructuring Program"). The plan includes the exit of the company's production activities at its site in Pittsburg, California, as well as ceasing operations in select manufacturing lines at other locations. In October 2024, management of the company amended the Crop Protection Operations Strategy Restructuring Program to include updates to its previous estimates and decommissioning and demolition costs associated with the ceasing of operations, primarily at the Pittsburg, California site.

The company expects to record aggregate pre-tax restructuring and asset related charges of $650 million to $700 million, comprised of $85 million to $105 million of severance and related benefit costs, $320 million to $340 million of asset-related and impairment charges, and $245 million to $255 million of costs related to exiting the company's production activities and ceasing operations (inclusive of decommissioning and demolition costs and contract terminations). Decommissioning and demolition costs are expensed on an as-incurred basis. Reductions in workforce are subject to local regulatory requirements. Through the year ended December 31, 2025, the company recorded net pre-tax restructuring and asset related charges of $611 million inception-to-date under the Crop Protection Operations Strategy Restructuring Program, consisting of $102 million of severance and related benefit costs, $340 million of asset-related and impairment charges, $70 million of decommissioning and demolition costs and $99 million of costs related to contract terminations.

Cash payments related to these charges are anticipated to be $330 million to $360 million, which primarily relate to the payment of severance and related benefits, decommissioning and demolition costs and contract terminations. Through December 31, 2025, the company paid $177 million associated with these charges. The restructuring actions associated with these charges are expected to be substantially complete by the end of 2026.

The Crop Protection Operations Strategy Restructuring Program is expected to contribute to the company's ongoing cost and productivity improvement efforts through achieving an estimated $180 million of savings on a run rate basis by 2027. Future actions by the company or changes in circumstances from current assumptions, including any site disposition gains or losses, may cause actual results and future cash payments to differ. See Note 5 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements, for additional information.

***Share Buyback Plan***

On November 19, 2024, Corteva, Inc. announced that its Board of Directors authorized a $3 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2024 Share Buyback Plan"). The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. In connection with the 2024 Share Buyback Plan, the company repurchased and retired 8,318,000 shares in the open market for a cost (excluding excise taxes) of $571 million during the year ended December 31, 2025.

On September 13, 2022, Corteva, Inc. announced that its Board of Directors authorized a $2 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2022 Share Buyback Plan"). The company completed the 2022 Share Buyback Plan during the second quarter of 2025 and repurchased and retired 7,815,000, 17,909,000 and 10,026,000 shares in the open market and through privately-negotiated transactions for a cost (excluding excise taxes) of $500 million, $1 billion and $500 million during the years ended December 31, 2025, 2024 and 2023, respectively.

On August 5, 2021, Corteva, Inc. announced that its Board of Directors authorized a $1.5 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2021 Share Buyback Plan"). The company completed the 2021 Share Buyback Plan during the first quarter of 2023 and repurchased and retired 4,098,000, 17,425,000 and 5,572,000 shares in the open market for a total cost of $250 million, $1 billion and $250 million during the years ended December 31, 2023, 2022 and 2021, respectively.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Results of Operations** 

**Net Sales**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Net sales | $17401 | $16908 | $17226 |

---

***2025 versus 2024***

Net sales were $17,401 million for the year ended December 31, 2025, compared to $16,908 million for the year ended December 31, 2024. The increase was primarily driven by a 1 percent increase in price and a 3 percent increase in volume, partially offset by a 1 percent unfavorable currency impact. Improvements in Crop Protection volume were driven by demand for new products and biologicals, while Seed experienced volume growth primarily due to increased corn area in North America and Brazil. Pricing improvements were driven by Seed, led by North America and EMEA with continued execution on the company's price for value strategy, partially offset by a decline in Crop Protection pricing primarily due to the market dynamics in Latin America. The unfavorable currency impacts were led by the Canadian Dollar and Turkish Lira.

***2024 versus 2023***

Net sales were $16,908 million for the year ended December 31, 2024, compared to $17,226 million for the year ended December 31, 2023. The decrease was primarily driven by a 1 percent decrease in price and a 3 percent unfavorable currency impact, partially offset by a 2 percent increase in volume. Lower pricing reflects the continued competitive price environment in Crop Protection, particularly in Latin America, partially offset by improvement in Seed pricing driven by strong demand for top technology offerings and operational execution globally. Crop Protection volume growth was the result of demand recovery in Latin America and growth of new products. Seed volume growth was driven by the expected recovery in Brazil Safrinha corn and North America soybeans and cotton, which more than offset corn area reduction and challenges in other geographies. The unfavorable currency impacts were led by the Brazilian Real and Turkish Lira.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*($ In millions)* | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
|  | Net Sales | % of Net Sales | Net Sales | % of Net Sales | Net Sales | % of Net Sales |
| Worldwide | $17401 | 100% | $16908 | 100% | $17226 | 100% |
| &nbsp;&nbsp;&nbsp;North America | 9024 | 52% | 8660 | 51% | 8590 | 50% |
| &nbsp;&nbsp;&nbsp;EMEA | 3110 | 18% | 3124 | 19% | 3367 | 19% |
| &nbsp;&nbsp;&nbsp;Latin America | 3928 | 22% | 3776 | 22% | 3906 | 23% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | 1339 | 8% | 1348 | 8% | 1363 | 8% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2025 vs. 2024** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| | **Net Sales Change** | | | | |
|<br>*($ In millions)* | $**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| North America | 4% | 2% | 3% | (1)% | —% |
| EMEA | —% | 2% | —% | (2)% | —% |
| Latin America | 4% | (3)% | 7% | —% | —% |
| Asia Pacific | (1)% | 2% | —% | (2)% | (1)% |
| Total | 3% | 1% | 3% | (1)% | —% |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2024 vs. 2023** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| | **Net Sales Change** | | | | |
|<br>*($ In millions)* | $**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| North America | 1% | 1% | —% | —% | —% |
| EMEA | (7)% | 5% | (7)% | (3)% | (2)% |
| Latin America | (3)% | (12)% | 16% | (8)% | 1% |
| Asia Pacific | (1)% | 2% | (1)% | (2)% | —% |
| Total | (2)% | (1)% | 2% | (3)% | —% |

---

**Cost of Goods Sold ("COGS")**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Cost of goods sold | $9172 | $9529 | $9920 |

---

***2025 versus 2024***

COGS was $9,172 million (53 percent of net sales) for the year ended December 31, 2025 compared to $9,529 million (56 percent of net sales) for the year ended December 31, 2024. The decrease was primarily driven by ongoing cost and productivity actions, a reduction in net royalty expense, lower commodity prices and raw material deflation, with a partial offset from higher volumes.

***2024 versus 2023***

COGS was $9,529 million (56 percent of net sales) for the year ended December 31, 2024 compared to $9,920 million (58 percent of net sales) for the year ended December 31, 2023. The decrease was primarily driven by favorable currency effects, ongoing cost and productivity actions, Crop Protection raw material deflation, and a reduction in net royalty expense, partially offset by an increase in volumes and higher commodity costs.

**Research and Development Expense ("R&D")**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Research and development expense | $1474 | $1402 | $1337 |

---

***2025 versus 2024***

R&D expense was $1,474 million (8 percent of net sales) for the year ended December 31, 2025 and $1,402 million (8 percent of net sales) for the year ended December 31, 2024. The increase in R&D expense is in support of the company's long-term growth plans and was primarily driven by higher employee compensation costs due to variable compensation increases, as well as higher contractor, consulting and field, lab and facilities costs.

***2024 versus 2023***

R&D expense was $1,402 million (8 percent of net sales) for the year ended December 31, 2024 and $1,337 million (8 percent of net sales) for the year ended December 31, 2023. The increase in R&D expense is in support of the company's long-term growth plans and was primarily driven by an increase in salaries due to higher headcount, variable compensation and contractor costs, partially offset by favorable currency impacts.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Selling, General and Administrative Expenses ("SG&A")**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Selling, general and administrative expenses | $3492 | $3196 | $3176 |

---

***2025 versus 2024***

SG&A expenses were $3,492 million (20 percent of net sales) for the year ended December 31, 2025 and $3,196 million (19 percent of net sales) for the year ended December 31, 2024. The increase was primarily driven by an increase in commissions, variable compensation, bad debt expense, legal support fees and personnel and information technology costs, partially offset by favorable currency impacts.

***2024 versus 2023***

SG&A expenses were $3,196 million (19 percent of net sales) for the year ended December 31, 2024 and $3,176 million (18 percent of net sales) for the year ended December 31, 2023. The increase was primarily driven by an increase in salaries and variable compensation, commissions, bad debt expense, legal support fees and portfolio impact from the Stoller and Symborg acquisitions, partially offset by favorable currency impacts and lower consulting and professional fees and marketing costs.

**Amortization of Intangibles**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Amortization of intangibles | $644 | $685 | $683 |

---

***2025 versus 2024***

Intangible asset amortization was $644 million for the year ended December 31, 2025 and $685 million for the year ended December 31, 2024. The decrease was primarily driven by lower amortization on certain intangible assets arising from the Merger that became fully amortized in 2024.

***2024 versus 2023***

Intangible asset amortization was $685 million for the year ended December 31, 2024 and $683 million for the year ended December 31, 2023. The increase was primarily driven by the impact of amortization relating to the intangible assets recognized in connection with the Stoller and Symborg acquisitions, which were completed on March 1, 2023, partially offset by lower amortization on certain intangible assets arising from the Merger that became fully amortized in 2024.

See Note 12 - Goodwill and Other Intangible Assets, to the Consolidated Financial Statements, for additional information.

**Restructuring and Asset Related Charges - Net**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Restructuring and asset related charges - net | $146 | $288 | $336 |

---

***2025***

Restructuring and asset related charges - net were $146 million for the year ended December 31, 2025, which was primarily comprised of a $150 million charge associated with the Crop Protection Operations Strategy Restructuring Program consisting of $11 million of severance and related benefit costs, $13 million of asset related charges, $60 million in decommissioning and demolition costs and $66 million of contract termination charges.

***2024***

Restructuring and asset related charges - net were $288 million for the year ended December 31, 2024, which was primarily comprised of a $232 million charge associated with the Crop Protection Operations Strategy Restructuring Program and a $55 million net charge from non-cash accelerated prepaid royalty amortization expense related to the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. The $232 million charge associated with the Crop Protection Operations

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

Strategy Restructuring Program was primarily comprised of $91 million of severance and related benefit costs, $101 million of asset related charges, $10 million in decommissioning and demolition costs and $30 million of contract termination charges.

***2023***

Restructuring and asset related charges - net were $336 million for the year ended December 31, 2023, which was primarily comprised of a $217 million charge related to the Crop Protection Operations Strategy Restructuring Program, a $72 million net charge related to non-cash accelerated prepaid royalty amortization expense related to the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits and $42 million related to severance and related benefit costs, asset related charges and contract termination charges (including early lease terminations) associated with the 2022 Restructuring Actions. The $217 million net charge associated with the Crop Protection Operations Strategy Restructuring Program was primarily comprised of $214 million of asset related charges, which includes non-cash impairment charges of $152 million consisting of $92 million and $60 million related to operating lease assets and property, plant and equipment, respectively, associated with the exit of the company's production activities at its site in Pittsburg, California.

See Note 5 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements, for additional information.

**Other Income (Expense) - Net**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Other income (expense) - net | $(570) | $(300) | $(448) |

---

***2025 versus 2024***

Other income (expense) - net was $(570) million and $(300) million for the years ended December 31, 2025 and 2024, respectively. Higher other expense was primarily driven by the resolution of litigation matters and the one-time receipt of an indemnification payment negotiated with the former Stoller owners during the first quarter of 2024. These increases were partially offset by the receipt of insurance proceeds, the absence of charges related to estimated settlement reserves, a more favorable net exchange loss, a favorable tax indemnification adjustment and lower non-operating pension and OPEB costs.

***2024 versus 2023***

Other income (expense) - net was $(300) million and $(448) million for the years ended December 31, 2024 and 2023, respectively. Lower other expense was primarily driven by decreases in net exchange losses and charges related to estimated settlement reserves, as well as the receipt of insurance proceeds and an indemnification payment negotiated with the former Stoller owners, partially offset by a decrease in interest income.

See Note 6 - Supplementary Information, to the Consolidated Financial Statements, for additional information.

**Interest Expense**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Interest expense | $180 | $233 | $233 |

---

***2025 versus 2024***

Interest expense was $180 million and $233 million for the years ended December 31, 2025 and 2024, respectively. The change was primarily driven by lower short-term borrowings and lower interest rates.

***2024 versus 2023***

Interest expense was $233 million and $233 million for the years ended December 31, 2024 and 2023, respectively. The impact of lower short-term borrowings and lower interest rates was offset by higher interest related to the senior notes issued in 2023 and higher foreign currency borrowings.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Provision for (Benefit from) Income Taxes on Continuing Operations** 

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Provision for (benefit from) income taxes on continuing operations | $484 | $412 | $152 |
| Effective tax rate | 28.7% | 32.3% | 13.9% |

---

***2025*** For the year ended December 31, 2025, the company's effective tax rate of 28.7 percent on pre-tax income from continuing operations of $1,688 million was unfavorably impacted by a $132 million charge on the establishment of a valuation allowance recorded against the net deferred tax asset position of a legal entity in Brazil, unfavorable geographic mix of earnings, a $27 million charge associated with repatriation of cash held outside of the U.S. primarily from current year earnings, and the unfavorable tax impact of certain net exchange losses recognized on the re-measurement of the net monetary asset positions. These items were partially offset by a $(55) million deferred tax benefit associated with a change in a legal entity's U.S. tax characterization, a $(47) million benefit related to U.S. tax credits for increasing research activities, a $(29) million benefit related to a capital loss (net of valuation allowance), as well as net tax benefits associated with changes in accruals for certain prior year tax positions.

***2024***

For the year ended December 31, 2024, the company's effective tax rate of 32.3 percent on pre-tax income from continuing operations of $1,275 million was unfavorably impacted by a $120 million charge on the establishment of a valuation allowance recorded against the net deferred tax asset position of a legal entity in Brazil, unfavorable geographic mix of earnings, a $22 million charge associated with repatriation of cash held outside of the U.S. primarily from current year earnings, and the unfavorable tax impact of certain net exchange losses recognized on the re-measurement of the net monetary asset positions. These items were partially offset by a $(59) million benefit related to U.S. tax credits for increasing research activities and $(32) million in net tax benefits associated with changes to deferred taxes and accruals for certain prior year tax positions.

***2023***

For the year ended December 31, 2023, the company's effective tax rate of 13.9 percent on pre-tax income from continuing operations of $1,093 million was favorably impacted by a $(65) million benefit related to U.S. tax credits for increasing research activities, changes to deferred taxes and a tax currency change for legal entities within Switzerland in the amount of $(62) million and $(24) million, respectively, as well as favorable geographic mix of earnings. These items were partially offset by the unfavorable tax impact of certain net exchange losses recognized on the re-measurement of the net monetary asset positions, which were not deductible in their local jurisdictions, a $46 million charge associated with intellectual property realignment, and a $32 million charge associated with repatriation of cash held outside of the U.S. primarily from current year earnings.

**Income (Loss) from Discontinued Operations After Income Taxes**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from discontinued operations after income taxes | $(99) | $56 | $(194) |

---

***2025***

Income (loss) from discontinued operations after income taxes was $(99) million for the year ended December 31, 2025. The after-tax charge was driven by charges recognized relating to the MOU with Chemours and DuPont, including a charge associated with the NJ Statewide Settlement as well as PFAS environmental remediation activities primarily at Chemours' Fayetteville Works facility, along with other environmental matters.

***2024***

Income (loss) from discontinued operations after income taxes was $56 million for the year ended December 31, 2024. The after-tax benefit was driven by charges pursuant to the MOU with Chemours and DuPont relating to PFAS remediation activities primarily at Chemours' Fayetteville Works facility and litigation activity, which were more than offset by a favorable adjustment of certain prior year tax positions for previously divested businesses, the derecognition of an indemnification liability associated with the Water District Settlement Fund contribution, and insurance proceeds related to legacy matters.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

***2023***

Income (loss) from discontinued operations after income taxes was $(194) million for the year ended December 31, 2023, which was primarily comprised of charges associated with the settlement of certain PFAS related legal matters that are subject to the MOU with Chemours and DuPont, including the Nationwide Water District Settlement and the State of Ohio for natural resources damage claims, and charges associated with PFAS environmental remediation activities primarily at Chemours' Fayetteville Works facility.

See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for further discussion.

**EIDP Analysis of Operations**

As discussed in EIDP Note 1 - Basis of Presentation, to the EIDP Consolidated Financial Statements, EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The below relates to EIDP only and is presented to provide an Analysis of Operations, only for the differences between EIDP and Corteva, Inc.

**Other Income (Expense) - Net**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Other income (expense) - net | $(570) | $(261) | $(448) |

---

***2025 versus 2024***

Other income (expense) - net was $(570) million and $(261) million for the years ended December 31, 2025 and 2024, respectively. Higher other expense was primarily driven by the items noted on page 36, under the header "Other Income (Expense) – Net – 2025 versus 2024." See EIDP Note 2 - Related Party Transactions, to the EIDP Consolidated Financial Statements, for further information.

***2024 versus 2023***

Other income (expense) - net was $(261) million and $(448) million for the years ended December 31, 2024 and 2023, respectively. Lower other expense was primarily driven by the items noted on page 36, under the header "Other Income (Expense) – Net – 2024 versus 2023." In addition, EIDP earned interest income from Corteva, Inc. of $38 million under the Master In-House Banking Agreement for the year ended December 31, 2024. See EIDP Note 2 - Related Party Transactions, to the EIDP Consolidated Financial Statements, for further information.

**Interest Expense**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Interest expense | $180 | $233 | $253 |

---

***2025 versus 2024***

EIDP's interest expense was $180 million and $233 million for the years ended December 31, 2025 and 2024, respectively. The change was primarily driven by the items noted on page 36, under the header "Interest Expense – 2025 versus 2024."

***2024 versus 2023***

EIDP's interest expense was $233 million and $253 million for the years ended December 31, 2024 and 2023, respectively. The change was primarily driven by the items noted on page 36, under the header "Interest Expense – 2024 versus 2023," and lower average borrowings on the related party loan between EIDP and Corteva, Inc., as the loan was repaid in the fourth quarter of 2023. See Note 2 - Related Party Transactions, to the EIDP Consolidated Financial Statements, for further information.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Provision for (Benefit from) Income Taxes on Continuing Operations**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Provision for (benefit from) income taxes on continuing operations | $484 | $421 | $147 |
| Effective tax rate | 28.7% | 32.0% | 13.7% |

---

***2025***

For the year ended December 31, 2025, EIDP had an effective tax rate of 28.7 percent on pre-tax income from continuing operations of $1,688 million, driven by the items noted on page 37, under the header "Provision for (Benefit from) Income Taxes on Continuing Operations - 2025". See Note 3 - Income Taxes, to the EIDP Consolidated Financial Statements, for further information.

***2024***

For the year ended December 31, 2024, EIDP had an effective tax rate of 32.0 percent on pre-tax income from continuing operations of $1,314 million, driven by the items noted on page 37, under the header "Provision for (Benefit from) Income Taxes on Continuing Operations - 2024." See Note 3 - Income Taxes, to the EIDP Consolidated Financial Statements, for further information.

***2023***

For the year ended December 31, 2023, EIDP had an effective tax rate of 13.7 percent on pre-tax income from continuing operations of $1,073 million, driven by the items noted on page 37, under the header "Provision for (Benefit from) Income Taxes on Continuing Operations - 2023" and a tax benefit related to the interest expense incurred on the related party loan between EIDP and Corteva, Inc. See Note 3 - Income Taxes, to the EIDP Consolidated Financial Statements, for further information.

**Recent Accounting Pronouncements**

See Note 3 - Recent Accounting Guidance, to the Consolidated Financial Statements, for a description of recent accounting pronouncements.

**Segment Reviews** 

The company operates in two reportable segments: Seed and Crop Protection. The company's Seed segment is a global leader in developing and supplying commercial seed combining superior germplasm with advanced traits to produce high yield potential for farmers around the world. The segment offers seed and trait technologies that improve resistance to weather, diseases, pests and herbicides used to manage weeds. Its digital solutions provide data driven insights that assist farmer decision-making with a view to optimize product selection and, ultimately, help maximize yield and profitability. The segment competes in a wide variety of agricultural markets. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment offers crop protection solutions and digital solutions that provide farmers the tools they need to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The segment is a leader in global herbicides, insecticides, nitrogen stabilizers, pasture and range management herbicides and biologicals.

Summarized below are comments on individual segment net sales and segment operating EBITDA for the years ended December 31, 2025, 2024 and 2023. The company defines segment operating EBITDA as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. See Note 22 - Segment Information, to the Consolidated Financial Statements, for details related to significant pre-tax benefits (costs) excluded from segment operating EBITDA. All references to prices are based on local price unless otherwise specified.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

A reconciliation of segment operating EBITDA to income (loss) from continuing operations after income taxes for the years ended December 31, 2025, 2024 and 2023 is included in Note 22 - Segment Information, to the Consolidated Financial Statements.

---

| | | | |
|:---|:---|:---|:---|
| **Seed** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Net sales | $9898 | $9545 | $9472 |
| Segment operating EBITDA | $2636 | $2219 | $2117 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2025 vs. 2024** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Seed**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;North America | 4% | 2% | 2% | —% | —% |
| &nbsp;&nbsp;&nbsp;EMEA | (1)% | 5% | (1)% | (5)% | —% |
| &nbsp;&nbsp;&nbsp;Latin America | 6% | 2% | 3% | 1% | —% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | 11% | 7% | 7% | (3)% | —% |
| **Total** | 4% | 3% | 2% | (1)% | —% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2025 vs. 2024** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Seed**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;Corn | 8% | 3% | 6% | (1)% | —% |
| &nbsp;&nbsp;&nbsp;Soybeans | (3)% | 2% | (4)% | (1)% | —% |
| &nbsp;&nbsp;&nbsp;Other oilseeds | (1)% | 3% | (1)% | (3)% | —% |
| &nbsp;&nbsp;&nbsp;Other | (20)% | 1% | (20)% | (1)% | —% |
| **Total** | 4% | 3% | 2% | (1)% | —% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2024 vs. 2023** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Seed**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;North America | 5% | 4% | 1% | —% | —% |
| &nbsp;&nbsp;&nbsp;EMEA | (3)% | 9% | (3)% | (5)% | (4)% |
| &nbsp;&nbsp;&nbsp;Latin America | (7)% | (7)% | 8% | (8)% | —% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | (8)% | 9% | (15)% | (2)% | —% |
| **Total** | 1% | 3% | 1% | (2)% | (1)% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2024 vs. 2023** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Seed**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;Corn | 1% | 2% | 2% | (3)% | —% |
| &nbsp;&nbsp;&nbsp;Soybeans | 4% | 2% | 2% | —% | —% |
| &nbsp;&nbsp;&nbsp;Other oilseeds | (8)% | 8% | (7)% | (4)% | (5)% |
| &nbsp;&nbsp;&nbsp;Other | 2% | 8% | (5)% | (1)% | —% |
| **Total** | 1% | 3% | 1% | (2)% | (1)% |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Seed**

Seed net sales were $9,898 million in 2025, up 4 percent from $9,545 million in 2024. The sales increase was driven by a 3 percent increase in price and a 2 percent increase in volume, partially offset by a 1 percent unfavorable currency impact.

Pricing gains in most regions, led by North America, demonstrate demand for top technology and the strength of the portfolio, coupled with increased out-licensing income. Volume growth was driven primarily by increased corn area and share gains in North America and Brazil, partially offset by lower soybean area in North America. The unfavorable currency impacts were led by the Turkish Lira and Canadian Dollar.

Seed operating EBITDA was $2,636 million in 2025, up 19 percent from $2,219 million in 2024. Commercial execution and market share gains in North America and Brazil, product mix, reduction of net royalty expense and ongoing cost and productivity actions more than offset increased compensation, research and development expense, bad debt expense, selling expenses and the unfavorable impact of currency. Segment operating EBITDA margin improved by approximately 340 basis points versus the prior-year period.

Seed net sales were $9,545 million in 2024, up 1 percent from $9,472 million in 2023. The sales increase was driven by a 3 percent increase in price and 1 percent increase in volume partially offset by a 2 percent unfavorable currency impact and a 1 percent unfavorable portfolio impact.

The increase in price was driven by improvement in many products in all regions, excluding Latin America. Global corn and soybean pricing were up 2 percent. Pricing actions more than offset currency impacts in EMEA. Volume growth was driven primarily by the expected recovery in Brazil Safrinha corn and growth in North America soybeans and cotton, partially offset by reduced planted areas in EMEA, Asia Pacific and corn in Argentina. Unfavorable currency impacts were led by the Brazilian Real and Turkish Lira.

Seed operating EBITDA was $2,219 million in 2024, up 5 percent from $2,117 million in 2023. Price execution and market share gains in North America, reduction of net royalty expense and ongoing cost and productivity actions more than offset the investment in R&D, higher commodity costs, and the unfavorable impact of currency. Segment operating EBITDA margin improved by approximately 90 basis points versus the prior-year period.

---

| | | | |
|:---|:---|:---|:---|
| **Crop Protection** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Net sales | $7503 | $7363 | $7754 |
| Segment operating EBITDA | $1350 | $1272 | $1374 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2025 vs. 2024** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Crop Protection**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;North America | 5% | 1% | 4% | —% | —% |
| &nbsp;&nbsp;&nbsp;EMEA | —% | —% | 1% | (1)% | —% |
| &nbsp;&nbsp;&nbsp;Latin America | 3% | (7)% | 11% | (1)% | —% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | (6)% | —% | (4)% | (1)% | (1)% |
| **Total** | 2% | (2)% | 5% | (1)% | —% |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2025 vs. 2024** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Crop Protection**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;Herbicides | 4% | —% | 4% | —% | —% |
| &nbsp;&nbsp;&nbsp;Insecticides | (3)% | (4)% | 2% | (1)% | —% |
| &nbsp;&nbsp;&nbsp;Fungicides | 5% | —% | 7% | (1)% | (1)% |
| &nbsp;&nbsp;&nbsp;Biologicals | 9% | (7)% | 16% | —% | —% |
| &nbsp;&nbsp;&nbsp;Other | (10)% | (6)% | (3)% | (1)% | —% |
| **Total** | 2% | (2)% | 5% | (1)% | —% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2024 vs. 2023** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Crop Protection**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;North America | (7)% | (3)% | (4)% | —% | —% |
| &nbsp;&nbsp;&nbsp;EMEA | (12)% | 1% | (10)% | (3)% | —% |
| &nbsp;&nbsp;&nbsp;Latin America | (1)% | (15)% | 21% | (8)% | 1% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | 2% | (1)% | 6% | (3)% | —% |
| **Total** | (5)% | (5)% | 3% | (3)% | —% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2024 vs. 2023** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Crop Protection**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;Herbicides | (11)% | (5)% | (4)% | (2)% | —% |
| &nbsp;&nbsp;&nbsp;Insecticides | 7% | (5)% | 17% | (5)% | —% |
| &nbsp;&nbsp;&nbsp;Fungicides | (3)% | (9)% | 12% | (6)% | —% |
| &nbsp;&nbsp;&nbsp;Biologicals | (3)% | (8)% | 6% | (7)% | 6% |
| &nbsp;&nbsp;&nbsp;Other | (5)% | —% | (3)% | (2)% | —% |
| **Total** | (5)% | (5)% | 3% | (3)% | —% |

---

**Crop Protection** 

Crop Protection net sales were $7,503 million in 2025, up 2 percent from $7,363 million in 2024. The sales increase was driven by a 5 percent increase in volume, partially offset by a 2 percent decrease in price and a 1 percent unfavorable impact from currency.

Volume growth was driven by demand for new products, herbicides and biologicals, while price declined primarily due to market dynamics in Latin America, partially offset by North America price increases. The unfavorable currency impacts were led by the Turkish Lira and Brazilian Real.

Segment operating EBITDA was $1,350 million in 2025, up 6 percent from $1,272 million from 2024. Raw material deflation, productivity savings and volume growth more than offset the unfavorable impact from currency, price pressure and higher compensation and bad debt expense. Segment operating EBITDA margin improved by approximately 70 basis points versus the prior-year period.

Crop Protection net sales were $7,363 million in 2024, down 5 percent from $7,754 million in 2023. The sales decrease was driven by a 5 percent decrease in price and a 3 percent unfavorable impact from currency, partially offset by a 3 percent increase in volume.

The price decline was primarily due to market dynamics in Latin America. Unfavorable currency impacts were led by the Brazilian Real and Turkish Lira. The increase in volumes was driven by growth in Latin America on demand for new products

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

and spinosyns, partially offset by unfavorable weather impacts in EMEA as well as just-in-time purchasing behavior in North America.

Segment operating EBITDA was $1,272 million in 2024, down 7 percent from $1,374 million in 2023. Pricing pressure and the unfavorable impact of currency more than offset productivity savings, raw material deflation, and volume growth. Segment operating EBITDA margin contracted by approximately 45 basis points versus the prior-year period.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Non-GAAP Financial Measures**

The company presents certain financial measures that do not conform to U.S. GAAP and are considered non-GAAP measures. These measures include operating EBITDA and operating earnings (loss) per share. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the company and a more useful comparison of year-over-year results. These non-GAAP measures supplement the company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided below.

Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating earnings (loss) per share is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of separation costs, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Corteva Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

The company also uses Free Cash Flow as a non-GAAP measure to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. Management believes that Free Cash Flow provides investors with meaningful information regarding the company's ongoing ability to generate cash through core operations, and the company's ability to service its indebtedness, pay dividends (when declared), make share repurchases, and meet its ongoing cash needs for its operations.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Reconciliation of Income (Loss) from Continuing Operations after Income Taxes to Operating EBITDA**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from continuing operations after income taxes **(GAAP)** | $1204 | $863 | $941 |
| Provision for (benefit from) income taxes on continuing operations | 484 | 412 | 152 |
| **Income (loss) from continuing operations before income taxes (GAAP)** | $1688 | $1275 | $1093 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1203 | 1227 | 1211 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (136) | (132) | (283) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 180 | 233 | 233 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exchange (gains) losses - net | 181 | 284 | 397 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating (benefits) costs - net | 39 | 174 | 151 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Significant items (benefit) charge | 658 | 315 | 579 |
| &nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 35 |  |  |
| **Operating EBITDA (Non-GAAP)** | $3848 | $3376 | $3381 |

---

**Significant Items**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Restructuring and asset related charges - net | $146 | $288 | $336 |
| Bayer resolution <sup>1</sup> | 610 |  |  |
| Estimated settlement expense <sup>2</sup> |  | 101 | 204 |
| Inventory write-offs <sup>3</sup> |  | (2) | 7 |
| Spare parts write-off <sup>4</sup> |  |  | 12 |
| (Gain) loss on sale of business, assets and equity investments <sup>3,4</sup> | (37) | (7) | (14) |
| Seed sale associated with Russia Exit <sup>3,5</sup> |  |  | (18) |
| Acquisition-related costs <sup>6</sup> |  | 6 | 45 |
| Employee Retention Credit |  |  | (3) |
| AltEn facility remediation charges <sup>7</sup> | 37 |  | 10 |
| Insurance proceeds <sup>8</sup> | (98) | (71) |  |
| **Total pre-tax significant items (benefit) charge** | $658 | $315 | $579 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total tax (benefit) provision impact of significant items <sup>9</sup> | (153) | (80) | (131) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax only significant item (benefit) charge <sup>10</sup> | 77 | 116 | (45) |
| **Total significant items (benefit) charge, after tax** | $582 | $351 | $403 |

---

1. Consists of a charge relating to the resolution of litigation with Bayer. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information.

2. Consists of estimated Lorsban® related charges.

3. Incremental (gains) losses associated with activities related to the 2022 Restructuring Actions. Within (gain) loss on sale of business, assets and equity investments, such benefits are $(14) million, $(7) million and $(14) million for the years ended December 31, 2025, 2024 and 2023, respectively.

4. Incremental (gains) losses associated with activities related to the Crop Protection Operations Strategy Restructuring Program. Within (gain) loss on sale of business, assets and equity investments, a $(23) million benefit was recorded for the year ended December 31, 2025.

5. Includes a benefit of $(18) million for the year ended December 31, 2023, relating to the sale of seeds already under production in Russia when the decision to exit the country was made and that the company was contractually required to purchase. It consists of $71 million of net sales and $53 million of cost of goods sold for the year ended December 31, 2023.

6. Relates to acquisition-related costs, including transaction and third-party integration costs associated with the completed acquisitions of Stoller and Symborg as well as the recognition of the inventory fair value step-up.

7. Relates to a charge to increase the remediation accrual at the AltEn facility relating to Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information.

8. Includes proceeds received related to prior significant items.

9. Unless specifically addressed above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

10. The tax only significant item for the year ended December 31, 2025 relates to the establishment of a valuation allowance recorded against the net deferred tax asset position of a legal entity in Brazil (Crop Protection business) in the amount of $132 million, as well as a deferred tax benefit associated with a change in a legal entity's U.S. tax characterization in the amount of $(55) million. The tax only significant item charge for the year ended December 31, 2024 relates to the establishment of a valuation allowance recorded against the net deferred tax asset position of a legal entity in Brazil (Seed business) in the amount of $120 million, as well as a change in estimate related to intellectual property realignment. The tax only significant item benefit for the year ended December 31, 2023 relates to the impact of changes to deferred taxes and a tax currency change for legal entities within Switzerland of $(62) million and $(24) million, respectively, as well as adjustments due to intellectual property realignment of $46 million and a change in estimate related to a worthless stock deduction in the U.S.

**Reconciliation of Income (Loss) from Continuing Operations Attributable to Corteva and Earnings (Loss) Per Share of Common Stock from Continuing Operations - Diluted to Operating Earnings (Loss) and Operating Earnings (Loss) Per Share**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from continuing operations attributable to Corteva common stockholders **(GAAP)** | $1193 | $851 | $929 |
| Less: Non-operating benefits (costs), after tax | (36) | (127) | (111) |
| Less: Amortization of intangibles (existing as of Corteva Separation), after tax | (434) | (459) | (471) |
| Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax |  |  |  |
| Less: Significant items benefit (charge), after tax | (582) | (351) | (403) |
| Less: Separation costs, after tax | (31) |  |  |
| **Operating Earnings (Loss) (Non-GAAP)** | $2276 | $1788 | $1914 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(Dollars per Share)* | **2025** | **2024** | **2023** |
| Earnings (loss) per share of common stock from continuing operations attributable to Corteva common stockholders - diluted **(GAAP)** | $1.75 | $1.22 | $1.30 |
| Less: Non-operating benefits (costs), after tax | (0.05) | (0.18) | (0.16) |
| Less: Amortization of intangibles (existing as of Corteva Separation), after tax | (0.64) | (0.67) | (0.66) |
| Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax |  |  |  |
| Less: Significant items benefit (charge), after tax | (0.85) | (0.50) | (0.57) |
| Less: Separation costs, after tax | (0.05) |  |  |
| **Operating Earnings (Loss) Per Share (Non-GAAP)** | $3.34 | $2.57 | $2.69 |
| **Diluted Shares Outstanding** *(In millions)* | 681.4 | 696.0 | 711.9 |

---

**Reconciliation of Cash Provided by (Used for) Operating Activities – Continuing Operations to Free Cash Flow**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Cash provided by (used for) operating activities - continuing operations | $3457 | $2296 | $1809 |
| Less: Capital expenditures | (591) | (597) | (595) |
| **Free Cash Flow (Non-GAAP)** | $2866 | $1699 | $1214 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Liquidity & Capital Resources**

The company continually reviews its sources of liquidity and debt portfolio and occasionally may make adjustments to one or both to ensure adequate liquidity.

---

| | | |
|:---|:---|:---|
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| **Cash, cash equivalents and marketable securities** | $4530 | $3169 |
| **Total debt** | $2580 | $2703 |

---

The company's credit ratings impact its access to the debt capital markets and cost of capital. The company remains committed to a strong financial position and strong investment-grade rating. The company's long-term and short-term credit ratings assigned to EIDP are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Long-term** | **Short-term** | **Outlook** |
| Standard & Poor's <sup>1</sup> | A- | A-2 | Watch Negative |
| Moody's Investors Service | Baa1 | P-2 | Watch Negative |
| Fitch Ratings <sup>1</sup> | A | F1 | Watch Negative |

---

1. In addition, Corteva, Inc. has been assigned a long-term issuer credit rating of A- with Watch Negative outlook by Standard & Poor's and an Issuer Default Rating of A with Watch Negative outlook by Fitch Ratings.

The company believes its cash on hand, as well as its ability to generate cash from operations and access to capital markets and commercial paper markets, will be adequate to meet anticipated cash requirements to fund its operations, including seasonal working capital, capital spending, dividend payments, share repurchases, pension obligations and litigation costs, net of recoveries. Corteva's strong financial position, liquidity and credit ratings will provide access as needed to capital markets and commercial paper markets to fund seasonal working capital needs. The company's liquidity needs can be met through a variety of sources, including cash provided by operating activities, commercial paper, syndicated credit lines, bilateral credit lines, long-term debt markets, bank financing and committed receivable repurchase facilities. Corteva considers the borrowing costs and lending terms when selecting the source to fund its operations and working capital needs.

The company had access to approximately $6.2 billion and $6.3 billion at December 31, 2025 and 2024 in committed and uncommitted unused credit lines, which includes the uncommitted revolving credit lines relating to the Foreign Currency Loans. These facilities provide support to meet the company's short-term liquidity needs and for general corporate purposes, which may include funding of discretionary and non-discretionary contributions to certain benefit plans, severance payments, repayment and refinancing of debt, working capital, capital expenditures, repurchases and redemptions of securities, funding of acquisitions and funding Corteva's costs and expenses, including the settlement of litigation. These facilities are provided to the company by highly rated and well capitalized global financial institutions.

In May 2025, the company issued $500 million of 5.125 percent Senior Notes due in May 2032 (the "May 2025 Debt Offering"). The proceeds were used to repay the $500 million senior notes that matured in July 2025.

In May 2023, the company issued $600 million of 4.50 percent Senior Notes due in 2026 and $600 million of 4.80 percent Senior Notes due in 2033 (the "May 2023 Debt Offering").

In January 2023, the company amended and restated its May 2022 364-day revolving credit agreement (the "364-Day Revolving Credit Facility") increasing the facility amount to $1 billion and extending the expiration date to January 2024. Borrowings under the 364-Day Revolving Credit Facility have an interest rate equal to Adjusted Term SOFR, which is Term SOFR plus 0.10 percent, plus the applicable margin. The 364-Day Revolving Credit Facility includes a provision under which the company may convert any advances outstanding prior to the maturity date into term loans having a maturity date up to one year later. In February 2023, the company drew down $1 billion under the 364-Day Revolving Credit Facility, which was used for general corporate purposes, including funding seasonal working capital needs, capital spending, dividend payments, share repurchases and to partially fund the Stoller and Symborg acquisitions. In May 2023, the company repaid the $1 billion loan using the proceeds from the May 2023 Debt Offering and subsequently, in July 2023 reduced the available credit from $1 billion to $500 million. In February 2024, the company amended and restated the 364-Day Revolving Credit Facility, increasing the facility amount to $1 billion and extending the expiration date to February 2025. In February 2025, the company amended and restated the 364-Day Revolving Credit Facility, decreasing the facility amount from $1 billion to $750 million and extending the expiration date to February 2026. In February 2026, the company amended and restated the 364-Day Revolving

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

Credit Facility, increasing the facility amount from $750 million to $1.25 billion, extended the expiration date to February 2027 and amended the interest rate to Term SOFR plus the applicable margin. The 364-Day Revolving Credit Facility contains customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the 364-Day Revolving Credit Facility contains a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At December 31, 2025, the company was in compliance with these covenants.

In May 2022, the company entered into a $3 billion, five year revolving credit facility and a $2 billion, three-year revolving credit facility (the "Revolving Credit Facilities") expiring in May 2027 and May 2025, respectively. In June 2024, the Revolving Credit Facilities were refinanced for purposes of extending the maturity dates for the five-year and three-year revolving credit facilities to June 2029 and June 2027, respectively, and lowering the facility amount of the five-year revolving credit facility to $2.85 billion and the three-year revolving credit facility to $1.9 billion. Borrowings under the Revolving Credit Facilities will have an interest rate equal to Adjusted Term SOFR, which is Term SOFR plus 0.10 percent, plus the applicable margin. The Revolving Credit Facilities may serve as a substitute to the company's commercial paper program, and can be used, from time to time, for general corporate purposes including, but not limited to, the funding of seasonal working capital needs. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the Revolving Credit Facilities contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At December 31, 2025, the company was in compliance with these covenants.

The company enters into short-term and long-term foreign currency loans from time-to-time by accessing uncommitted revolving credit lines to fund working capital needs of foreign subsidiaries in the normal course of business ("Foreign Currency Loans"). Interest rates are variable and determined at the time of borrowing. Total unused bank credit lines on the Foreign Currency Loans at December 31, 2025 was approximately $86 million. The company's long-term Foreign Currency Loans are maturing in March 2026.

The company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations affecting manufacturing plants, mineral producing properties or research facilities located in the U.S. and the consolidated subsidiaries owning such plants, properties and facilities subject to certain limitations. The outstanding long-term debt also contains customary default provisions.

In September 2023 and in accordance with the Nationwide Water District Settlement, Chemours, DuPont and Corteva established a settlement fund (the "Water District Settlement Fund") and collectively contributed $1.185 billion, with Chemours contributing 50 percent, and DuPont and Corteva collectively contributing the remaining 50 percent pursuant to the terms of the Letter Agreement. The settling companies utilized the balance in the MOU Escrow Account, along with amounts previously expected to be contributed to the MOU Escrow Account in 2023, among other sources, to make their respective contributions to the Water District Settlement Fund. In April 2024, the settlement was deemed final resulting in the release of the previously restricted cash in the Water District Settlement Fund and derecognition of the associated liability. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information.

The company has meaningful seasonal working capital needs based in part on providing financing to its customers. Working capital is funded through multiple methods including cash, commercial paper, the Revolving Credit Facilities, the 364-Day Revolving Credit Facility, and factoring.

In May 2023, in line with seasonal working capital requirements, the company entered into a committed receivable repurchase facility of up to $500 million (the "2023 Repurchase Facility") which expired in December 2023. Under the 2023 Repurchase Facility, Corteva sold a portfolio of available and eligible outstanding customer notes receivables to participating institutions and simultaneously agreed to repurchase at a future date.

The company has factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds in an effort to reduce its receivables risk. For arrangements that include an element of recourse, the company provides a guarantee of the trade receivables in the event of customer default. See Note 9 - Accounts and Notes Receivable - Net, to the Consolidated Financial Statements, for additional information.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

The company also organizes agreements with third-party financial institutions that directly provide financing for select customers of its seed and crop protection products in each region. Terms of the third-party loans are less than a year and programs are renewed on an annual basis. In some cases, the company guarantees a portion of the extension of such credit to such customers. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for more information on the company's guarantees.

The company's cash, cash equivalents and marketable securities at December 31, 2025 and 2024 are $4.5 billion and $3.2 billion, respectively, of which $2.1 billion and $1.7 billion, respectively, was held by subsidiaries in foreign countries, including United States territories. Cash, cash equivalents and marketable securities are concentrated subject to local restrictions with highly rated and well capitalized global financial institutions. The underlying credit worthiness and exposures to these counterparties are monitored on a regular basis in line with the company's overall risk management procedures. Upon actual repatriation, such earnings could be subject to withholding taxes, foreign and/or U.S. state income taxes, and taxes resulting from the impact of foreign currency movements. The cash held by foreign subsidiaries is generally used to finance the subsidiaries' operational activities and future foreign investments. At December 31, 2025, management believed that sufficient liquidity is available in the United States with global operating cash flows, borrowing capacity from existing committed credit facilities, and access to capital markets and commercial paper markets.

*Summary of Cash Flows*

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Cash provided by (used for) operating activities – continuing operations | $3457 | $2296 | $1809 |

---

Cash provided by (used for) operating activities – continuing operations for the year ended December 31, 2025 was $3,457 million compared to $2,296 million for the year ended December 31, 2024. The change was primarily driven by higher net income, favorable changes in customer prepayments and collections, and favorable changes in accounts payable due to lower payments to third-party growers resulting from lower commodity costs and planted area, partially offset by an unfavorable change in inventories due to a lower comparable decline in volumes and the sale of lower-cost inventory in the current year.

Cash provided by (used for) operating activities – continuing operations for the year ended December 31, 2024 was $2,296 million compared to $1,809 million for the year ended December 31, 2023. The change was primarily driven by favorable changes in working capital. The favorable changes in inventories were driven by production reductions to match demand. Within accounts payable, lower payments to third-party growers resulted from lower commodity costs and production plans, supplemented by a change in inventory purchasing patterns. Accrued and other current liabilities benefited from a decrease in soybean royalties, while noncurrent assets and liabilities benefited from derivative settlements driven by a weaker Brazilian Real currency. These movements were partially offset by unfavorable changes in receivables driven by slower collections and higher sales on credit terms.

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Cash provided by (used for) operating activities – discontinued operations | $(51) | $(151) | $(40) |

---

Cash provided by (used for) operating activities – discontinued operations for the years ended December 31, 2025 and 2024 was $(51) million and $(151) million, respectively. The cash outflows were primarily related to PFAS activities that are subject to the MOU with Chemours and DuPont associated with environmental remediation activities primarily at Chemours' Fayetteville Works facility. In addition, the disbursement of cash held in the Water District Settlement Fund is reflected in the year ended December 31, 2024.

Cash provided by (used for) operating activities – discontinued operations for the years ended December 31, 2024 and 2023 was $(151) million and $(40) million, respectively. The cash outflows were primarily related to PFAS activities that are subject to the MOU with Chemours and DuPont associated with environmental remediation activities primarily at Chemours' Fayetteville Works facility. In addition, the disbursement of the cash held in the Water District Settlement Fund is reflected in the year ended December 31, 2024. These outflows were partially offset by the receipt of insurance proceeds related to legacy matters.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Cash provided by (used for) investing activities | $(543) | $(589) | $(1987) |

---

Cash provided by (used for) investing activities was $(543) million for the year ended December 31, 2025 compared to $(589) million for the year ended December 31, 2024. The change was primarily due to lower purchases of investments and proceeds from sales of property, partially offset by higher payments to settle net investment hedges.

Cash provided by (used for) investing activities was $(589) million for the year ended December 31, 2024 compared to $(1,987) million for the year ended December 31, 2023. The change was primarily due to the acquisitions of Stoller and Symborg in 2023, partially offset by lower current year proceeds from sales and maturities of investments and higher proceeds from sales of property, businesses, and consolidated companies in 2023.

Capital expenditures totaled $591 million, $597 million, and $595 million for the years ended December 31, 2025, 2024 and 2023, respectively. The company expects 2026 capital expenditures to be approximately $600 million.

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Cash provided by (used for) financing activities | $(1644) | $(1199) | $(99) |

---

Cash provided by (used for) financing activities was $(1,644) million for the year ended December 31, 2025 compared to $(1,199) million for the year ended December 31, 2024. The change was primarily due to lower borrowings in 2025, and higher dividend payments and share repurchases.

Cash provided by (used for) financing activities was $(1,199) million for the year ended December 31, 2024 compared to $(99) million for the year ended December 31, 2023. The change was primarily due lower required borrowings in 2024 to fund working capital needs, capital spending, dividend payments and share repurchases. In addition, there were additional borrowings in 2023 to partially fund the Stoller and Symborg acquisitions. These lower current year borrowings were offset by higher payments on debt and higher repurchases of common stock and paid dividends in 2024.

During 2025, the company's Board of Directors authorized and paid quarterly dividends on its common stock of $0.17 in the first and second quarters and $0.18 in third and fourth quarters, respectively.

On November 19, 2024, Corteva, Inc. announced that its Board of Directors authorized a $3 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2024 Share Buyback Plan"). The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. In connection with the 2024 Share Buyback Plan, the company repurchased and retired 8,318,000 shares in the open market for a cost (excluding excise taxes) of $571 million during the year ended December 31, 2025.

On September 13, 2022, Corteva, Inc. announced that its Board of Directors authorized a $2 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2022 Share Buyback Plan"). The company completed the 2022 Share Buyback Plan during the second quarter of 2025 and repurchased and retired 7,815,000, 17,909,000 and 10,026,000 shares in the open market and through privately-negotiated transactions for a cost (excluding excise taxes) of $500 million, $1 billion and $500 million during the year ended December 31, 2025, 2024 and 2023, respectively.

On August 5, 2021, the company's Board of Directors authorized a $1.5 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2021 Share Buyback Plan"). The company completed the 2021 Share Buyback Plan during the first quarter of 2023 and repurchased and retired 4,098,000, 17,425,000 and 5,572,000 shares in the open market for a total cost of $250 million, $1 billion, and $250 million during the years ended December 31, 2023, 2022 and 2021, respectively.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

For the first half of 2026, the company expects repurchases of approximately $500 million under the 2024 Share Buyback Plan discussed above. The total amount, timing, price and volume of purchases will be based on market conditions, relevant securities laws and other market and company specific factors.

See Note 16 - Stockholders' Equity, to the Consolidated Financial Statements, for additional information related to the share buyback plans.

**EIDP Liquidity Discussion**

As discussed in EIDP Note 1 - Basis of Presentation, to the EIDP Consolidated Financial Statements, EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The discussion below relates to EIDP only and is presented to provide a Liquidity discussion, only for the differences between EIDP and Corteva, Inc.

**Cash provided by (used for) operating activities - continuing operations**

EIDP's cash provided by (used for) operating activities - continuing operations for the year ended December 31, 2025 was $3,457 million compared to $2,338 million for the year ended December 31, 2024. The change was primarily driven by the items noted on page 49, under the header "Cash provided by (used for) operating activities - continuing operations."

EIDP's cash provided by (used for) operating activities - continuing operations for the year ended December 31, 2024 was $2,338 million compared to $1,768 million for the year ended December 31, 2023. The change was primarily driven by the items noted on page 49, under the header "Cash provided by (used for) operating activities - continuing operations," as well as lower net interest expense related to loan activity with Corteva.

**Cash provided by (used for) operating activities - discontinued operations**

EIDP's cash provided by (used for) operating activities - discontinued operations for the year ended December 31, 2025 was $(51) million compared to $(151) million for the year ended December 31, 2024. The change was primarily driven by the items noted on page 49, under the header "Cash provided by (used for) operating activities - discontinued operations."

EIDP's cash provided by (used for) operating activities - discontinued operations for the year ended December 31, 2024 was $(151) million compared to $(40) million for the year ended December 31, 2023. The change was primarily driven by the items noted on page 49, under the header "Cash provided by (used for) operating activities - discontinued operations."

**Cash provided by (used for) investing activities**

EIDP's cash provided by (used for) investing activities for the year ended December 31, 2025 was $(543) million compared to $(228) million for the year ended December 31, 2024. The change was primarily driven by the items noted on page 50, under the header "Cash provided by (used for) investing activities."

EIDP's cash provided by (used for) investing activities for the year ended December 31, 2024 was $(228) million compared to $(2,007) million for the year ended December 31, 2023. The change was primarily driven by the items noted on page 50, under the header "Cash provided by (used for) investing activities," in addition to loan repayments by Corteva during 2024 on the related party Master In-House Banking Agreement.

**Cash provided by (used for) financing activities**

EIDP's cash provided by (used for) financing activities was $(1,644) million for the year ended December 31, 2025 compared to $(1,602) million for the year ended December 31, 2024. The change was primarily driven by the items noted on page 50, under the header "Cash provided by (used for) financing activities".

EIDP's cash provided by (used for) financing activities was $(1,602) million for the year ended December 31, 2024 compared to $(38) million for the year ended December 31, 2023. The change was primarily due to lower debt borrowings and higher debt payments and issuance of a cash dividend by EIDP to Corteva, Inc., partially offset by lower related party debt payments.

See EIDP Note 2 - Related Party Transactions, to the EIDP Consolidated Financial Statements for further information on the related party loan between EIDP and Corteva, Inc.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

**Critical Accounting Estimates**

The company's significant accounting policies are more fully described in Note 2 - Summary of Significant Accounting Policies, to the Consolidated Financial Statements. Management believes that the application of these policies on a consistent basis enables the company to provide the users of the financial statements with useful and reliable information about the company's operating results and financial condition.

The preparation of the Consolidated Financial Statements in conformity with generally accepted accounting principles ("GAAP") in the United States of America requires management to make estimates and assumptions that affect the reported amounts, including, but not limited to, receivable and inventory valuations, impairment of tangible and intangible assets, long-term employee benefit obligations, income taxes, environmental matters and litigation. Management's estimates are based on historical experience, facts and circumstances available at the time and various other assumptions that are believed to be reasonable. The company reviews these matters and reflects changes in estimates as appropriate. Management believes that the following represent the more critical judgment areas in the application of the company's accounting policies which could have a material effect on the company's financial position, liquidity or results of operations.

*Pension Plans and Other Post-Employment Benefits*

Accounting for employee benefit plans involves assumptions and estimates. Discount rate and expected long-term rate of return on plan assets are two critical assumptions in measuring the cost and benefit obligation of the company's pension and other post-employment benefit ("OPEB") plans. Management reviews these two key assumptions when plans are re-measured. These and other assumptions are updated periodically to reflect the actual experience and expectations on a plan specific basis as appropriate. As permitted by GAAP, actual results that differ from the assumptions are accumulated on a plan by plan basis and to the extent that such differences exceed 10 percent of the greater of the plan's benefit obligation or the applicable plan assets, the excess is amortized over the average remaining service period of active employees or the average remaining life expectancy of plan participants if all or almost all of a plan's participants are inactive.

Most of the company's benefit obligation for pensions and OPEB plans are attributable to the U.S. benefit plans. For U.S. benefit plans, the single equivalent discount rate is developed by matching the expected cash flow of the benefit plans to a yield curve constructed from a portfolio of high quality fixed-income instruments provided by the plans' actuaries as of the measurement date. The company measures the service and interest cost components utilizing a full yield curve approach by applying the specific spot rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. For the non-U.S. benefit plans, the company primarily utilizes prevailing long-term high quality corporate bond indices to determine the discount rate, applicable to each country, at the measurement date. The weighted average discount rates used in developing the expected 2026 net periodic pension and OPEB costs were 5.31 percent and 5.14 percent, respectively.

For the U.S. plan, the company establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Where appropriate, asset-liability studies are also taken into consideration. The expected long-term rate of return on plan assets is based upon historical real returns (net of inflation) for the asset classes covered by the investment policy, expected performance, and projections of inflation and interest rates over the long-term period during which benefits are payable to plan participants. In determining the 2025 net periodic pension cost in the U.S., an assumption of 6.00 percent for expected long-term rate of return on plan assets was used. After re-evaluating the current strategic asset allocation and market conditions, the company maintained the expected long-term rate of return on plan assets assumption at 6.00 percent to be used in determining the 2026 net periodic pension cost in the U.S. Consistent with prior years, the expected long-term rate of return on plan assets in the U.S. reflects the asset allocation of the plan and the effect of the company's active management of the plan's assets. For the non-U.S. plans, the strategic asset allocations are selected in accordance with the laws and practices for each country.

In determining annual expense for the principal U.S. pension plan, the company uses a market-related value of assets rather than the fair value. Accordingly, there may be a lag in recognition of changes in market valuation. As a result, changes in the fair value of assets are not immediately reflected in the company's calculation of net periodic pension cost. For the years ended December 31, 2025, 2024 and 2023, the market-related value of assets is calculated by averaging market returns over 36 months.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

The following table shows the market-related value and fair value of plan assets for the principal U.S. pension plan:

---

| | | | |
|:---|:---|:---|:---|
| *(In billions)* | **December 31, 2025** | **December 31, 2024** | **December 31, 2023** |
| Market-related value of assets | $10.0 | $10.6 | $11.9 |
| Fair value of plan assets  | $10.0 | $10.4 | $11.4 |

---

For plans other than the principal U.S. pension plan, pension expense is determined using the fair value of assets.

The following table highlights the potential impact on the company's pre-tax earnings due to changes in certain key assumptions with respect to the company's pension and OPEB plans, based on assets and liabilities at December 31, 2025:

---

| | | |
|:---|:---|:---|
| **Pre-tax Earnings Benefit (Charge)**<br>*(Dollars in millions)* | **1/4 Percentage<br>Point<br>Increase** | **1/4 Percentage<br>Point<br>Decrease** |
| Discount rate | $(15) | $16 |
| Expected rate of return on plan assets | $24 | $(24) |

---

Additional information with respect to pension and OPEB expenses, liabilities and assumptions is discussed under "Long-Term Employee Benefits" beginning on page 53 and in Note 17 - Pension Plans and Other Post-Employment Benefits, to the Consolidated Financial Statements.

*Environmental Matters*

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. At December 31, 2025, the company had accrued obligations of $562 million for probable environmental remediation and restoration costs, including $49 million for the remediation of Superfund sites. As remediation activities vary substantially in duration and cost from site to site, it is difficult to develop precise estimates of future site remediation costs. The company's estimates are based on a number of factors, including the complexity of the geology, the nature and extent of contamination, the type of remedy, the outcome of discussions with regulatory agencies and other Potentially Responsible Parties ("PRPs") at multi-party sites and the number of and financial viability of other PRPs. Therefore, considerable uncertainty exists with respect to environmental remediation and costs, and, under adverse changes in circumstances, it is reasonably possible that the ultimate cost with respect to these particular matters could range up to approximately $553 million above the accrued obligations amount. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the company's results of operations, financial condition and cash flows. For further discussion, see the "Environmental Matters" section on page 58 and Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

*Legal Contingencies*

The company's results of operations could be affected by significant litigation adverse to the company, including product liability claims, patent infringement and antitrust claims, and claims for third-party property damage or personal injury stemming from alleged environmental torts. The company records accruals for legal matters when the information available indicates that it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Management makes adjustments to these accruals to reflect the impact and status of negotiations, settlements, rulings, advice of counsel and other information and events that may pertain to a particular matter. Predicting the outcome of claims and lawsuits and estimating related costs and exposure involves substantial uncertainties that could cause actual costs to vary materially from estimates. In making determinations of likely outcomes of litigation matters, management considers many factors. These factors include, but are not limited to, the nature of specific claims including unasserted claims, the company's experience with similar types of claims, the jurisdiction in which the matter is filed, input from outside legal counsel, the likelihood of resolving the matter through alternative dispute resolution mechanisms, and the matter's current status. Considerable judgment is required in determining whether to establish a litigation accrual when an adverse judgment is rendered against the company in a court proceeding. In such situations, the company will not recognize a loss if, based upon a thorough review of all relevant facts and information, management believes that it is probable that the pending judgment will be successfully overturned on appeal. A detailed discussion of significant litigation matters is contained in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

*Indemnification Assets* 

The company has entered into various agreements where the company is indemnified for certain liabilities by DuPont, Dow and Chemours. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. In assessing the probability of recovery, the company considers the contractual rights under the separation agreements and any potential credit risk. Future events, such as potential disputes related to recovery as well as the solvency of DuPont, Dow and/or Chemours, could cause the indemnification assets to have a lower value than anticipated and recorded. The company evaluates the recovery of the indemnification assets recorded when events or changes in circumstances indicate the carrying values may not be fully recoverable. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information related to indemnifications.

*Income Taxes* 

The breadth of the company's operations and the global complexity of tax regulations require assessments of uncertainties and judgments in estimating taxes the company will ultimately pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of disputes arising from federal, state and international tax audits in the normal course of business. The resolution of these uncertainties may result in adjustments to the company's tax assets and tax liabilities. It is reasonably possible that changes to the company's global unrecognized tax benefits could be significant; however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of increases or decreases that may occur within the next twelve months cannot be made.

Deferred income taxes result from differences between the financial and tax basis of the company's assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Significant judgment is required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. The realization of these assets is dependent on generating future taxable income, as well as successful implementation of various tax planning strategies. For example, changes in facts and circumstances that alter the probability that the company will realize deferred tax assets could result in recording a valuation allowance, thereby reducing the deferred tax asset and generating a deferred tax expense in the relevant period. In some situations, these changes could be material.

At December 31, 2025, the company had a net deferred tax asset balance of $69 million, inclusive of a valuation allowance of $887 million. Realization of deferred tax assets is expected to occur over an extended period of time. As a result, changes in tax laws, assumptions with respect to future taxable income, and tax planning strategies could result in adjustments to deferred tax assets.

See Note 7 - Income Taxes, to the Consolidated Financial Statements, for additional information.

*Valuation of Assets and Impairment Considerations*

The assets and liabilities of acquired businesses are measured at their estimated fair values at the dates of acquisition. The excess of the purchase price over the estimated fair value of the net assets acquired, including identified intangible assets, is recorded as goodwill. The determination and allocation of fair value to the assets acquired and liabilities assumed is based on various assumptions and valuation methodologies requiring considerable management judgment, including estimates based on historical information, current market data and future expectations. The principal assumptions utilized in the company's valuation methodologies include revenue growth rates, EBITDA margin estimates, royalty rates, and discount rates. Although the estimates are deemed reasonable by management based on information available at the dates of acquisition, those estimates are inherently uncertain.

Assessment of the potential impairment of goodwill, other intangible assets, property, plant and equipment, investments in nonconsolidated affiliates, and other assets is an integral part of the company's normal ongoing review of operations. Testing for potential impairment of these assets is significantly dependent on numerous assumptions and reflects management's best estimates at a particular point in time. The dynamic economic environment in which the company's segments operate, and key economic and business assumptions with respect to projected selling prices, market growth and inflation rates, can significantly affect the outcome of impairment tests. Estimates based on these assumptions may differ significantly from actual results. Changes in factors and assumptions used in assessing potential impairments can have a significant impact on the existence and

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

magnitude of impairments, as well as the time at which such impairments are recognized. In addition, the company continually reviews its portfolio of assets to ensure they are achieving their greatest potential and are aligned with the company's growth strategy. Strategic decisions involving a particular group of assets may trigger an assessment of the recoverability of the related assets. Such an assessment could result in impairment losses.

The company tests goodwill and other indefinite-lived intangible assets for impairment annually (during the fourth quarter), or more frequently when events or changes in circumstances indicate it is more likely than not that the fair value of a reporting unit has declined below its carrying value. Goodwill is evaluated for impairment using qualitative and/or quantitative testing procedures. The company performs goodwill impairment testing at the reporting unit level, which is defined as the operating segment or one level below the operating segment. One level below the operating segment, or component, is a business in which discrete financial information is available and regularly reviewed by segment management. The company aggregates certain components into reporting units based on economic similarities. The company's reporting units are Seed and Crop Protection.

For purposes of goodwill impairment testing, the company has the option to first perform qualitative testing to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors assessed at the company level include GDP growth rates, long-term commodity prices, equity and credit market activity, discount rates, and overall financial performance. Qualitative factors assessed at the reporting unit level include changes in industry and market structure, competitive environments and new product launches, cost factors such as raw material prices, and financial performance of the reporting unit. If the company chooses not to complete a qualitative assessment for a given reporting unit or if the initial assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, additional quantitative testing is required.

If additional quantitative testing is required, the reporting unit's fair value is compared with its carrying amount, and an impairment charge, if any, is recognized for the amount by which the carrying amount exceeds the reporting unit's fair value, limited to the amount of goodwill associated with the reporting unit. The company determines fair values for each of the reporting units using a discounted cash flow model (a form of the income approach), utilizing Level 3 unobservable inputs.

Under the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. The company's significant assumptions in these analyses include future cash flow projections, weighted average cost of capital, the terminal growth rate and the tax rate. The company's estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and assumed business strategy from a market participant perspective and includes an estimate of long-term future growth rates based on such strategy. Actual results may differ from those assumed in the company's forecasts. The company derives its discount rates using a capital asset pricing model and analyzes published rates for industries relevant to its reporting units to estimate the cost of equity financing. The company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in its internally developed forecasts.

Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including actual operating results. It is reasonably possible that the judgments and estimates described above could change in future periods. The company believes the current assumptions and estimates utilized are both reasonable and appropriate. Based on the qualitative annual goodwill impairment analyses performed in the fourth quarter of 2025, it was concluded more likely than not that the fair value of each reporting unit exceeded its respective carrying value and, therefore, a quantitative test was not performed. No goodwill impairment charge was necessary.

**Off-Balance Sheet Arrangements** 

*Certain Guarantee Contracts*

Information with respect to the company's guarantees is included in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements. Historically, the company has not made significant payments to satisfy guarantee obligations; however, the company believes it has the financial resources to satisfy these guarantees.

*MOU Escrow Contributions*

On January 22, 2021, Chemours, DuPont, Corteva and EIDP entered into a binding memorandum of understanding containing a settlement to resolve legal disputes originating from the Delaware Litigation and Pending Arbitration, and to establish a cost sharing arrangement for potential future legacy per- and polyfluoroalkyl substances ("PFAS") liabilities arising out of pre-July

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

1, 2015 conduct (the "MOU"). Under the terms of the MOU, Corteva's estimated aggregate share of the potential $2 billion is approximately $600 million. In order to support and manage any potential future PFAS liabilities, the parties have also agreed to establish an escrow account ("MOU Escrow Account"). The MOU provides that contributions to the MOU Escrow Account will be made by Chemours, DuPont and Corteva, annually over an eight-year period through 2028. Over this period, Chemours will deposit a total of $500 million in the account and DuPont and Corteva, together, will deposit an additional $500 million pursuant to the terms of the Letter Agreement. Additionally, if on December 31, 2028, the balance of the MOU Escrow Account (including interest) is less than $700 million, Chemours will make 50% of the deposits and DuPont and Corteva, together, will make 50% of the deposits necessary to restore the balance of the escrow account to $700 million pursuant to the terms of the Letter Agreement.

The company made its annual installment deposits due to the MOU Escrow Account through December 31, 2025, when considering the 2023 waiver and 2025 suspension pursuant to supplemental agreements to the MOU executed by Chemours, DuPont and Corteva as certain conditions were met. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for further details on the MOU and funding of the MOU Escrow Account.

*Contractual Obligations*

Our principal commitments consist of long-term debt, operating and finance lease obligations and environmental remediation obligations. See Note 14 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities, Note 13 – Leases, and Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, respectively, for further discussion.

Information related to the company's other significant contractual obligations are summarized in the following table:

---

| | | | |
|:---|:---|:---|:---|
| | | **Payments Due In** | **Payments Due In** |
|<br>*(In millions)* | **Total at<br>December 31, 2025** | **2026** | **2027 and<br>beyond** |
| Expected cumulative cash requirements for interest payments <br>&nbsp;&nbsp;&nbsp;&nbsp; through maturity | $515 | $89 | $426 |
| Purchase obligations <sup>1</sup> | 2022 | 821 | 1201 |
| License agreements <sup>2, 3</sup> | 160 | 46 | 114 |
| Other liabilities <sup>2, 4</sup> | 276 | 44 | 232 |
| Total <sup>5</sup> | $2973 | $1000 | $1973 |

---

1. Represents enforceable and legally binding agreements in excess of $1 million to purchase goods or services that specify fixed or minimum quantities; fixed, minimum or variable price provisions; and the approximate timing of the agreement.

2. Included in the Consolidated Financial Statements.

3.&nbsp;&nbsp;&nbsp;&nbsp;Represents undiscounted remaining payments under Pioneer license agreements (approximately $145 million on a discounted basis).

4.&nbsp;&nbsp;&nbsp;&nbsp;Includes liabilities related to employee-related benefits other than pension and other post-employment benefits, asset retirement obligations and other noncurrent liabilities.

5.&nbsp;&nbsp;&nbsp;&nbsp;Due to uncertainty regarding the completion of tax audits and possible outcomes, the timing of certain payments of obligations related to unrecognized tax benefits cannot be made and have been excluded from the table above. See Note 7 - Income Taxes, to the Consolidated Financial Statements, for additional detail.

The company expects to meet its contractual obligations through its normal sources of liquidity and believes it has the financial resources to satisfy the contractual obligations that arise in the ordinary course of business.

**Long-Term Employee Benefits** 

The company has various obligations to its employees and retirees. The company maintains retirement-related programs in many countries that have a long-term impact on the company's earnings and cash flows. These plans are typically defined benefit pension plans, as well as medical, dental and life insurance benefits for pensioners and survivors and disability benefits for employees ("other post-employment benefits" or "OPEB"). Substantially all of the company's worldwide benefit obligation for pensions and OPEB obligations are attributable to the U.S. benefit plans.

Pension coverage for employees of the company's non-U.S. consolidated subsidiaries is provided, to the extent deemed appropriate, through separate plans. The company regularly explores alternative solutions to meet its global pension obligations in the most cost-effective manner possible as demographics, life expectancy and country-specific pension funding rules change. Where permitted by applicable law, the company reserves the right to change, modify or discontinue its plans that provide pension, medical, dental, life insurance and disability benefits.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

Benefits under defined benefit pension plans are based primarily on years of service and employees' pay near retirement. In November 2016, the company announced changes to the U.S. pension and OPEB plans, and on November 30, 2018, the company froze the pay and service amounts used to calculate pension benefits for active employees who participate in the U.S. pension plans, resulting in the participants no longer accruing additional benefits. In addition, OPEB eligible employees who were under the age of 50 as of November 30, 2018 will not receive post-employment medical, dental and life insurance benefits. The majority of employees hired in the U.S. on or after January 1, 2007 are not eligible to participate in the pension and post-employment medical, dental and life insurance plans, but are eligible to participate in the defined contribution plans.

In December 2020, the company amended its retiree medical, dental and life insurance plans resulting in the company no longer providing retiree dental and life insurance benefits effective January 1, 2022 and Corteva's portion of the cost of non-Medicare retiree medical coverage no longer being adjusted for cost increases, which capped the Corteva cost at the level as of December 31, 2021 ("2020 OPEB Plan Amendments").

Pension benefits are paid primarily from trust funds established to comply with applicable laws and regulations. The actuarial assumptions and procedures utilized are reviewed periodically by the plans' actuaries to provide reasonable assurance that there will be adequate funds for the payment of benefits. The company did not make contributions to the principal U.S. pension plan for the years ended December 31, 2025, 2024 or 2023.

Funding for each pension plan other than the principal U.S. pension plan is governed by the rules of the sovereign country in which it operates. Thus, there is not necessarily a direct correlation between pension funding and pension expense. In general, however, improvements in plans' funded status tend to moderate subsequent funding needs. The company contributed $5 million, $5 million and $5 million to its funded pension plans other than the principal U.S. pension plan for the years ended December 31, 2025, 2024 and 2023, respectively.

U.S. pension benefits that exceed federal limitations are covered by separate unfunded plans and these benefits are paid to pensioners and survivors from operating cash flows. The company's remaining pension plans with no plan assets are paid from operating cash flows. The company made benefit payments of $34 million, $45 million, and $47 million to its unfunded plans for the years ended December 31, 2025, 2024 and 2023, respectively.

The company's OPEB plans are unfunded and the cost of the approved claims is paid from operating cash flows. Pre-tax cash requirements to cover actual net claims costs and related administrative expenses were $96 million, $101 million, and $97 million for the years ended December 31, 2025, 2024 and 2023, respectively. Changes in cash requirements reflect the net impact of per capita health care cost, demographic changes, plan amendments and changes in participant premiums, co-pays and deductibles.

In 2026, the company expects to contribute approximately $40 million to its pension plans other than the principal U.S. pension plan and approximately $100 million to its OPEB plans. In planning for the Proposed Separation, including the future capital structures of the two new companies, the company expects to evaluate discretionary contributions to its principal U.S. pension plan in 2026.

The company's income can be significantly affected by pension and defined contribution benefits as well as OPEB costs. The following table summarizes the extent to which the company's income (loss) from continuing operations before income taxes for the years ended December 31, 2025, 2024 and 2023 was affected by pre-tax charges related to long-term employee benefits:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Net periodic benefit (credit) cost - pension and OPEB | $36 | $160 | $138 |
| Defined contributions | 150 | 146 | 146 |
| Long-term employee benefit plan (credit) charges - continuing operations | $186 | $306 | $284 |

---

The above (credit) charges for pension and OPEB are determined as of the beginning of each period. Long-term employee benefit plan (credits) costs were $186 million and $306 million for the years ended December 31, 2025 and 2024, respectively. The change is mainly due to the increase in the expected long-term rate of return on plan assets assumption for the U.S plan net

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

of the increase in the discount rates. See "Pension Plans and Other Post-Employment Benefits" under the Critical Accounting Estimates section beginning on page 52 of this report for additional information on determining annual expense.

For 2026, long-term employee benefit costs are expected to decrease by approximately $50 million. The change is mainly due to the decrease in the discount rates.

**Environmental Matters**

The company operates global manufacturing, product handling and distribution facilities that are subject to a broad array of environmental laws and regulations. Such rules are subject to change by the implementing governmental agency, and the company monitors these changes closely. Company policy requires that all operations fully meet or exceed legal and regulatory requirements. In addition, the company implements voluntary programs to reduce air emissions, minimize the generation of hazardous waste, decrease the volume of water use and discharges, increase the efficiency of energy use and reduce the generation of persistent, bioaccumulative and toxic materials. Management has noted a global upward trend in the amount and complexity of proposed chemicals regulation. The costs to comply with complex environmental laws and regulations, as well as internal voluntary programs and goals, are significant and will continue to be significant for the foreseeable future.

Pre-tax environmental expenses charged to income (loss) from continuing operations before income taxes are summarized below:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Environmental operating costs | $155 | $168 | $178 |
| Environmental remediation costs <sup>1</sup> | 67 | 42 | 47 |
|  | $222 | $210 | $225 |

---

1. Environmental remediation costs include costs that are subject to the $200 million threshold and sharing arrangements as discussed in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, under the header Corteva Separation Agreement.

*Environmental Operating Costs* 

As a result of its operations, the company incurs costs for pollution abatement activities including waste collection and disposal, installation and maintenance of air pollution controls and wastewater treatment, emissions testing and monitoring, and obtaining permits. The company also incurs costs related to environmental related research and development activities including environmental field and treatment studies as well as toxicity and degradation testing to evaluate the environmental impact of products and raw materials.

Approximately 85 percent of total pre-tax environmental operating costs charged to income (loss) from continuing operations for the year ended December 31, 2025 resulted from operations in the U.S. Based on existing facts and circumstances, management does not believe that year-over-year changes, if any, in environmental operating costs charged to current operations will have a material impact on the company's financial position, liquidity or results of operations. Annual expenditures in the near term are not expected to vary significantly from the range of such expenditures experienced in the past few years. Over the longer term, expenditures are subject to considerable uncertainty and may fluctuate significantly.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,** *continued* 

*Remediation Accrual* 

Changes in the remediation accrual balance are summarized below:

---

| | |
|:---|:---|
| *(In millions)* |  |
| Balance at December 31, 2023 | $501 |
| Remediation payments <sup>1</sup> | (58) |
| Net increase in remediation accrual <sup>1</sup> | 42 |
| Net change, indemnification <sup>2</sup> | (7) |
| Balance at December 31, 2024 | $478 |
| Remediation payments <sup>1</sup> | (40) |
| Net increase in remediation accrual <sup>1</sup> | 67 |
| Net change, indemnification <sup>2</sup> | 57 |
| Balance at December 31, 2025 <sup>3</sup> | $562 |

---

1. Environmental remediation activity relates to Corteva-specific sites, along with accruals and payments made that are subject to the Corteva Separation Agreement as discussed in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

2. Represents the net change in indemnified remediation obligations. Substantially all relates to activity pursuant to the Chemours Separation Agreement and subsequent MOU, as discussed in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, in which EIDP is indemnified by Chemours and DuPont for certain environmental matters.

3. Includes accrued obligations of $137 million due in the next twelve months with the remainder being due subsequent to 2025.

Considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $553 million above the amount accrued as of December 31, 2025. See Note 15 – Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for further details on the company's accrued obligations at December 31, 2025.

As of December 31, 2025, the company has been notified of potential liability under the Comprehensive Environmental Response, Compensation and Liability Act ("Superfund") or similar state laws at approximately 500 sites around the U.S., including approximately 80 sites for which the company does not believe it has liability based on current information. Active remediation is under way at approximately 60 of the 500 sites. In addition, the company has resolved its liability at about 212 sites, either by completing remedial actions with other PRPs or by participating in "de minimis buyouts" with other PRPs whose waste, like the company's, represented only a small fraction of the total waste present at a site. There were no new notices in 2025 and 2024.

*Environmental Capital Expenditures* 

Capital expenditures for environmental projects, either required by law or necessary to meet the company's internal environmental goals, were approximately $9 million for the year ended December 31, 2025. The company currently estimates expenditures for environmental-related capital projects to be approximately $14 million in 2026.

*Climate Impact* 

Shifts in climate are an important global environmental concern that presents risks and opportunities to the company, of which the Sustainability and Innovation Committee of the company's Board of Directors maintains oversight. Management regularly assesses and manages climate-related issues. The company integrates processes for identifying, assessing and managing climate-related risk into its enterprise risk management program. Across its business, individuals who are responsible for climate-related initiatives may have annual performance goals tied to the delivery of projects related to these initiatives.

Extreme and volatile weather events, which may be amplified by, or become more frequent with, climate change may have an adverse impact on our customers' ability to use the company's products and seed supply, potentially reducing sales volumes, revenues and margins. These events may also shift or exacerbate existing pest and disease pressures. These pressures, along with the desire for climate-smart and climate-resilient technologies may present opportunities for the company to meet these shifting demands. Therefore, the company invests in enabling innovation that can create a more resilient agriculture value chain, while also working to reduce greenhouse gas emissions through cost effective operational improvements.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The company's global operations are exposed to financial market risks relating to fluctuations in foreign currency exchange rates, commodity prices and interest rates. The company has established a variety of programs including the use of derivative instruments and other financial instruments to manage the exposure to financial market risks as to minimize volatility of financial results. In the ordinary course of business, the company enters into derivative instruments to hedge its exposure to foreign currency and commodity price risks under established procedures and controls. For additional information on these derivatives and related exposures, see Note 19 - Financial Instruments, to the Consolidated Financial Statements. Decisions regarding whether or not to hedge a given commitment are made on a case-by-case basis, taking into consideration the amount and duration of the exposure, market volatility and economic trends. Foreign currency exchange contracts may be used, from time to time, to manage near-term foreign currency cash requirements.

**Foreign Currency Exchange Rate Risks** 

The company has significant international operations resulting in a large number of currency transactions that result from international sales, purchases, investments and borrowings. The primary currencies for which the company has an exchange rate exposure are the Brazilian real, Euro, Canadian dollar and Argentine peso. The company uses foreign exchange contracts, where possible, to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The company also uses foreign currency exchange contracts to offset a portion of the company's exposure to certain forecasted transactions, investment in foreign subsidiaries, as well as the translation of foreign currency-denominated earnings and uses commodity contracts to offset risks associated with foreign currency devaluation in certain countries. In addition to the contracts disclosed in Note 19 - Financial Instruments, to the Consolidated Financial Statements, from time to time, the company may enter into foreign currency exchange contracts to establish with certainty the U.S. Dollar ("USD") amount of future firm commitments denominated in a foreign currency.

The following table illustrates the fair values of outstanding foreign currency contracts at December 31, 2025 and 2024, and the effect on fair values of a hypothetical adverse change in the foreign exchange rates that existed at December 31, 2025 and 2024. The sensitivities for foreign currency contracts are based on a 10 percent adverse change in foreign exchange rates.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value<br>(Liability)/Asset** | **Fair Value<br>(Liability)/Asset** | **Fair Value<br>Sensitivity** | **Fair Value<br>Sensitivity** |
|<br>*(In millions)* | **2025** | **2024** | **2025** | **2024** |
| Foreign currency contracts | $(13) | $(33) | $(471) | $(460) |

---

The potential gain/loss in value for each risk management portfolio described above would be offset in part by changes in the value of the underlying exposure.

**Concentration of Credit Risk** 

The company maintains cash and cash equivalents, marketable securities, derivatives and certain other financial instruments with various financial institutions. These financial institutions are generally highly rated and geographically dispersed and the company has a policy to limit the dollar amount of credit exposure with any one institution.

As part of the company's financial risk management processes, it continuously evaluates the relative credit standing of all of the financial institutions that service Corteva and monitors actual exposures versus established limits. The company has not sustained credit losses from instruments held at financial institutions.

The company's sales are not materially dependent on any single customer. Credit risk associated with its receivables balance is representative of the geographic, industry and customer diversity associated with the company's global product lines.

The company also maintains strong credit controls in evaluating and granting customer credit. As a result, it may require that customers provide some type of financial guarantee in certain circumstances. Length of terms for customer credit varies by region.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA** 

The financial statements and supplementary data required by this Item are included herein, commencing on page F-1 of this report.

**ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE**

None.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 9A. CONTROLS AND PROCEDURES** 

**Corteva, Inc.**

a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluation of Disclosure Controls and Procedures

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of December 31, 2025, the company's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in Internal Control over Financial Reporting

There have been no changes in the company's internal control over financial reporting that occurred during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

**EIDP, Inc.**

a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluation of Disclosure Controls and Procedures

EIDP maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in EIDP's reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of December 31, 2025, EIDP's CEO and CFO, together with management, conducted an evaluation of the effectiveness of EIDP's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in Internal Control over Financial Reporting

There have been no changes in EIDP's internal control over financial reporting that occurred during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, EIDP's internal control over financial reporting.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part II**

**ITEM 9B. OTHER INFORMATION** 

None.

**ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS**

Not applicable.

**ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE** 

Information with respect to this Item is incorporated herein by reference to the Proxy, including information within the sections entitled, "Election of Directors," and "Corporate Governance."

**Code of Financial Ethics**

The company has adopted a Code of Financial Ethics for its CEO, CFO, and Controller that may be accessed from the company's website at www.corteva.com by clicking on "Investors" and then "Corporate Governance." Any amendments to, or waiver from, any provision of the code will be posted on the company's website at the above address.

**Insider Trading Policies and Procedures**

The company has adopted insider trading policies and procedures governing the purchase, sale, and other dispositions of the company's securities by directors, officers and employees, and the company, that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and any listing standards applicable to the company.

**Executive Officers of the Registrant**

Our executive officers serve at the discretion of the Board of Directors. The names of our executive officers and their ages, titles, and biographies as of February 12, 2026 are set forth below:

*Charles V. Magro,* age 56, was named Chief Executive Officer and Director of Corteva effective November 2021. Prior to joining Corteva, Mr. Magro served as President and CEO of Nutrien Ltd. from the company's launch in 2018 until April 2021. From 2014 to 2018, he served as President and CEO of Agrium Inc., which merged with Potash Corporation of Saskatchewan Inc. to create Nutrien Ltd. As President and CEO of Nutrien Ltd., Mr. Magro led more than 27,000 employees to achieve best-in-class engagement, top safety performance and exceptional business results. While at Nutrien he also led the company through numerous M&A transactions thereby, expanding its global footprint. Prior to this role, Mr. Magro held a variety of other key leadership positions with the company, including Chief Operating Officer, Chief Risk Officer, Executive Vice President of Corporate Development, and Vice President of Manufacturing. He joined Agrium Inc. in 2009 following a productive career with NOVA Chemicals Corp. Mr. Magro has served on the board of directors of Ingredion Inc., a global provider of ingredient solutions to the food and beverage manufacturing industry, since May 2022. He was also recently named Chair of the Board of Directors for CropLife International, effective January 1, 2026. Mr. Magro previously served on the Canada Pension Plan Investment Board from 2018 until March 2022.

*David P. Johnson*, age 59, was named Executive Vice President and Chief Financial Officer effective in September 2024. Prior to joining Corteva, Mr. Johnson served as Chief Financial Officer and Chief Accounting Officer of Atkore Inc. from August 2018 through August 9, 2024, and has more than 30 years of experience in strategic and financial planning, risk assessment, mergers & acquisitions, global tax strategies, international operations and internal controls. Prior to joining Atkore Inc., Mr. Johnson served in various finance leadership roles at Eaton Corporation from 1989 through 2018. Most recently at Eaton, Mr. Johnson was Vice President-Finance & Operations for the electrical sector business, where he was responsible for sector financial planning, analysis, and reporting; compliance, credit & collections; government accounting; as well as global purchasing, manufacturing strategies, logistics and distribution. Prior to that, Mr. Johnson was Vice President-Finance and Planning for the Americas region (Eaton Electrical) where he was responsible for reporting, planning, acquisitions, and implementing common financial policies / reporting across numerous recently acquired businesses. During his tenure at Eaton, Mr. Johnson held other roles of progressive responsibilities, including Plant Controller, Division Controller, Director of Finance & Business Development, Vice President Finance & Business Development, and Vice President Finance & Planning-Europe, Middle East, and Asia.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part III** 

*Judd O'Connor,* age 55, was named Executive Vice President, Seed Business Unit of Corteva, effective December 2024. Mr. O'Connor has over 30 years of experience in agriculture and served as the Company's President for the North America commercial business since July 2022. Prior to that, Mr. O'Connor served as the President for the company's U.S. commercial business since August 2018. Prior to the Company's spin from DowDuPont, Inc., Mr. O'Connor was the North America Commercial Leader for DuPont Pioneer, where he was responsible for integration activities supporting the merger of DuPont and The Dow Chemical Company. Mr. O'Connor held various leadership positions in the Company's seed business including Vice President of Integrated Operations & Commercial Effectiveness for DuPont Pioneer, Business Director and Vice President for the Pioneer® brand sales organization. He previously served as Regional President for DuPont Latin America and was based in Sao Paulo, Brazil. Prior to joining Corteva, Mr. O'Connor began his career in the crop protection sector with American Cyanamid where he held a number of sales, marketing and leadership positions.

*Robert King*, age 55, was named Executive Vice President, Crop Protection Business Unit of Corteva effective April 2022. Mr. King is a highly experienced specialty chemicals and agriculture industry executive with experience leading teams in the U.S., Canada, China, and the U.K. and a long track record of leading transformational improvements growing shareholder value through operational excellence. Prior to joining Corteva, Mr. King served as Senior Vice President and Chief Integrated Supply Chain Officer at Nouryon from December 2020 to March 2022, where he spearheaded the global and cross-business integration of the company's supply chain. From December 2019 to December 2020, he previously served as Vice President of Global Operations for PPG's industrial segment. Mr. King was also the Vice President of Global Supply Chain from July 2018 to December 2019 for Nutrien Ltd., where he worked for five years and was appointed to lead the centralization of the company's supply chain. Prior to this, he served as a Regional Manager at Nutrien Ltd. and as the Vice President of Nitrogen Operations and Services at Agrium Inc. in Canada before the company became Nutrien in July 2018. Mr. King started his career at Celanese Corp., where he worked for nearly two decades and held management roles around the world. Mr. King currently serves on the Board of Directors of the American Chemistry Council, on the Executive Committee of AgriNovus Indiana, and represents Corteva on the Indianapolis Chamber of Commerce. Further, Mr. King serves on the Dean's Council for Texas Tech University's College of Engineering.

*Dr. Samuel Eathington*, age 57, was named Executive Vice President, Chief Technology and Digital Officer of Corteva effective April 2022, where he is responsible for leading the company's global research and development organization, building and expanding its industry-leading pipeline, and overseeing all aspects of Corteva's digital farming strategy and investments. He joined Corteva in November 2020 and served as Senior Vice President, Chief Technology Officer from January 2021 until April 2022. A recognized leader in agricultural innovation, Dr. Eathington served as Chief Science Officer of The Climate Corporation (part of the crop science division of Bayer AG) from December 2015 until April 2020. Prior to assuming that role, Dr. Eathington spent 19 years with Monsanto Corporation, in various roles and becoming Vice President, Global Plant Breeding beginning in February 2011.

*Jennifer A. Johnson*, age 51, was named Senior Vice President, Chief Legal Officer, effective September 15, 2025 and Corporate Secretary as of January 1, 2026. As of December 8, 2025, she provides oversight of the Company's public affairs function. Prior to joining Corteva, Dr. Johnson served as the Executive Vice President, General Counsel and Corporate Secretary of International Flavors & Fragrances Inc. ("IFF") from February 2021 to July 2025. Prior to joining IFF, Dr. Johnson held various roles at DuPont where she was associate general counsel for the nutrition and biosciences business from 2019 to February 2021. During her career at DuPont, she held various legal leadership roles supporting its commercial and intellectual property teams, including with the company's seed business. Prior to joining DuPont in 2013, Dr. Johnson was a partner at the global intellectual property law firm, Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. Dr. Johnson earned a Ph.D. in plant biology and a bachelor of science degree in genetics and plant biology from the University of California, Berkeley, and a juris doctorate from the University of Washington.

*Audrey Grimm*, age 45, was named Senior Vice President and Chief People Officer of Corteva effective March 2022. Beginning in 2021, she served as Vice President, Europe, Middle East and Africa (EMEA) HR, with added responsibility for the company's global culture and Inclusion and Belonging efforts, and before that as HR Director for the EMEA region from 2017 to 2021. Ms. Grimm spent her early career with Dow Chemical, where she held a series of progressive HR roles leading to her appointment as Vice President, HR of the Agricultural division of Dow Chemical in 2015.

*Brian Titus*, age 53, was named Vice President, Controller and Principal Accounting Officer of Corteva effective May 2019. Mr. Titus previously served as the Controller and Principal Accounting Officer of the agriculture division of DowDuPont Inc. since February 2019. Prior to this, he was general auditor of DuPont since August 2015 and previously served as the Director of Corporate Accounting from 2014 to 2015 and Global Finance Leader of DuPont Crop Protection from 2013 to 2014. Prior to

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part III** 

joining DuPont's corporate accounting group in 2010, he spent 14 years in public accounting, primarily with PricewaterhouseCoopers LLP, providing audit and transactional support services. Mr. Titus is a certified public accountant.

**ITEM 11. EXECUTIVE COMPENSATION** 

Information relating to executive compensation and the company's equity compensation plans is incorporated herein by reference to the definitive Proxy Statement for the 2026 Annual Meeting of Stockholders of Corteva, Inc., including information within "Compensation Discussion and Analysis," "Compensation of Executive Officers, "Director Compensation," "Compensation Committee Interlocks and Insider Participation" and "Compensation Committee Report."

**ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

Information with respect to beneficial ownership of Corteva, Inc. common stock by each director, executive officer, and all directors and executive officers of the Company as a group is contained in the definitive Proxy Statement for the 2026 Annual Meeting of Stockholders of Corteva, Inc. and is incorporated herein by reference.

Information relating to any person who beneficially owns in excess of 5 percent of the total outstanding shares of Corteva, Inc. common stock is contained in the definitive Proxy Statement for the 2026 Annual Meeting of Stockholders of Corteva, Inc. and is incorporated herein by reference.

Information with respect to compensation plans under which equity securities are authorized for issuance is contained in the definitive Proxy Statement for the 2026 Annual Meeting of Stockholders of Corteva, Inc. and is incorporated herein by reference.

**ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

Information with respect to this Item is incorporated herein by reference to the definitive Proxy Statement for the 2026 Annual Meeting of Stockholders of Corteva, Inc., including information within the sections entitled, "Certain Relationships and Related Transactions", and "Director Independence."

**ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES**

Information with respect to this Item is incorporated herein by reference to the definitive Proxy Statement for the 2026 Annual Meetings of Stockholders of Corteva, Inc., including information within the section entitled, "Ratification of Independent Registered Public Accounting Firm."

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

Financial Statements, Financial Statement Schedules and Exhibits:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Corteva, Inc. Financial Statements (See the Index to the Consolidated Financial Statements on page F-1 of this report).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Corteva, Inc. Financial Statement Schedule (presented below)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.EIDP, Inc. Financial Statements (Starting on page F-73 of this report).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.EIDP, Inc. Financial Statement Schedule (presented below)

Schedule II—Valuation and Qualifying Accounts (Corteva, Inc. and EIDP, Inc.)

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In Millions)* | **2025** | **2024** | **2023** |
| **Accounts Receivable—Allowance for Doubtful Receivables** |  |  |  |
| Balance at beginning of period | $179 | $205 | $194 |
| Additions charged to expenses | 132 | 55 | 24 |
| Deductions from reserves <sup>1</sup> | (70) | (81) | (13) |
| Balance at end of period | $241 | $179 | $205 |
| **Deferred Tax Assets—Valuation Allowance** |  |  |  |
| Balance at beginning of period | $666 | $510 | $342 |
| Additions to reserves <sup>2</sup> | 283 | 301 | 225 |
| Purchase accounting adjustments |  |  | 8 |
| Deductions from reserves <sup>3</sup> | (62) | (145) | (65) |
| Balance at end of period | $887 | $666 | $510 |

---

1. Deductions include write-offs, recoveries collected and currency translation adjustments.

2. Additions include currency translation adjustments.

3. Deductions include amounts recorded to other comprehensive income and currency translation adjustments.

Financial Statement Schedules listed under the Securities and Exchange Commission ("SEC") rules but not included in this report are omitted because they are not applicable or the required information is shown in the Consolidated Financial Statements or notes thereto.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES,** *continued*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.Exhibits

The following list of exhibits includes both exhibits submitted with this Form 10-K as filed with the SEC and those incorporated by reference to other filings:

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| [2.1](https://www.sec.gov/Archives/edgar/data/1755672/000119312519106808/d615112dex21.htm) | Separation and Distribution Agreement by and among DowDuPont Inc., Dow Inc. and Corteva, Inc. (incorporated by reference to Exhibit No. 2.1 to Amendment 3 to Corteva's Registration Statement on Form 10 (Commission file number 001-38710), filed on April 16, 2019). |
| [3.1](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001755672/000175567224000010/ctva-20240426.htm) | Amended and Restated Certificate of Incorporation of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva's Current Report on Form 8-K (Commission file number 001-38710), filed on May 2, 2024). |
| [3.2](https://www.sec.gov/Archives/edgar/data/1755672/000119312522310161/d768701dex31.htm) | Amended and Restated Bylaws of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva's Current Report on Form 8-K (Commission file number 001-38710), filed on December 21, 2022). |
| [3.3](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001755672/000175567223000011/ctva-20230331.htm) | Amended and Restated Certificate of Incorporation of EIDP, Inc. (incorporated by reference to Exhibit No. 3.3 to Corteva's and EIDP's Quarterly Report on Form 10-Q (Commission file numbers 001-38710 and 001-00815), filed on May 4, 2023) |
| [3.4](https://www.sec.gov/Archives/edgar/data/30554/000119312517274840/d438565dex32.htm) | Amended and Restated Bylaws of EIDP, Inc. (incorporated by reference to Exhibit 3.2 to EIDP's Current Report on Form 8-K (Commission file number 1-815) dated September 1, 2017). |
| [4.1](https://www.sec.gov/Archives/edgar/data/30554/000175567220000006/ctva-12312019xex41.htm) | Description of Corteva, Inc. registered securities (incorporated by reference from Exhibit 4.1 to the Company's Annual Report on Form 10-K (Commission file number 001-38710) filed February 14, 2020). |
| [4.2](https://www.sec.gov/Archives/edgar/data/30554/000175567220000006/ctva-12312019xex42.htm) | Description of E. I. du Pont de Nemours and Company registered securities (incorporated by reference from Exhibit 4.2 to the Company's Annual Report on Form 10-K (Commission file number 001-38710) filed February 14, 2020). |
| [10.1\*](https://www.sec.gov/Archives/edgar/data/1755672/000119312519163314/d753864dex103.htm) | Amended and Restated Tax Matters Agreement, effective as of June 1, 2019 by and among DowDuPont Inc., Dow Inc. and Corteva, Inc. (incorporated by reference to Exhibit 10.3 of Corteva's Current Report on Form 8-K (Commission file number 001-38710) filed on June 3, 2019). |
| [10.2\*](https://www.sec.gov/Archives/edgar/data/1755672/000119312519106808/d615112dex102.htm) | Employee Matters Agreement by and among DowDuPont Inc., Dow Inc., and Corteva, Inc. (incorporated by reference to Exhibit No. 10.2 to Amendment 3 to Corteva's Registration Statement on Form 10 (Commission file number 001-38710), filed on April 16, 2019). |
| [10.3\*](https://www.sec.gov/Archives/edgar/data/1755672/000119312519163314/d753864dex101.htm) | SpecCo/AgCo Intellectual Property Cross-License Agreement, effective as of June 1, 2019, by and among DowDuPont Inc., Corteva, Inc. and the other parties identified therein (incorporated by reference to Exhibit 10.1 to Corteva's Current Report on Form 8-K (Commission file number 001-38710), filed on June 3, 2019). |
| [10.4\*](https://www.sec.gov/Archives/edgar/data/1755672/000119312519106808/d615112dex104.htm) | Intellectual Property Cross-License Agreement by and between Corteva, Inc. and Dow Inc. (incorporated by reference to Exhibit No. 10.4 to Amendment 3 to Corteva's Registration Statement on Form 10 (Commission file number 001-38710), filed on April 16, 2019). |
| [10.5](https://www.sec.gov/Archives/edgar/data/1755672/000119312519138437/d615112dex105.htm) | Corteva, Inc. 2019 Omnibus Incentive Plan. (incorporated by reference to Exhibit No. 10.5 to Corteva's Registration Statement on Form 10 (Commission file number 001-38710), filed on May 6, 2019). |
| [10.6](https://www.sec.gov/Archives/edgar/data/30554/000003055415000065/exhibit21separationagreeme.htm) | Separation Agreement by and between E. I. du Pont de Nemours and Company and The Chemours Company (incorporated by reference to Exhibit 2.1 to E. I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015). |
| [10.7](https://www.sec.gov/Archives/edgar/data/30554/000003055417000037/exhibit_2x1.htm) | Amendment No. 1 to Separation Agreement by and between E. I. du Pont de Nemours and Company and The Chemours Company, dated August 24, 2017 (incorporated by reference to Exhibit 2.1 to E. I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated August 25, 2017). |
| [10.8](https://www.sec.gov/Archives/edgar/data/30554/000003055415000065/exhibit22taxmattersagreeme.htm) | Tax Matters Agreement by and between E. I. du Pont de Nemours and Company and The Chemours Company (incorporated by reference to Exhibit 2.2 to E. I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015). |
| [10.9](https://www.sec.gov/Archives/edgar/data/1666700/000119312517275738/d447567dex43.htm) | Amended and Restated Management Deferred Compensation Plan (incorporated by reference to Exhibit 10.1 to Corteva's and EIDP's Quarterly Report on Form 10-Q (Commission file numbers 001-38710 and 001-00815), filed on August 4, 2023). |
| [10.10](https://www.sec.gov/Archives/edgar/data/1666700/000119312517275738/d447567dex44.htm) | The E. I. du Pont de Nemours and Company Stock Accumulation and Deferred Compensation Plan for Directors, (incorporated by reference to Exhibit 4.4 to DowDuPont Inc. Registration Statement on Form S-8 (Commission file number 333-220324) filed September 1, 2017.) |
| [10.11](https://www.sec.gov/Archives/edgar/data/30554/000003055415000070/dd-ex103_2015630xq2.htm) | E. I. du Pont de Nemours and Company's Pension Restoration Plan, as last amended effective June 29, 2015 (incorporated by reference to Exhibit 10.3 to E. I. du Pont de Nemours and Company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2015). |
| [10.12](https://www.sec.gov/Archives/edgar/data/30554/000003055415000070/dd-ex104_2015630xq2.htm) | E. I. du Pont de Nemours and Company's Rules for Lump Sum Payments, as last amended effective May 15, 2014 (incorporated by reference to Exhibit 10.4 to E. I. du Pont de Nemours and Company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2015). |
| [10.13](https://www.sec.gov/Archives/edgar/data/30554/000003055414000043/dd-ex108_2014630xq2.htm) | E. I. du Pont de Nemours and Company's Retirement Savings Restoration Plan, as last amended effective May 15, 2014. (incorporated by reference to Exhibit 10.08 to E. I. du Pont de Nemours and Company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2014). |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Part IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES,** *continued*

---

| | |
|:---|:---|
| [10.14](https://www.sec.gov/Archives/edgar/data/30554/000003055412000011/dd-ex109xretirementincomep.htm) | E. I. du Pont de Nemours and Company's Retirement Income Plan for Directors, as last amended January 2011 (incorporated by reference to Exhibit 10.9 to E. I. du Pont de Nemours and Company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March 31, 2012). |
| [10.15](https://www.sec.gov/Archives/edgar/data/1755672/000175567223000025/corteva-9302023xex101.htm) | Supplemental Agreement to the Memorandum of Understanding between The Chemours Company, Corteva, Inc., E. I. du Pont de Nemours and Company and DuPont de Nemours, Inc., dated September 5, 2023 (incorporated by reference to Exhibit 10.1 to Corteva's Quarterly Report on Form 10-Q (Commission file number 001-38710), filed on November 9, 2023). |
| [10.16](https://www.sec.gov/Archives/edgar/data/1755672/000119312521310412/d249489dex102.htm) | Corteva, Inc. Severance Plan (incorporated by reference to Exhibit 10.2 to Corteva's Current Report on Form 8-K (Commission file number 001-38710), filed on October 28, 2021). |
| [10.17\*](https://www.sec.gov/Archives/edgar/data/1755672/000119312519163314/d753864dex102.htm) | Letter Agreement effective as of June 1, 2019 by and between DowDuPont Inc. and Corteva, Inc. (incorporated by reference to Exhibit 10.2 to Corteva's Current Report on Form 8-K (Commission file number 001-38710) filed June 3, 2019) |
| [10.18\*](https://www.sec.gov/ix?doc=/Archives/edgar/data/1755672/000119312521014180/d108516d8k.htm) | Memorandum of Understanding, dated January 22, 2021, by and among The Chemours Company, Corteva, Inc., E. I. du Pont de Nemours and Company and DuPont de Nemours, Inc. (incorporated by reference from the Form 8-K (Commission file number 001-38710) filed January 22, 2021) |
| [10.19](https://www.sec.gov/Archives/edgar/data/1755672/000175567225000017/njstatewidesettlementjco.htm) | Judicial Consent Order between The State of New Jersey and The Chemours Company, DuPont de Nemours, Inc., together with Corteva, Inc. and EIDP, Inc. |
| [10.20](ctva-12312025xex1020.htm) | Letter Agreement, effective November 1, 2025, between DuPont de Nemours, Inc., Corteva, Inc., and Qnity Electronics, Inc. |
| [10.21](https://www.sec.gov/Archives/edgar/data/30554/000175567220000014/corteva-3312020xex105.htm) | Form of Award Terms for Restricted Stock Units granted under the Corteva, Inc. 2019 Omnibus Incentive Plan for U.S. grantees. |
| [10.22](https://www.sec.gov/Archives/edgar/data/1755672/000119312521106971/d159355dex101.htm) | Form of Award Terms of Options granted under the Corteva, Inc. 2019 Omnibus Incentive Plan for .U.S. grantees. |
| [10.23](https://www.sec.gov/Archives/edgar/data/1755672/000119312520287000/d826078dex43.htm) | Form of Performance Stock Units granted under the Corteva, Inc. 2019 Omnibus Incentive Plan for U.S. grantees. |
| [10.24](https://www.sec.gov/Archives/edgar/data/1755672/000175567223000018/corteva-6302023xex102.htm) | Amendment to EIDP, Inc.'s Retirement Savings Restoration Plan. (incorporated by reference to Exhibit No. 10.2 to Corteva's and EIDP's Quarterly Report on Form 10-Q (Commission file numbers 001-38710 and 001-00815, respectively), filed on August 4, 2023). |
| 10.25 | Corteva, Inc. Global Omnibus Employee Stock Purchase Plan (incorporated by reference from Exhibit 4.3 to Corteva's Registration Statement on Form S-8 (Commission file number 333-249887), filed November 5, 2020). |
| [19](ctva-12312025xex19.htm) | Corteva Insider Trading Policy |
| [21](ctva-12312025xex21.htm) | Subsidiaries of the Registrant. |
| [23.1](ctva-12312025xex231.htm) | Consent of Independent Registered Public Accounting Firm, PricewaterhouseCoopers LLP - Corteva, Inc. |
| [23.2](ctva-12312025xex232.htm) | Consent of Independent Registered Public Accounting Firm, PricewaterhouseCoopers LLP - EIDP, Inc. |
| [31.1](corteva-12312025xex311.htm) | Rule 13a-14(a)/15d-14(a) Certification of the company's and EIDP's Principal Executive Officer. |
| [31.2](corteva-12312025xex312.htm) | Rule 13a-14(a)/15d-14(a) Certification of the company's and EIDP's Principal Financial Officer. |
| [32.1](corteva-12312025xex321.htm) | Section 1350 Certification of the company's and EIDP's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. |
| [32.2](corteva-12312025xex322.htm) | Section 1350 Certification of the company's and EIDP's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. |
| [97](https://www.sec.gov/Archives/edgar/data/30554/000175567224000004/clawbackpolicy.htm) | Corteva, Inc. Clawback Policy (incorporated by reference from Exhibit 97 to Corteva's and EIDP's Annual Report on Form 10-K (Commission file numbers 001-38710 and 001-00815, respectively), filed on February 8, 2024). |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File – The Cover Page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101.INS) |

---

\* Upon request of the U.S. Securities and Exchange Commission (the "SEC"), Corteva hereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to such agreement; provided, however, that Corteva may omit confidential information pursuant to Item 601(b)(10) or request confidential treatment pursuant to Rule 24b-2 of the Exchange Act of any schedule or exhibit so furnished.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.**

---

| | | |
|:---|:---|:---|
| February 12, 2026 |  |  |
|  | Corteva, Inc. | Corteva, Inc. |
|  | By: | /s/ Brian Titus |
|  |  | Brian Titus<br>Vice President, Controller <br>(Principal Accounting Officer) |

---

_____________________________________________

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:**

---

| | | |
|:---|:---|:---|
| **Signature** | **Title(s)** | **Date** |
| /s/ Charles V. Magro | Chief Executive Officer and Director <br>(Principal Executive Officer) | February 12, 2026 |
| Charles V. Magro | Chief Executive Officer and Director <br>(Principal Executive Officer) |  |
| /s/ Gregory R. Page | Non-Executive Chairman of the Board of Directors and Director | February 12, 2026 |
| Gregory R. Page | Non-Executive Chairman of the Board of Directors and Director |  |
| /s/ Lamberto Andreotti | Director | February 12, 2026 |
| Lamberto Andreotti |  |  |
| /s/ David C. Everitt | Director | February 12, 2026 |
| David C. Everitt |  |  |
| /s/ Klaus A. Engel | Director | February 12, 2026 |
| Klaus A. Engel |  |  |
| /s/ Michael O. Johanns | Director | February 12, 2026 |
| Michael O. Johanns |  |  |
| /s/ Janet P. Giesselman | Director | February 12, 2026 |
| Janet P. Giesselman |  |  |
| /s/ Karen H. Grimes | Director | February 12, 2026 |
| Karen H. Grimes |  |  |
| /s/ Marcos M. Lutz | Director | February 12, 2026 |
| Marcos M. Lutz |  |  |
| /s/ Nayaki R. Nayyar | Director | February 12, 2026 |
| Nayaki R. Nayyar |  |  |
| /s/ Kerry J. Preete | Director | February 12, 2026 |
| Kerry J. Preete |  |  |
| /s/ Patrick J. Ward | Director | February 12, 2026 |
| Patrick J. Ward |  |  |
| /s/ David P. Johnson | Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer) | February 12, 2026 |
| David P. Johnson | Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer) |  |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.**

---

| | | |
|:---|:---|:---|
| February 12, 2026 |  |  |
|  | EIDP, Inc. | EIDP, Inc. |
|  | By: | /s/ Brian Titus |
|  |  | Brian Titus<br>Vice President, Controller <br>(Principal Accounting Officer) |

---

_____________________________________________

**Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:**

---

| | | |
|:---|:---|:---|
| **Signature** | **Title(s)** | **Date** |
| /s/ Charles V. Magro | Chief Executive Officer and Director <br>(Principal Executive Officer) | February 12, 2026 |
| Charles V. Magro | Chief Executive Officer and Director <br>(Principal Executive Officer) |  |
| /s/ David P. Johnson | Executive Vice President, <br>Chief Financial Officer and Director<br>(Principal Financial Officer) | February 12, 2026 |
| David P. Johnson | Executive Vice President, <br>Chief Financial Officer and Director<br>(Principal Financial Officer) |  |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Index to the Consolidated Financial Statements**

---

| | |
|:---|:---|
| | **Page(s)** |
| [Management's Reports on Responsibility for Financial Statements and Internal Control over Financial Reporting](#i46860590cf424b89b8159966786b56bb_136) | F-[2](#i46860590cf424b89b8159966786b56bb_136) |
| [Report of Independent Registered Public Accounting Firm (PCAOB ID](#i46860590cf424b89b8159966786b56bb_139)238[)](#i46860590cf424b89b8159966786b56bb_139) | F-[3](#i46860590cf424b89b8159966786b56bb_139) |
| Consolidated Financial Statements: |  |
| [Consolidated Statements of Operations for the years ended December 31, 2025, 2024, and 2023](#i46860590cf424b89b8159966786b56bb_142) | F-[5](#i46860590cf424b89b8159966786b56bb_142) |
| [Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2025, 2024, and 2023](#i46860590cf424b89b8159966786b56bb_145) | F-[6](#i46860590cf424b89b8159966786b56bb_145) |
| [Consolidated Balance Sheets as of December 31, 2025 and 2024](#i46860590cf424b89b8159966786b56bb_148) | F-[7](#i46860590cf424b89b8159966786b56bb_148) |
| [Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024, and 2023](#i46860590cf424b89b8159966786b56bb_154) | F-[8](#i46860590cf424b89b8159966786b56bb_154) |
| [Consolidated Statements of Equity for the years ended December 31, 2025, 2024, and 2023](#i46860590cf424b89b8159966786b56bb_157) | F-[9](#i46860590cf424b89b8159966786b56bb_157) |
| [Notes to the Consolidated Financial Statements](#i46860590cf424b89b8159966786b56bb_163) | F-[10](#i46860590cf424b89b8159966786b56bb_163) |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Management's Reports on Responsibility for Financial Statements and**

**Internal Control over Financial Reporting**

**Management's Report on Responsibility for Financial Statements**

Management is responsible for the Consolidated Financial Statements and the other financial information contained in this Annual Report on Form 10-K. The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and are considered by management to present fairly the company's financial position, results of operations and cash flows. The financial statements include some amounts that are based on management's best estimates and judgments. The Consolidated Financial Statements have been audited by the company's independent registered public accounting firm, PricewaterhouseCoopers LLP. The purpose of their audit is to express an opinion as to whether the Consolidated Financial Statements included in this Annual Report on Form 10-K present fairly, in all material respects, the company's financial position, results of operations and cash flows in conformity with GAAP. Their report is presented on the following pages.

**Management's Report on Internal Control over Financial Reporting**

Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The company's internal control over financial reporting includes those policies and procedures that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the company's assets that could have a material effect on the financial statements.

Internal control over financial reporting has certain inherent limitations which may not prevent or detect misstatements. In addition, changes in conditions and business practices may cause variation in the effectiveness of internal controls.

Management assessed the effectiveness of the company's internal control over financial reporting as of December 31, 2025, based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in *Internal Control-Integrated Framework (2013)*. Based on its assessment and those criteria, management concluded that the company maintained effective internal control over financial reporting as of December 31, 2025.

PricewaterhouseCoopers LLP, an independent registered public accounting firm, has audited the effectiveness of the company's internal control over financial reporting as of December 31, 2025, as stated in their report, which is presented on the following pages.

![CM Signature.jpg](ctva-20251231_g6.jpg)![DJ Signature B&W.jpg](ctva-20251231_g7.jpg)

Charles V. MagroChief Executive Officer and Director David P. JohnsonExecutive Vice President andChief Financial Officer

February 12, 2026

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Report of Independent Registered Public Accounting Firm**

To the Board of Directors and Stockholders of Corteva, Inc.

***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of Corteva, Inc. and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of operations, of comprehensive income (loss), of equity and of cash flows for each of the three years in the period ended December 31, 2025, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2025 appearing under Item 15 (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

***Basis for Opinions***

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

***Definition and Limitations of Internal Control over Financial Reporting***

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***Critical Audit Matters***

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

*Revenue Recognition - Product Sales*

As described in Notes 2 and 4 to the consolidated financial statements, net sales were $17.401 billion for the year ended December 31, 2025. Substantially all of Corteva's revenue is derived from product sales. Revenue is recognized from product sales when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. Control transfer occurs at a point in time according to shipping terms. The transaction price includes estimates of variable consideration, such as rights of return, rebates, and discounts, that are reductions in revenue. All estimates are based on the Company's historical experience, anticipated performance, and management's best judgment at the time the estimate is made. Estimates of variable consideration included in the transaction price primarily utilize the expected value method based on historical experience. These estimates are reassessed each reporting period and are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur upon resolution of uncertainty associated with the variable consideration. The majority of contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as quantity times price per unit.

The principal consideration for our determination that performing procedures relating to revenue recognition for product sales is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company's revenue recognition.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process. These procedures also included, among others (i) evaluating revenue transactions by testing, on a sample basis, the revenue recognized by obtaining and inspecting source documents, such as purchase orders, invoices, shipment or delivery documents, and cash receipts, as applicable; (ii) testing, on a sample basis, the recognition of variable consideration for rebates issued and discounts granted during the year by obtaining and inspecting source documents, such as support for the nature of the variable consideration, amount, and agreement with the customer; and (iii) confirming, on a sample basis, outstanding customer invoice balances as of year-end, and, for confirmations not returned, obtaining and inspecting source documents, including invoices, shipment or delivery documents, and subsequent cash receipts, as applicable.

/s/ PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania

February 12, 2026

We have served as the Company's or its predecessor's auditor since 1946.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions, except per share amounts)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|  | **2025** | **2024** | **2023** |
| Net sales | $17401 | $16908 | $17226 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 9172 | 9529 | 9920 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense | 1474 | 1402 | 1337 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 3492 | 3196 | 3176 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 644 | 685 | 683 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 146 | 288 | 336 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 35 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense) - net | (570) | (300) | (448) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 180 | 233 | 233 |
| Income (loss) from continuing operations before income taxes | 1688 | 1275 | 1093 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) income taxes on continuing operations | 484 | 412 | 152 |
| Income (loss) from continuing operations after income taxes | 1204 | 863 | 941 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations after income taxes | (99) | 56 | (194) |
| Net income (loss) | 1105 | 919 | 747 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to noncontrolling interests | 11 | 12 | 12 |
| Net income (loss) attributable to Corteva | $1094 | $907 | $735 |
| Basic earnings (loss) per share of common stock: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per share of common stock from continuing operations | $1.75 | $1.23 | $1.31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per share of common stock from discontinued operations | (0.15) | 0.08 | (0.27) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per share of common stock | $1.60 | $1.31 | $1.04 |
| Diluted earnings (loss) per share of common stock: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share of common stock from continuing operations | $1.75 | $1.22 | $1.30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share of common stock from discontinued operations | (0.15) | 0.08 | (0.27) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share of common stock | $1.60 | $1.30 | $1.03 |

---

See Notes to the Consolidated Financial Statements beginning on page F-11.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Net income (loss) | $1105 | $919 | $747 |
| Other comprehensive income (loss) - net of tax: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustments | 867 | (1014) | 425 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to pension benefit plans | (152) | 127 | (190) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to other benefit plans | (26) | 30 | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on investments | 6 | (6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative instruments | (23) | 71 | (135) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | 672 | (792) | 129 |
| Comprehensive income (loss) | 1777 | 127 | 876 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income (loss) attributable to noncontrolling interests - net of tax | 11 | 12 | 12 |
| Comprehensive income (loss) attributable to Corteva | $1766 | $115 | $864 |

---

See Notes to the Consolidated Financial Statements beginning on page F-11.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED BALANCE SHEETS** 

---

| | | |
|:---|:---|:---|
| *(In millions, except share and per share amounts)* | **December 31, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $4521 | $3106 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 9 | 63 |
| &nbsp;&nbsp;&nbsp;Accounts and notes receivable - net | 6371 | 5676 |
| &nbsp;&nbsp;&nbsp;Inventories | 5667 | 5432 |
| &nbsp;&nbsp;&nbsp;Other current assets | 767 | 820 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 17335 | 15097 |
| Investment in nonconsolidated affiliates | 160 | 134 |
| Property, plant and equipment | 9551 | 9074 |
| Less: Accumulated depreciation | 5331 | 4975 |
| Net property, plant and equipment | 4220 | 4099 |
| Goodwill | 10465 | 10408 |
| Other intangible assets | 8301 | 8876 |
| Deferred income taxes | 320 | 401 |
| Other assets | 2044 | 1810 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $42845 | $40825 |
| **Liabilities and Equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Short-term borrowings and finance lease obligations | $894 | $750 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 4398 | 4039 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 155 | 207 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 3579 | 3287 |
| &nbsp;&nbsp;&nbsp;Accrued and other current liabilities | 3099 | 2103 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 12125 | 10386 |
| Long-term debt | 1686 | 1953 |
| Other noncurrent liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Deferred income tax liabilities | 251 | 478 |
| &nbsp;&nbsp;&nbsp;Pension and other post-employment benefits | 2434 | 2271 |
| &nbsp;&nbsp;&nbsp;Other noncurrent obligations | 1963 | 1707 |
| &nbsp;&nbsp;&nbsp;Total noncurrent liabilities | 6334 | 6409 |
| Commitments and contingent liabilities |  |  |
| Stockholders' equity |  |  |
| Common stock, $0.01 par value;1,666,667,000 shares authorized; <br>issued at December 31, 2025 - 672,163,000 and December 31, 2024 - 685,595,000 | 7 | 7 |
| Additional paid-in capital | 27001 | 27196 |
| Retained earnings (accumulated deficit) | (67) | 55 |
| Accumulated other comprehensive income (loss) | (2797) | (3469) |
| &nbsp;&nbsp;&nbsp;Total Corteva stockholders' equity | 24144 | 23789 |
| Noncontrolling interests | 242 | 241 |
| &nbsp;&nbsp;&nbsp;Total equity | 24386 | 24030 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Equity | $42845 | $40825 |

---

See Notes to the Consolidated Financial Statements beginning on page F-11.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| **Operating activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net income (loss) | $1105 | $919 | $747 |
| &nbsp;&nbsp;&nbsp;(Income) loss from discontinued operations after income taxes | 99 | (56) | 194 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1203 | 1227 | 1211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) deferred income tax | (41) | (365) | (438) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension and OPEB (benefit) cost, net | 36 | 160 | 138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and OPEB contributions | (136) | (151) | (149) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (gain) loss on sales of property, businesses, consolidated companies, and investments | (41) | (17) | (22) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 146 | 288 | 336 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other net loss | 545 | 383 | 578 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable | (261) | (705) | 358 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (35) | 1110 | 57 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 231 | (115) | (663) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 270 | (86) | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | 336 | (296) | (527) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - continuing operations | 3457 | 2296 | 1809 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - discontinued operations | (51) | (151) | (40) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities | 3406 | 2145 | 1769 |
| **Investing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (591) | (597) | (595) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of property, businesses, and consolidated companies - net of cash divested | 54 | 5 | 57 |
| &nbsp;&nbsp;&nbsp;Acquisitions of businesses - net of cash acquired |  |  | (1456) |
| &nbsp;&nbsp;&nbsp;Investments in and loans to nonconsolidated affiliates | (20) | (7) | (32) |
| &nbsp;&nbsp;&nbsp;Purchases of investments |  | (144) | (148) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales and maturities of investments | 135 | 130 | 147 |
| &nbsp;&nbsp;&nbsp;Proceeds from (payments for) settlement of net investment hedge | (83) | 63 | 42 |
| &nbsp;&nbsp;&nbsp;Other investing activities, net | (38) | (39) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) investing activities | (543) | (589) | (1987) |
| **Financing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net change in borrowings (less than 90 days) |  | 53 | (6) |
| &nbsp;&nbsp;&nbsp;Proceeds from debt | 1730 | 3072 | 3429 |
| &nbsp;&nbsp;&nbsp;Payments on debt | (1871) | (2885) | (2309) |
| &nbsp;&nbsp;&nbsp;Repurchase of common stock | (1071) | (1009) | (756) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | 88 | 60 | 31 |
| &nbsp;&nbsp;&nbsp;Dividends paid to stockholders | (475) | (458) | (439) |
| &nbsp;&nbsp;&nbsp;Other financing activities, net | (45) | (32) | (49) |
| &nbsp;&nbsp;&nbsp;Cash provided by (used for) financing activities | (1644) | (1199) | (99) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 84 | (93) | (143) |
| Increase (decrease) in cash, cash equivalents and restricted cash equivalents | 1303 | 264 | (460) |
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 3422 | 3158 | 3618 |
| **Cash, cash equivalents and restricted cash equivalents at end of period** <sup>1</sup> | $4725 | $3422 | $3158 |
| **Supplemental cash flow information** |  |  |  |
| **Cash paid during the period for** |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest, net of amounts capitalized | $191 | $244 | $234 |
| &nbsp;&nbsp;&nbsp;Income taxes | 750 | 707 | 535 |

---

1. See page F-22 for reconciliation of cash and cash equivalents and restricted cash equivalents presented in the Consolidated Balance Sheets to total cash, cash equivalents and restricted cash equivalents presented in the Consolidated Statements of Cash Flows.

See Notes to the Consolidated Financial Statements beginning on page F-11.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF EQUITY**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(In millions)* | *Common Stock* | *Additional Paid-in Capital* | *Retained Earnings (Accum. Deficit)* | *Accumulated Other Comp. Income (Loss)* | *Non-Controlling Interests* | *Total Equity* |
| Balance at January 1, 2023 | $7 | $27851 | $250 | $(2806) | $239 | $25541 |
| Net income (loss) |  |  | 735 |  | 12 | 747 |
| Other comprehensive income (loss) |  |  |  | 129 |  | 129 |
| Share-based compensation |  | 28 | (2) |  |  | 26 |
| Common dividends ($0.62 per share) |  |  | (439) |  |  | (439) |
| Repurchase of common stock |  | (171) | (585) |  |  | (756) |
| Issuance of Corteva stock |  | 40 |  |  |  | 40 |
| Other - net |  |  |  |  | (9) | (9) |
| Balance at December 31, 2023 | $7 | $27748 | $(41) | $(2677) | $242 | $25279 |
| Net income (loss) |  |  | 907 |  | 12 | 919 |
| Other comprehensive income (loss) |  |  |  | (792) |  | (792) |
| Share-based compensation |  | 47 | (2) |  |  | 45 |
| Common dividends ($0.66 per share) |  | (229) | (229) |  |  | (458) |
| Repurchase of common stock |  | (430) | (579) |  |  | (1009) |
| Issuance of Corteva stock |  | 60 |  |  |  | 60 |
| Other - net |  |  | (1) |  | (13) | (14) |
| Balance at December 31, 2024 | $7 | $27196 | $55 | $(3469) | $241 | $24030 |
| Net income (loss) |  |  | 1094 |  | 11 | 1105 |
| Other comprehensive income (loss) |  |  |  | 672 |  | 672 |
| Share-based compensation |  | 57 | (2) |  |  | 55 |
| Common dividends ($0.70 per share) |  | (116) | (359) |  |  | (475) |
| Repurchase of common stock |  | (221) | (850) |  |  | (1071) |
| Issuance of Corteva stock |  | 88 |  |  |  | 88 |
| Other - net |  | (3) | (5) |  | (10) | (18) |
| Balance at December 31, 2025 | $7 | $27001 | $(67) | $(2797) | $242 | $24386 |

---

See Notes to the Consolidated Financial Statements beginning on page F-11.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements**

**Table of Contents**

---

| | | |
|:---|:---|:---|
| **Note** | | **Page** |
| 1 | [Background and Basis of Presentation](#i46860590cf424b89b8159966786b56bb_166) | F-[11](#i46860590cf424b89b8159966786b56bb_166) |
| 2 | [Summary of Significant Accounting Policies](#i46860590cf424b89b8159966786b56bb_169) | F-[12](#i46860590cf424b89b8159966786b56bb_169) |
| 3 | [Recent Accounting Guidance](#i46860590cf424b89b8159966786b56bb_172) | F-[16](#i46860590cf424b89b8159966786b56bb_172) |
| 4 | [Revenue](#i46860590cf424b89b8159966786b56bb_178) | F-[17](#i46860590cf424b89b8159966786b56bb_178) |
| 5 | [Restructuring and Asset Related Charges - Net](#i46860590cf424b89b8159966786b56bb_181) | F-[19](#i46860590cf424b89b8159966786b56bb_181) |
| 6 | [Supplementary Information](#i46860590cf424b89b8159966786b56bb_187) | F-[21](#i46860590cf424b89b8159966786b56bb_187) |
| 7 | [Income Taxes](#i46860590cf424b89b8159966786b56bb_190) | F-[23](#i46860590cf424b89b8159966786b56bb_190) |
| 8 | [Earnings Per Share of Common Stock](#i46860590cf424b89b8159966786b56bb_193) | F-[28](#i46860590cf424b89b8159966786b56bb_193) |
| 9 | [Accounts and Notes Receivable - Net](#i46860590cf424b89b8159966786b56bb_196) | F-[29](#i46860590cf424b89b8159966786b56bb_196) |
| 10 | [Inventories](#i46860590cf424b89b8159966786b56bb_199) | F-[30](#i46860590cf424b89b8159966786b56bb_199) |
| 11 | [Property, Plant and Equipment](#i46860590cf424b89b8159966786b56bb_202) | F-[30](#i46860590cf424b89b8159966786b56bb_202) |
| 12 | [Goodwill and Other Intangible Assets](#i46860590cf424b89b8159966786b56bb_208) | F-[30](#i46860590cf424b89b8159966786b56bb_208) |
| 13 | [Leases](#i46860590cf424b89b8159966786b56bb_211) | F-[31](#i46860590cf424b89b8159966786b56bb_211) |
| 14 | Short-Term Borrowings, [Long-Term Debt and Available Credit Facilities](#i46860590cf424b89b8159966786b56bb_214) | F-[33](#i46860590cf424b89b8159966786b56bb_214) |
| 15 | [Commitments and Contingent Liabilities](#i46860590cf424b89b8159966786b56bb_220) | F-[35](#i46860590cf424b89b8159966786b56bb_220) |
| 16 | [Stockholders' Equity](#i46860590cf424b89b8159966786b56bb_223) | F-[45](#i46860590cf424b89b8159966786b56bb_223) |
| 17 | [Pension Plans and Other Post-Employment Benefits](#i46860590cf424b89b8159966786b56bb_229) | F-[47](#i46860590cf424b89b8159966786b56bb_229) |
| 18 | [Stock-Based Compensation](#i46860590cf424b89b8159966786b56bb_232) | F-[56](#i46860590cf424b89b8159966786b56bb_232) |
| 19 | [Financial Instruments](#i46860590cf424b89b8159966786b56bb_235) | F-[58](#i46860590cf424b89b8159966786b56bb_235) |
| 20 | [Fair Value Measurements](#i46860590cf424b89b8159966786b56bb_238) | [F-65](#i46860590cf424b89b8159966786b56bb_238) |
| 21 | [Geographic Information](#i46860590cf424b89b8159966786b56bb_241) | F-[64](#i46860590cf424b89b8159966786b56bb_241) |
| 22 | [Segment Information](#i46860590cf424b89b8159966786b56bb_244) | F-[65](#i46860590cf424b89b8159966786b56bb_244) |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 1 - BACKGROUND AND BASIS OF PRESENTATION**

Corteva, Inc. is a leading global provider of seed and crop protection solutions focused on the agriculture industry. The company intends to leverage its rich heritage of scientific achievement to advance its robust innovation pipeline and continue to shape the future of responsible agriculture. The company's broad portfolio of agriculture solutions fuels farmer productivity around the globe. Corteva has two operating segments: Seed and Crop Protection. See Note 22 - Segment Information, to the Consolidated Financial Statements, for additional information on the company's operating segments.

Throughout these financial statements, except as otherwise noted by the context, the terms "Corteva" or "company" used herein mean Corteva, Inc. and its consolidated subsidiaries (including EIDP) and the term "EIDP" used herein means EIDP, Inc. (formerly known as E. I. du Pont de Nemours and Company) and its consolidated subsidiaries or EIDP, Inc. excluding its consolidated subsidiaries, as the context may indicate.

**Principles of Consolidation and Basis of Presentation**

The consolidated financial statements contained in this Annual Report were prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for all periods presented and include the accounts of the company, its majority owned subsidiaries over which the company exercises control. The Consolidated Financial Statements and other financial information included in this Annual Report, unless otherwise specified, have been presented to separately show the effects of discontinued operations.

On June 1, 2019, Corteva, Inc. became an independent, publicly traded company through the completed separation of the agriculture business (the "Corteva Separation") of DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.) ("DowDuPont" or "DuPont"). The Corteva Separation was effectuated through a pro rata distribution (the "Corteva Distribution") of all of the then-issued and outstanding shares of common stock of Corteva, Inc.

Prior to the Corteva Separation, subsequent to the Merger, Historical Dow and EIDP engaged in a series of internal reorganization and realignment steps to realign their businesses into three subgroups: agriculture, materials science and specialty products ("Internal Reorganization"). On April 1, 2019, DowDuPont completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow common stock to holders of DowDuPont's common stock (the "Dow Distribution" and together with the Corteva Distribution, the "Distributions").

On April 1, 2019, Historical Dow entities, which held certain assets and liabilities aligned with Historical Dow's agriculture business and the assets and liabilities associated with its specialty products business, respectively, were transferred and conveyed to DowDuPont.

On April 1, 2019 and May 1, 2019, EIDP's materials science and specialty products entities, along with their respective assets and liabilities, were conveyed to Dow and DowDuPont, respectively. On May 2, 2019, DowDuPont conveyed Historical Dow agricultural entities to EIDP.

On May 6, 2019, the Board of Directors of DowDuPont approved the distribution of all the then issued and outstanding shares of common stock of Corteva, Inc., then a wholly-owned subsidiary of DowDuPont, to DowDuPont stockholders. On May 31, 2019, DowDuPont contributed EIDP to Corteva, Inc. and on June 1, 2019, the Corteva Separation was completed. Information related to the Corteva Distribution and its effect on the company's financial statements is discussed throughout these Notes to the Consolidated Financial Statements.

Since 2018, Argentina has been considered a highly-inflationary economy under U.S. GAAP and, therefore, the U.S. Dollar ("USD") is the functional currency for our related subsidiaries. Argentina contributes approximately 3 percent to the company's annual net sales and approximately 1 percent to each of the company's annual Seed and Crop Protection segment operating EBITDA. The company remeasures net monetary assets and translates the financial statements utilizing the official Argentine Peso ("Peso") to USD exchange rate. The ability to draw down Peso cash balances is limited at this time due to government restrictions and market availability of U.S. Dollars. The devaluation of the Peso relative to the USD over the last several years has resulted in the recognition of exchange losses (refer to Note 6 – Supplementary Information, to the Consolidated Financial Statements). The Argentina government has offered USD-denominated bonds to importers, the proceeds from which could be used to pay off outstanding intercompany payables. As of December 31, 2025, the company holds these foreign government bonds with an amortized cost of $30 million as part of its strategy to manage its net monetary asset exposure in Argentina. Refer to the "Debt Securities" section in Note 19 - Financial Instruments, to the Consolidated Financial Statements, for additional information. As of December 31, 2025, a further 10 percent deterioration in the official Peso to USD exchange rate

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

would not have a significant impact on the USD value of our net monetary assets or pre-tax earnings. The company will continue to assess the implications to its operations and financial reporting.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The Consolidated Financial Statements include the accounts of the company and subsidiaries in which a controlling interest is maintained. For those consolidated subsidiaries in which the company's ownership is less than 100 percent, the outside stockholders' interests are shown as noncontrolling interests. Investments in affiliates over which the company has the ability to exercise significant influence but does not have a controlling interest are accounted for under the equity method.

The company is also involved with certain joint ventures accounted for under the equity method of accounting that are variable interest entities ("VIEs"). The company is not the primary beneficiary, as the nature of the company's involvement with each VIE does not provide it the power to direct the VIE's significant activities. Future events may require these VIEs to be consolidated if the company becomes the primary beneficiary. At December 31, 2025 and 2024, the maximum exposure to loss related to the nonconsolidated VIEs is not considered material to the Consolidated Financial Statements.

**Use of Estimates in Financial Statement Preparation**

The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The company's consolidated financial statements include amounts that are based on management's best estimates and judgments. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

Cash equivalents represent highly liquid investments with maturities of three months or less from time of purchase. They are carried at cost plus accrued interest.

**Restricted Cash Equivalents**

Restricted cash equivalents primarily relates to a trust funded by EIDP for cash obligations under certain non-qualified benefit and deferred compensation plans due to the Merger, which was a change in control event, and contributions to escrow accounts established for the settlement of certain legal matters and the settlement of legacy PFAS matters and the associated qualified spend. Corteva classifies restricted cash equivalents as current or noncurrent based on the nature of the restrictions, which are included in other current assets and other assets, respectively, in the Consolidated Balance Sheets. See Note 6 - Supplementary Information, to the Consolidated Financial Statements, for further information.

**Marketable Securities**

Marketable securities represent investments in fixed and floating rate financial instruments with maturities greater than three months and up to twelve months at time of purchase. Investments classified as held-to-maturity are recorded at amortized cost. The carrying value approximates fair value due to the short-term nature of the investments. Investments classified as debt securities that are available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss) or current period earnings if an allowance for credit losses has been established. The cost of investments sold is determined by specific identification.

**Fair Value Measurements**

Under the accounting guidance for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The company uses the following hierarchy to classify assets and liabilities measured at fair value:

---

| | |
|:---|:---|
| Level 1 | Quoted market prices in active markets for identical assets or liabilities. |
| Level 2 | Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs). |
| Level 3 | Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability. |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**Foreign Currency Translation**

The company's worldwide operations utilize the USD or a related foreign currency as the functional currency, where applicable. The company identifies its separate and distinct foreign entities and groups the foreign entities into two categories: (i) extension of the parent or foreign subsidiaries operating in a highly-inflationary environment (USD functional currency) and (ii) self-contained (related foreign functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency.

For foreign entities where the USD is the functional currency, all foreign currency-denominated asset and liability amounts are re-measured into USD at end-of-period exchange rates, except for inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, which are re-measured at historical rates. Foreign currency income and expenses are re-measured at average exchange rates in effect during each month, except for expenses related to balance sheet amounts re-measured at historical exchange rates. Exchange gains and losses arising from re-measurement of foreign currency-denominated monetary assets and liabilities are included in income in the period in which they occur.

For foreign entities where a related foreign currency is the functional currency, assets and liabilities denominated in the related foreign currencies are translated into USD at end-of-period exchange rates and the resultant translation adjustments are reported, net of their related tax effects, as a component of accumulated other comprehensive income (loss) in equity. Assets and liabilities denominated in other than the functional currency are re-measured into the functional currency prior to translation into USD and the resultant exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into USD at average exchange rates in effect during each month.

The company changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed.

**Inventories**

The company's inventories are valued at the lower of cost or net realizable value. Elements of cost in inventories include raw materials, direct labor and manufacturing overhead. Stores and supplies are valued at cost or net realizable value, whichever is lower; cost is generally determined by the average cost method.

As of both December 31, 2025 and 2024, approximately 60 percent and 40 percent of the company's inventories were accounted for under the first-in, first-out ("FIFO") and average cost methods, respectively. Inventories accounted for under the FIFO method are primarily comprised of products with shorter shelf lives such as seeds. See Note 10 - Inventories, to the Consolidated Financial Statements, for further information.

The company establishes an obsolescence reserve for inventory based upon quality considerations and assumptions about future demand and market conditions.

**Goodwill and Other Intangible Assets**

The company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is tested for impairment at the reporting unit level at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. The company performs an annual goodwill impairment test in the fourth quarter at the reporting unit level, which is defined as the operating segment or one level below the operating segment. One level below the operating segment, or component, is a business in which discrete financial information is available and regularly reviewed by segment management. The company aggregates certain components into reporting units based on economic similarities. The company's reporting units are Seed and Crop Protection.

When testing goodwill for impairment, the company has the option to first perform qualitative testing to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the company chooses not to complete a qualitative assessment for a given reporting unit or if the initial assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, additional quantitative testing is required. If additional quantitative testing is required, the reporting unit's fair value is compared with its carrying amount, and an impairment charge, if any, is recognized for the amount by which the carrying amount exceeds the reporting unit's fair value, limited to the amount of goodwill associated with the reporting unit. The company determines fair values for each of the reporting units using a discounted cash flow model (a form of the income approach). Under the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. The company's significant assumptions in this analysis include future cash flow projections, weighted average cost of capital, the terminal growth rate, and the tax rate. See Note 12 - Goodwill and Other Intangible Assets, to the Consolidated Financial Statements, for further information on goodwill.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Definite-lived intangible assets are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging primarily from 2 years to 25 years. The company continually evaluates the reasonableness of the useful lives of these assets. Once these assets are no longer considered held and used, they are removed from the Consolidated Balance Sheets.

**Acquisitions**

Acquisitions are recorded using the acquisition method of accounting which recognizes and measures the identifiable assets acquired and liabilities assumed as of the acquisition date at fair value, where applicable. The excess, if any, of total consideration transferred in a business combination over the fair value of identifiable assets acquired and liabilities assumed is recognized as goodwill. Costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred. The company includes the operating results of acquired entities from their respective dates of acquisition.

**Leases**

The company determines whether an arrangement is a lease at the inception of the arrangement based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the company has the right to control the asset. Operating lease right-of-use ("ROU") assets are included in other assets on the company's Consolidated Balance Sheets. Operating lease liabilities are included in accrued and other current liabilities and other noncurrent obligations on the company's Consolidated Balance Sheets. Finance lease assets are included in property, plant and equipment on the company's Consolidated Balance Sheets. Finance lease liabilities are included in short-term borrowings and finance lease obligations and long-term debt on the company's Consolidated Balance Sheets.

Operating lease ROU assets represent the company's right to use an underlying asset for the lease term and lease liabilities represent the company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the company's leases do not provide the lessor's implicit rate, the company uses its incremental borrowing rate at the commencement date in determining the present value of lease payments. Lease terms include options to extend the lease when it is reasonably certain those options will be exercised. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The company recognizes lease expense for these leases on a straight-line basis over the lease term.

The company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. In the Consolidated Statements of Operations, lease expense for operating leases is recognized on a straight-line basis over the lease term. For finance leases, interest expense is recognized on the lease liability and the ROU asset is amortized over the lease term. See Note 13 - Leases, to the Consolidated Financial Statements, for further information.

**Impairment of Long-Lived Assets**

The company evaluates the carrying value of long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. The carrying value of a long-lived asset group is considered impaired when the total projected undiscounted cash flows from the assets are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset group. The company's fair value methodology is an estimate of fair market value which is made based on prices of similar assets or other valuation methodologies including present value techniques. Long-lived assets to be disposed of by sale, if material, are classified as held for sale and reported at the lower of carrying amount or fair value less cost to sell, and depreciation is ceased. Long-lived assets to be disposed of other than by sale are classified as held and used until they are disposed of and reported at the lower of carrying amount or fair value. Depreciation is recognized over the remaining useful life of the assets.

**Derivative Instruments**

Derivative instruments are reported in the Consolidated Balance Sheets at their fair values. The company utilizes derivatives to manage exposures to foreign currency exchange rates and commodity prices. Changes in the fair values of derivative instruments that are not designated as hedges are recorded in current period earnings. For derivative instruments designated as cash flow hedges, the gain (loss) is reported in accumulated other comprehensive income (loss) until it is cleared to earnings during the same period in which the hedged item affects earnings. For derivative instruments designated as net investment hedges, the gain (loss) is reported within accumulated other comprehensive income (loss) until the subsidiary is divested.

In the event that a derivative designated as a hedge of a firm commitment or an anticipated transaction is terminated prior to the maturation of the hedged transaction, the net gain or loss in accumulated other comprehensive income (loss) generally remains in accumulated other comprehensive income (loss) until the item that was hedged affects earnings. If a hedged transaction

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

matures, or is sold, extinguished, or terminated prior to the maturity of a derivative designated as a hedge of such transaction, gains or losses associated with the derivative through the date the transaction matured are included in the measurement of the hedged transaction and the derivative is reclassified as for trading purposes. Derivatives designated as hedges of anticipated transactions are reclassified as for trading purposes if the anticipated transaction is no longer probable.

The company included foreign currency exchange contract settlements within cash flows from operating activities, regardless of hedge accounting qualification. See Note 19 - Financial Instruments, to the Consolidated Financial Statements, for additional discussion regarding the company's objectives and strategies for derivative instruments.

**Environmental Matters**

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. These accruals are adjusted periodically as assessment and remediation efforts progress or as additional technical or legal information becomes available. Accruals for environmental liabilities are included in the Consolidated Balance Sheets in accrued and other current liabilities and other noncurrent obligations at undiscounted amounts. Accruals for related insurance or other third-party recoveries for environmental liabilities are recorded when it is probable that a recovery will be realized and are included in the Consolidated Balance Sheets as accounts and notes receivable - net.

Environmental costs are capitalized if the costs extend the life of the property, increase its capacity, and/or mitigate or prevent contamination from future operations. Environmental costs are also capitalized in recognition of legal asset retirement obligations resulting from the acquisition, construction and/or normal operation of a long-lived asset. Costs related to environmental contamination treatment and cleanup are charged to expense. Estimated future incremental operations, maintenance and management costs directly related to remediation are accrued when such costs are probable and reasonably estimable.

**Revenue Recognition**

The company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. To determine the revenue recognition for an arrangement considered to be a contract with a customer, the company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. See Note 4 - Revenue, to the Consolidated Financial Statements, for additional information on revenue recognition.

**Cost of Goods Sold** 

Cost of goods sold primarily includes the cost of manufacture and delivery, ingredients or raw materials, direct salaries, wages and benefits and overhead, non-capitalizable costs associated with capital projects, royalties and other operational expenses. No amortization of intangibles is included within cost of goods sold.

**Research and Development**

Research and development costs are expensed as incurred. Research and development expense includes costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products.

**Selling, General and Administrative Expenses** 

Selling, general and administrative expenses primarily include selling and marketing expenses, commissions, functional costs, and business management expenses.

**Litigation and Other Contingencies**

Accruals for legal matters and other contingencies are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Legal costs, such as outside counsel fees and expenses, are charged to expense in the period incurred.

**Severance Costs**

Severance benefits are provided to employees under the company's ongoing benefit arrangements. Severance costs are accrued when management commits to a plan of termination and it becomes probable that employees will be entitled to benefits at amounts that can be reasonably estimated.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**Insurance/Self-Insurance**

The company self-insures certain risks where permitted by law or regulation, including workers' compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. For other risks, the company uses a combination of insurance and self-insurance, reflecting comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable.

**Income Taxes** 

The company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities using enacted tax rates. The effect of a change in tax rates on deferred tax assets or liabilities is recognized in income in the period that includes the enactment date.

The company recognizes the financial statement effects of an uncertain income tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. The current portion of uncertain income tax positions is included in income taxes payable or accounts and notes receivable - net, and the long-term portion is included in other noncurrent obligations or other assets in the Consolidated Balance Sheets.

Income tax related penalties are included in the provision for (benefit from) income taxes in the Consolidated Statements of Operations. Interest accrued related to unrecognized tax benefits is included within the provision for (benefit from) income taxes from continuing operations in the Consolidated Statements of Operations.

**Earnings per Common Share**

The calculation of earnings per common share is based on the weighted-average number of the company's common shares outstanding for the applicable period. The calculation of diluted earnings per common share reflects the effect of all potential common shares that were outstanding during the respective periods, unless the effect of doing so is antidilutive.

**NOTE 3 - RECENT ACCOUNTING GUIDANCE**

**Recently Adopted Accounting Guidance** 

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The company adopted this guidance on a prospective basis and has included enhanced income tax related disclosures in Note 7 - Income Taxes, to the Consolidated Financial Statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment's profit or loss measure(s) that are regularly provided to the chief operating decision maker (the "CODM") to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The company adopted this guidance and has included enhanced disclosures relating to its reportable segments. See Note 22 - Segment Information, to the Consolidated Financial Statements, for the company's updated disclosure.

**Accounting Guidance Issued But Not Adopted as of December 31, 2025**

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU includes amendments that require entities to bifurcate specified expense line items on the income statement into underlying components, including purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion, as applicable. Qualitative descriptions of the remaining components are required. These enhanced disclosures are required for both interim and annual periods. Selling expenses must also be separately disclosed for both interim and annual periods, along with an annual qualitative description of the composition of selling expenses. In January 2025, the FASB subsequently issued ASU

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, to provide clarification on the ASU's effective date. The new standard is effective for fiscal years beginning after December 15, 2026 on a prospective basis with the option to apply it retrospectively, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced disclosures around income statement expenses.

**NOTE 4 - REVENUE**

**Revenue Recognition**

*Products*

Substantially all of Corteva's revenue is derived from product sales, which consist of sales of Corteva's products to farmers, distributors, and manufacturers. Corteva considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year. However, the company has some long-term contracts which can span multiple years.

Revenue from product sales is recognized when the customer obtains control of the company's product, which occurs at a point in time according to shipping terms. Payment terms are generally less than one year from invoicing. The company elected the practical expedient and does not adjust the promised amount of consideration for the effects of a significant financing component when the company expects it will be one year or less between when a customer obtains control of the company's product and when payment is due. When the company performs shipping and handling activities after the transfer of control to the customer (e.g., when control transfers prior to or at shipment), these are considered fulfillment activities, and accordingly, the costs are accrued when the related revenue is recognized. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. In addition, the company elected the practical expedient to expense any costs to obtain contracts as incurred, as the amortization period for these costs would have been one year or less.

The transaction price includes estimates of variable consideration, such as rights of return, rebates, and discounts, that are reductions in revenue. All estimates are based on the company's historical experience, anticipated performance, and the company's best judgment at the time the estimate is made. Estimates of variable consideration included in the transaction price primarily utilize the expected value method based on historical experience. These estimates are reassessed each reporting period and are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur upon resolution of uncertainty associated with the variable consideration. The majority of contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as quantity times price per unit. For contracts with multiple performance obligations, the company allocates the transaction price to each performance obligation based on the relative standalone selling price. The standalone selling price is the observable price which depicts the price as if sold to a similar customer in similar circumstances.

*Licenses of Intellectual Property*

Corteva enters into licensing arrangements with customers to license its intellectual property. Revenue from the majority of intellectual property licenses is derived from sales-based royalties. Revenue for licensing agreements that contain sales-based royalties is recognized at the later of (i) when the subsequent sale occurs or (ii) when the performance obligation to which some or all of the royalty has been allocated is satisfied.

**Remaining Performance Obligations**

Remaining performance obligations represent the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. The company applies the practical expedient to disclose the transaction price allocated to the remaining performance obligations for only those contracts with an original duration of more than one year. The transaction price allocated to remaining performance obligations with an original duration of more than one year related to material rights granted to customers for contract renewal options were $150 million and $139 million at December 31, 2025 and December 31, 2024, respectively. The company expects revenue to be recognized for the remaining performance obligations evenly over a period of six years.

**Contract Balances**

Contract liabilities primarily reflect deferred revenue from prepayments under contracts with customers where the company receives advance payments for products to be delivered in future periods. Corteva classifies deferred revenue as current or noncurrent based on the timing of when the company expects to recognize revenue. Contract assets primarily include amounts related to conditional rights to consideration for completed performance not yet invoiced. Accounts receivable are recorded when the right to consideration becomes unconditional.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| **Contract Balances**<br>*(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Accounts and notes receivable - trade <sup>1</sup> | $5034 | $4615 |
| Contract assets - current <sup>2</sup> | 34 | 30 |
| Contract assets - noncurrent <sup>3</sup> | 83 | 74 |
| Deferred revenue - current | 3579 | 3287 |
| Deferred revenue - noncurrent <sup>4</sup> | 125 | 114 |

---

1. Included in accounts and notes receivable - net in the Consolidated Balance Sheets.

2. Included in other current assets in the Consolidated Balance Sheets.

3. Included in other assets in the Consolidated Balance Sheets.

4. Included in other noncurrent obligations in the Consolidated Balance Sheets.

Revenue recognized during the years ended December 31, 2025, 2024 and 2023 from amounts included in deferred revenue at the beginning of the period was $3,247 million, $3,359 million and $3,342 million, respectively.

**Disaggregation of Revenue**

Corteva's operations are classified into two operating segments: Seed and Crop Protection. The company disaggregates its revenue by major product line and geographic region, as the company believes it best depicts the nature, amount and timing of its revenue and cash flows. Net sales by major product line are included below:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| &nbsp;&nbsp;&nbsp;&nbsp;Corn | $7002 | $6496 | $6447 |
| &nbsp;&nbsp;&nbsp;&nbsp;Soybean | 1878 | 1927 | 1858 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other oilseeds | 644 | 653 | 708 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 374 | 469 | 459 |
| Seed | 9898 | 9545 | 9472 |
| &nbsp;&nbsp;&nbsp;&nbsp;Herbicides | 3730 | 3599 | 4034 |
| &nbsp;&nbsp;&nbsp;&nbsp;Insecticides | 1669 | 1715 | 1598 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fungicides | 1140 | 1081 | 1112 |
| &nbsp;&nbsp;&nbsp;&nbsp;Biologicals | 519 | 476 | 491 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 445 | 492 | 519 |
| Crop Protection | 7503 | 7363 | 7754 |
| **Total** | $17401 | $16908 | $17226 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Sales are attributed to geographic regions based on customer location. Net sales by geographic region and segment are included below:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Seed**<br>*(In millions)* | **2025** | **2024** | **2023** |
| North America <sup>1</sup> | $6271 | $6033 | $5768 |
| EMEA <sup>2</sup> | 1560 | 1581 | 1622 |
| Latin America | 1614 | 1523 | 1637 |
| Asia Pacific | 453 | 408 | 445 |
| **Total** | $9898 | $9545 | $9472 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Crop Protection**<br>*(In millions)* | **2025** | **2024** | **2023** |
| North America <sup>1</sup> | $2753 | $2627 | $2822 |
| EMEA <sup>2</sup> | 1550 | 1543 | 1745 |
| Latin America | 2314 | 2253 | 2269 |
| Asia Pacific | 886 | 940 | 918 |
| **Total** | $7503 | $7363 | $7754 |

---

1. Represents U.S. & Canada.

2. Europe, Middle East, and Africa ("EMEA").

Refer to Note 21 - Geographic Information, to the Consolidated Financial Statements, for the breakout of consolidated net sales by geographic area.

**NOTE 5 - RESTRUCTURING AND ASSET RELATED CHARGES - NET** 

**Crop Protection Operations Strategy Restructuring Program**

On November 5, 2023, management of the company approved a plan to further optimize its Crop Protection network of manufacturing and external partners (the "Crop Protection Operations Strategy Restructuring Program"). The plan includes the exit of the company's production activities at its site in Pittsburg, California, as well as ceasing operations in select manufacturing lines at other locations. In October 2024, management of the company amended the Crop Protection Operations Strategy Restructuring Program to include updates to its previous estimates and decommissioning and demolition costs associated with the ceasing of operations, primarily at the Pittsburg, California site.

The company expects to record aggregate pre-tax restructuring and asset related charges of $650 million to $700 million, comprised of $85 million to $105 million of severance and related benefit costs, $320 million to $340 million of asset-related and impairment charges, and $245 million to $255 million of costs related to exiting the company's production activities and ceasing operations (inclusive of decommissioning and demolition costs and contract terminations). Decommissioning and demolition costs are expensed on an as-incurred basis. Reductions in workforce are subject to local regulatory requirements. Through the year ended December 31, 2025, the company recorded net pre-tax restructuring and asset related charges of $611 million inception-to-date under the Crop Protection Operations Strategy Restructuring Program, consisting of $102 million of severance and related benefit costs, $340 million of asset-related and impairment charges, $70 million of decommissioning and demolition costs and $99 million of costs related to contract terminations. The pre-tax restructuring and asset related charges noted above include charges relating to spare parts write-offs recognized during the fourth quarter of 2023, which impacted the Crop Protection segment, and were included in cost of goods sold, in the company's Consolidated Statements of Operations for the year ended December 31, 2023. See Note 22 - Segment Information, to the Consolidated Financial Statements, for additional information.

Cash payments related to these charges are anticipated to be $330 million to $360 million, which primarily relate to the payment of severance and related benefits, decommissioning and demolition costs and contract terminations. Through December 31, 2025, the company paid $177 million associated with these charges. The restructuring actions associated with these charges are expected to be substantially complete by the end of 2026.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The following table is a summary of charges incurred related to the Crop Protection Operations Strategy Restructuring Program for the years ended December 31, 2025, 2024 and 2023:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Severance and related benefit costs <sup>1</sup> | $11 | $91 | $— |
| Asset related charges <sup>2,3</sup> | 13 | 101 | 214 |
| Decommissioning and demolition costs <sup>2</sup> | 60 | 10 |  |
| Contract termination charges <sup>2</sup> | 66 | 30 | 3 |
| Total restructuring and asset related charges - net <sup>4</sup> | $150 | $232 | $217 |

---

1. Reflects corporate related charges.

2. Reflects charges which are substantially all associated with the Crop Protection segment.

3. Asset-related charges includes impairment charges related to operating lease assets and property, plant and equipment.

4. This amount excludes charges relating to spare parts write-offs included in cost of goods sold for the year ended December 31, 2023, in the company's Consolidated Statement of Operations.

The following table summarizes changes to liability balances related to the Crop Protection Operations Strategy Restructuring Program for the years ended December 31, 2024 and 2025, respectively:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *(In millions)* | *Severance and Related Benefit Costs* | *Asset Related Charges*<sup>1</sup> | *Decommissioning and Demolition Costs* | *Contract Termination Charges* | *Total* |
| Balance at December 31, 2023 | $— | $— | $— | $— | $— |
| Charges to income from continuing operations | 91 | 101 | 10 | 30 | 232 |
| Payments | (21) |  | (10) | (30) | (61) |
| Asset write-offs |  | (101) |  |  | (101) |
| Balance at December 31, 2024 | $70 | $— | $— | $— | $70 |
| Charges to income from continuing operations | 11 | 13 | 60 | 66 | 150 |
| Payments | (49) |  | (52) | (12) | (113) |
| Asset write-offs |  | (13) |  |  | (13) |
| Balance at December 31, 2025 | $32 | $— | $8 | $54 | $94 |

---

1. Asset-related charges includes impairment charges related to operating lease assets and property, plant and equipment.

**Other Asset Related Charges**

The company holds a non-exclusive license in the United States and Canada for the Monsanto Company's Genuity<sup>®</sup> Roundup Ready 2 Yield<sup>®</sup> glyphosate tolerance trait and Roundup Ready 2 Xtend<sup>®</sup> glyphosate and dicamba tolerance trait for soybeans, which was obtained by the company's wholly owned subsidiary, Pioneer Hi-Bred International, Inc. ("Pioneer") ("Roundup Ready 2 License Agreement"). Each of these licensed technologies are now trademarks of the Bayer Group, which acquired the Monsanto Company in 2018. The prepaid royalty asset relates to a series of up-front, fixed and variable royalty payments to utilize the traits in Pioneer's soybean product mix. The company's historical expectation was that the technology licensed under the Roundup Ready 2 License Agreement would be used as the primary herbicide tolerance trait platform in the Pioneer<sup>®</sup> brand soybean through the term of the agreement. Dow Agrosciences LLC and MS Technologies, L.L.C. jointly developed and own the Enlist E3<sup>TM</sup> herbicide tolerance trait for soybeans which provides tolerance to 2,4-D choline in Enlist Duo<sup>®</sup> and Enlist One<sup>®</sup> herbicides, as well as glyphosate and glufosinate herbicides. In connection with the validation of breeding plans and large-scale product development timelines, during 2019 the company committed to accelerate the ramp up of the Enlist E3<sup>TM</sup> trait platform in the company's soybean portfolio mix across all brands, including Pioneer<sup>®</sup> brands. Due to the five-year ramp-up of Enlist E3<sup>TM</sup>, the company significantly reduced the volume of products with the Roundup Ready 2 Yield<sup>®</sup> and Roundup Ready 2 Xtend<sup>®</sup> herbicide tolerance traits, with expected minimal use of the trait platform thereafter for the remainder of the Roundup Ready 2 License Agreement (the "Transition Plan"). The rate of royalty expense had therefore increased significantly through higher amortization of the prepaid royalty as fewer seeds containing the respective trait were expected to be utilized.

In connection with the departure from these traits, beginning January 1, 2020 the company presents and discloses the non-cash accelerated prepaid royalty amortization expense as a component of restructuring and asset related charges - net, in the Consolidated Statements of Operations. For the years ended December 31, 2025, 2024 and 2023, the company recognized $— million, $55 million and $72 million, respectively, in restructuring and asset related charges - net in the Consolidated

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Statements of Operations, from non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits, which as of the end of the second quarter of 2024 was complete.

**NOTE 6 - SUPPLEMENTARY INFORMATION**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Other Income (Expense) - Net**<br>*(In millions)* | **2025** | **2024** | **2023** |
| Interest income | $136 | $132 | $283 |
| Equity in earnings (losses) of affiliates - net | 13 | 15 | 10 |
| Net gain (loss) on sales of businesses and other assets | 41 | 17 | 22 |
| Net exchange gains (losses) <sup>1</sup> | (181) | (284) | (397) |
| Non-operating pension and other post-employment benefit credits (costs) <sup>2</sup> | (23) | (144) | (119) |
| Miscellaneous income (expenses) - net <sup>3</sup> | (556) | (36) | (247) |
| Other income (expense) - net | $(570) | $(300) | $(448) |

---

1.&nbsp;&nbsp;&nbsp;&nbsp;Includes net pre-tax exchange gains (losses) of $(34) million, $(66) million and $(284) million, associated with impacts from the devaluation of the Argentine peso for the years ended December 31, 2025, 2024 and 2023, respectively.

2.&nbsp;&nbsp;&nbsp;&nbsp;Includes non-service related components of net periodic benefit credits (costs) (interest cost, expected return on plan assets, amortization of unrecognized gain (loss), amortization of prior service benefit and settlement gain (loss)).

3.&nbsp;&nbsp;&nbsp;&nbsp;Includes losses from sale of receivables, tax indemnification adjustments related to changes in indemnification balances as a result of the application of the terms of the Tax Matters Agreement between Corteva and Dow and/or DuPont, and other items. The year ended December 31, 2025 includes a charge related to the Bayer resolution offset by the receipt of insurance proceeds. The year ended December 31, 2024 includes the receipt of insurance proceeds and an indemnification payment negotiated with the prior Stoller owners. The years ended December 31, 2024 and 2023 also include estimated settlement reserves. The year ended December 31, 2023 also includes an Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security ("CARES") Act as enhanced by the Consolidated Appropriations Act ("CAA") and American Rescue Plan Act ("ARPA"). See Note 22 - Segment Information, to the Consolidated Financial Statements, for additional information on significant items.

The following table summarizes the impacts of the company's foreign currency hedging program on the company's results of operations. The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the United States, whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income (expense) - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the Consolidated Statements of Operations.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| **Subsidiary Monetary Position Gain (Loss)** |  |  |  |
| Pre-tax exchange gain (loss) | $(254) | $(152) | $(371) |
| Local tax (expenses) benefits | 11 | 11 | 55 |
| Net after-tax impact from subsidiary exchange gain (loss) | $(243) | $(141) | $(316) |
| **Hedging Program Gain (Loss)** |  |  |  |
| Pre-tax exchange gain (loss) | $73 | $(132) | $(26) |
| Tax (expenses) benefits | (8) | 26 | 7 |
| Net after-tax impact from hedging program exchange gain (loss) | $65 | $(106) | $(19) |
| **Total Exchange Gain (Loss)** |  |  |  |
| Pre-tax exchange gain (loss) | $(181) | $(284) | $(397) |
| Tax (expenses) benefits | 3 | 37 | 62 |
| Net after-tax exchange gain (loss) | $(178) | $(247) | $(335) |
| Noncontrolling interest adjustment |  | 1 |  |
| Net after-tax exchange gain (loss) attributable to Corteva | $(178) | $(246) | $(335) |

---

**Cash, Cash Equivalents and Restricted Cash Equivalents**

The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents presented in the Consolidated Balance Sheets to the total cash, cash equivalents and restricted cash equivalents presented in the Consolidated Statements of Cash Flows. Corteva classifies restricted cash equivalents as current or noncurrent based on the nature of the restrictions, which are included in other current assets and other assets, respectively, in the Consolidated Balance Sheets.

---

| | | |
|:---|:---|:---|
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Cash and cash equivalents | $4521 | $3106 |
| Restricted cash equivalents | 204 | 316 |
| Total cash, cash equivalents and restricted cash equivalents | $4725 | $3422 |

---

Restricted cash equivalents primarily relates to a trust funded by EIDP for cash obligations under certain non-qualified benefit and deferred compensation plans due to the Merger, which was a change in control event, and contributions to escrow accounts established for the settlement of certain legal matters and the settlement of legacy PFAS matters and the associated qualified spend. During the second quarter of 2024, the company's previously-restricted cash in the Water District Settlement Fund, which was established by Corteva, EIDP, Inc., DuPont and Chemours in September 2023 under the Nationwide Water District Settlement, was released. All of the company's restricted cash equivalents are classified as current as of December 31, 2025 and 2024, except for the $15 million MOU Escrow Account balance at December 31, 2024.

**Accounts Payable**

Accounts payable was $4,398 million and $4,039 million at December 31, 2025 and 2024, respectively. Accounts payable - trade, which is a component of accounts payable, was $2,871 million and $2,632 million at December 31, 2025 and 2024, respectively. Included in accounts payable – trade was seed grower compensation of approximately $420 million and $410 million at December 31, 2025 and 2024, respectively, which is measured at fair value using Level 2 inputs. Accrued discounts and rebates, which is a component of accounts payable, was $1,328 million and $1,207 million at December 31, 2025 and 2024, respectively. No other components of accounts payable were more than five percent of total current liabilities.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 7 - INCOME TAXES** 

Domestic and foreign components of income (loss) from continuing operations before income taxes and the provision for (benefit from) current and deferred tax expense (benefit) are shown below:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Geographic Allocation of Income (Loss) and Provision for (Benefit from) Income Taxes**<br>*(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from continuing operations before income taxes |  |  |  |
| &nbsp;&nbsp;&nbsp;Domestic | $325 | $324 | $(414) |
| &nbsp;&nbsp;&nbsp;Foreign | 1363 | 951 | 1507 |
| Income (loss) from continuing operations before income taxes | $1688 | $1275 | $1093 |
| Current tax expense (benefit) |  |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $87 | $285 | $143 |
| &nbsp;&nbsp;&nbsp;State and local | 26 | 45 | 40 |
| &nbsp;&nbsp;&nbsp;Foreign | 412 | 447 | 407 |
| Total current tax expense (benefit) | $525 | $777 | $590 |
| Deferred tax expense (benefit) |  |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $(139) | $(300) | $(326) |
| &nbsp;&nbsp;&nbsp;State and local | (24) | (28) | (50) |
| &nbsp;&nbsp;&nbsp;Foreign | 122 | (37) | (62) |
| Total deferred tax expense (benefit) | $(41) | $(365) | $(438) |
| Provision for (benefit from) income taxes on continuing operations | 484 | 412 | 152 |
| Net income (loss) from continuing operations after taxes | $1204 | $863 | $941 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The table below provides the updated disclosure requirements of ASU 2023-09, which was adopted on a prospective basis for the year ended December 31, 2025. See Note 3 - Recent Accounting Guidance, to the Consolidated Financial Statements, for a description of the relevant disclosure requirements.

The effective income tax rate applicable to income (loss) from continuing operations before income taxes was different from the statutory U.S. federal income tax rate due to the factors listed in the following table:

---

| | |
|:---|:---|
| **Reconciliation to U.S. Statutory Rate** | **For the Year Ended December 31,** |
|  | **2025** |
| *($ In millions)* | $% |
| U.S. Federal statutory tax rate | 21.0% |
| State and local income tax, net of federal (national) income tax effect <sup>1</sup> | 0.3% |
| Foreign tax effects |  |
| &nbsp;&nbsp;*Argentina* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Statutory tax rate differential | (1.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Withholding tax | 1.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Exchange gains/losses | (1.8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in valuation allowances | 4.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (0.2)% |
| &nbsp;&nbsp;*Brazil* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Withholding tax | 2.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in valuation allowances <sup>2</sup> | 9.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (0.2)% |
| &nbsp;&nbsp;*India* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Statutory tax rate differential | 1.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Agriculture exemption | (2.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Withholding tax | 1.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 0.1% |
| &nbsp;&nbsp;*Switzerland* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Statutory tax rate differential | (5.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Cantonal income tax, net | 3.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (0.1)% |
| &nbsp;&nbsp;*Other foreign jurisdictions* | 2.9% |
| Effect of cross-border tax laws (net of related foreign tax credits) |  |
| &nbsp;&nbsp;Global Intangible Low-Taxed Income (GILTI) | 1.4% |
| &nbsp;&nbsp;Other | 0.7% |
| Tax credits |  |
| &nbsp;&nbsp;U.S. research and development credit | (2.8)% |
| &nbsp;&nbsp;Other foreign tax credits | (3.1)% |
| Changes in valuation allowances <sup>3</sup> | 4.4% |
| Nontaxable or nondeductible items | 1.8% |
| Changes in unrecognized tax benefits | (1.1)% |
| Other |  |
| &nbsp;&nbsp;Capital loss <sup>3</sup> | (4.6)% |
| &nbsp;&nbsp;Legal entity tax characterization <sup>4</sup> | (2.9)% |
| &nbsp;&nbsp;Other | (1.3)% |
| Effective tax rate | 28.7% |

---

1. State taxes in Minnesota made up the majority (greater than 50%) of the tax effect in this category.

2. For the year ended December 31, 2025, the company established a valuation allowance recorded against the net deferred tax asset position of a legal entity in Brazil (Crop Protection business) in the amount of $132 million.

3. For the year ended December 31, 2025, a U.S. federal tax benefit of $(27) million, net of valuation allowance, was recorded to recognize a capital loss in a wholly owned foreign investment.

4. For the year ended December 31, 2025, a U.S. federal deferred tax benefit was recorded associated with a change in a legal entity's U.S. tax characterization in the amount of $(49) million.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:

---

| | | |
|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Reconciliation to U.S. Statutory Rate** | **2024** | **2023** |
| Statutory U.S. federal income tax rate | 21.0% | 21.0% |
| Effective tax rates on international operations - net <sup>1</sup> | 4.8 | (1.8) |
| Acquisitions, divestitures and ownership restructuring activities <sup>2</sup> | (1.1) | 3.6 |
| U.S. research and development credit | (4.7) | (5.9) |
| Exchange gains/losses <sup>3</sup> | 1.7 | 2.0 |
| State and local incomes taxes - net | 1.3 | 0.9 |
| Impact of Swiss Tax Changes <sup>4</sup> |  | (7.9) |
| Excess tax benefits/deficiencies from stock compensation | (0.2) | (0.5) |
| Tax settlements and expiration of statute of limitations | (1.7) | (0.3) |
| Impact of Brazil valuation allowance <sup>6</sup> | 9.4 |  |
| Repatriation of foreign earnings <sup>5</sup> | 1.7 | 2.9 |
| Other – net | 0.1 | (0.1) |
| Effective tax rate on income from continuing operations | 32.3% | 13.9% |

---

1.&nbsp;&nbsp;&nbsp;&nbsp;Includes the effects of local and U.S. taxes related to earnings of non-U.S. subsidiaries, changes in the amount of unrecognized tax benefits associated with these earnings, losses at non-U.S. subsidiaries without local tax benefits due to valuation allowances, and other permanent differences between tax and U.S. GAAP results.

2. &nbsp;&nbsp;&nbsp;&nbsp;Includes net tax charge of $46 million for the year ended December 31, 2023, associated with intellectual property realignment.

3.&nbsp;&nbsp;&nbsp;&nbsp;Principally reflects the impact of foreign exchange gains and losses on net monetary assets for which no corresponding tax impact is realized. Further information about the company's foreign currency hedging program is included in Note 6 - Supplementary Information, and Note 19 - Financial Instruments, to the Consolidated Financial Statements, under the heading "Foreign Currency Risk."

4. Includes net tax benefits of $(62) million and $(24) million for the year ended December 31, 2023, related to changes in deferred taxes and a tax currency change, respectively.

5. Includes the effect of withholding tax on distribution of foreign earnings to the U.S., net of U.S. foreign tax credits.

6. For the year ended December 31, 2024, a charge of $120 million was recorded to establish a valuation allowance against the net deferred tax asset position of

a legal entity in Brazil (Seed business).

Significant jurisdictions in which income taxes were paid (net of refunds received) are shown below:

---

| | |
|:---|:---|
| **Income Taxes Paid, Net**<br>*(In millions)* | **For the Year Ended December 31,**<br>**2025** |
| US Federal | $195 |
| US State and Local | 49 |
| Brazil | 72 |
| India | 42 |
| Switzerland, Federal | 59 |
| Switzerland, Geneva | 46 |
| Other Foreign | 287 |
| Total | $750 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Significant components of the company's net deferred tax asset (liability) were attributable to:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Deferred Tax Balances** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** |
| *(In millions)* | *Assets* | *Liabilities* | *Assets* | *Liabilities* |
| Property | $— | $347 | $— | $278 |
| Operating loss and tax credit carryforwards <sup>1</sup> | 631 |  | 552 |  |
| Accrued employee benefits | 678 |  | 671 |  |
| Other accruals and reserves | 767 |  | 590 |  |
| Intangibles |  | 1828 |  | 1950 |
| Inventory | 275 |  | 184 |  |
| Research and development capitalization | 689 |  | 761 |  |
| Investments | 53 |  | 69 |  |
| Unrealized exchange gains/losses |  | 4 |  | 50 |
| Other – net | 42 |  | 40 |  |
| Subtotal | $3135 | $2179 | $2867 | $2278 |
| Valuation allowances <sup>2</sup> | (887) |  | (666) |  |
| Total | $2248 | $2179 | $2201 | $2278 |
| Net deferred tax asset (liability) | $69 |  | $(77) |  |

---

1.&nbsp;&nbsp;&nbsp;&nbsp;Primarily related to tax loss and credit carryforwards from operations in the United States, Argentina, Brazil, Switzerland, and Spain.

2.&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December 31, 2025, the company established a valuation allowance recorded against the net deferred tax asset position of a legal entity in Brazil (Crop Protection business) in the amount of $132 million. During the year ended December 31, 2024, the company established a valuation allowance against the net deferred tax asset position of a legal entity in Brazil (Seed business) in the amount of $120 million.

Details of the company's operating loss and tax credit carryforwards are shown in the following table:

---

| | | |
|:---|:---|:---|
| **Operating Loss and Tax Credit Carryforwards** | *Deferred Tax Asset* | *Deferred Tax Asset* |
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Operating loss carryforwards |  |  |
| &nbsp;&nbsp;&nbsp;Expire within 5 years | $290 | $222 |
| &nbsp;&nbsp;&nbsp;Expire after 5 years or indefinite expiration | 213 | 226 |
| Total operating loss carryforwards | $503 | $448 |
| Tax credit carryforwards |  |  |
| &nbsp;&nbsp;&nbsp;Expire within 5 years | $25 | $13 |
| &nbsp;&nbsp;&nbsp;Expire after 5 years or indefinite expiration | 103 | 91 |
| Total tax credit carryforwards | $128 | $104 |
| Total operating loss and tax credit carryforwards | $631 | $552 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Total Gross Unrecognized Tax Benefits**<br>*(In millions)* | **2025** | **2024** | **2023** |
| Total unrecognized tax benefits as of beginning of period | $263 | $390 | $357 |
| Decreases related to positions taken on items from prior years | (1) | (4) |  |
| Increases related to positions taken on items from prior years | 94 | 13 | 23 |
| Increases related to positions taken in the current year | 9 | 12 | 16 |
| Settlement of uncertain tax positions with tax authorities | (24) | (140) | (4) |
| Decreases due to expiration of statutes of limitations | (5) | (5) | (2) |
| Exchange (gain) loss | (1) | (3) |  |
| Total unrecognized tax benefits as of end of period | $335 | $263 | $390 |
| Total unrecognized tax benefits that, if recognized, would impact the effective tax rate | $243 | $176 | $173 |
| Total amount of interest and penalties (benefits) recognized in provision for (benefit from) income taxes on continuing operations | $(9) | $(4) | $1 |
| Total accrual (receivable) for interest and penalties associated with unrecognized tax benefits at end of period | $(15) | $(2) | $11 |

---

Each year the company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the company. As a result, there is an uncertainty in income taxes recognized in the company's financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. As of December 31, 2025 and 2024, the company has an advance deposit balance of $95 million and $100 million, respectively, to a foreign taxing authority, partially as a prerequisite to petition the court related to an open tax examination. These payments are accounted for as a prepaid asset, included in other assets in the Consolidated Balance Sheets.

Tax years that remain subject to examination for the company's major tax jurisdictions are shown below:

---

| | |
|:---|:---|
| **Tax Years Subject to Examination by Major Tax Jurisdiction at December 31, 2025** | *Earliest Open Year* |
| *Jurisdiction* | *Earliest Open Year* |
| Argentina | 2018 |
| Brazil | 2018 |
| Canada | 2017 |
| China | 2015 |
| France | 2023 |
| India | 2023 |
| Italy | 2019 |
| Spain | 2020 |
| Switzerland | 2020 |
| United States: |  |
| &nbsp;&nbsp;&nbsp;Federal income tax | 2012 |
| &nbsp;&nbsp;&nbsp;State and local income tax | 2012 |

---

Undistributed earnings of foreign subsidiaries and related companies that are deemed to be indefinitely invested amounted to $4,158 million at December 31, 2025. Distributions of profits from non-U.S. subsidiaries are subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply; these taxes are partially offset by U.S. foreign tax credits. The company is asserting indefinite reinvestment related to certain investments in foreign subsidiaries. Determination of the amount of unrecognized deferred tax liability related to indefinitely reinvested profits is not feasible primarily due to our legal entity structure and the complexity of U.S. and local tax laws.

For periods between the Merger on August 31, 2017, and the Corteva Distribution, Corteva and its subsidiaries were included in DowDuPont's consolidated federal income tax group and consolidated tax return. Generally, the consolidated tax liability of the DowDuPont U.S. tax group for each year was apportioned among the members of the consolidated group based on each member's separate taxable income. Corteva, DuPont and Dow intend that to the extent federal and/or state corporate income tax

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party's sub-group attributes will be in accordance with a tax sharing agreement and/or Tax Matters Agreement. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements for further information related to indemnifications between Corteva, DuPont and Dow.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law, enacting changes in a wide array of policy areas, including federal tax law. The impacts of OBBBA are included in the financial statements for the year ended December 31, 2025, including the reinstatement of expensing of domestic research and development expenditures.

On August 16, 2022, the U.S. federal government enacted the Inflation Reduction Act of 2022 ("the Act"). The Act includes tax provisions, among other things, which implement (i) a 15 percent minimum tax on book income of certain large corporations and (ii) a one percent excise tax on net stock repurchases. The Act did not have a material impact on the company's financial position, results of operations or cash flows.

In December 2021, the Organization for Economic Cooperation and Development ("OECD") released the Pillar Two Model rules (also referred to as the global minimum tax or Global Anti-Base Erosion "GloBE" rules), which were designed to ensure multinational enterprises pay a certain level of tax within every jurisdiction in which they operate. Several jurisdictions in which we operate have enacted these rules. For the year ended December 31, 2025, there is no material tax charge associated with these rules. The company will continue to monitor and evaluate legislative developments.

**NOTE 8 - EARNINGS PER SHARE OF COMMON STOCK**

The following tables provide earnings per share calculations for the periods indicated below:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Net Income (Loss) for Earnings Per Share Calculations - Basic and Diluted**<br>*(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from continuing operations after income taxes | $1204 | $863 | $941 |
| Net income (loss) attributable to continuing operations noncontrolling interests | 11 | 12 | 12 |
| Income (loss) from continuing operations available to Corteva common stockholders | $1193 | $851 | $929 |
| Income (loss) from discontinued operations available to Corteva common stockholders | (99) | 56 | (194) |
| Net income (loss) available to common stockholders | $1094 | $907 | $735 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Earnings (Loss) Per Share Calculations - Basic**<br>*(Dollars per share)* | **2025** | **2024** | **2023** |
| Earnings (loss) per share of common stock from continuing operations | $1.75 | $1.23 | $1.31 |
| Earnings (loss) per share of common stock from discontinued operations | (0.15) | 0.08 | (0.27) |
| Earnings (loss) per share of common stock | $1.60 | $1.31 | $1.04 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Earnings (Loss) Per Share Calculations - Diluted**<br>*(Dollars per share)* | **2025** | **2024** | **2023** |
| Earnings (loss) per share of common stock from continuing operations | $1.75 | $1.22 | $1.30 |
| Earnings (loss) per share of common stock from discontinued operations | (0.15) | 0.08 | (0.27) |
| Earnings (loss) per share of common stock | $1.60 | $1.30 | $1.03 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Share Count Information**<br>*(Shares in millions)* | **2025** | **2024** | **2023** |
| Weighted-average common shares - basic | 680.0 | 693.7 | 709.0 |
| Plus dilutive effect of equity compensation plans <sup>1</sup> | 1.4 | 2.3 | 2.9 |
| Weighted-average common shares - diluted | 681.4 | 696.0 | 711.9 |
| Potential shares of common stock excluded from EPS calculations <sup>2</sup> | 2.3 | 3.1 | 2.3 |

---

1. Diluted earnings (loss) per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

2. These outstanding potential shares of common stock relating to stock options, restricted stock units and performance-based restricted stock units were excluded from the calculation of diluted earnings (loss) per share because (i) the effect of including them would have been anti-dilutive; or (ii) the

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

performance metrics have not yet been achieved for the outstanding potential shares relating to performance-based restricted stock units, which are deemed to be contingently issuable.

**NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE - NET** 

---

| | | |
|:---|:---|:---|
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Accounts receivable – trade <sup>1</sup> | $4881 | $4448 |
| Notes receivable – trade <sup>1,2</sup> | 153 | 167 |
| Other <sup>3</sup> | 1337 | 1061 |
| Total accounts and notes receivable - net | $6371 | $5676 |

---

1. Accounts and notes receivable – trade are net of allowances of $241 million and $179 million at December 31, 2025 and 2024, respectively.

2. Notes receivable – trade primarily consists of receivables for deferred payment loan programs for the sale of seed and crop protection products to customers. These loans have terms of one year or less and are primarily concentrated in North America. The company maintains a rigid pre-approval process for extending credit to customers in order to manage overall risk and exposure associated with credit losses. As of December 31, 2025 and 2024, there were no significant impairments related to current loan agreements.

3. Other includes receivables in relation to indemnification assets, royalties, value added tax, general sales tax and other taxes. No individual group represents more than 5 percent of total current assets. In addition, Other includes amounts due from nonconsolidated affiliates of $117 million and $144 million as of December 31, 2025 and 2024, respectively.

Accounts and notes receivable are carried at the expected amount to be collected, which approximates fair value. The company establishes the allowance for doubtful receivables using a loss-rate method where the loss rate is developed using past events, historical experience, current conditions and forecasts that affect the collectability of the financial assets.

The following table summarizes changes in the allowance for doubtful receivables for the years ended December 31, 2024 and 2025, respectively:

---

| | |
|:---|:---|
| *(In millions)* | *(In millions)* |
| Balance at December 31, 2023 | $205 |
| Net provision for credit losses | 39 |
| Other - net of write-offs charged against allowance | (65) |
| Balance at December 31, 2024 | $179 |
| Net provision for credit losses | 104 |
| Other - net of write-offs charged against allowance | (42) |
| Balance at December 31, 2025 | $241 |

---

The company enters into various factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds. These financing arrangements result in a transfer of the company's receivables and risks to the third-party. As these transfers qualify as true sales under the applicable accounting guidance, the receivables are derecognized from the Consolidated Balance Sheets upon transfer, and the company receives a payment for the receivables from the third-party within a mutually agreed upon time period. For arrangements involving an element of recourse, which is typically provided through a guarantee of accounts in the event of customer default, the guarantee obligation is measured using market data from similar transactions and reported as a current liability in the Consolidated Balance Sheets.

Trade receivables sold under these agreements were $166 million, $131 million, and $112 million for the years ended December 31, 2025, 2024 and 2023, respectively. The trade receivables sold that remained outstanding under these agreements which include an element of recourse as of December 31, 2025 and 2024 were $17 million and $15 million, respectively. The net proceeds received were included in cash provided by (used for) operating activities, in the Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in other income (expense) - net in the Consolidated Statements of Operations. The loss on sale of receivables were $5 million, $9 million and $17 million for the years ended December 31, 2025, 2024 and 2023, respectively. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information on the company's guarantees.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 10 - INVENTORIES**

---

| | | |
|:---|:---|:---|
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Finished products | $2956 | $2649 |
| Semi-finished products | 2276 | 2297 |
| Raw materials and supplies | 435 | 486 |
| Total inventories | $5667 | $5432 |

---

**NOTE 11 - PROPERTY, PLANT AND EQUIPMENT**

---

| | | |
|:---|:---|:---|
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Land and land improvements | $449 | $425 |
| Buildings | 1867 | 1715 |
| Machinery and equipment | 6849 | 6472 |
| Construction in progress | 386 | 462 |
| Total property, plant and equipment | $9551 | $9074 |
| Accumulated depreciation | (5331) | (4975) |
| Total property, plant and equipment - net | $4220 | $4099 |

---

Buildings, machinery and equipment and land improvements are depreciated over useful lives on a straight-line basis ranging from 2 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over 2 to 7 years.

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Depreciation expense | $559 | $542 | $528 |

---

**NOTE 12 - GOODWILL AND OTHER INTANGIBLE ASSETS**

**Goodwill**

The following table summarizes changes in the carrying amount of goodwill by segment for the years ended December 31, 2024 and 2025, respectively.

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Total** |
| Balance at December 31, 2023 | $5422 | $5183 | $10605 |
| Currency translation adjustment | (96) | (139) | (235) |
| Other goodwill adjustments <sup>1</sup> |  | 38 | 38 |
| Balance at December 31, 2024 | $5326 | $5082 | $10408 |
| Currency translation adjustment | (14) | 71 | 57 |
| Balance at December 31, 2025 | $5312 | $5153 | $10465 |

---

1. Includes measurement period adjustments related to the acquisitions of Stoller and Symborg, which were not material.

The company performed annual qualitative testing on all of its reporting units in 2025 and 2024, determining that no goodwill impairments existed in either year. As of December 31, 2025, accumulated impairment losses on goodwill were $4,503 million.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**Other Intangible Assets**

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|<br>*(In millions)* | **Gross** | **Accumulated<br>Amortization** | **Net** | **Gross** | **Accumulated<br>Amortization** | **Net** |
| **Intangible assets subject to amortization (finite-lived):** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Germplasm | $6291 | $(1587) | $4704 | $6291 | $(1336) | $4955 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer-related | 2394 | (1024) | 1370 | 2350 | (863) | 1487 |
| &nbsp;&nbsp;&nbsp;&nbsp;Developed technology | 1860 | (1283) | 577 | 1838 | (1161) | 677 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks/trade names | 2056 | (466) | 1590 | 2056 | (380) | 1676 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>1</sup> | 368 | (313) | 55 | 388 | (312) | 76 |
| Total other intangible assets with finite lives | $12969 | $(4673) | $8296 | $12923 | $(4052) | $8871 |
| **Intangible assets not subject to amortization (indefinite-lived):** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;In-process research and development | 5 |  | 5 | 5 |  | 5 |
| Total other intangible assets with indefinite lives | 5 |  | 5 | 5 |  | 5 |
| **Total other intangible assets** | $12974 | $(4673) | $8301 | $12928 | $(4052) | $8876 |

---

1. Primarily consists of sales and farmer networks, marketing and manufacturing alliances and noncompetition agreements.

The aggregate pre-tax amortization expense from continuing operations for finite-lived intangible assets was $644 million, $685 million, and $683 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Total estimated amortization expense for the next five fiscal years is as follows:

---

| | |
|:---|:---|
| *(In millions)* |  |
| 2026 | $637 |
| 2027 | 576 |
| 2028 | 555 |
| 2029 | 531 |
| 2030 | 521 |

---

 **NOTE 13 - LEASES**

The company has operating and finance leases for real estate, transportation, certain machinery and equipment, and information technology assets. The company's leases have remaining lease terms of approximately 1 to 37 years. For purposes of calculating operating lease liabilities, lease terms may be deemed to include options to extend the lease when it is reasonably certain that the company will exercise that option. Some leasing arrangements require variable payments that are dependent on usage, output, or may vary for other reasons, such as insurance and tax payments. The variable lease payments are not presented as part of the initial ROU asset or lease liability.

Certain of the company's leases include residual value guarantees. These residual value guarantees are based on a percentage of the lessor's asset acquisition price and the amount of such guarantee generally declines over the course of the lease term. The portion of residual value guarantees that are probable of payment are included in the related lease liability. At December 31, 2025, the company has future maximum payments for residual value guarantees in operating leases of $183 million with final expirations through 2035. The company's lease agreements do not contain any material restrictive covenants.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The components of lease cost for the years ended December 31, 2025, 2024 and 2023 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Operating lease cost | $161 | $176 | $169 |
| Finance lease cost |  |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of right-of-use assets |  | 1 | 1 |
| Total finance lease cost | $— | $1 | $1 |
| Short-term lease cost | 37 | 27 | 23 |
| Variable lease cost | 7 | 8 | 11 |
| Total lease cost | $205 | $212 | $204 |

---

Supplemental cash flow information related to leases for the years ended December 31, 2025, 2024 and 2023 was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;Operating cash outflows from operating leases | $166 | $188 | $169 |
| &nbsp;&nbsp;&nbsp;Financing cash outflows from finance leases | $— | $1 | $1 |

---

New leases entered into during the years ended December 31, 2025 and 2024 were not material, on an individual basis*.* 

Supplemental balance sheet information related to leases is as follows:

---

| | | |
|:---|:---|:---|
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| **Operating Leases** |  |  |
| Operating lease right-of-use assets <sup>1</sup> | $411 | $414 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current operating lease liabilities <sup>2</sup> | 122 | 134 |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncurrent operating lease liabilities <sup>3</sup> | 293 | 342 |
| Total operating lease liabilities | $415 | $476 |
| **Finance Leases** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant, and equipment, gross | $14 | $14 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated depreciation | (14) | (14) |
| Property, plant, and equipment, net | $— | $— |
| &nbsp;&nbsp;&nbsp;Short-term borrowings and finance lease obligations |  |  |
| &nbsp;&nbsp;&nbsp;Long-term debt |  |  |
| Total finance lease liabilities | $— | $— |

---

1. Included in other assets in the Consolidated Balance Sheets.

2. Included in accrued and other current liabilities in the Consolidated Balance Sheets.

3. Included in other noncurrent obligations in the Consolidated Balance Sheets.

The company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable.

---

| | | |
|:---|:---|:---|
| **Lease Term and Discount Rate** | **December 31, 2025** | **December 31, 2024** |
| Weighted-average remaining lease term (years) |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | 6.20 | 6.44 |
| &nbsp;&nbsp;&nbsp;Finance leases | 0 | 0.38 |
| Weighted average discount rate |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | 3.85% | 3.32% |
| &nbsp;&nbsp;&nbsp;Finance leases | —% | 3.29% |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Maturities of lease liabilities are as follows:

---

| | |
|:---|:---|
| **Maturity of Lease Liabilities at December 31, 2025** | *Operating Leases* |
| *(In millions)* | *Operating Leases* |
| 2026 | $136 |
| 2027 | 95 |
| 2028 | 71 |
| 2029 | 51 |
| 2030 | 33 |
| 2031 and thereafter | 87 |
| Total lease payments | $473 |
| Less: Interest | 58 |
| Present value of lease liabilities | $415 |

---

**NOTE 14 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES**

The following tables summarize Corteva's short-term borrowings and finance lease obligations and long-term debt:

---

| | | |
|:---|:---|:---|
| **Short-Term Borrowings and Finance Lease Obligations** | **Short-Term Borrowings and Finance Lease Obligations** | **Short-Term Borrowings and Finance Lease Obligations** |
| *(In millions)* | **December 31, 2025** | **December 31, 2024** |
| 364-Day Revolving Credit Facility | $— | $— |
| Other loans - various currencies | 112 | 250 |
| Long-term debt payable within one year | 782 | 500 |
| Finance lease obligations payable within one year |  |  |
| Total short-term borrowings and finance lease obligations | $894 | $750 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Long-Term Debt** | **Long-Term Debt** | **Long-Term Debt** | **Long-Term Debt** | **Long-Term Debt** |
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** |
| *(In millions)* | *Amount* | *Weighted Average Rate* | *Amount* | *Weighted Average Rate* |
| Promissory notes and debentures: |  |  |  |  |
| &nbsp;&nbsp;Maturing in July 2025 | $— | —% | $500 | 1.70% |
| &nbsp;&nbsp;Maturing in May 2026 | 600 | 4.50% | 600 | 4.50% |
| &nbsp;&nbsp;Maturing in July 2030 | 500 | 2.30% | 500 | 2.30% |
| &nbsp;&nbsp;Maturing in May 2032 | 500 | 5.125% |  | —% |
| &nbsp;&nbsp;Maturing in May 2033 | 600 | 4.80% | 600 | 4.80% |
| Other loans: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency loans, various rates and maturities | 182 | 12.70% | 161 | 12.70% |
| &nbsp;&nbsp;&nbsp;Medium-term notes, varying maturities through 2041 | 102 | 3.76% | 104 | 4.41% |
| &nbsp;&nbsp;&nbsp;Finance lease obligations |  |  |  |  |
| Less: Unamortized debt discount and issuance costs | 16 |  | 12 |  |
| Less: Long-term debt due within one year | 782 |  | 500 |  |
| Total long-term debt | $1686 |  | $1953 |  |

---

Principal payments of long-term debt are $782 million and $500 million for debt maturing in 2026 and 2030, respectively. There is no debt maturing in 2027, 2028 or 2029.

The estimated fair value of the company's short-term and long-term borrowings, including interest rate financial instruments was determined using Level 2 inputs within the fair value hierarchy, as described in Note 2 - Summary of Significant Accounting Policies. Based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities, the fair value of the company's short-term borrowings and finance lease obligations was approximately carrying value.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The fair value of the company's long-term borrowings, including long-term debt due within one year, was $2,462 million and $2,366 million at December 31, 2025 and 2024, respectively.

*Debt Offering*

In May 2025, the company issued $500 million of 5.125 percent Senior Notes due in May 2032 (the "May 2025 Debt Offering"). The proceeds were used to repay the $500 million senior notes that matured in July 2025.

In May 2023, the company issued $600 million of 4.5 percent Senior Notes due in 2026 and $600 million of 4.8 percent Senior Notes due in 2033 (the "May 2023 Debt Offering"). The proceeds of this offering are intended to be used for general corporate purposes, which may include funding of working capital, capital expenditures and share repurchases.

*Foreign Currency Loans*

The company enters into short-term and long-term foreign currency loans from time-to-time by accessing uncommitted revolving credit lines to fund working capital needs of foreign subsidiaries in the normal course of business ("Foreign Currency Loans"). Interest rates are variable and determined at the time of borrowing. Total unused bank credit lines on the Foreign Currency Loans at December 31, 2025 was approximately $86 million. The company's long-term Foreign Currency Loans are maturing in March 2026.

**Available Committed Credit Facilities** 

The following table summarizes the company's credit facilities:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Committed and Available Credit Facilities at December 31, 2025** | **Committed and Available Credit Facilities at December 31, 2025** | **Committed and Available Credit Facilities at December 31, 2025** | **Committed and Available Credit Facilities at December 31, 2025** | | |
| *(In millions)* | *Effective Date* | *Committed Credit* | *Credit Available* | *Maturity Date* | *Interest* |
| Revolving Credit Facility | June 2024 | $2850 | $2850 | June 2029 | Floating Rate |
| Revolving Credit Facility | June 2024 | 1900 | 1900 | June 2027 | Floating Rate |
| 364-Day Revolving Credit Facility | February 2025 | 750 | 750 | February 2026 | Floating Rate |
| Total committed and available credit facilities |  | $5500 | $5500 |  |  |

---

*Revolving Credit Facilities*

In May 2022, the company entered into a $3 billion, five year revolving credit facility and a $2 billion, three-year revolving credit facility (the "Revolving Credit Facilities") expiring in May 2027 and May 2025, respectively. Borrowings under the revolving credit facilities have an interest rate equal to Adjusted Term SOFR, which is Term SOFR plus 0.10 percent, plus the applicable margin. In June 2024, the Revolving Credit Facilities were refinanced for purposes of extending the maturity dates for the five-year and three-year revolving credit facilities to June 2029 and June 2027, respectively, and lowering the facility amount of the five-year revolving credit facility to $2.85 billion and the three-year revolving credit facility to $1.9 billion. The Revolving Credit Facilities may serve as a substitute to the company's commercial paper program, and can be used from time to time, for general corporate purposes including, but not limited to, the funding of seasonal working capital needs. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the Revolving Credit Facilities contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At December 31, 2025, the company was in compliance with these covenants.

*364-Day Revolving Credit Facility*

In January 2023, the company amended and restated its May 2022 364-day revolving credit agreement (the "364-Day Revolving Credit Facility") increasing the facility amount to $1 billion and extending the expiration date to January 2024. Borrowings under the 364-Day Revolving Credit Facility have an interest rate equal to Adjusted Term SOFR, which is Term SOFR plus 0.10 percent, plus the applicable margin. The 364-Day Revolving Credit Facility includes a provision under which the company may convert any advances outstanding prior to the maturity date into term loans having a maturity date up to one year later. In February 2023, the company drew down $1 billion under the 364-Day Revolving Credit Facility, which was used for general corporate purposes, including funding seasonal working capital needs, capital spending, dividend payments, share repurchases and to partially fund the Stoller and Symborg acquisitions. In May 2023, the company repaid the $1 billion loan using the proceeds from the May 2023 Debt Offering and subsequently, in July 2023 reduced the available credit from $1 billion to $500 million. In February 2024, the company amended and restated the 364-Day Revolving Credit Facility, increasing the facility amount to $1 billion and extending the expiration date to February 2025. In February 2025, the company amended and restated the 364-Day Revolving Credit Facility, decreasing the facility amount from $1 billion to $750 million and extending the expiration date to February 2026. In February 2026, the company amended and restated the 364-Day Revolving Credit Facility, increasing the facility amount from $750 million to $1.25 billion, extended the expiration date to

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

February 2027 and amended the interest rate to Term SOFR plus the applicable margin. The 364-Day Revolving Credit Facility contains customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the 364-Day Revolving Credit Facility contains a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At December 31, 2025, the company was in compliance with these covenants.

**Uncommitted Credit Facilities and Outstanding Letters of Credit**

Unused bank credit lines on uncommitted credit facilities were $696 million at December 31, 2025. These lines are available to support short-term liquidity needs and general corporate purposes, including letters of credit. Outstanding letters of credit were $248 million at December 31, 2025. These letters of credit support commitments made in the ordinary course of business.

**NOTE 15 - COMMITMENTS AND CONTINGENT LIABILITIES**

**Guarantees**

*Indemnifications*

In connection with acquisitions and divestitures, the company has indemnified respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. In addition, the company indemnifies its duly elected or appointed directors and officers to the fullest extent permitted by Delaware law, against liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future payments is generally unlimited. See below for additional information relating to the indemnification obligations under the Chemours Separation Agreement and the Corteva Separation Agreement.

*Obligations for Supplier Finance Programs*

The company enters into supplier finance programs with various finance providers in which the company agrees to pay these finance providers the stated amount of confirmed invoices from participating suppliers by the original maturity date. The company or the finance provider may terminate the agreement upon providing at least thirty days' written notice. The payment terms that the company has with its finance providers under supplier finance programs are less than one year. At December 31, 2025 and 2024, the outstanding obligations under supplier finance programs was approximately $121 million and $88 million, respectively, and included within accounts payable in the Consolidated Balance Sheets.

The rollforward of the company's outstanding obligations confirmed as valid under its supplier finance programs for the years ended December 31, 2024 and 2025 is as follows:

---

| | |
|:---|:---|
| *(In millions)* |  |
| Confirmed obligations outstanding at December 31, 2023 | $115 |
| Invoices confirmed during the year | 571 |
| Confirmed invoices paid during the year | (598) |
| Confirmed obligations outstanding at December 31, 2024 | $88 |
| Invoices confirmed during the year | 690 |
| Confirmed invoices paid during the year | (657) |
| Confirmed obligations outstanding at December 31, 2025 | $121 |

---

*Obligations for Customers and Other Third Parties*

The company has directly guaranteed various debt obligations under agreements with third parties related to customers and other third parties. At December 31, 2025 and 2024, the company had directly guaranteed $71 million and $64 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the company could be required to make under the guarantees in the event of default by the guaranteed party. The maximum future payments include $5 million and $4 million of guarantees related to the various factoring agreements that the company enters into with third-party financial institutions to sell its trade receivables at December 31, 2025 and 2024, respectively. See Note 9 - Accounts and Notes Receivable - Net, to the Consolidated Financial Statements, for additional information.

The maximum future payments also include agreements with lenders to establish programs that provide financing for select customers. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

customer invoices. The total amounts owed from customers to the lenders relating to these agreements was $234 million and $223 million at December 31, 2025 and 2024, respectively.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

*Indemnifications under Separation Agreements*

The company has entered into various agreements where the company is indemnified for certain liabilities. The term of this indemnification is generally indefinite, with exceptions, and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable.

<u>Chemours Separation Agreement (Performance Chemicals)</u>

Pursuant to the Chemours Separation Agreement resulting from the 2015 spin-off of the Performance Chemicals segment from Historical DuPont, Chemours indemnifies the company against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the distribution.

In 2017, the Chemours Separation Agreement was amended to provide for a limited sharing of potential future liabilities related to alleged historical releases of perfluorooctanoic acids and its ammonium salts ("PFOA") for a five-year period that began on July 6, 2017. Additionally, in January 2021, a binding memorandum of understanding as described below replaced the potential future liability sharing arrangements established in the 2017 amendment to the Chemours Separation Agreement. At December 31, 2025 and December 31, 2024, the indemnification assets from Chemours were $138 million and $43 million, respectively, within accounts and notes receivable - net and $470 million and $280 million, respectively, within other assets in the interim Consolidated Balance Sheets. These indemnification assets are regularly assessed for collectability and the company has concluded that these assets are recoverable. The liabilities subject to Chemours indemnification are considered stray liabilities under the Corteva Separation Agreement. Therefore, if Chemours fails to indemnify the company, these stray liabilities are subject to proportionate cost sharing between Corteva and DuPont, on a 29 percent and 71 percent basis, respectively, as further described in this footnote below.

On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against DuPont, EIDP, and Corteva, seeking, among other things, to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement (the "Delaware Litigation"). On March 30, 2020, the Court of Chancery granted a motion to dismiss. On December 15, 2020, the Delaware Supreme Court affirmed the judgment of the Court of Chancery. Meanwhile, a confidential arbitration process regarding the same and other claims proceeded (the "Arbitration").

On January 22, 2021, Chemours, DuPont, Corteva and EIDP entered into a binding memorandum of understanding resolving legal disputes originating from the Delaware Litigation and Arbitration, and establishing a cost sharing arrangement and escrow account supporting and managing potential future legacy per- and polyfluoroalkyl substances ("PFAS") liabilities arising out of pre-July 1, 2015 conduct (the "MOU"). The MOU replaced a prior 2017 amendment to the Chemours Separation Agreement. According to the terms of the MOU, Corteva and DuPont together, on one hand, and Chemours, on the other hand, agreed to a 50-50 split of certain qualified expenses related to PFAS liabilities incurred over a term not to exceed twenty years or $4 billion of qualified spend and escrow account contributions (see below for discussion of the escrow account) in the aggregate. DuPont's and Corteva's 50 percent share under the MOU will be limited to $2 billion, including qualified expenses and escrow account contributions. These expenses and escrow account contributions will be subject to the existing Letter Agreement, under which DuPont and Corteva will each bear 50 percent of the first $300 million (up to $150 million each), and thereafter DuPont bears 71 percent and Corteva bears the remaining 29 percent. Under the terms of the MOU, Corteva's estimated aggregate share of the potential $2 billion is approximately $600 million.

In order to support and manage any potential future PFAS liabilities, the parties also agreed to establish an escrow account ("MOU Escrow Account"). The MOU provides that (1) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 million into an escrow account and DuPont and Corteva shall together deposit $100 million in the aggregate into an escrow account and (2) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 million into an escrow account and DuPont and Corteva shall together deposit $50 million in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Over this period, Chemours will deposit a total of $500 million in the account and DuPont and Corteva will deposit an additional $500 million pursuant to the terms of the Letter Agreement. Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700 million, Chemours will make 50

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

percent of the deposits and DuPont and Corteva together will make 50 percent of the deposits necessary to restore the balance of the escrow account to $700 million, pursuant to the terms of the Letter Agreement. Such payments will be made in a series of consecutive annual equal installments commencing on September 30, 2029, pursuant to the escrow account replenishment terms as set forth in the MOU. The MOU provides that no withdrawals from the MOU Escrow Account can be made before year six, except to fund mutually agreed upon third-party settlements in excess of $125 million. Starting with year six, withdrawals can only be made to fund qualified spend if the parties' aggregate qualified spend in that particular year is greater than $200 million. Beginning with year 11, the amounts in the MOU Escrow Account can be used to fund any qualified spend.

In April 2024, Corteva, EIDP, DuPont, and Chemours received a final judgment resolving all drinking water claims related to PFAS of a defined class of U.S. public water systems that serve the vast majority of the United States population (the "Nationwide Water District Settlement"). In connection with the Nationwide Water District Settlement, the MOU was supplemented to waive funding due to the MOU Escrow Account by Chemours, DuPont and Corteva for 2023 provided that each party fully funds its portion of the Nationwide Water District Settlement and said settlement is consummated. The funding obligation to the MOU Escrow Account with respect to 2024 and due September 30, 2024 was to be waived if (i) between October 1, 2023 and September 30, 2024, the parties had entered into settlement agreements resolving liabilities under the MOU that in the aggregate exceed $100 million; (ii) each company had fully funded its respective share, in accordance with the MOU, of such settlements; and (iii) such settlements were consummated. No such waiver was triggered for the 2024 escrow funding obligation due September 30, 2024 and, therefore, the company made its required contribution.

The company made its annual installment deposits due to the MOU Escrow Account through December 31, 2025. The MOU escrow account contains $105 million as of December 31, 2025, representing the aggregate contributions from Chemours, DuPont and Corteva, less withdrawals to fund related settlements.

After the term of this arrangement, Chemours' indemnification obligations under the original 2015 Chemours Separation Agreement, would continue unchanged, subject in each case to certain exceptions set out in the MOU. Under the MOU, Chemours waived specified claims regarding the construct of its 2015 spin-off transaction, and the parties dismissed the pending arbitration regarding those claims. Additionally, the parties have agreed to resolve the Ohio MDL PFOA personal injury litigation (as discussed below). The parties are expected to cooperate in good faith to enter into additional agreements reflecting the terms set forth in the MOU.

The Chemours Separation Agreement obligates Chemours to defend and indemnify EIDP in legacy asbestos cases. As of December 31, 2025, there were approximately 900 pending lawsuits, with most being allegations of personal injury from Historical DuPont contractors. At December 31, 2025 and 2024, the company has a litigation accrual of $88 million and $38 million, respectively, and related indemnification assets of $87 million and $38 million, respectively, recorded.

<u>Corteva Separation Agreement</u>

On April 1, 2019, in connection with the Dow Distribution, Corteva, DuPont and Dow entered into the Corteva Separation Agreement, the Tax Matters Agreement ("TMA"), the Employee Matters Agreement, and certain other agreements (collectively, the "Corteva Separation Agreements"). The Corteva Separation Agreements allocate among Corteva, DuPont and Dow assets, employees, certain liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) and provides for indemnification obligation among the parties. Under the Corteva Separation Agreement, DuPont indemnifies Corteva against certain litigation, environmental, tax, workers' compensation and other liabilities that arose prior to the Corteva Distribution, Dow indemnifies Corteva against certain litigation, environmental, tax, workers' compensation and other liabilities that relate to the Historical Dow business, and Corteva indemnifies DuPont and Dow for certain liabilities.

Under the Corteva Separation Agreements, certain legacy EIDP liabilities from discontinued and/or divested operations and businesses of EIDP (including Performance Chemicals) (a "stray liability") were allocated to Corteva or DuPont. Costs and liabilities have been shared based on the terms of the Corteva Separation Agreement. All future stray liabilities are allocated to Corteva and DuPont proportionally on the basis of 29 percent and 71 percent, respectively, subject to a $1 million de minimis requirement.

On November 1, 2025, DuPont spun off its electronics business, Qnity Electronics, Inc. ("Qnity"). DuPont, Corteva and Qnity entered into a letter agreement, effective November 1, 2025, affirming that DuPont is not novated from its obligations with respect to Corteva for legacy liabilities allocated to Qnity in its spin-off ("Qnity Letter Agreement"). Additionally, under the Qnity Letter Agreement, Corteva has certain third-party beneficiary rights to enforce indemnity and payment obligations of DuPont's with respect to legacy liabilities allocated to Qnity subject to: (i) DuPont's consent; or (ii) Corteva's receipt of a judgment that includes payment obligations for legacy liabilities attributable to Qnity, and either DuPont does not use commercially reasonable efforts to enforce the payment obligation against Qnity, or DuPont files for bankruptcy.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

At December 31, 2025 and 2024, the aggregate indemnification assets from DuPont and Dow were $104 million and $47 million, respectively, within accounts and notes receivable - net and $263 million and $143 million, respectively, within other assets in the Consolidated Balance Sheets. At December 31, 2025 and December 31, 2024, the aggregate indemnification liabilities were $26 million and $9 million, respectively, within accrued and other current liabilities and $154 million and $149 million, respectively, within other noncurrent obligations in the Consolidated Balance Sheets.

<u>Discontinued Operations Activity</u>

For the years ended December 31, 2025 and 2024, the company recorded benefits (charges) of $(99) million and $56 million, to income (loss) from discontinued operations after income taxes, in the Consolidated Statement of Operations. The after-tax charge recognized during the year ended December 31, 2025 was driven by charges relating to the MOU with Chemours and DuPont, comprised of a litigation charge associated with the NJ Statewide Settlement as well as PFAS environmental remediation activities primarily at Chemours' Fayetteville Works facility, along with other environmental matters. The after-tax benefit recognized during the year ended December 31, 2024 was driven by charges pursuant to the MOU with Chemours and DuPont relating to PFAS remediation activities primarily at Chemours' Fayetteville Works facility and litigation activity, which were more than offset by a favorable adjustment of certain prior year tax positions for previously divested businesses, the derecognition of an indemnification liability associated with the Water District Settlement Fund contribution, and insurance proceeds related to legacy matters.

**Litigation** 

The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EIDP businesses unrelated to Corteva's current businesses but allocated to Corteva as part of the Corteva Separation from DuPont. It is not possible to predict the outcome of these various proceedings, as considerable uncertainty exists. The company records accruals for legal matters when the information available indicates that it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Accruals may reflect the impact and status of negotiations, settlements, rulings, advice from counsel and other information and events that may pertain to a particular matter. For the litigation matters discussed below, management believes that it is reasonably possible that the company could incur liabilities in excess of amounts accrued, for which the ultimate liability could be material to the results of operations and the cash flows in the period recognized. However, the company is unable to estimate the possible loss beyond amounts accrued due to various reasons, including, among others, that the underlying matters are either in early stages and/or have significant factual issues to be resolved. In addition, even when the company believes it has substantial defenses, the company may consider settlement of matters if it believes it is in the best interest of the company. At December 31, 2025 and 2024, current accrued litigation was $874 million and $228 million, respectively, within accrued and other current liabilities. A current indemnification asset of $188 million was recorded within accounts and notes receivable - net at December 31, 2025 in relation to the current accrued litigation. See the "Chemours Separation Agreement (Performance Chemicals)" and the "Corteva Separation Agreement" sections for further details on the indemnifications.

<u>Bayer Dispute</u>

In August 2022, Bayer filed a breach of contract/declaratory judgment lawsuit in Delaware state court against Corteva relating to an agrobacterium cross-license agreement and Enlist E3® soybeans. Bayer alleged that Corteva practiced two Bayer patents in developing Enlist E3® soybeans, and therefore, is entitled pursuant to the terms of the cross-license agreement to royalties for sales between 2019 through 2029, along with interest. In January 2025, the court issued several rulings precluding Corteva's invalidity and inequitable conduct defenses, while also aligning on key aspects of Corteva's patent claim construction. In May 2025, the Delaware state court granted Corteva's motion for partial summary judgment agreeing that U.S. Supreme Court precedent precludes the collection of royalties after patent expiration. Bayer's motion for reconsideration was denied in June 2025. In July 2025, a stipulated order allowed Bayer to appeal the summary judgment finding, while also allowing Corteva's cross-appeal of the dismissal of its invalidity and inequitable conduct defenses.

In August 2022, Corteva filed a lawsuit against Bayer CropScience LLP and Monsanto Company (collectively "Bayer") in federal court in Delaware for alleged infringement of Corteva's patented AAD-1 herbicide resistance technology used in Enlist® corn. The complaint for this lawsuit was amended to include additional patents that are closely related to this patented technology for soybeans. Corteva seeks to enjoin Bayer from continuing to infringe, as well as appropriate monetary damages. Bayer has filed an answer to the complaint and has asserted various affirmative defenses including invalidity. In August 2023, the court issued a decision adopting Corteva's claim construction for all five disputed patent terms subject to this litigation.

In December 2023, the Patent Trial and Appeal Board ("PTAB") authorized an Inter Partes Review ("IPR") proceeding initiated by Bayer to review the patentability of three patents subject to the AAD-1 litigation. Inari joined the IPR proceeding. In

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

December 2024, the PTAB issued a decision invalidating these patents on the basis they were unpatentable. Corteva appealed this decision and Corteva's AAD-1 lawsuit remains stayed during pendency of the IPR appeal. Corteva holds numerous additional patents covering its Enlist® traits or Enlist® weed control system. Therefore, the IPR process is not expected to impact its ability to license and protect Enlist E3® traits.

In October 2022, Corteva filed a lawsuit against Bayer in Delaware state court seeking a declaration that, under the terms of Corteva's licensing agreement and the law, Bayer is not entitled to collect patent royalties on the Roundup Ready® Corn 2 trait after Bayer's U.S. patent protection expires, and therefore is no longer required to pay royalties under the licensing agreement and entitled to recover relevant royalties paid. In September 2024, the court granted Bayer's motion for summary judgment. Corteva's appeal was heard by the Delaware Supreme Court, en banc, in May 2025. Additionally, Corteva initiated arbitration of two additional agreements with Bayer seeking similar relief. The Delaware Supreme Court stayed the appeal proceedings pending resolution discussions between Corteva and Bayer.

As of January 2026, the parties agreed to settle the agrobacterium cross-license agreement dispute. In addition, Corteva and Bayer resolved several other disputes regarding post-patent royalties and other matters, including post-patent regulatory support, resulting in the termination or amendment of the related licenses, as applicable. As part of the resolution of these matters, the cross-license agreement has been terminated and Corteva has agreed to a payment of $610 million and to drop its AAD-1 patent claims against Bayer. Also as a result of the resolution of this litigation and the related license terminations and amendments, potential royalty obligations for Corteva's Enlist E3® soybeans, as well as future royalty payments due to Bayer under other licensing agreements in dispute were terminated. The settlement agreements support Corteva's product out-licensing growth in competitive corn, cotton and canola markets, including for the out-licensing of above and below ground triple-stack corn technology. In conjunction with resolution of these matters, the companies also agreed to new cotton licensing arrangements at terms reflective of market rates. There is no remaining litigation between the parties.

<u>Federal Trade Commission Investigation</u>

On May 26, 2020, Corteva received a subpoena from the Federal Trade Commission ("FTC") directing it to submit documents pertaining to its Crop Protection products generally, as well as business plans, rebate programs, offers, pricing and marketing materials specifically related to its acetochlor, oxamyl, rimsulfuron and other related products in order to determine whether Corteva engaged in unfair methods of competition through anticompetitive conduct. Corteva has fully cooperated with all requests related to this subpoena. On September 29, 2022, the FTC, along with ten state attorneys general in California, Colorado, Illinois, Indiana, Iowa, Minnesota, Nebraska, Oregon, Wisconsin, and Texas, filed a lawsuit against Corteva and another competitor alleging the parties engaged in unfair methods of competition, unlawful conditioning of payments, unreasonably restrained trade, and have an unlawful monopoly (the "FTC lawsuit"). In December 2022, attorneys general in Tennessee and Washington joined the FTC lawsuit and the Arkansas state attorney general filed a separate lawsuit against Corteva and another competitor based on the allegations set forth in the FTC lawsuit. In July 2025, the Arkansas state attorney general amended the complaint to include methoxyfenozide, cyhalofop, picloram, triclopyr, and aminopyralid products. Several proposed private class action lawsuits were also filed in federal court alleging anticompetitive conduct based on the allegations set forth in the FTC lawsuit.

Virtually all of these private lawsuits were centralized into a multi-district litigation in the U.S. District Court for the Middle District of North Carolina. In January 2025, federal court for the multi-district litigation granted in part, and denied in part, Corteva's motion to dismiss. Specifically, the court order dismissed the plaintiff's federal damages claims and 13 of the 27 state consumer protection act claims. The plaintiffs amended their complaint to include methoxyfenozide products. The trials for these claims are expected to begin in 2027.

<u>Lorsban® Lawsuits</u>

As of December 31, 2024, there were asserted claims for personal injury against the former Dow Agrosciences LLC, alleging injuries related to chlorpyrifos exposure, the active ingredient in Lorsban®, an insecticide used by commercial farms for field fruit, nut and vegetable crops. Corteva ended its production of Lorsban® in 2020. Chlorpyrifos products are restricted-use pesticides, which are not available for purchase or use by the general public, and may only be sold to, and used by, certified applicators or someone under the certified applicator's direct supervision. These lawsuits do not relate to Dursban®, a residential type chlorpyrifos product that was authorized for indoor purposes, which was discontinued over two decades ago prior to the merger of Dow and Historical DuPont and Corteva's formation and Separation. Claimants allege personal injury, including autism, developmental delays and/or decreased neurologic function, resulting from farm worker exposure and bystander drift and in utero exposure to chlorpyrifos. Certain claimants have also put forth remediation claims due to alleged property contamination from chlorpyrifos. As of December 31, 2025, an accrual has been established for the estimated resolution of certain claims.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

*Litigation related to legacy EIDP businesses unrelated to Corteva's current businesses*

For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs").

EIDP is a party to various legal proceedings relating to the use of PFOA by its former Performance Chemicals segment for which potential liabilities would be subject to the cost sharing arrangement under the MOU as long as it remains effective.

<u>Leach Settlement and Ohio MDL Settlement</u>

EIDP has residual liabilities under its 2004 settlement of a West Virginia state court class action, Leach v. EIDP, which alleged that PFOA from EIDP's former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. The settlement class has about 80,000 members. In addition to relief that was provided to class members years ago, the settlement requires EIDP to continue providing PFOA water treatment to six area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members. As of December 31, 2025, approximately $2 million had been disbursed from the account since its establishment in 2012 and the remaining balance is approximately $1 million.

<u>PFOA Personal Injury Claims</u>

In December 2024, the defendants reached a settlement of all of the currently filed and unfiled personal injury cases in the Ohio MDL for $59 million. The settlement was payable in two installments, with $8 million contributed in aggregate by Corteva. The final installment was paid upon the court dissolving the MDL in March 2025.

<u>Other PFOA Matters</u>

EIDP is a party to other PFOA lawsuits involving claims for property damage, medical monitoring and personal injury. Defense costs and any future liabilities that may arise out of these lawsuits are subject to the MOU and the cost sharing arrangement disclosed above. Under the MOU, fraudulent conveyance claims associated with these matters are not qualified expenses, unless Corteva, Inc. and EIDP would prevail on the merits of these claims.

EIDP did not make film-forming foams, PFOS, or PFOS products. While EIDP made surfactants and intermediaries that some manufacturers used in making foams, which may have contained PFOA as an unintended byproduct or an impurity, EIDP's products were not formulated with PFOA, nor was PFOA an ingredient of these products. EIDP has never made or sold PFOA as a commercial product.

*Aqueous Film-Forming Foams.* Approximately 10,100 cases filed against 3M and other defendants, including EIDP and Chemours, and some including Corteva and DuPont, alleging personal injury (primarily kidney, testicular, liver and thyroid cancer) from the use of aqueous film-forming foams ("AFFF") or contamination, in most cases due to migration from military installations or airports, consolidated in a multi-district litigation proceeding in federal district court in South Carolina ("SC MDL"). Most of these recent cases also assert claims that the EIDP and Chemours separation constituted a fraudulent conveyance.

In August 2025, the SC MDL entered multiple case management orders requiring cases filed outside the SC MDL to be transferred to the SC MDL, establishing a 21-day window for unfiled cases to be filed, and allowing the filing of multi-plaintiff complaints. A significant number of new cases asserting personal injury were filed or transferred to the SC MDL. Many of the personal injury cases both inside and outside the SC MDL include and continue to include, as new cases are threatened, multiple plaintiffs. Therefore, the number of plaintiffs asserting such claims is substantially higher than the number of cases set forth above. The first bellwether personal injury trial is expected to be scheduled for 2026. Discussions between the parties on a resolution to these cases remain ongoing.

*Nationwide Water District Settlement.* On June 1, 2023, Corteva, EIDP, Inc., DuPont, and Chemours (collectively, the "settling companies") entered into a binding agreement in principle to comprehensively resolve all drinking water claims related to PFAS of a defined class of U.S. public water systems that serve the vast majority of the United States population, including, but not limited to the AFFF claims in the SC MDL, under the Nationwide Water District Settlement, for $1.185 billion in the aggregate. PFAS, as defined in the settlement, includes PFOA and HFPO-DA, among a broad range of fluorinated organic substances. In April 2024, the settlement was deemed final resulting in the release of the previously restricted cash in the Water District Settlement Fund and derecognition of the associated liability. The Nationwide Water District Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by Corteva or EIDP.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The class represented by the Nationwide Water District Settlement is composed of all Public Water Systems, as defined in 42 U.S.C. § 300f, with a current detection of PFAS or that are currently required to monitor for PFAS under the Environmental Protection Agency's Fifth Unregulated Contaminant Monitoring Rule ("UCMR 5") or other applicable federal or state law (the "Class"). Approximately 88 percent of the U.S. is served by systems required to test under UCMR 5. The Class does not include water systems owned and operated by a State or the United States government; small systems that have not detected the presence of PFAS and are not currently required to monitor for it under federal or state requirements; and, unless they otherwise request to be included, water systems in the lower Cape Fear River Basin of North Carolina.

The total number of requests for exclusion ("opt-outs") was approximately 900 water districts while most public water districts (approximately 93 percent of the Class) remain in the class settlement. The company has been served complaints from opt-outs, as well as water district and municipal authority claims not covered by the Nationwide Water District Settlement.

*New Jersey.* In late March 2019, the New Jersey State Attorney General filed four lawsuits against EIDP, Chemours, and others alleging that operations at and discharges from former EIDP sites in New Jersey (Chambers Works, Parlin, Pompton Lakes, and Repauno) damaged the State's natural resources. Two of these lawsuits (those involving the Chambers Works and Parlin sites) allege contamination from PFAS. DuPont and Corteva were subsequently added as defendants to these lawsuits. These lawsuits include claims for remediation, fraudulent conveyance, as well as claims under the New Jersey Water Pollution Control Act and the New Jersey Industrial Site Recovery Act ("ISRA").

On August 3, 2025, the company, together with Chemours and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey (the "NJ Statewide Settlement") to resolve all outstanding claims by the State of New Jersey pending against the companies related to the legacy use of a wide variety of substances of concern, including, but not limited to DNAPL (dense non-aqueous phase liquids), chemical solvents, and PFAS. Subject to a public notice and comment period and subject to court approval following that period, the NJ Statewide Settlement will also resolve legacy claims related to four Historical DuPont operating sites (Chambers Works, Parlin, Pompton Lakes and Repauno) in the State, including claims under ISRA, alleged statewide PFAS contamination, including from the use of AFFF, claims of fraudulent conveyance, and claims for known natural resource damages from these Historical DuPont sites that the State of New Jersey and its departments have, or may have, in the future against the companies.

The NJ Statewide Settlement, after the expiration of the public notice and comment period, is subject to court approval. The court hearing for this approval occurred in January 2026 with a conclusion on the approval expected during the first half of 2026. The NJ Statewide Settlement includes aggregate cash payments to the State of New Jersey of $875 million, payable over a period of 25 years (net present value of approximately $500 million, using an 8 percent discount rate), responsibility for which will be allocated among the settling companies in accordance with the terms of the MOU. Of the $875 million, approximately $16 million is allocated to statewide natural resource damages unrelated to the four Historical DuPont sites, 25 percent of which relates to alleged statewide AFFF contamination. Accordingly, in the second quarter of 2025, the company recorded a pre-tax loss of $72 million ($58 million after-tax) within discontinued operations, reflecting the net present value of the company's share of the aggregate cash payment in accordance with the MOU. The settling companies have agreed to count the NJ Statewide Settlement against the MOU limit at net present value as of the date of the NJ Statewide Settlement. Entry into the NJ Statewide Settlement suspended the companies' 2025 MOU escrow funding obligations and funding of the initial payment under the NJ Statewide Settlement, expected in 2026, will be deemed to satisfy these obligations for 2025.

In addition to the cash payment, the NJ Statewide Settlement obligates certain settling companies to continue to undertake remediation at the four Historical DuPont sites, which will be determined in accordance with applicable law and the respective cost sharing arrangements between the settling companies, to the extent applicable. DuPont and Chemours will be responsible for the remediation at the sites under their current respective ownership. As part of the NJ Statewide Settlement, the companies have agreed to a binding third party review process of the remedial funding source ("RFS") for each of the four Historical DuPont sites (in the form of a surety bond or similar financial instrument) to ensure available funds for future remediation of these sites. This review process could identify additional required remediation, and an increase to the RFS for each of these sites.

The company and DuPont will also establish a reserve fund (in the form of a surety bond or similar financial instrument) in the amount of $475 million (the "Reserve Fund") with DuPont funding 71 percent and the company bearing the remaining 29 percent. The Reserve Fund is further financial security, separate from, and secondary to, the RFS, and the Reserve Fund will be accessible only in the event the RFS for a site has been exhausted and the party responsible for a site is not otherwise performing the required remediation. If a responsible party under the NJ Statewide Settlement defaults on their remediation or payment obligations (subject first to the cost sharing arrangements under the Corteva Separation Agreements, which provides that these obligations are "stray liabilities"), EIDP will become responsible for such obligations.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Under the NJ Statewide Settlement, no settling party admits any liability or wrongdoing or agrees to waive any defenses as to any such liability or wrongdoing.

Pursuant to a separate agreement among the company, DuPont, and Chemours, DuPont and the company will purchase Chemours' future interest, if any, in certain insurance proceeds. DuPont and the company will make the purchase by contributing a total of $150 million, with $106 million from DuPont and $44 million from the company, into an escrow fund, with funds to be released to pay Chemours' share of the NJ Statewide Settlement. DuPont and the company will pay Chemours, as additional contingent consideration, amounts received from the acquired insurance proceeds in excess of $150 million plus an accrued fee. The accrued fee will equal the lesser of (a) $35 million, and (b) $3 million plus interest (at prime minus 2 percent) on an initial balance of $150 million, as reduced by any amounts received by DuPont and Corteva from the acquired insurance proceeds, until DuPont and the company have so received $150 million, plus the accrued fee. The purchase price to be paid to Chemours, and the insurance proceeds recovered, by DuPont and the company from the insurance proceeds acquired from Chemours, are subject to the sharing percentages under the Letter Agreement.

*Ohio*. EIDP is a defendant in two lawsuits, including an action by the State of Ohio based on alleged damage to natural resources. The natural resources damage claim was preliminarily resolved in December 2023 for $110 million, with Corteva's share of the settlement under the MOU being approximately $16 million of which $13 million has been paid. As of December 31, 2025, an accrual has been established. The second, a putative nationwide class action ("the Hardwick Class Action") brought on behalf of anyone who has detectable levels of PFAS in their blood serum seeks declaratory and injunctive relief, including the establishment of a "PFAS Science Panel." In December 2023, the Sixth Circuit Court of Appeals dismissed the Hardwick Class Action due to lack of standing by Mr. Hardwick. With further opportunities for appeals expired, the plaintiffs filed a new case, narrowing their original claims, in June 2024. In January 2025, EIDP filed a motion to dismiss the new case on the grounds it remains similar to the original claim.

*New York*. EIDP is a defendant in a putative class action (the "Baker Class Action"), brought by persons who live in and around Hoosick Falls, New York. These lawsuits assert claims for medical monitoring, property damage and personal injury based on alleged PFOA releases from manufacturing facilities owned and operated by co-defendants in Hoosick Falls. The lawsuits allege that EIDP and others supplied materials used at these facilities resulting in PFOA air and water contamination. A court approved settlement was reached between the plaintiffs and the other co-defendants regarding the Baker Class Action case. In September 2022, the class certification of the Baker Class Action was granted, with the court certifying three separate classes consisting of a private well property damage class, a medical monitoring class and a nuisance class. A settlement in principle of the Baker Class Action was reached in June 2025 for $22 million, plus funding $1 million annually to a medical monitoring fund for five years. As of December 31, 2025, an accrual for Corteva's share of the expected settlement under the MOU was established.

EIDP is a defendant in a lawsuit brought by the Town of East Hampton, New York alleging PFOA and PFOS contamination of the town's well water. This district submitted a timely opt-out request from the Nationwide Water District Settlement. EIDP and Chemours are also defendants in two lawsuits by a private water utility provider in New Jersey and New York alleging damages from PFAS releases into the environment, that impacted water sources that the utilities use to provide water, as well as product liability, negligence, nuisance, and trespass claims. The court dismissed the New York plaintiff's trespass claims and limited plaintiffs' nuisance claims to abatement damages

*Other Natural Resource Damage Cases.* In addition to the natural resource damage cases in New Jersey and New York, natural resource damage lawsuits against EIDP, Chemours, and others, claiming, among other things, PFC (including PFOA) contamination of groundwater and drinking water, have been filed by attorneys general in 31 states, the District of Columbia and three U.S. territories. Certain cases also name DuPont and Corteva as defendants and include claims of fraudulent conveyance. The complaints seek reimbursement for past and future costs to monitor and remediate the alleged contamination and compensation for the loss of value and use of the state's natural resources, as well as punitive damages. Due to overlapping AFFF allegations, virtually all of these cases have been transferred, or are pending transfer to the SC MDL. These cases are largely in the discovery phase.

On July 13, 2021, Chemours, DuPont, EIDP and Corteva entered into a settlement agreement with the State of Delaware reflecting the companies' and the State's agreement to settle and fully resolve claims alleged against the companies regarding their historical Delaware operations, manufacturing, use and disposal of all chemical compounds, including PFAS. Under the settlement, if the companies, individually or jointly, within 8 years of the settlement, enter into a proportionally similar agreement to settle or resolve claims of another state for PFAS-related natural resource damages, for an amount greater than $50 million, the companies shall make a supplemental payment directly to the Natural Resources and Sustainability Trust (the "NRS Trust") in an amount equal to such other states' recovery in excess of $50 million ("Supplemental Payment"). Supplemental Payment(s), if any, will not exceed $25 million in the aggregate. All amounts paid by the companies under the

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

settlement are subject to the MOU and the Corteva Separation Agreement. Due to the settlement of natural resource damages claims with the State of Ohio, the one-time Supplemental Payment will be triggered when the further opportunity for appeals expires under the Ohio judicial consent order process. As of December 31, 2025, an accrual has been established for Corteva's share under the MOU. Under the settlement, if the state sues other parties and those parties seek contribution from the companies, the companies will have protection from contribution up to the amounts previously paid under the settlement agreement. The companies will also receive a credit up to the amount of the payment if the state seeks natural resource damage claims against the companies outside the scope of the settlement's release of claims.

*Canada*. The Province of British Columbia, filed a class action against various defendants, including 3M, DuPont Canada, EIDP, and Chemours alleging harms caused by PFAS/AFFF. The class consists of all municipalities, regional districts, and other governance authorities and other persons in Canada that were responsible for a "Drinking Water System" from 1970 to the present. The plaintiff seeks to recover costs for the treatment and restoration of natural resources, as well as property, economic, and punitive damages. A putative class action was also filed in July 2024 on behalf of citizens of Quebec, Canada seeking class certification to recover for alleged PFAS and AFFF contamination of private wells and public water treatment facilities. In January 2024, a class action was also filed in Canada against 3M and other defendants, including EIDP and Chemours, alleging PFOS and PFOA environmental contamination and personal injury from use of AFFF. Additionally, several lawsuits on behalf of consumers of PFAS-infused products in the Province of British Columbia for personal injury and PFAS contamination in Manitoba, Canada have been filed.

*Netherlands*. In April 2021, four municipalities in the Netherlands filed complaints alleging contamination of land and groundwater resulting from the emission of PFOA and GenX by Corteva, DuPont and Chemours. The municipalities seek to recover costs incurred due to the alleged emissions, including damages for investigation costs, construction project delays, depreciation of land, soil remediation, liabilities to contractors, and attorneys' fees. In September 2023, the court entered a second interlocutory judgment, ruling, inter alia, that defendants were liable to the municipalities for PFOA emissions during a certain time period, and the removal costs of deposited emissions on the municipalities' land infringes their property rights by an objective standard. In June 2024, Chemours and these Dutch municipalities signed a letter of intent that included the implementation of a specific remediation plan for the restoration of restricted vegetable gardens in certain areas of those municipalities to be funded by Chemours, sampling and developing a program to address a recreational lake, and further settlement discussions, including a potential fund to cover certain other expenditures aimed at environmental-related activities. While the letter of intent contemplates the possibility of settlement, discussions between the parties related to the resolution to these matters remain ongoing. Although the company believes a loss is probable, it is not estimable at this time due to various reasons including, among others, the status of discussions between the parties. As of December 31, 2025, an accrual has been established for the estimated environmental remediation set forth in the letter of intent. Additionally, the Office of Public Prosecutor in the Netherlands opened a criminal investigation against certain Dutch subsidiaries of Chemours and Historical DuPont, as well as each subsidiary's directors, alleging unlawful PFOA and GenX emissions from Chemours' Dordrecht Works facility.

*Carpet Mill Cases.* The city of Centre, Alabama water district alleged defendants, including EIDP, Chemours, other chemical suppliers and large carpet mills, discharged PFAS in their industrial wastewater, and that this wastewater after treatment, resulted in PFAS contamination of drinking water supplies. The trial for the Centre, Alabama water district carpet mill case is set to begin January 2026. In July 2024, the town of Lyerly, Georgia filed a case making similar allegations as those brought in the Centre, Alabama case. Numerous carpet, textile and paper manufacturers, their alleged suppliers and former suppliers, including EIDP and Chemours, and certain municipal or utility defendants are also subject to several lawsuits in Georgia, Alabama and South Carolina, alleging negligence, nuisance and trespass related to the release of PFOA, and requesting injunctive relief related to PFOA contamination.

<u>Fayetteville Works Facility, North Carolina</u>

Prior to the separation of Chemours, EIDP introduced GenX as a polymerization processing aid and a replacement for PFOA at the Fayetteville Works facility in Bladen County, North Carolina. This Historical DuPont facility is now owned and operated by Chemours, which continues to manufacture and use GenX. The current natural resources damage claims in North Carolina allege that direct discharges from this legacy facility are a source of PFOA contamination.

At December 31, 2025, several actions, including personal injury, are pending in the North Carolina federal court against Chemours and EIDP relating to PFC discharges from the Fayetteville Works facility. One of these is a consolidated putative class action that asserts claims for medical monitoring and property damage on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority ("CFPUA") and Brunswick County, that seek actual and punitive damages as well as injunctive relief. EIDP and Chemours filed a motion for summary judgment on this consolidated action in March 2025. Cumberland County, North Carolina, which is not part of the

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

forgoing consolidation action or the Nationwide Water District Settlement, filed an action for alleged PFOA contamination to its groundwater sources used in drinking water and seeking recovery for costs associated with water filtration, monitoring, and compliance costs. The pending mediation and trial for this matter are no longer scheduled.

In March 2023, CFPUA filed a Delaware Chancery Court action claiming the spin-off of Chemours and the Dow and Historical DuPont merger were unlawful and should be voided, so CFPUA is not precluded from recovering amounts it is entitled in its pending litigation. EIDP filed a motion to dismiss the Delaware Chancery Court action based upon failure to state a claim under Delaware law in June 2023, along with a counterclaim in October 2023. CFPUA's motion to stay the case was granted in January 2024.

In a state court action approximately 2,400 private property owners near the Fayetteville Works facility seek compensatory and punitive damages for their claims of private nuisance, trespass, negligence, water monitoring and property damage allegedly caused by release of certain PFCs. In addition, several personal injury cases have been filed in the North Carolina federal court alleging thyroid disease, and prostate, breast and kidney cancers as a result of PFAS exposure.

Generally, site-related expenses related to GenX claims are subject to the cost sharing arrangements as defined in the MOU.

**Environmental**

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. These obligations are included in accrued and other current liabilities and other noncurrent obligations in the Consolidated Balance Sheets. It is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the company's results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration.

For a discussion of the allocation of environmental liabilities under the Chemours Separation Agreement and the Corteva Separation Agreement, see page F-36-37.

The accrued environmental obligations and indemnification assets include the following:

---

| | | | |
|:---|:---|:---|:---|
| | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
| *(In millions)* | **Indemnification asset** | **Accrual** <br>**balance** <sup>3</sup> | **Potential exposure above amount** <br>**accrued** <sup>3</sup> |
| *Environmental Remediation Stray Liabilities* |  |  |  |
| &nbsp;&nbsp;Chemours related obligations - subject to indemnity <sup>1,2</sup> | $254 | $264 | $204 |
| &nbsp;&nbsp;Other discontinued or divested businesses obligations <sup>1</sup> | 33 | 71 | 201 |
| Environmental remediation liabilities primarily related to DuPont - subject to indemnity from DuPont <sup>2</sup> | 50 | 55 | 55 |
| Environmental remediation liabilities not subject to indemnity |  | 112 | 86 |
| Indemnification liabilities related to the MOU <sup>4</sup> |  | 60 | 7 |
| Total | $337 | $562 | $553 |

---

1. Represents liabilities that are subject to the $200 million threshold and sharing arrangements as discussed on page F-37, under the header "Corteva Separation Agreement."

2. The company has recorded an indemnification asset related to these accruals, including $22 million related to the Superfund sites.

3. Accrual balance represents management's best estimate of the costs of remediation and restoration, although it is reasonably possible that the potential exposure, as indicated, could range above the amounts accrued, as there are inherent uncertainties in these estimates. Accrual balance includes $49 million for remediation of Superfund sites. Amounts do not include possible impacts from the remediation elements of the EPAs October 2021 PFAS Strategic Roadmap (as applicable), except as disclosed on page F-43 relating to Chemours' remediation activities at the Fayetteville Works Facility pursuant to the Consent Order with the North Carolina Department of Environmental Quality ("NC DEQ").

4. Represents liabilities that are subject to the $150 million threshold and sharing agreements as discussed on page F-36, under the header "Chemours Separation Agreement (Performance Chemicals).

*Nebraska Department of Environment and Energy, AltEn Facility*

The EPA and the Nebraska Department of Environment and Energy ("NDEE") are pursuing investigations, response and removal actions, litigation and enforcement action related to an ethanol plant located near Mead, Nebraska that is owned and

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

operated by AltEn LLC ("AltEn"). The agencies have alleged violations under the Resource Conservation and Recovery Act ("RCRA") and other federal and state laws stemming from AltEn's lack of compliance with the terms and conditions of its operating permits and other regulatory requirements. Corteva is one of six seed companies, who were customers of AltEn (collectively, the "Facility Response Group"), participating in the NDEE's Voluntary Cleanup Program to address certain interim remediation needs at the site. In March 2025, the Facility Response Group reached an agreement to settle its lawsuit against AltEn and certain of its affiliates to preserve certain contractual and common law indemnification claims. The settlement agreement, among other things, limits AltEn's ability to dispose of the property or take any adverse action with respect to its property or assets. As of December 31, 2025, an accrual was established for Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans for the AltEn location.

*California Department of Toxic Substances Control, Pittsburg Plant*

The California Department of Toxic Substances Control ("DTSC") has filed a state court lawsuit over challenging whether the Pittsburg plant's high purity water system ("HPWS"), as operated by Dow and now Corteva, required a permit pursuant to the RCRA. Discussions between the parties remain ongoing and further litigation, including discovery, is stayed.

**NOTE 16 - STOCKHOLDERS' EQUITY**

**Common Stock**

Set forth below is a reconciliation of common stock share activity for the years ended December 31, 2025, 2024, and 2023:

---

| | |
|:---|:---|
| **Shares of common stock** | **Issued** |
| Balance at December 31, 2022 | 713419000 |
| Issued | 1965000 |
| Repurchased and retired | (14124000) |
| Balance at December 31, 2023 | 701260000 |
| Issued | 2244000 |
| Repurchased and retired | (17909000) |
| Balance at December 31, 2024 | 685595000 |
| Issued | 2701000 |
| Repurchased and retired | (16133000) |
| Balance at December 31, 2025 | 672163000 |

---

**Share Buyback Plan**

On November 19, 2024, Corteva, Inc. announced that its Board of Directors authorized a $3 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2024 Share Buyback Plan"). The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. In connection with the 2024 Share Buyback Plan, the company repurchased and retired 8,318,000 shares in the open market for a cost (excluding excise taxes) of $571 million during the year ended December 31, 2025.

On September 13, 2022, Corteva, Inc. announced that its Board of Directors authorized a $2 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2022 Share Buyback Plan"). The company completed the 2022 Share Buyback Plan during the second quarter of 2025 and repurchased and retired 7,815,000, 17,909,000 and 10,026,000 shares in the open market and through privately-negotiated transactions for a cost (excluding excise taxes) of $500 million, $1 billion and $500 million during the years ended December 31, 2025, 2024 and 2023, respectively. Included within the shares repurchased during the years ended December 31, 2025 and 2024 were $145 million and $125 million, respectively, of shares from the master trust fund of the principal U.S. pension plan, as part of the Pension Investment Committee's periodic portfolio rebalancing process. Shares were repurchased by the company at the prevailing market rate authorized and agreed to by a third-party independent fiduciary for the plan.

On August 5, 2021, Corteva, Inc. announced that its Board of Directors authorized a $1.5 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2021 Share Buyback Plan"). The company completed the 2021 Share Buyback Plan during the first quarter of 2023 and repurchased and retired 4,098,000, 17,425,000 and 5,572,000 shares in the open market for a total cost of $250 million, $1 billion and $250 million during the years ended December 31, 2023, 2022 and 2021, respectively.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Shares repurchased pursuant to Corteva's share buyback plans are immediately retired upon repurchase. Repurchased common stock is reflected as a reduction of stockholders' equity. The company's accounting policy related to its share repurchases is to reduce its common stock based on the par value of the shares and to reduce its retained earnings for the excess of the repurchase price over the par value. When Corteva has an accumulated deficit balance, the excess over the par value is applied to additional paid-in capital ("APIC"). When Corteva has retained earnings, the excess is charged entirely to retained earnings.

**Noncontrolling Interest**

Corteva, Inc. owns 100 percent of the outstanding common shares of EIDP. However, EIDP has preferred stock outstanding to third parties which is accounted for as a non-controlling interest in Corteva's Consolidated Balance Sheets. Each share of EIDP Preferred Stock - $4.50 Series and EIDP Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EIDP and was unaffected by the Corteva Distribution.

Below is a summary of the EIDP Preferred Stock at December 31, 2025 and 2024 which is classified as noncontrolling interests in the Corteva Consolidated Balance Sheets.

---

| | |
|:---|:---|
| *(Shares in thousands)* | **Number of Shares** |
| Authorized | 23000 |
| $4.50 Series, callable at $120 | 1673 |
| $3.50 Series, callable at $102 | 700 |

---

**Other Comprehensive Income (Loss)**

The changes and after-tax balances of components comprising accumulated other comprehensive income (loss) are summarized below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(In millions)* | **Cumulative Translation Adjustment**<sup>1</sup>  | **Derivative Instruments** | **Pension Benefit Plans** | **Other Benefit Plans** | **Unrealized Gain (Loss) on Investments** | **Total** |
| **2023** |  |  |  |  |  |  |
| Balance at January 1, 2023 | $(2883) | $80 | $(163) | $160 | $— | $(2806) |
| Other comprehensive income (loss) before reclassifications | 425 | (123) | (188) | 38 |  | 152 |
| Amounts reclassified from accumulated other comprehensive income (loss) |  | (12) | (2) | (9) |  | (23) |
| Net other comprehensive income (loss) | $425 | $(135) | $(190) | $29 | $— | $129 |
| Balance at December 31, 2023 | $(2458) | $(55) | $(353) | $189 | $— | $(2677) |
| **2024** |  |  |  |  |  |  |
| Other comprehensive income (loss) before reclassifications | (1014) | 27 | 127 | 40 | (6) | (826) |
| Amounts reclassified from accumulated other comprehensive income (loss) |  | 44 |  | (10) |  | 34 |
| Net other comprehensive income (loss) | $(1014) | $71 | $127 | $30 | $(6) | $(792) |
| Balance at December 31, 2024 | $(3472) | $16 | $(226) | $219 | $(6) | $(3469) |
| **2025** |  |  |  |  |  |  |
| Other comprehensive income (loss) before reclassifications | 867 | (65) | (149) | (12) | 6 | 647 |
| Amounts reclassified from accumulated other comprehensive income (loss) |  | 42 | (3) | (14) |  | 25 |
| Net other comprehensive income (loss) | $867 | $(23) | $(152) | $(26) | $6 | $672 |
| Balance at December 31, 2025 | $(2605) | $(7) | $(378) | $193 | $— | $(2797) |

---

1. The cumulative translation adjustment gain for the year ended December 31, 2025 was primarily driven by the weakening of the U.S. Dollar ("USD") against the Euro ("EUR"), Brazilian Real ("BRL"), South African Rand ("ZAR") and Mexican Peso ("MXN"). The cumulative translation adjustment loss for the year ended December 31, 2024 was primarily driven by the strengthening of the U.S. Dollar against the Brazilian Real, Euro, Swiss Franc ("CHF") and Mexican Peso. The cumulative translation adjustment gain for the year ended December 31, 2023 was primarily driven by the weakening of the U.S. Dollar against the Swiss Franc, Brazilian Real and Euro.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The tax (expense) benefit on the net activity related to each component of other comprehensive income (loss) was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Derivative instruments | $(5) | $(12) | $50 |
| Pension benefit plans - net | 51 | (35) | 60 |
| Other benefit plans - net | 7 | (8) | (9) |
| Unrealized gains (losses) on investments |  |  |  |
| (Provision for) benefit from income taxes related to other comprehensive income (loss) items | $53 | $(55) | $101 |

---

A summary of the reclassifications out of accumulated other comprehensive income (loss) is provided as follows:

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|  | **2025** | **2024** | **2023** |
| **Derivative instruments:** <sup>1</sup> | $66 | $65 | $(8) |
| Tax (benefit) expense <sup>2</sup> | (24) | (21) | (4) |
| After-tax | $42 | $44 | $(12) |
| **Amortization of pension benefit plans:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior service (benefit) cost <sup>3,4</sup> | $(4) | $(4) | $(3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Actuarial (gains) losses <sup>3,4</sup> |  | 1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Settlement (gain) loss <sup>3,4</sup> |  | 2 |  |
| Total before tax | $(4) | $(1) | $(3) |
| Tax (benefit) expense <sup>2</sup> | 1 | 1 | 1 |
| After-tax | $(3) | $— | $(2) |
| **Amortization of other benefit plans:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior service (benefit) cost <sup>3,4</sup> | $(1) | $(1) | $(2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Actuarial (gains) losses <sup>3,4</sup> | (17) | (13) | (10) |
| Total before tax | $(18) | $(14) | $(12) |
| Tax (benefit) expense <sup>2</sup> | 4 | 4 | 3 |
| After-tax | $(14) | $(10) | $(9) |
| **Total reclassifications for the period, after-tax** | $25 | $34 | $(23) |

---

1. Reflected in cost of goods sold in the Consolidated Statements of Operations.

2. Reflected in provision for (benefit from) income taxes from continuing operations in the Consolidated Statements of Operations.

3. These accumulated other comprehensive income (loss) components are included in the computation of net periodic benefit (credit) cost of the company's pension and other benefit plans. See Note 17 - Pension Plans and Other Post-Employment Benefits, to the Consolidated Financial Statements, for additional information.

4. Reflected in other income (expense) - net in the Consolidated Statements of Operations.

**NOTE 17 - PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS**

The company offers various long-term benefits to its employees. Where permitted by applicable law, the company reserves the right to change, modify or discontinue the plans.

**Defined Benefit Pension Plans**

The company has both funded and unfunded noncontributory defined benefit pension plans covering employees in the U.S. and non-U.S. countries. The principal U.S. pension plan is the largest pension plan held by Corteva. Effective January 1, 2007, most new hires were no longer eligible to participate in the U.S. defined benefit pension plans. On November 30, 2018, the company froze the pay and service amounts used to calculate the pension benefits for active employees who participate in the pension plan. As a result, no participants are currently accruing additional benefits in the pension plan.

The company's funding policy is consistent with the funding requirements of federal laws and regulations. Pension coverage for employees of the company's non-U.S. consolidated subsidiaries is provided, to the extent deemed appropriate, through separate

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

plans. Obligations under such plans are funded by depositing funds with trustees, covered by insurance contracts, or remain unfunded.

The company made total contributions of $40 million, $50 million and $52 million to its pension plans other than the principal U.S. pension plan for the years ended December 31, 2025, 2024 and 2023, respectively. Corteva expects to contribute approximately $40 million to its pension plans other than the principal U.S. pension plan in 2026. In planning for the Proposed Separation, including the future capital structures of the two new companies, the company expects to evaluate discretionary contributions to its principal U.S. pension plan in 2026.

The weighted-average assumptions used to determine pension plan obligations for all pension plans are summarized in the table below:

---

| | | |
|:---|:---|:---|
| **Weighted-Average Assumptions used to Determine Benefit Obligations** | **December 31, 2025** | **December 31, 2024** |
| Discount rate | 5.31% | 5.59% |
| Rate of increase in future compensation levels <sup>1</sup> | 2.82% | 2.87% |

---

1. The rate of compensation increase excludes U.S. pension plans since the employees who participate in the U.S. pension plans no longer accrue additional benefits for future service and eligible compensation.

The weighted-average assumptions used to determine net periodic benefit costs for all pension plans are summarized in the table below:

---

| | | | |
|:---|:---|:---|:---|
| **Weighted-Average Assumptions used to Determine Net Periodic Benefit Cost** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Weighted-Average Assumptions used to Determine Net Periodic Benefit Cost** | **2025** | **2024** | **2023** |
| Discount rate | 5.59% | 4.97% | 5.17% |
| Rate of increase in future compensation levels <sup>1</sup> | 2.87% | 2.87% | 2.83% |
| Expected long-term rate of return on plan assets | 4.56% | 4.57% | 4.55% |

---

1. The rate of compensation increase excludes U.S. pension plans since the employees who participate in the U.S. pension plans no longer accrue additional benefits for future service and eligible compensation.

**Other Post-Employment Benefits**

The company has historically provided medical, dental and life insurance benefits to certain pensioners and survivors. The majority of U.S. employees hired on or after January 1, 2007, and eligible employees under the age of 50 as of November 30, 2018, are not eligible to participate in the post-employment medical, dental and life insurance plans. Substantially all of the cost and liabilities for these retiree benefit plans are attributable to the U.S. benefit plans. The non-Medicare eligible retiree medical plan is contributory with costs shared between the company and pensioners and survivors. For Medicare eligible pensioners and survivors, Corteva provides a company-funded Health Reimbursement Arrangement ("HRA"). In December 2020, the company amended its retiree medical, dental and life insurance plans to no longer provide retiree dental and life insurance benefits effective January 1, 2022 and to cap Corteva's portion of the cost of non-Medicare retiree medical coverage to the level in effect as of December 31, 2021 ("2020 OPEB Plan Amendments").

The company also provides disability benefits to employees. In most countries, employee disability benefit plans are insured. In the U.S., these plans are generally self-insured. Obligations and expenses for self-insured plans are reflected in the change in projected benefit obligations table on page F-50.

The company's OPEB plans are unfunded and the cost of the approved claims is paid from operating cash flows. Pre-tax cash requirements to cover actual net claims costs and related administrative expenses were $96 million, $101 million, and $97 million for the years ended December 31, 2025, 2024 and 2023, respectively. Changes in cash requirements reflect the net impact of per capita health care costs, demographic changes, plan amendments and changes in participant premiums, co-payments and deductibles. In 2026, the company expects to contribute approximately $100 million for its OPEB plans.

The weighted-average assumptions used to determine benefit obligations for OPEB plans are summarized in the table below:

---

| | | |
|:---|:---|:---|
| **Weighted-Average Assumptions used to Determine Benefit Obligations** | **December 31, 2025** | **December 31, 2024** |
| Discount rate | 5.14% | 5.50% |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The weighted-average assumptions used to determine net periodic benefit costs for the OPEB plans are summarized in the table below:

---

| | | | |
|:---|:---|:---|:---|
| **Weighted-Average Assumptions used to Determine Net Periodic Benefit Cost** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Weighted-Average Assumptions used to Determine Net Periodic Benefit Cost** | **2025** | **2024** | **2023** |
| Discount rate | 5.50% | 4.92% | 5.09% |

---

As of December 31, 2025, 2024 and 2023, health care cost trend rates do not impact the benefit obligations for the OPEB plans because of the 2020 OPEB Plan Amendments.

**Assumptions**

For the U.S. plan, the company establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Where appropriate, asset-liability studies are also taken into consideration. The expected long-term rate of return on plan assets is based upon historical real returns (net of inflation) for the asset classes covered by the investment policy, expected performance, and projections of inflation and interest rates over the long-term period during which benefits are payable to plan participants. For non-U.S. plans, assumptions reflect economic assumptions applicable to each country.

In the U.S., Corteva calculates service costs and interest costs by applying individual spot rates from a yield curve (based on high-quality corporate bond yields) to the separate expected cash flows components of service cost and interest cost. Service cost and interest cost for all other plans are determined based on the single equivalent discount rates derived in determining those plan obligations.

For U.S. benefit plans, the discount rates utilized to measure the pension and other post-employment benefit obligations are based on the yield of high-quality corporate fixed income investments at the measurement date. Future expected actuarially determined cash flows are individually discounted at the spot rates under the Aon AA_Above Median yield curve (based on high-quality corporate bond yields) to arrive at the plan's obligations as of the measurement date. For non-U.S. benefit plans, historically the company utilized prevailing long-term high quality corporate bond indices to determine the discount rate, applicable to each country, at the measurement date.

The company adopts the most recently published mortality tables and mortality improvement scale released by the Society of Actuaries in measuring its U.S. pension and other post-employment benefit obligations. The effect of these adoptions is amortized into net periodic benefit cost for the years following the adoption.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Summarized information on the company's pension and other post-employment benefit plans is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Change in Projected Benefit Obligations, Plan Assets and Funded Status** | **Change in Projected Benefit Obligations, Plan Assets and Funded Status** | **Change in Projected Benefit Obligations, Plan Assets and Funded Status** | **Change in Projected Benefit Obligations, Plan Assets and Funded Status** | **Change in Projected Benefit Obligations, Plan Assets and Funded Status** |
|  | *Defined Benefit Pension Plans* | *Defined Benefit Pension Plans* | *Other Post-Employment Benefits* | *Other Post-Employment Benefits* |
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2025** | **2024** |
| *Change in benefit obligations:* |  |  |  |  |
| Benefit obligation at beginning of the period | $12222 | $13440 | $812 | $925 |
| Service cost | 13 | 16 |  |  |
| Interest cost | 627 | 648 | 40 | 42 |
| Plan participants' contributions | 1 | 2 | 16 | 18 |
| Actuarial (gain) loss | 383 | (580) | 15 | (51) |
| Benefits paid | (1228) | (1241) | (112) | (120) |
| Plan amendments | 1 |  |  | (1) |
| New plans/merger | 1 |  |  |  |
| Effect of foreign exchange rates | 37 | (63) | 1 | (1) |
| Benefit obligations at end of the period | $12057 | $12222 | $772 | $812 |
| *Change in plan assets:* |  |  |  |  |
| Fair value of plan assets at beginning of the period | $10630 | $11755 | $— | $— |
| Actual return on plan assets | 805 | 116 |  |  |
| Employer contributions | 40 | 50 | 96 | 101 |
| Plan participants' contributions | 1 | 2 | 16 | 18 |
| Benefits paid | (1228) | (1241) | (112) | (120) |
| Effect of foreign exchange rates | 27 | (52) |  | 1 |
| Fair value of plan assets at end of the period | $10275 | $10630 | $— | $— |
| **Funded status** |  |  |  |  |
| U.S. plan with plan assets | $(1463) | $(1268) | $— | $— |
| Non-U.S. plans with plan assets | (32) | (41) |  |  |
| All other plans <sup>1,2</sup> | (287) | (283) | (772) | (812) |
| Funded status at end of the period | $(1782) | $(1592) | $(772) | $(812) |

---

1. As of December 31, 2025 and 2024, $112 million and $131 million, respectively, of the benefit obligations are supported by funding under the Trust agreement, defined in the "Trust Assets" section below.

2. Includes pension plans maintained around the world where funding is not customary.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Defined Benefit Pension Plans* | *Defined Benefit Pension Plans* | *Other Post-Employment Benefits* | *Other Post-Employment Benefits* |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| *(In millions)* | **2025** | **2024** | **2025** | **2024** |
| *Amounts recognized in the Consolidated Balance Sheets:* |  |  |  |  |
| Other assets | $10 | $2 | $— | $— |
| Accrued and other current liabilities | (32) | (32) | (98) | (103) |
| Pension and other post-employment benefits | (1760) | (1562) | (674) | (709) |
| Net amount recognized | $(1782) | $(1592) | $(772) | $(812) |
| *Pre-tax amounts recognized in accumulated other comprehensive income (loss):* |  |  |  |  |
| Net gain (loss) | $(518) | $(320) | $244 | $276 |
| Prior service benefit (cost) | 14 | 17 | 13 | 14 |
| Pre-tax balance in accumulated other comprehensive income (loss) at end of year | $(504) | $(303) | $257 | $290 |

---

The loss related to the change in pension benefit obligations for the period ended December 31, 2025 is primarily due to the decrease in discount rates, net of asset returns above the expected long-term rate.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The accumulated benefit obligation for all pension plans was $12.0 billion and $12.2 billion at December 31, 2025 and 2024, respectively.

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| **Pension Plans with Projected Benefit Obligations in Excess of Plan Assets**<br>*(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Projected benefit obligations | $11821 | $12094 |
| Fair value of plan assets | $10028 | $10500 |

---

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| **Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets**<br>*(In millions)* | **December 31, 2025** | **December 31, 2024** |
| Accumulated benefit obligations | $11806 | $11995 |
| Fair value of plan assets | $10027 | $10414 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(In millions)* | *Defined Benefit Pension Plans* | *Defined Benefit Pension Plans* | *Defined Benefit Pension Plans* | *Other Post-Employment Benefits* | *Other Post-Employment Benefits* | *Other Post-Employment Benefits* |
|  | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *Components of net periodic benefit (credit) cost and amounts recognized in other comprehensive income (loss)* | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| *Net Periodic Benefit (Credit) Cost:* |  |  |  |  |  |  |
| Service cost | $13 | $16 | $18 | $— | $— | $1 |
| Interest cost | 627 | 648 | 690 | 40 | 42 | 49 |
| Expected return on plan assets | (622) | (531) | (605) |  |  |  |
| Amortization of unrecognized loss (gain) |  | 1 |  | (17) | (13) | (10) |
| Amortization of prior service (benefit) cost | (4) | (4) | (3) | (1) | (1) | (2) |
| Settlement loss |  | 2 |  |  |  |  |
| Net periodic benefit (credit) cost - Total | $14 | $132 | $100 | $22 | $28 | $38 |
| *Changes in plan assets and benefit obligations recognized in other comprehensive income (loss):* |  |  |  |  |  |  |
| Net gain (loss) | $(199) | $164 | $(255) | $(15) | $51 | $49 |
| Amortization of unrecognized (gain) loss |  | 1 |  | (17) | (13) | (10) |
| Prior service benefit (cost) | (1) |  |  |  | 1 |  |
| Amortization of prior service (benefit) cost | (4) | (4) | (3) | (1) | (1) | (2) |
| Settlement loss |  | 2 |  |  |  |  |
| Effect of foreign exchange rates | 1 | (1) | 8 |  |  | 1 |
| Total benefit (loss) recognized in other comprehensive income (loss), attributable to Corteva | $(203) | $162 | $(250) | $(33) | $38 | $38 |
| Total recognized in net periodic benefit (credit) cost and other comprehensive income (loss) | $(217) | $30 | $(350) | $(55) | $10 | $— |

---

**Estimated Future Benefit Payments**

The estimated future benefit payments, reflecting expected future service, as appropriate, are presented in the following table:

---

| | | |
|:---|:---|:---|
| **Estimated Future Benefit Payments at December 31, 2025** | *Defined Benefit Pension Plans* | *Other Post-Employment Benefits* |
| *(In millions)* | *Defined Benefit Pension Plans* | *Other Post-Employment Benefits* |
| 2026 | $1199 | $98 |
| 2027 | 1162 | 91 |
| 2028 | 1126 | 85 |
| 2029 | 1088 | 79 |
| 2030 | 1048 | 73 |
| Years 2031-2035 | 4644 | 293 |
| Total | $10267 | $719 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**Plan Assets**

All pension plan assets in the U.S. are invested through a single master trust fund. The general principles guiding U.S. pension asset investment policies are those embodied in the Employee Retirement Income Security Act of 1974 ("ERISA"). These principles include discharging Corteva's investment responsibilities for the exclusive benefit of plan participants and in accordance with the "prudent expert" standard and other ERISA rules and regulations. Corteva establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. The strategic asset allocation for this trust fund is approved by the Pension Investment Committee. Strategic asset allocations in other countries are selected in accordance with the laws and practices of those countries. Where appropriate, asset-liability studies are utilized in this process.

U.S. plan assets are managed by investment professionals employed by Corteva, and plan assets for non-U.S. plans are managed by professional investment firms unrelated to the company. Corteva's pension investment professionals have discretion to manage the assets within established asset allocation ranges approved by the Pension Investment Committee. Additionally, pension trust funds are permitted to enter into certain contractual arrangements generally described as "derivatives." Derivatives are primarily used to reduce specific market risks, hedge currency and adjust portfolio duration and asset allocation in a cost-effective manner.

The weighted-average allocation for plan assets of the company's pension plans is summarized as follows:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| **Allocation for Plan Assets**<br>*Asset Category* | **December 31, 2025** | **December 31, 2024** |
| U.S. equity securities | 8% | 9% |
| Non-U.S. equity securities | 5 | 5 |
| Fixed income securities | 67 | 67 |
| Hedge funds |  |  |
| Private market securities | 13 | 12 |
| Real estate | 7 | 7 |
| Cash and cash equivalents |  |  |
| Total | 100% | 100% |

---

U.S. equity investments are primarily large-cap companies. Non-U.S. equity securities include varying market capitalization levels. Fixed income securities include corporate-issued, government-issued and asset-backed securities of both U.S. and non-U.S. issuers. Corporate debt investments include a range of credit risk and industry diversification. U.S. fixed income investments are weighted heavier than non-U.S. fixed income securities. Other investments include cash and cash equivalents, hedge funds, real estate and private market securities such as interests in private equity and venture capital partnerships.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

For pension plan assets classified as Level 1 measurements (measured using quoted prices in active markets), total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For pension plan assets classified as Level 2 measurements, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates, interest rates and implied volatilities obtained from various market sources.

For pension plan assets classified as Level 3 measurements, total fair value is based on significant unobservable inputs including assumptions where there is little, if any, market activity for the investment. Investment managers, fund managers, or

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

investment contract issuers provide valuations of the investment on a monthly or quarterly basis. These valuations are reviewed for reasonableness based on applicable sector, benchmark and company performance. Adjustments to valuations are made where appropriate. Where available, audited financial statements are obtained and reviewed for the investments as support for the manager's investment valuation.

The tables below present the fair values of the company's pension assets by level within the fair value hierarchy, as described in Note 2 - Summary of Significant Accounting Policies, in the Consolidated Financial Statements:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Basis of Fair Value Measurements** | *Total* | *Level 1* | *Level 2* | *Level 3* |
| For the year ended December 31, 2025 | *Total* | *Level 1* | *Level 2* | *Level 3* |
| *(In millions)* | *Total* | *Level 1* | *Level 2* | *Level 3* |
| Cash and cash equivalents | $876 | $876 | $— | $— |
| U.S. equity securities <sup>1</sup> | 837 | 836 | 1 |  |
| Non-U.S. equity securities | 417 | 417 |  |  |
| Debt – government-issued | 1540 |  | 1540 |  |
| Debt – corporate-issued | 3728 |  | 3728 |  |
| Debt – asset-backed | 440 |  | 440 |  |
| Hedge funds | 5 |  | 2 | 3 |
| Private market securities | 5 |  |  | 5 |
| Real estate funds | 4 |  |  | 4 |
| Other | 62 |  |  | 62 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal | $7914 | $2129 | $5711 | $74 |
| Investments measured at net asset value |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt - government issued | $42 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt - corporate-issued | 3 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. equity securities | 23 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-U.S. equity securities | 22 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Hedge funds | 3 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Private market securities | 1750 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate funds | 647 |  |  |  |
| Total investments measured at net asset value | $2490 |  |  |  |
| Other items to reconcile to fair value of plan assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension trust receivables <sup>2</sup> | 79 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension trust payables <sup>3</sup> | (208) |  |  |  |
| Total | $10275 |  |  |  |

---

1. The Corteva pension plans directly held no Corteva, Inc. common stock at December 31, 2025.

2. Primarily receivables for investment securities sold.

3. Primarily payables for investment securities purchased.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Basis of Fair Value Measurements** | | | | |
| For the year ended December 31, 2024 |  |  |  |  |
| *(In millions)* | *Total* | *Level 1* | *Level 2* | *Level 3* |
| Cash and cash equivalents | $1030 | $1030 | $— | $— |
| U.S. equity securities <sup>1</sup> | 1030 | 1026 | 1 | 3 |
| Non-U.S. equity securities | 389 | 388 |  | 1 |
| Debt – government-issued | 1628 |  | 1628 |  |
| Debt – corporate-issued | 3540 |  | 3540 |  |
| Debt – asset-backed | 590 |  | 590 |  |
| Hedge funds | 5 |  | 2 | 3 |
| Private market securities | 3 |  |  | 3 |
| Real estate funds | 101 |  |  | 101 |
| Other | 51 |  |  | 51 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal | $8367 | $2444 | $5761 | $162 |
| Investments measured at net asset value |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt - government issued | $39 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt - corporate-issued | 3 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. equity securities | 21 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-U.S. equity securities | 20 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Hedge funds | 11 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Private market securities | 1810 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate funds | 642 |  |  |  |
| Total investments measured at net asset value | $2546 |  |  |  |
| Other items to reconcile to fair value of plan assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension trust receivables <sup>2</sup> | 79 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension trust payables <sup>3</sup> | (362) |  |  |  |
| Total | $10630 |  |  |  |

---

1. The Corteva pension plans directly held $132 million (approximately 1 percent of total plan assets) of Corteva, Inc. common stock at December 31, 2024.

2. Primarily receivables for investments securities sold.

3. Primarily payables for investment securities purchased.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The following table summarizes the changes in fair value of Level 3 pension plan assets for the years ended December 31, 2025 and 2024:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Fair Value Measurement of <br>Level 3 Pension Plan Assets** | *U.S. equity securities* | *Non-U.S. equity securities* | *Debt – corporate-issued* | *Hedge funds* | *Private market securities* | *Real estate funds* | *Other* | *Total* |
| *(In millions)* | *U.S. equity securities* | *Non-U.S. equity securities* | *Debt – corporate-issued* | *Hedge funds* | *Private market securities* | *Real estate funds* | *Other* | *Total* |
| Balance at January 1, 2024 | $1 | $2 | $2 | $3 | $6 | $52 | $55 | $121 |
| Actual return on assets: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Relating to assets sold during the year ended December 31, 2024 |  | 3 | (14) |  |  |  |  | (11) |
| &nbsp;&nbsp;&nbsp;Relating to assets held at December 31, 2024 | 2 |  | 14 |  | (3) | (68) | (2) | (57) |
| Purchases, sales and settlements, net |  | (4) |  |  |  | 1 | (2) | (5) |
| Transfers in or out of Level 3, net |  |  | (2) |  |  | 116 |  | 114 |
| Balance at December 31, 2024 | $3 | $1 | $— | $3 | $3 | $101 | $51 | $162 |
| Actual return on assets: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Relating to assets sold during the year ended December 31, 2025 | (1) | (1) |  |  |  |  |  | (2) |
| &nbsp;&nbsp;&nbsp;Relating to assets held at December 31, 2025 | 1 |  |  |  | 2 | (3) | 9 | 9 |
| Purchases, sales and settlements, net | (3) |  |  |  |  |  | 2 | (1) |
| Transfers in or out of Level 3, net |  |  |  |  |  | (94) |  | (94) |
| Balance at December 31, 2025 | $— | $— | $— | $3 | $5 | $4 | $62 | $74 |

---

**Trust Assets**

EIDP entered into a trust agreement in 2013 (as amended and restated in 2017, "the Trust") that established and requires EIDP to fund the Trust for cash obligations under certain non-qualified benefit and deferred compensation plans upon a change in control event as defined in the Trust agreement. Under the Trust agreement, the consummation of the Merger was a change in control event and resulted in a contribution to the Trust by EIDP. Additionally, the Corteva Separation resulted in Corteva transferring a portion of the balance of the Trust to DuPont at the Corteva Separation date. During the years ended December 31, 2025 and 2024, $37 million and $48 million, respectively, was distributed by EIDP according to the Trust agreement, and at December 31, 2025 and 2024, the balance in the Trust was $147 million and $176 million, respectively. The Trust Assets are classified as current restricted cash equivalents and included within other current assets in the Consolidated Balance Sheets. See Note 6 - Supplementary Information, to the Consolidated Financial Statements, for further information.

**Defined Contribution Plans**

Corteva provides defined contribution benefits to its employees. The most significant is the U.S. Retirement Savings Plan ("the Plan"), which covers almost all of the U.S. full-service employees. This Plan includes a non-leveraged Employee Stock Ownership Plan ("ESOP"). Employees are not required to participate in the ESOP and those who do are free to diversify out of the ESOP. The purpose of the Plan is to provide retirement savings benefits for employees and to provide employees an opportunity to become stockholders of the company. The Plan is a tax qualified contributory profit sharing plan, with cash or deferred arrangement and any eligible employee of Corteva may participate. Currently, Corteva contributes 100 percent of the first six percent of the employee's contribution election and also contributes three percent of each eligible employee's eligible compensation regardless of the employee's contribution.

Corteva's contributions to the Plan were $99 million, $100 million and $101 million for the years ended December 31, 2025, 2024 and 2023, respectively. Corteva's matching contributions vest immediately upon contribution. The three percent nonmatching company contribution vests after employees complete three years of service. In addition, Corteva made contributions to other defined contribution plans of $51 million, $46 million and $45 million for the years ended December 31, 2025, 2024 and 2023, respectively.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 18 - STOCK-BASED COMPENSATION**

Prior to the Corteva Separation, Corteva employees held equity awards, including stock options, share appreciation rights ("SARs"), restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs"), which were denominated in DowDuPont common stock and, in some cases, in Dow Inc. common stock, and which had originally been issued under the DuPont Equity and Incentive Plan ("EIP"), the Dow Chemical Company 2012 Stock Incentive Plan or the Dow Chemical Company 1988 Award and Option Plan.

As discussed in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, on April 1, 2019 the company entered into an Employee Matters Agreement (the "EMA") with DuPont and Dow that identifies employees and employee-related liabilities (and attributable assets) to be allocated (either retained, transferred and accepted, or assigned and assumed, as applicable) to the Parties as part of the Distributions and describes when and how the relevant transfers and assignments were to occur. With some exceptions, the EMA provides for the equitable adjustment of existing equity incentive compensation awards denominated in the common stock of DowDuPont to reflect the occurrence of the Distributions.

In connection with the Corteva Separation on June 1, 2019, outstanding DowDuPont-denominated stock options, SARs, RSU and PSU awards were converted into Corteva-denominated awards under the "Employer Method," or into both DuPont-denominated awards and Corteva-denominated awards under the "Shareholder Method," using a formula designed to preserve the intrinsic value of the awards immediately prior to and subsequent to the Corteva Separation. The awards have the same terms and conditions under the applicable plans and award agreements prior to the Corteva Separation transactions. The conversions of equity awards did not have a material impact on the company's Consolidated Financial Statements.

On June 1, 2019 ("Adoption Date"), in connection with the Corteva Separation, the Omnibus Incentive Plan (the "OIP") became effective. Under the OIP, the company may grant incentive awards, including stock options (both "incentive stock options" and nonqualified stock options), share appreciation rights, restricted shares, restricted stock units, other share-based awards and cash awards, to its and its subsidiaries' eligible employees, non-employee directors, independent contractors and consultants following the Corteva Separation until the tenth anniversary of the Adoption Date, subject to an aggregate limit and annual individual limits. Under the OIP, the maximum number of shares reserved for the grant or settlement of awards is 20 million shares, excluding shares underlying certain exempt awards, such as the awards converted to Corteva-denominated awards pursuant to the Corteva Separation. At December 31, 2025, approximately 8 million shares were authorized for future grants under the OIP. The company generally satisfies stock option exercises and the vesting of RSUs and PSUs with newly issued shares of Corteva common stock, although RSU awards granted under Historical Dow plans in certain countries are settled in cash.

The Board of Directors' Compensation Committee determines the long-term incentive mix, including stock options, RSUs and PSUs and may authorize new grants annually. The company estimates expected forfeitures.

The total stock-based compensation cost included in income (loss) from continuing operations before income taxes within the Consolidated Statement of Operations was $78 million, $64 million and $54 million for the years ended December 31, 2025, 2024 and 2023, respectively. The income tax benefits related to stock-based compensation arrangements were $(15) million, $(12) million and $(10) million for the years ended December 31, 2025, 2024 and 2023, respectively.

**Stock Options**

The exercise price of shares subject to option is equal to the market price of the company's common stock on the date of grant. All options vest serially over a period of three years. Stock option awards granted under the EIP (previous plan) between 2016 and May 2019 and the OIP between June 2019 and December 31, 2025 expire 10 years after the grant date.

To measure the fair value of the awards on the date of grant, the company uses the Black-Scholes option pricing model and the assumptions set forth in the table below. The weighted-average grant-date fair value of options granted for the years ended December 31, 2025, 2024 and 2023 was $23.83, $18.80 and $21.42, respectively.

---

| | | | |
|:---|:---|:---|:---|
| **Weighted-Average Assumptions** | **For the Year ended December 31,** | **For the Year ended December 31,** | **For the Year ended December 31,** |
| **Weighted-Average Assumptions** | **2025** | **2024** | **2023** |
| Dividend yield | 1.05% | 1.18% | 0.96% |
| Expected volatility | 34.09% | 32.17% | 31.07% |
| Risk-free interest rate | 4.4% | 4.2% | 4.1% |
| Expected life of stock options granted during period (years) | 6.0 | 6.0 | 6.0 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The company determined the dividend yield by dividing the annualized dividend on Corteva's common stock by the option exercise price. A historical daily measurement of volatility is determined based on the expected life of the option granted. For the year ended December 31, 2025, the measurement of volatility is based on the historical volatility of Corteva. For the years ended December 31, 2024, and 2023, the measurement of volatility is based on the average volatility of eight of Corteva's peer companies. Corteva's peer volatility is based on the historical volatility of each business respectively. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. Expected life is determined by utilizing the simplified method for estimating expected term.

The following table summarizes stock option activity for the year ended December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Stock Options** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** |
|  | *Number of Shares <br>(in thousands)* | *Weighted Average Exercise Price (per share)* | *Weighted Average Remaining Contractual Term (in years)* | *Aggregate Intrinsic Value<br>(in thousands)* |
| Outstanding at January 1, 2025 | 3257 | $43.97 | 4.46 | $43761 |
| Granted | 288 | 64.70 |  |  |
| Exercised | (1606) | 40.40 |  |  |
| Forfeited/Expired | (58) | 58.31 |  |  |
| Outstanding at December 31, 2025 | 1881 | $49.74 | 5.08 | $32565 |
| Exercisable at December 31, 2025 | 1299 | $44.95 | 3.70 | $28689 |

---

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the closing stock price on the last trading day of the period ended December 31, 2025 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at period end. The total intrinsic value of options exercised for the years ended December 31, 2025, 2024 and 2023 were $42 million, $20 million, and $14 million, respectively. The company recognized tax benefits from options exercised for the years ended December 31, 2025, 2024 and 2023 of $(8) million, $(4) million and $(3) million, respectively.

As of December 31, 2025, $7 million of total unrecognized pre-tax compensation expense related to nonvested stock options is expected to be recognized over a weighted-average period of about 1.14 years.

**Restricted Stock Units and Performance Share Units**

RSUs granted serially vest over three years. Upon vesting, these RSUs convert one-for-one to Corteva Common Stock. A retirement-eligible employee retains any granted awards upon retirement for one year provided the employee has rendered at least six months of service following the grant date. Additional RSUs are also granted periodically to key senior management employees. These RSUs generally vest over periods ranging from three years to five years. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

The company grants PSUs to senior leadership. In 2025, there were 292,890 PSUs granted. Vesting for PSUs granted in 2025, 2024 and 2023 is partially based on the realization of the company's improvement of its Return on Net Assets ("RONA") and Operating Earnings Per Share ("EPS") during the Performance Period. Performance and payouts are determined independently for each metric. The actual award, delivered in Corteva common stock, can range from zero percent to 200 percent of the original grant. The weighted-average grant date fair value of the PSUs granted in 2025 of $64.71 was based upon the market price of the underlying common stock as of the grant date.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

Nonvested awards of RSUs and PSUs are shown below.

---

| | | |
|:---|:---|:---|
| **RSUs and PSUs** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** |
|  | *Number of Shares <br>(in thousands)* | *Weighted Average Grant Date Fair Value (per share)* |
| Nonvested at January 1, 2025 | 3643 | $55.12 |
| Granted | 1344 | 64.49 |
| Vested | (1352) | 53.99 |
| Forfeited | (272) | 58.04 |
| Nonvested at December 31, 2025 | 3363 | $59.10 |

---

The total fair value of stock units vested for the years ended December 31, 2025, 2024 and 2023 was $73 million, $63 million and $58 million, respectively. The weighted-average grant-date fair value of stock units granted for the years ended December 31, 2025, 2024 and 2023 was $64.49, $54.56 and $62.22, respectively.

As of December 31, 2025, $65 million of total unrecognized pre-tax compensation expense related to RSUs and PSUs is expected to be recognized over a weighted average period of 1.07 years.

**NOTE 19 - FINANCIAL INSTRUMENTS**

**Time Deposits and Money Market Funds**

At December 31, 2025 and 2024, the company held investments in held-to-maturity securities at amortized cost, which approximates fair value. At these periods, the company held additional held-to-maturity securities, as well as available-for-sale securities, consisting of investments in foreign government bonds which are discussed further in the "Debt Securities" section. Reclassifications of prior year held-to-maturity balances have been made in the current year to disaggregate between those that are time deposits and foreign government bonds.

The following table summarizes investments in time deposits and money market funds classified as held-to-maturity securities at December 31, 2025 and 2024:

---

| | | | |
|:---|:---|:---|:---|
| **Held-to-Maturity Securities** | **Held-to-Maturity Securities** | **Amortized Cost** | **Amortized Cost** |
| <br>*(in millions)* | **Balance Sheet Location** | **December 31, 2025** | **December 31, 2024** |
| Time deposits and money market funds | Cash equivalents <sup>1</sup> | $3431 | $2179 |
| Time deposits | Marketable securities <sup>2</sup> | $1 | $8 |

---

1. Maturity at time of purchase was three months or less.

2. Maturity at time of purchase was more than three months to less than one year.

**Derivative Instruments**

*Objectives and Strategies for Holding Derivative Instruments*

In the ordinary course of business, the company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency and commodity price risks. The company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. The company has not designated any non-derivatives as hedging instruments.

The company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges, and multinational grain exporters. The company is exposed to credit losses in the event of nonperformance by these counterparties. The company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.

The aggregate notional amounts for the company's derivative instruments that are designated and not designated as hedging instruments was a net buy (sell) position of $1,280 million and $(1,056) million at December 31, 2025 and 2024, respectively.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**Foreign Currency Risk**

The company's objective in managing exposure to foreign currency fluctuations is to reduce earnings and cash flow volatility associated with foreign currency rate changes and to mitigate the exposure of certain investments in foreign subsidiaries against

changes in the Euro/USD exchange rate. Accordingly, the company enters into various contracts that change in value as foreign

exchange rates change to protect the value of its existing foreign currency-denominated assets, liabilities, commitments, investments and cash flows.

The company uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The primary business objective of this hedging program is to maintain an approximately balanced position in foreign currencies so that exchange gains and losses resulting from exchange rate changes, after related tax effects, are minimized. The company also uses foreign currency exchange contracts to offset a portion of the company's exposure to certain forecasted transactions as well as the translation of foreign currency-denominated earnings. The company also uses commodity contracts to offset risks associated with foreign currency devaluation in certain countries.

**Commodity Price Risk**

Commodity price risk management programs serve to reduce exposure to price fluctuations on purchases of inventory such as corn and soybeans. The company enters into over-the-counter and exchange-traded derivative commodity instruments to hedge the commodity price risk associated with agricultural commodity exposures.

**Derivatives Designated as Cash Flow Hedges**

*Commodity Contracts*

The company enters into over-the-counter and exchange-traded derivative commodity instruments, including options, futures and swaps, to hedge the commodity price risk associated with agriculture commodity exposures.

While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two years. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is not probable of occurring.

The following table summarizes the after-tax effect of commodity contract cash flow hedges on accumulated other comprehensive income (loss):

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| Beginning balance | $(49) | $(71) | $55 |
| Additions and revaluations of derivatives designated as cash flow hedges | 3 | (29) | (87) |
| Clearance of hedge results to earnings | 55 | 51 | (39) |
| Ending balance | $9 | $(49) | $(71) |

---

At December 31, 2025, an after-tax net gain of $19 million is expected to be reclassified from accumulated other comprehensive income (loss) into earnings over the next twelve months.

*Foreign Currency Contracts*

The company enters into forward contracts to hedge the foreign currency risk associated with forecasted transactions within certain foreign subsidiaries.

While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two years. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is not probable of occurring.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The following table summarizes the after-tax effect of foreign currency cash flow hedges on accumulated other comprehensive

income (loss):

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Beginning balance | $13 | $1 | $10 |
| Additions and revaluations of derivatives designated as cash flow hedges | 5 | 19 | (36) |
| Clearance of hedges results to earnings | (13) | (7) | 27 |
| Ending balance | $5 | $13 | $1 |

---

At December 31, 2025, an after-tax net gain of $5 million is expected to be reclassified from accumulated other comprehensive income (loss) into earnings over the next twelve months.

**Derivatives Designated as Net Investment Hedges**

*Foreign Currency Contracts*

In March 2025, the company designated €1.7 billion of forward contracts to exchange Euro as net investment hedges. Of these hedges, €1.2 billion expired and were settled in May 2025, while the remaining €500 million expired and were settled in December 2025. The purpose of these forward contracts was to mitigate foreign exchange exposure related to a portion of the company's Euro net investments in certain foreign subsidiaries against changes in EUR/USD exchange rates.

In May 2024, the company designated €500 million of forward contracts to exchange Euro as net investment hedges. An additional tranche of €500 million of forward contracts to exchange Euro were executed in July 2024 and also designated as net investment hedges. These hedges expired and were settled in December 2024. The company had previously designated €1.2 billion and €450 million of forward contracts to exchange Euro as net investment hedges, which expired and were settled in May 2024 and March 2023, respectively.

Prior to maturity, the company had elected to apply the spot method in testing for effectiveness of the hedging relationship.

**Derivatives not Designated in Hedging Relationships**

*Foreign Currency Contracts*

The company uses foreign exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The company also uses foreign currency exchange contracts to offset a portion of the company's exposure to the translation of certain foreign currency-denominated earnings so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated earnings over the relevant aggregate period.

*Commodity Contracts*

The company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as corn and soybeans. The company uses commodity contracts to offset a portion of the company's exposure to commodity price fluctuations so that gains and losses on the contracts offset changes in the commodity price over the relevant aggregate period. The company uses forward agreements, with durations less than one year, to buy and sell USD priced commodities in order to reduce its exposure to currency devaluation for a portion of its local currency cash balances. Counterparties to the forward sales agreements are multinational grain exporters and subject to the company's financial risk management procedures.

**Fair Value of Derivative Instruments**

Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Consolidated Balance Sheets.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

The presentation of the company's derivative assets and liabilities is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| *(In millions)* | **Balance Sheet Location** | **Gross** | **Counterparty and Cash Collateral Netting** <sup>1</sup> | **Net Amounts Included in the Consolidated Balance Sheet** |
| **Asset derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | $5 | $— | $5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | 23 | (21) | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | 3 |  | 3 |
| &nbsp;&nbsp;&nbsp;Total asset derivatives |  | $32 | $(21) | $11 |
| **Liability derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | $1 | $— | $1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 3 |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | 40 | (21) | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 6 |  | 6 |
| &nbsp;&nbsp;&nbsp;Total liability derivatives |  | $50 | $(21) | $29 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| *(In millions)* | **Balance Sheet Location** | **Gross** | **Counterparty and Cash Collateral Netting** <sup>1</sup> | **Net Amounts Included in the Consolidated Balance Sheet** |
| **Asset derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | 8 |  | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | 71 | (45) | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | 12 |  | 12 |
| &nbsp;&nbsp;&nbsp;Total asset derivatives |  | $91 | $(45) | $46 |
| **Liability derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 2 |  | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | 104 | (45) | 59 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 5 |  | 5 |
| &nbsp;&nbsp;&nbsp;Total liability derivatives |  | $111 | $(45) | $66 |

---

1.&nbsp;&nbsp;&nbsp;&nbsp;Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

*Effect of Derivative Instruments*

---

| | | | |
|:---|:---|:---|:---|
| | **Amount of Gain (Loss) Recognized in OCI** <sup>1</sup> **- Pre-Tax** | **Amount of Gain (Loss) Recognized in OCI** <sup>1</sup> **- Pre-Tax** | **Amount of Gain (Loss) Recognized in OCI** <sup>1</sup> **- Pre-Tax** |
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Derivatives designated as hedging instruments: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | $(94) | $48 | $— |
| &nbsp;&nbsp;&nbsp;Cash flow hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | 5 | 29 | (54) |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 5 | (59) | (123) |
| Total derivatives designated as hedging instruments | $(84) | $18 | $(177) |

---

1. OCI is defined as other comprehensive income (loss).

---

| | | | |
|:---|:---|:---|:---|
| *(in millions)* | **Amount of Gain (Loss) Recognized in Income - Pre-Tax** <sup>1</sup> | **Amount of Gain (Loss) Recognized in Income - Pre-Tax** <sup>1</sup> | **Amount of Gain (Loss) Recognized in Income - Pre-Tax** <sup>1</sup> |
| *(in millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|  | **2025** | **2024** | **2023** |
| Derivatives designated as hedging instruments: |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash flow hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts <sup>2</sup> | $6 | $9 | $(41) |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts <sup>2</sup> | (72) | (74) | 49 |
| Total derivatives designated as hedging instruments | (66) | (65) | 8 |
| Derivatives not designated as hedging instruments: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts <sup>3</sup> | 73 | (130) | (28) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts <sup>2</sup> | (103) | 23 | (77) |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts <sup>2,4</sup> |  | (34) | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts <sup>3</sup> |  | (2) | 2 |
| Total derivatives not designated as hedging instruments | (30) | (143) | (123) |
| Total derivatives | $(96) | $(208) | $(115) |

---

1. For cash flow hedges, this represents the portion of the gain (loss) reclassified from accumulated OCI into income during the period.

2. Recorded in cost of goods sold, in the Consolidated Statement of Operations.

3. Recognized in other income (expense) - net, in the Consolidated Statement of Operations. Note that the net loss from foreign currency contracts was partially offset by the related gain on the foreign currency-denominated monetary assets and liabilities of the company's operations. See Note 6 - Supplementary Information, to the Consolidated Financial Statements for additional information.

4. The net gain (loss) relating to commodity contracts that are not designated as hedging instruments that were recorded in cost of goods sold, in the Consolidated Statement of Operations, are mostly offset by the related net gain (loss) on third-party grower contracts denominated as liabilities.

**Debt Securities**

At December 31, 2025 and 2024, the company held investments in held-to-maturity debt securities consisting of foreign government bonds. The company's investments in held-to-maturity securities are held at amortized cost, which approximates fair value. These foreign government bonds are held by certain foreign subsidiaries in which the USD is the functional currency.

---

| | | | |
|:---|:---|:---|:---|
| **Held-to-Maturity Securities** | **Held-to-Maturity Securities** | **Amortized Cost** | **Amortized Cost** |
| *(in millions)* | **Balance Sheet Location** | **December 31, 2025** | **December 31, 2024** |
| Foreign government bonds | Marketable securities <sup>1</sup> | $— | $55 |

---

1. Maturity at time of purchase was more than three months to less than one year.

The company also held debt securities, which consisted of foreign government bonds classified as available-for-sale securities, at December 31, 2025 and 2024. The company's investments in available-for-sale securities are recorded at fair value with unrealized gains and losses recorded in accumulated other comprehensive income (loss), within the Consolidated Statements of Equity, or current period earnings if an allowance for credit losses has been established, within the Consolidated Statements of Operations.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

---

| | | | |
|:---|:---|:---|:---|
| **Available-for-Sale Securities** | **Available-for-Sale Securities** | **Fair Value** | **Fair Value** |
| *(in millions)* | **Balance Sheet Location** | **December 31, 2025** | **December 31, 2024** |
| Foreign government bonds | Marketable securities <sup>1</sup> | $8 | $— |
| Foreign government bonds | Other assets <sup>2</sup> | $22 | $97 |

---

1. Maturity at time of purchase was more than three months to less than one year.

2. Maturity at time of purchase was more than one year.

At December 31, 2025, available for sale debt securities with a contractual maturities of less than one year and of one to five years included gross unrealized gains (losses) of $— million and $— million, respectively.

The estimated fair value of the available-for-sale securities as of December 31, 2025 and 2024 was determined using Level 2 inputs within the fair value hierarchy. Level 2 measurements were based on the closing price at the end of the period quoted market prices in active markets for identical assets and liabilities.

**NOTE 20 - FAIR VALUE MEASUREMENTS**

The table below summarizes the basis used to measure certain assets and liabilities relating to marketable securities and derivative assets and liabilities at fair value on a recurring basis.

---

| | | |
|:---|:---|:---|
| **Significant Other Observable Inputs** | **December 31, 2025** | **December 31, 2024** |
| *(In millions)* | *Level 2* <sup>1</sup> | *Level 2* <sup>1</sup> |
| Assets at fair value: |  |  |
| &nbsp;&nbsp;&nbsp;Marketable securities | $1 | $63 |
| &nbsp;&nbsp;&nbsp;Debt securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign government bonds <sup>2</sup> | 30 | 97 |
| &nbsp;&nbsp;&nbsp;Derivatives relating to: <sup>3</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency | 28 | 71 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 4 | 20 |
| Total assets at fair value | $63 | $251 |
| Liabilities at fair value: |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives relating to: <sup>3</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency | $41 | $104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 9 | 7 |
| Total liabilities at fair value | $50 | $111 |

---

1. Reflects significant other observable inputs.

2. Represents the company's investments in debt securities that are classified as available-for-sale, which are included in the Consolidated Balance Sheets.

3. See Note 19 - Financial Instruments, to the Consolidated Financial Statements, for the classification of derivatives in the Consolidated Balance Sheets.

For assets and liabilities classified as Level 1 measurements (measured using quoted prices in active markets), total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For assets and liabilities classified as Level 2 measurements, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability, or by using observable market data points of similar, more liquid securities to imply the price. For time deposits classified as held-to-maturity investments and reported at amortized cost, fair value is based on an observable interest rate for similar securities. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks.

For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance/quality checks.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

For all other assets and liabilities for which observable inputs are used, fair value is derived through the use of fair value models, such as a discounted cash flow model or other standard pricing models. See Note 19 - Financial Instruments, to the Consolidated Financial Statements, for further information on the types of instruments used by the company for risk management.

There were no transfers between Levels 1 and 2 during the years ended December 31, 2025 and 2024.

For assets classified as Level 3 measurements, the fair value is based on significant unobservable inputs including assumptions where there is little, if any, market activity. The fair value of the company's interests held in trade receivable conduits is determined by calculating the expected amount of cash to be received using the key input of anticipated credit losses in the portfolio of receivables sold that have not yet been collected. Given the short-term nature of the underlying receivables, discount rate and prepayments are not factors in determining the fair value of the interests.

**Fair Value Measurements on a Nonrecurring Basis**

As part of the Crop Protection Operations Strategy Restructuring Program, the company plans to exit its production activities at its site in Pittsburg, California, as well as cease operations in select manufacturing lines at other locations. During the year ended December 31, 2023, the company recognized a pre-tax non-cash impairment charge of $152 million to restructuring and asset related charges – net, in the Consolidated Statement of Operations, consisting of a charge of $92 million and $60 million relating to operating lease assets and property, plant and equipment, respectively, which were classified as Level 3 measurements using unobservable inputs.

See Note 5 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements, for additional information.

**NOTE 21 - GEOGRAPHIC INFORMATION**

Sales are attributed to geographic areas based on customer location; long-lived assets are attributed to geographic areas based on asset location.

---

| | | | |
|:---|:---|:---|:---|
| | **Net Sales** | **Net Sales** | **Net Sales** |
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| United States | $8269 | $7866 | $7783 |
| Canada | 755 | 794 | 807 |
| EMEA | 3110 | 3124 | 3367 |
| Latin America <sup>1</sup> | 3928 | 3776 | 3906 |
| Asia Pacific | 1339 | 1348 | 1363 |
| **Total** | $17401 | $16908 | $17226 |

---

1. Net sales for Brazil for the years ended December 31, 2025, 2024 and 2023 were $2,900 million, $2,618 million and $2,523 million, respectively.

---

| | | | |
|:---|:---|:---|:---|
| | **Net Property** | **Net Property** | **Net Property** |
| | **As of December 31,** | **As of December 31,** | **As of December 31,** |
|<br>*(In millions)* | **2025** | **2024** | **2023** |
| United States | $2879 | $2878 | $2922 |
| Canada | 100 | 101 | 119 |
| EMEA | 573 | 522 | 548 |
| Latin America | 586 | 514 | 608 |
| Asia Pacific | 82 | 84 | 90 |
| **Total** | $4220 | $4099 | $4287 |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 22 - SEGMENT INFORMATION**

Corteva's reportable segments reflect the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance, which is at the operating segment level (Seed and Crop Protection). The company's CODM is the Chief Executive Officer. The primary measure used by Corteva's CODM for purposes of allocating resources to the segments and assessing segment performance is segment operating EBITDA.

Segment operating EBITDA is primarily utilized in the annual planning and monthly forecasting processes. On a monthly basis, the CODM considers variances between comparable prior year actual results and current year actual or forecasted results when evaluating the company's success in delivering its innovative proprietary technology to farmers and monitoring of expected savings from cost and productivity actions. The CODM also utilizes segment operating EBITDA when evaluating the impacts of market-driven trends on segment performance, such as input costs and inflationary and currency impacts.

The company defines segment operating EBITDA as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating (benefits) costs, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating (benefits) costs consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the respective segment results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

**Corporate Profile**

The company conducts its global operations through the following reportable segments:

**Seed**

The company's Seed segment is a global leader in developing and supplying commercial seed combining advanced germplasm and traits that offer maximum yield potential for farmers around the world. The segment is a leader in many key seed markets, including North America corn and soybeans, Europe corn and sunflower, as well as Brazil, India, South Africa and Argentina corn. The company offers seed and trait technologies that boost resilience to weather, pests, diseases, and herbicides used to manage weeds. Its digital solutions provide data-driven insights to help farmers optimize yield and profitability.

**Crop Protection**

The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that support overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment offers crop protection solutions and digital solutions that provide farmers tools to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The segment is a leader in global herbicides, insecticides, nitrogen stabilizers, pasture and range management herbicides and biologicals and other nature-based products.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Total** |
| **As of and for the Year Ended December 31, 2025** |  |  |  |
| Net sales | $9898 | $7503 | $17401 |
| Segment operating EBITDA | 2636 | 1350 | 3986 |
| Depreciation and amortization | 780 | 423 | 1203 |
| Purchases of property, plant and equipment | 377 | 214 | 591 |
| **As of and for the Year Ended December 31, 2024** |  |  |  |
| Net sales | $9545 | $7363 | $16908 |
| Segment operating EBITDA | 2219 | 1272 | 3491 |
| Depreciation and amortization | 805 | 422 | 1227 |
| Purchases of property, plant and equipment | 365 | 232 | 597 |
| **As of and for the Year Ended December 31, 2023** |  |  |  |
| Net sales | $9472 | $7754 | $17226 |
| Segment operating EBITDA | 2117 | 1374 | 3491 |
| Depreciation and amortization | 814 | 397 | 1211 |
| Purchases of property, plant and equipment | 332 | 263 | 595 |

---

**Reconciliation of Segment Profitability**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Total** |
| **For the Year Ended December 31, 2025** |  |  |  |
| Net sales | $9898 | $7503 | $17401 |
| Cost of goods sold | 4533 | 4585 | 9118 |
| Other expenses <sup>1</sup> | 2729 | 1568 | 4297 |
| Segment operating EBITDA | $2636 | $1350 | $3986 |
| *(In millions)* | **Seed** | **Crop Protection** | **Total** |
| **For the Year Ended December 31, 2024** |  |  |  |
| Net sales | $9545 | $7363 | $16908 |
| Cost of goods sold | 4876 | 4636 | 9512 |
| Other expenses <sup>1</sup> | 2450 | 1455 | 3905 |
| Segment operating EBITDA | $2219 | $1272 | $3491 |
| *(In millions)* | **Seed** | **Crop Protection** | **Total** |
| **For the Year Ended December 31, 2023** |  |  |  |
| Net sales | $9472 | $7754 | $17226 |
| Cost of goods sold | 4982 | 4913 | 9895 |
| Other expenses <sup>1</sup> | 2373 | 1467 | 3840 |
| Segment operating EBITDA | $2117 | $1374 | $3491 |

---

1. Other expenses consist primarily of selling, general and administrative expenses and research and development expense, net of depreciation add-back.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**Reconciliation to Consolidated Financial Statements**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Income (loss) from continuing operations after income taxes to segment operating EBITDA**<br>*(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from continuing operations after income taxes | $1204 | $863 | $941 |
| Provision for (benefit from) income taxes on continuing operations | 484 | 412 | 152 |
| Income (loss) from continuing operations before income taxes | $1688 | $1275 | $1093 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1203 | 1227 | 1211 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (136) | (132) | (283) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 180 | 233 | 233 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exchange (gains) losses - net | 181 | 284 | 397 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating (benefits) costs - net | 39 | 174 | 151 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Significant items | 658 | 315 | 579 |
| &nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 35 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate expenses | 138 | 115 | 110 |
| Segment operating EBITDA | $3986 | $3491 | $3491 |

---

**Significant Pre-tax (Charges) Benefits Not Included in Segment Operating EBITDA**

The years ended December 31, 2025, 2024 and 2023, respectively, included the following significant pre-tax (charges) benefits which are excluded from segment operating EBITDA:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Corporate** | **Total** |
| **For the Year Ended December 31, 2025** |  |  |  |  |
| Restructuring and asset related charges - net <sup>1</sup> | $(4) | $(135) | $(7) | $(146) |
| Bayer resolution <sup>2</sup> | (610) |  |  | (610) |
| Gain (loss) on sale of business, assets and equity investments <sup>3,4</sup> |  | 37 |  | 37 |
| AltEn facility remediation charges <sup>5</sup> | (37) |  |  | (37) |
| Insurance proceeds <sup>6</sup> |  | 98 |  | 98 |
| Total | $(651) | $— | $(7) | $(658) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Corporate** | **Total** |
| **For the Year Ended December 31, 2024** |  |  |  |  |
| Restructuring and asset related charges - net <sup>1</sup> | $(55) | $(142) | $(91) | $(288) |
| Gain (loss) on sale of business, assets and equity investments <sup>4</sup> | 4 | 3 |  | 7 |
| Inventory write-offs <sup>4</sup> | 2 |  |  | 2 |
| Insurance proceeds <sup>6</sup> |  | 71 |  | 71 |
| Estimated settlement expense <sup>7</sup> |  | (101) |  | (101) |
| Acquisition-related costs <sup>8</sup> |  | (6) |  | (6) |
| Total | $(49) | $(175) | $(91) | $(315) |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Corteva, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Corporate** | **Total** |
| **For the Year Ended December 31, 2023** |  |  |  |  |
| Restructuring and asset related charges - net <sup>1</sup> | $(86) | $(228) | $(22) | $(336) |
| Gain (loss) on sale of business, assets and equity investments <sup>4</sup> | 4 | 10 |  | 14 |
| Inventory write-offs <sup>4</sup> | (7) |  |  | (7) |
| Spare parts write-off <sup>3</sup> |  | (12) |  | (12) |
| Estimated settlement expense <sup>7</sup> |  | (204) |  | (204) |
| Acquisition-related costs <sup>8</sup> |  | (45) |  | (45) |
| AltEn facility remediation charges <sup>5</sup> | (10) |  |  | (10) |
| Employee Retention Credit |  | 3 |  | 3 |
| Seed sale associated with Russia Exit <sup>4,9</sup> | 18 |  |  | 18 |
| Total | $(81) | $(476) | $(22) | $(579) |

---

1. Includes restructuring plans and asset related charges as well as accelerated prepaid amortization expense. See Note 5 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements, for additional information.

2. Consists of a charge relating to the resolution of litigation with Bayer. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information.

3. Incremental gains (losses) associated with activities related to the Crop Protection Operations Strategy Restructuring Program. Within gain (loss) on sale of business, assets and equity investments, a $23 million benefit was recorded for the year ended December 31, 2025.

4. Incremental gains (losses) associated with activities related to the 2022 Restructuring Actions. Within gain (loss) on sale of business, assets and equity investments, such benefits are $14 million, $7 million and $14 million for the years ended December 31, 2025, 2024 and 2023, respectively.

5. Relates to a charge to increase the remediation accrual at the AltEn facility relating to Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information.

6. Includes proceeds received related to prior significant items.

7. Consists of estimated Lorsban® related charges.

8. Relates to acquisition-related costs, including transaction and third-party integration costs associated with the completed acquisitions of Stoller and Symborg as well as the recognition of the inventory fair value step-up.

9. Includes a benefit of $18 million for the year ended December 31, 2023, relating to the sale of seeds already under production in Russia when the decision to exit the country was made and that the company was contractually required to purchase. It consists of $71 million of net sales and $53 million of cost of goods sold for the year ended December 31, 2023.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc**.

**Index to the Consolidated Financial Statements**

---

| | |
|:---|:---|
| | **Page(s)** |
| [Management's Reports on Responsibility for Financial Statements and Internal Control over Financial Reporting](#i46860590cf424b89b8159966786b56bb_262) | F-[70](#i46860590cf424b89b8159966786b56bb_262) |
| [Report of Independent Registered Public Accounting Firm](#i46860590cf424b89b8159966786b56bb_265) (PCAOB ID 238) | F-[71](#i46860590cf424b89b8159966786b56bb_265) |
| Consolidated Financial Statements: |  |
| [Consolidated Statements of Operations for the years ended December 31, 2025, 2024, and 2023](#i46860590cf424b89b8159966786b56bb_271) | F-[73](#i46860590cf424b89b8159966786b56bb_271) |
| [Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2025, 2024 and 2023](#i46860590cf424b89b8159966786b56bb_274) | F-[74](#i46860590cf424b89b8159966786b56bb_274) |
| [Consolidated Balance Sheets as of December 31, 2025 and 2024](#i46860590cf424b89b8159966786b56bb_277) | F-[75](#i46860590cf424b89b8159966786b56bb_277) |
| [Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024, and 2023](#i46860590cf424b89b8159966786b56bb_283) | F-[76](#i46860590cf424b89b8159966786b56bb_283) |
| [Consolidated Statements of Equity for the years ended December 31, 2025, 2024, and 2023](#i46860590cf424b89b8159966786b56bb_286) | F-[77](#i46860590cf424b89b8159966786b56bb_286) |
| [Notes to the Consolidated Financial Statements](#i46860590cf424b89b8159966786b56bb_292) | F-[78](#i46860590cf424b89b8159966786b56bb_292) |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Management's Reports on Responsibility for Financial Statements and**

**Internal Control over Financial Reporting**

**Management's Report on Responsibility for Financial Statements**

Management is responsible for the Consolidated Financial Statements and the other financial information contained in this Annual Report on Form 10-K. The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and are considered by management to present fairly EIDP's financial position, results of operations and cash flows. The financial statements include some amounts that are based on management's best estimates and judgments. The Consolidated Financial Statements have been audited by EIDP's independent registered public accounting firm, PricewaterhouseCoopers LLP. The purpose of their audit is to express an opinion as to whether the Consolidated Financial Statements included in this Annual Report on Form 10-K present fairly, in all material respects, EIDP's financial position, results of operations and cash flows in conformity with GAAP. Their report is presented on the following pages.

**Management's Report on Internal Control over Financial Reporting** 

Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. EIDP's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. EIDP's internal control over financial reporting includes those policies and procedures that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of EIDP;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of EIDP are being made only in accordance with authorization of management and directors of EIDP; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of EIDP's assets that could have a material effect on the financial statements.

Internal control over financial reporting has certain inherent limitations which may not prevent or detect misstatements. In addition, changes in conditions and business practices may cause variation in the effectiveness of internal controls.

Management assessed the effectiveness of EIDP's internal control over financial reporting as of December 31, 2025, based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in *Internal Control-Integrated Framework (2013)*. Based on its assessment and those criteria, management concluded that EIDP maintained effective internal control over financial reporting as of December 31, 2025.

PricewaterhouseCoopers LLP, an independent registered public accounting firm, has audited the effectiveness of EIDP's internal control over financial reporting as of December 31, 2025, as stated in their report, which is presented on the following pages.

![CM Signature.jpg](ctva-20251231_g6.jpg)![DJ Signature B&W.jpg](ctva-20251231_g7.jpg)

Charles V. MagroChief Executive Officer and Director David P. JohnsonExecutive Vice President,Chief Financial Officer and Director

February 12, 2026

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**Report of Independent Registered Public Accounting Firm**

To the Board of Directors and Stockholders of EIDP, Inc.

***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of EIDP, Inc. and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of operations, of comprehensive income (loss), of equity and of cash flows for each of the three years in the period ended December 31, 2025, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2025 appearing under Item 15 (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

***Basis for Opinions***

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

***Definition and Limitations of Internal Control over Financial Reporting***

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***Critical Audit Matters***

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

*Revenue Recognition - Product Sales*

As described in Notes 2 and 4 to the Corteva, Inc. consolidated financial statements, net sales were $17.401 billion for the year ended December 31, 2025. Substantially all of the Company's revenue is derived from product sales. Revenue is recognized from product sales when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. Control transfer occurs at a point in time according to shipping terms. The transaction price includes estimates of variable consideration, such as rights of return, rebates, and discounts, that are reductions in revenue. All estimates are based on the Company's historical experience, anticipated performance, and management's best judgment at the time the estimate is made. Estimates of variable consideration included in the transaction price primarily utilize the expected value method based on historical experience. These estimates are reassessed each reporting period and are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur upon resolution of uncertainty associated with the variable consideration. The majority of contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as quantity times price per unit.

The principal consideration for our determination that performing procedures relating to revenue recognition for product sales is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company's revenue recognition.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process. These procedures also included, among others (i) evaluating revenue transactions by testing, on a sample basis, the revenue recognized by obtaining and inspecting source documents, such as purchase orders, invoices, shipment or delivery documents, and cash receipts, as applicable; (ii) testing, on a sample basis, the recognition of variable consideration for rebates issued and discounts granted during the year by obtaining and inspecting source documents, such as support for the nature of the variable consideration, amount, and agreement with the customer; and (iii) confirming, on a sample basis, outstanding customer invoice balances as of year-end, and, for confirmations not returned, obtaining and inspecting source documents, including invoices, shipment or delivery documents, and subsequent cash receipts, as applicable.

/s/ PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania

February 12, 2026

We have served as the Company's auditor since 1946.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions, except per share amounts)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|  | **2025** | **2024** | **2023** |
| Net sales | $17401 | $16908 | $17226 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 9172 | 9529 | 9920 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense | 1474 | 1402 | 1337 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 3492 | 3196 | 3176 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 644 | 685 | 683 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 146 | 288 | 336 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 35 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense) - net | (570) | (261) | (448) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 180 | 233 | 253 |
| Income (loss) from continuing operations before income taxes | 1688 | 1314 | 1073 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) income taxes on continuing operations | 484 | 421 | 147 |
| Income (loss) from continuing operations after income taxes | 1204 | 893 | 926 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations after income taxes | (99) | 56 | (194) |
| Net income (loss) | 1105 | 949 | 732 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to noncontrolling interests | 1 | 2 | 2 |
| Net income (loss) attributable to EIDP, Inc. | $1104 | $947 | $730 |

---

See Notes to the Consolidated Financial Statements beginning on page F-78.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)** 

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Net income (loss) | $1105 | $949 | $732 |
| Other comprehensive income (loss) - net of tax: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustments | 867 | (1014) | 425 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to pension benefit plans | (152) | 127 | (190) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to other benefit plans | (26) | 30 | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on investments | 6 | (6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative instruments | (23) | 71 | (135) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | 672 | (792) | 129 |
| Comprehensive income (loss) | 1777 | 157 | 861 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income (loss) attributable to noncontrolling interests - net of tax | 1 | 2 | 2 |
| Comprehensive income (loss) attributable to EIDP, Inc. | $1776 | $155 | $859 |

---

See Notes to the Consolidated Financial Statements beginning on page F-78.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED BALANCE SHEETS** 

---

| | | |
|:---|:---|:---|
| *(In millions, except share and per share amounts)* | **December 31, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $4521 | $3106 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 9 | 63 |
| &nbsp;&nbsp;&nbsp;Accounts and notes receivable - net | 6371 | 5676 |
| &nbsp;&nbsp;&nbsp;Inventories | 5667 | 5432 |
| &nbsp;&nbsp;&nbsp;Other current assets | 767 | 820 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 17335 | 15097 |
| Investment in nonconsolidated affiliates | 160 | 134 |
| Property, plant and equipment | 9551 | 9074 |
| Less: Accumulated depreciation | 5331 | 4975 |
| Net property, plant and equipment | 4220 | 4099 |
| Goodwill | 10465 | 10408 |
| Other intangible assets | 8301 | 8876 |
| Deferred income taxes | 320 | 401 |
| Other assets | 2044 | 1810 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $42845 | $40825 |
| **Liabilities and Equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Short-term borrowings and finance lease obligations | $894 | $750 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 4398 | 4039 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 155 | 207 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 3579 | 3287 |
| &nbsp;&nbsp;&nbsp;Accrued and other current liabilities | 3223 | 2096 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 12249 | 10379 |
| Long-term debt | 1686 | 1953 |
| Other noncurrent liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Deferred income tax liabilities | 251 | 478 |
| &nbsp;&nbsp;&nbsp;Pension and other post-employment benefits | 2434 | 2271 |
| &nbsp;&nbsp;&nbsp;Other noncurrent obligations | 1963 | 1707 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total noncurrent liabilities | 6334 | 6409 |
| Commitments and contingent liabilities |  |  |
| Stockholders' equity |  |  |
| Preferred stock, without par value – cumulative; 23,000,000 shares authorized; <br>&nbsp;&nbsp;&nbsp;&nbsp; issued at December 31, 2025 and December 31, 2024: |  |  |
| &nbsp;&nbsp;&nbsp;$4.50 Series – 1,673,000 shares (callable at $120) | 169 | 169 |
| &nbsp;&nbsp;&nbsp;$3.50 Series – 700,000 shares (callable at $102) | 70 | 70 |
| Common stock, $0.30 par value; 1,800,000,000 shares authorized; 200<br>issued at December 31, 2025 and December 31, 2024 |  |  |
| Additional paid-in capital | 24610 | 24464 |
| Due from Parent |  | (129) |
| Retained earnings (accumulated deficit) | 2207 | 2930 |
| Accumulated other comprehensive income (loss) | (2797) | (3469) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total EIDP, Inc. stockholders' equity | 24259 | 24035 |
| Noncontrolling interests | 3 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 24262 | 24037 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Equity | $42845 | $40825 |

---

See Notes to the Consolidated Financial Statements beginning on page F-78.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF CASH FLOWS** 

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| **Operating activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net income (loss) | $1105 | $949 | $732 |
| &nbsp;&nbsp;&nbsp;(Income) loss from discontinued operations after income taxes | 99 | (56) | 194 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1203 | 1227 | 1211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) deferred income tax | (41) | (365) | (438) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension and OPEB (benefit) cost, net | 36 | 160 | 138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and OPEB contributions | (136) | (151) | (149) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (gain) loss on sales of property, businesses, consolidated companies, and investments | (41) | (17) | (22) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 146 | 288 | 336 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other net loss | 545 | 383 | 578 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable | (261) | (705) | 358 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (35) | 1110 | 57 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 231 | (115) | (663) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 270 | (86) | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | 336 | (284) | (553) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - continuing operations | 3457 | 2338 | 1768 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - discontinued operations | (51) | (151) | (40) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities | 3406 | 2187 | 1728 |
| **Investing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (591) | (597) | (595) |
| &nbsp;&nbsp;&nbsp;Net payment from (advances to) Parent on in-house banking arrangement |  | 361 | (20) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of property, businesses, and consolidated companies - net of cash divested | 54 | 5 | 57 |
| &nbsp;&nbsp;&nbsp;Acquisitions of businesses - net of cash acquired |  |  | (1456) |
| &nbsp;&nbsp;&nbsp;Investments in and loans to nonconsolidated affiliates | (20) | (7) | (32) |
| &nbsp;&nbsp;&nbsp;Purchases of investments |  | (144) | (148) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales and maturities of investments | 135 | 130 | 147 |
| &nbsp;&nbsp;&nbsp;Proceeds from settlement of net investment hedge | (83) | 63 | 42 |
| &nbsp;&nbsp;&nbsp;Other investing activities, net | (38) | (39) | (2) |
| &nbsp;&nbsp;&nbsp;Cash provided by (used for) investing activities | (543) | (228) | (2007) |
| **Financing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net change in borrowings (less than 90 days) |  | 53 | (6) |
| &nbsp;&nbsp;&nbsp;Net payment from (advances to) Parent on in-house banking arrangement | 129 | (129) |  |
| &nbsp;&nbsp;&nbsp;Payments on related party debt |  |  | (1129) |
| &nbsp;&nbsp;&nbsp;Proceeds from debt | 1730 | 3072 | 3429 |
| &nbsp;&nbsp;&nbsp;Payments on debt | (1871) | (2885) | (2309) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | 88 | 60 | 31 |
| &nbsp;&nbsp;&nbsp;Dividends paid to Parent | (1682) | (1750) |  |
| &nbsp;&nbsp;&nbsp;Other financing activities, net | (38) | (23) | (54) |
| &nbsp;&nbsp;&nbsp;Cash provided by (used for) financing activities | (1644) | (1602) | (38) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 84 | (93) | (143) |
| Increase (decrease) in cash, cash equivalents and restricted cash equivalents | 1303 | 264 | (460) |
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 3422 | 3158 | 3618 |
| **Cash, cash equivalents and restricted cash equivalents at end of period** | $4725 | $3422 | $3158 |
| **Supplemental cash flow information** |  |  |  |
| **Cash paid during the period for** |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest, net of amounts capitalized <sup>1</sup> | $191 | $244 | $234 |
| &nbsp;&nbsp;&nbsp;Income taxes | 750 | 707 | 535 |

---

1. Reflects interest, net of amounts capitalized, paid to external parties. For information associated with interest paid on related party debt refer to EIDP Note 2 - Related Party Transactions, of the EIDP Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Notes to the Consolidated Financial Statements beginning on page F-78.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Consolidated Financial Statements**

**CONSOLIDATED STATEMENTS OF EQUITY** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *(In millions)* | *Preferred Stock* | *Common Stock* | *Additional Paid-in Capital* | *Due from Parent* | *Retained Earnings (Accum. Deficit)* | *Accumulated Other Comp. Income (Loss)* | *Non-Controlling Interests* | *Total Equity* |
| Balance at January 1, 2023 | $239 | $— | $24284 | $— | $3031 | $(2806) | $1 | $24749 |
| Net income (loss) |  |  |  |  | 730 |  | 2 | 732 |
| Other comprehensive income (loss) |  |  |  |  |  | 129 |  | 129 |
| Share-based compensation |  |  | 28 |  | (2) |  |  | 26 |
| Preferred dividends ($4.50 Series - $4.50 per share, $3.50 Series - $3.50 per share) |  |  |  |  | (10) |  |  | (10) |
| Issuance of Corteva Stock |  |  | 40 |  |  |  |  | 40 |
| Other - net |  |  | (3) |  | (2) |  | (1) | (6) |
| Balance at December 31, 2023 | $239 | $— | $24349 | $— | $3747 | $(2677) | $2 | $25660 |
| Net income (loss) |  |  |  |  | 947 |  | 2 | 949 |
| Other comprehensive income (loss) |  |  |  |  |  | (792) |  | (792) |
| Due from Parent |  |  |  | (129) |  |  |  | (129) |
| Share-based compensation |  |  | 47 |  | (2) |  |  | 45 |
| Preferred dividends ($4.50 Series - $4.50 per share, $3.50 Series - $3.50 per share) |  |  |  |  | (10) |  |  | (10) |
| Issuance of Corteva Stock |  |  | 60 |  |  |  |  | 60 |
| Dividend to Parent |  |  |  |  | (1750) |  |  | (1750) |
| Other - net |  |  | 8 |  | (2) |  | (2) | 4 |
| Balance at December 31, 2024 | $239 | $— | $24464 | $(129) | $2930 | $(3469) | $2 | $24037 |
| Net income (loss) |  |  |  |  | 1104 |  | 1 | 1105 |
| Other comprehensive income (loss) |  |  |  |  |  | 672 |  | 672 |
| Due from Parent |  |  |  | 129 |  |  |  | 129 |
| Share-based compensation |  |  | 57 |  | (2) |  |  | 55 |
| Preferred dividends ($4.50 Series - $4.50 per share, $3.50 Series - $3.50 per share) |  |  |  |  | (10) |  |  | (10) |
| Issuance of Corteva Stock |  |  | 88 |  |  |  |  | 88 |
| Dividend to Parent |  |  |  |  | (1815) |  |  | (1815) |
| Other - net |  |  | 1 |  |  |  |  | 1 |
| Balance at December 31, 2025 | $239 | $— | $24610 | $— | $2207 | $(2797) | $3 | $24262 |

---

See Notes to the Consolidated Financial Statements beginning on page F-78.

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Notes to the Consolidated Financial Statements**

**Table of Contents**

---

| | | |
|:---|:---|:---|
| **Note** | | **Page** |
| 1 | [Basis of Presentation](#i46860590cf424b89b8159966786b56bb_295) | [F-81](#i46860590cf424b89b8159966786b56bb_295) |
| 2 | [Related Party Transactions](#i46860590cf424b89b8159966786b56bb_298) | [F-82](#i46860590cf424b89b8159966786b56bb_298) |
| 3 | [Income Taxes](#i46860590cf424b89b8159966786b56bb_304) | [F-82](#i46860590cf424b89b8159966786b56bb_304) |
| 4 | [Segment Information](#i46860590cf424b89b8159966786b56bb_307) | [F-83](#i46860590cf424b89b8159966786b56bb_307) |

---

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 1 - BASIS OF PRESENTATION**

Corteva, Inc. owns 100 percent of the outstanding common stock of EIDP. EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The primary differences between Corteva, Inc. and EIDP are outlined below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Preferred Stock** - EIDP has preferred stock outstanding to third parties which is accounted for as a noncontrolling interest at the Corteva, Inc. level. Each share of EIDP Preferred Stock - $4.50 Series and EIDP Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Separation remains issued and outstanding as to EIDP and was unaffected by the Corteva Separation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Related Party Loan** - EIDP engaged in a series of debt redemptions during the second quarter of 2019 that were partially funded through an intercompany loan from Corteva, Inc. This was eliminated in consolidation at the Corteva, Inc. level but remained on EIDP's consolidated financial statements at the standalone level (including the associated interest) through its repayment date in the fourth quarter of 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Master In-House Banking Agreement** - A Master In-House Banking Agreement exists to which EIDP is a party, along with Corteva and certain consolidated subsidiaries, as more fully described in EIDP Note 2 – Related Party Transactions, of the EIDP Consolidated Financial Statements. Through the third quarter of 2024, EIDP earned interest on Corteva, Inc.'s borrowings under the Master In-House Banking Agreement; however, beginning in the fourth quarter of 2024 no interest has been recognized by EIDP and the amount due from Corteva, Inc. is classified within equity of EIDP due to a change in repayment intent related to the arrangement. Such transactions are eliminated in consolidation at the Corteva, Inc. level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Dividends** - The Board of Directors of EIDP authorizes and declares a quarterly dividend to Corteva, Inc., from which the proceeds are intended to be used to fund Corteva, Inc. share repurchases and common stock dividends during the subsequent quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Capital Structure** - At December 31, 2025, Corteva, Inc.'s capital structure consists of 672,163,000 issued shares of common stock, par value $0.01 per share.

The accompanying footnotes relate to EIDP only, and not to Corteva, Inc., and are presented to show differences between EIDP and Corteva, Inc.

For the footnotes listed below, refer to the following Corteva, Inc. footnotes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 1 - Background and Basis of Presentation - refer to page F-11 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 2 - Summary of Significant Accounting Policies - refer to page F-12 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 3 - Recent Accounting Guidance - refer to page F-16 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 4 - Revenue - refer to page F-17 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 5 - Restructuring and Asset Related Charges - Net - refer to page F-19 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 6 - Supplementary Information - refer to page F-21 of the Corteva, Inc. Consolidated Financial Statements. In addition, EIDP earned interest on a related party loan receivable from Corteva, Inc. through the third quarter of 2024; refer to EIDP Note 2 - Related Party Transactions, of the EIDP Consolidated Financial Statements, below

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 7 - Income Taxes - Differences exist between Corteva, Inc. and EIDP; refer to EIDP Note 3 - Income Taxes, of the EIDP Consolidated Financial Statements, below

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 8 - Earnings Per Share of Common Stock - Not applicable for EIDP

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 9 - Accounts and Notes Receivable - Net - refer to page F-29 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 10 - Inventories - refer to page F-30 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 11 - Property, Plant and Equipment - refer to page F-30 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 12 - Goodwill and Other Intangible Assets - refer to page F-30 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 13 - Leases - refer to page F-31 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 14 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities - refer to page F-33 of the Corteva, Inc. Consolidated Financial Statements. In addition, EIDP had a related party loan payable to Corteva, Inc. which was repaid during the fourth quarter of 2023; refer to EIDP Note 2 - Related Party Transactions, of the EIDP Consolidated Financial Statements, below

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 15 - Commitments and Contingent Liabilities - refer to page F-35 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 16 - Stockholders' Equity - refer to page F-45 of the Corteva, Inc. Consolidated Financial Statements

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 17 - Pension Plans and Other Post-Employment Benefits - refer to page F-47 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 18 - Stock-Based Compensation - refer to page F-56 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 19 - Financial Instruments - refer to page F-58 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 20 - Fair Value Measurements - refer to page F-63 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 21 - Geographic Information - refer to page F-64 of the Corteva, Inc. Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 22 - Segment Information - Differences exist between Corteva, Inc. and EIDP; refer to EIDP Note 4 - Segment Information, of the EIDP Consolidated Financial Statements, below

**NOTE 2 - RELATED PARTY TRANSACTIONS** 

**Transactions with Corteva**

EIDP and Corteva, including certain consolidated subsidiaries (collectively the "Participating Companies"), are party to a Master In-House Banking Agreement, which established banking arrangements to facilitate the management of the cash and liquidity needs of the Participating Companies. Historically, in periods where EIDP had a net amount due from Corteva, Inc., EIDP classified the amount within other assets given Corteva, Inc. had both the ability and intent to repay the amounts due. Beginning in the fourth quarter of 2024, Corteva, Inc.'s intent to repay the amounts due changed and therefore, borrowings under this agreement are now classified within equity of EIDP. Through the third quarter of 2024, EIDP earned interest income from Corteva, Inc. of $38 million under this agreement, which is reflected as other income (expense) - net in EIDP's Consolidated Statements of Operations. As of December 31, 2025 and 2024, EIDP had a due from parent of $— million and $129 million, respectively, classified within the equity section of EIDP's Consolidated Balance Sheets.

In December 2025, the Board of Directors of EIDP authorized and declared a dividend of $195 million to Corteva, Inc., from which the proceeds are intended to be used to fund Corteva, Inc. share repurchases and common stock dividends during the first quarter of 2026. At December 31, 2025, EIDP had a dividend payable to Corteva, Inc. of $133 million.

EIDP declared cash dividends of $1,815 million and $1,750 million for the years ended December 31, 2025 and 2024, respectively. Cash dividends paid to Corteva, Inc. during the years ended December 31, 2025 and 2024 were $1,682 million and $1,750 million, respectively.

In the second quarter of 2019, EIDP entered into a related party revolving loan from Corteva, Inc., with a maturity date in 2024.

EIDP repaid the outstanding related party revolving loan balance during the fourth quarter of 2023. EIDP incurred interest expense of $20 million and paid interest of $40 million for the year ended December 31, 2023 associated with the related party loan to Corteva, Inc., net of interest income earned from the Master In-House Banking Agreement.

As of December 31, 2025 and 2024, EIDP had payables to Corteva, Inc. of $27 million and $9 million, included in accrued and other current liabilities, respectively, and $154 million and $149 million included in other noncurrent obligations, respectively, in the Consolidated Balance Sheets related to Corteva's indemnification liabilities to Dow and DuPont per the Separation Agreements (refer to page F-37 of the Corteva, Inc. Consolidated Financial Statements for further details of the Separation Agreements).

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 3 - INCOME TAXES**

Refer to page F-23 of the Corteva, Inc. Consolidated Financial Statements for discussion of tax items that do not differ between Corteva, Inc. and EIDP. Since the reconciliation to the U.S. statutory rate for the year ended December 31, 2025 is the same for both Corteva, Inc. and EIDP, such information is omitted from the table below.

---

| | | | |
|:---|:---|:---|:---|
| **Geographic Allocation of Income (Loss) and Provision for (Benefit from) Income Taxes** | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| *(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from continuing operations before income taxes |  |  |  |
| &nbsp;&nbsp;&nbsp;Domestic | $325 | $363 | $(434) |
| &nbsp;&nbsp;&nbsp;Foreign | 1363 | 951 | 1507 |
| Income (loss) from continuing operations before income taxes | $1688 | $1314 | $1073 |
| Current tax expense (benefit) |  |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $87 | $292 | $138 |
| &nbsp;&nbsp;&nbsp;State and local | 26 | 47 | 40 |
| &nbsp;&nbsp;&nbsp;Foreign | 412 | 447 | 407 |
| Total current tax expense (benefit) | $525 | $786 | $585 |
| Deferred tax expense (benefit) |  |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $(139) | $(300) | $(326) |
| &nbsp;&nbsp;&nbsp;State and local | (24) | (28) | (50) |
| &nbsp;&nbsp;&nbsp;Foreign | 122 | (37) | (62) |
| Total deferred tax expense (benefit) | $(41) | $(365) | $(438) |
| Provision for (benefit from) income taxes on continuing operations | 484 | 421 | 147 |
| Net income (loss) from continuing operations | $1204 | $893 | $926 |

---

---

| | | |
|:---|:---|:---|
| **Reconciliation to U.S. Statutory Rate** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| | **2024** | **2023** |
| Statutory U.S. federal income tax rate | 21.0% | 21.0% |
| Effective tax rates on international operations - net <sup>1</sup> | 4.6 | (1.9) |
| Acquisitions, divestitures and ownership restructuring activities <sup>2</sup> | (1.1) | 3.6 |
| U.S. research and development credit | (4.5) | (6.0) |
| Exchange gains/losses <sup>3</sup> | 1.7 | 2.0 |
| State and local income taxes - net | 1.3 | 0.9 |
| Impact of Swiss Tax Changes <sup>4</sup> |  | (8.0) |
| Excess tax benefits/deficiencies from stock compensation | (0.2) | (0.6) |
| Tax settlements and expiration of statute of limitations | (1.6) | (0.4) |
| Impact of Brazil valuation allowance <sup>6</sup> | 9.1 |  |
| Repatriation of foreign earnings <sup>5</sup> | 1.7 | 2.9 |
| Other – net |  | 0.2 |
| Effective tax rate | 32.0% | 13.7% |

---

1.&nbsp;&nbsp;&nbsp;&nbsp;Includes the effects of local and U.S. taxes related to earnings of non-U.S. subsidiaries, changes in the amount of unrecognized tax benefits associated with these earnings, losses at non-U.S. subsidiaries without local tax benefits due to valuation allowances, and other permanent differences between tax and U.S. GAAP results.

2. &nbsp;&nbsp;&nbsp;&nbsp;Includes a tax charge of $46 million for the year ended December 31, 2023 associated with intellectual property realignment.

3.&nbsp;&nbsp;&nbsp;&nbsp;Principally reflects the impact of foreign exchange gains and losses on net monetary assets for which no corresponding tax impact is realized. Further information about the company's foreign currency hedging program is included in Note 6 - Supplementary Information, and Note 19 - Financial Instruments, under the heading Foreign Currency Risk.

4. Includes net tax benefits of $(62) million and $(24) million for the year ended December 31, 2023, related to changes in deferred taxes and a tax currency change, respectively.

5. &nbsp;&nbsp;&nbsp;&nbsp;Includes the effect of withholding tax on distribution of foreign earnings to the U.S., net of U.S. foreign tax credits.

6. For the year ended December 31, 2024, a charge of $120 million was recorded to establish a valuation allowance against the net deferred tax asset position of

a legal entity in Brazil (Seed business).

------

<u>[Table Of Contents](#i46860590cf424b89b8159966786b56bb_7)</u>

**EIDP, Inc.**

**Notes to the Consolidated Financial Statements (continued)**

**NOTE 4 - SEGMENT INFORMATION**

There are no differences in reporting structure or segments between Corteva, Inc. and EIDP. In addition, there are no differences between Corteva, Inc. and EIDP segment net sales, segment operating EBITDA or significant items by segment; refer to page F-65 of the Corteva, Inc. Consolidated Financial Statements for background information on the segments as well as further details regarding segment metrics. The tables below reconcile income (loss) from continuing operations after income taxes to segment operating EBITDA, as differences exist between Corteva, Inc. and EIDP.

**Reconciliation to Consolidated Financial Statements**

---

| | | | |
|:---|:---|:---|:---|
| **Income (loss) from continuing operations after income taxes to segment operating EBITDA**<br>*(In millions)* | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| **Income (loss) from continuing operations after income taxes to segment operating EBITDA**<br>*(In millions)* | **2025** | **2024** | **2023** |
| Income (loss) from continuing operations after income taxes | $1204 | $893 | $926 |
| Provision for (benefit from) income taxes on continuing operations | 484 | 421 | 147 |
| Income (loss) from continuing operations before income taxes | $1688 | $1314 | $1073 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1203 | 1227 | 1211 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (136) | (171) | (283) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 180 | 233 | 253 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exchange (gains) losses - net | 181 | 284 | 397 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating (benefits) costs - net | 39 | 174 | 151 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Significant items | 658 | 315 | 579 |
| &nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 35 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate expenses | 138 | 115 | 110 |
| Segment operating EBITDA | $3986 | $3491 | $3491 |

---

**ITEM 16. FORM 10-K SUMMARY**

Not applicable.

## Exhibit 10.20

**Exhibit 10.20**

**LETTER AGREEMENT**

This letter agreement (this "<u>Agreement</u>"), effective November 1, 2025, is made by and between DuPont de Nemours, Inc, a Delaware corporation ("<u>RemainCo</u>"), Corteva, Inc., a Delaware corporation ("<u>Corteva</u>") and Qnity Electronics, Inc., a Delaware corporation ("<u>ElectronicsCo</u>"). Reference is made to (a) that certain Separation and Distribution Agreement, dated as of November 1, 2025 (the "<u>2025 SDA</u>"), by and among RemainCo and ElectronicsCo, (b) that certain Partial Assignment Agreement, dated as of November 1, 2025 (the "<u>Partial Assignment Agreement</u>"), by and between RemainCo and ElectronicsCo, (c) that certain Separation and Distribution Agreement, dated as of April 1, 2019 (the "<u>2019 SDA</u>"), by and among RemainCo, Corteva and Dow Inc., a Delaware Corporation, (d) that certain letter agreement, dated as of June 1, 2019 (the "<u>2019 Letter Agreement</u>"), by and between RemainCo and Corteva and (e) that certain Memorandum of Understanding, dated as of January 22, 2021 (the "<u>MOU</u>"), by and among RemainCo, Corteva, E. I. du Pont de Nemours and Company, a Delaware corporation, and The Chemours Company, a Delaware corporation. Capitalized terms used herein without definition have the meaning given to them in the 2025 SDA. RemainCo, Corteva and ElectronicsCo are referred to herein as the "<u>Parties</u>".

WHEREAS, the Parties wish to enter into certain additional agreements in a manner effective as between the Parties and their respective Subsidiaries.

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements, provisions and covenants contained in this Agreement, the Parties hereby agree as follows:

**ARTICLE I**

**<u>THIRD PARTY BENEFICIARY RIGHTS</u>** 

Section 1.01&nbsp;&nbsp;&nbsp;&nbsp;<u>Corteva Third Party Beneficiary Rights</u>

.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Each of RemainCo and ElectronicsCo, on behalf of itself and each member of its Group, agrees that each of Corteva and each other member of the AgCo Group (as defined in the 2019 SDA) that is a subsidiary of Corteva as of the date hereof (each, a "<u>Corteva Third Party Beneficiary</u>") is a third party beneficiary of (i) Section 1(b) and Section 6 of the Partial Assignment Agreement and (ii) Sections 7.1, 8.3, 8.8(d) and 12.15(d) of the 2025 SDA, solely in respect of ElectronicsCo's obligations to, as directed by RemainCo, indemnify RemainCo, or remit payment directly to an applicable Corteva Third Party Beneficiary, for (x) the Applicable ElectronicsCo Percentage of any DWDP Legacy Liabilities and (y) the Applicable ElectronicsCo Percentage of any Liabilities in respect of the funding obligations of RemainCo under the MOU, including with respect to the funding of the escrow account thereunder ("<u>MOU Obligations</u>", and together with <u>clause (x)</u>, the "<u>Relevant ElectronicsCo Indemnity/Payment Obligations</u>"), including the right to enforce such Relevant ElectronicsCo Indemnity/Payment Obligations and the right to invoice for and direct that Corteva be, and to be, directly indemnified by ElectronicsCo in respect of the Relevant ElectronicsCo Indemnity/Payment Obligations not previously indemnified by RemainCo (collectively, under this clause (ii) the "<u>Corteva Third Party Indemnity Rights</u>", and together with the third party beneficiary rights under the foregoing <u>clause (i)</u>, the "<u>Corteva Third Party Beneficiary Rights</u>"); <u>provided</u>,

------

<u>however</u>, that none of the Corteva Third Party Beneficiaries shall enforce, or seek to enforce, any such Corteva Third Party Indemnity Rights directly against ElectronicsCo as a third party beneficiary unless (i)(A) RemainCo has agreed in writing with such Corteva Third Party Beneficiary that the matter in respect of which the Corteva Third Party Beneficiary seeks indemnity or payment constitutes a DWDP Legacy Liability or MOU Obligation, or (B) a final, binding and non-appealable arbitration award has been issued in favor of the Corteva Third Party Beneficiary against RemainCo by an Arbitral Tribunal (as defined in the 2019 SDA), pursuant to the dispute resolution provisions set forth in Article X of the 2019 SDA and the Corteva Letter Agreement, concluding that the matter in respect of which the Corteva Third Party Beneficiary seeks indemnity or payment constitutes a DWDP Legacy Liability or MOU Obligation, and (ii) either (A) a final, binding and non-appealable arbitration award has been issued in favor of the Corteva Third Party Beneficiary against RemainCo by an Arbitral Tribunal (as defined in the 2019 SDA), pursuant to the dispute resolution provisions set forth in Article X of the 2019 SDA and the Corteva Letter Agreement, concluding that RemainCo has not used commercially reasonable efforts to enforce its rights against ElectronicsCo under the 2025 SDA in respect of the Relevant ElectronicsCo Indemnity/Payment Obligations, or (B)(1) RemainCo commences a voluntary case under Title 11 of the United States Code or (2)(x) an involuntary case is commenced against RemainCo under Title 11 of the United States Code and (y) an order for relief is entered against RemainCo in such case finding that, among other things, RemainCo is generally not paying its debts when due, unless such debts are the subject of a bona fide dispute as to liability or amount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that (i) the conditions set forth under <u>Section 1.01(a) (ii)(B)(1)</u> or <u>(2)</u> are satisfied and (ii) a final, binding and non-appealable order has been entered by a bankruptcy court finding that RemainCo has no indemnity obligations to any Corteva Third Party Beneficiary under the 2019 SDA in respect of DWDP Legacy Liabilities (and for the avoidance of doubt, none of the Corteva Third Party Beneficiaries is hereby waiving any of its rights in respect of any such bankruptcy proceeding), then (A) notwithstanding anything to the contrary in the 2025 SDA or the Partial Assignment Agreement, as between any Corteva Third Party Beneficiary and ElectronicsCo, the DWDP Legacy Liabilities shall be managed by Corteva pursuant to the provisions of this <u>Section 1.01(b)</u> and Article VII of the 2025 SDA shall not apply in any respect except for Section 7.01 of the 2025 SDA and (B) Corteva shall become the Managing Party (as defined in the 2019 SDA) under Article VII of the 2019 SDA with respect to such DWDP Legacy Liabilities and, notwithstanding anything to the contrary in the 2019 SDA, shall have the right to appoint all members of the Shared Historical DuPont Claim Committee (as defined in the 2019 SDA) and may assume and control the defense of any Third Party Claim related to, arising out of or resulting from the relevant DWDP Legacy Liability that gives rise to the Relevant ElectronicsCo Indemnity/Payment Obligations (each a "<u>Relevant Legacy Liability</u>") (including exclusive authority to manage, control, conduct or defend (or assume the defense of) or otherwise determine all matters whatsoever (including, as applicable, litigation strategy and choice of legal counsel or other professionals and any amendment, modification or supplement to any Contract related to Relevant Legacy Liabilities that includes parties other than the Parties (and their respective Affiliates) as party to such Contract (but, without the express written consent of ElectronicsCo, not any portion thereof that, (w) under the terms of such Contract, is binding only as between the Parties and/or their respective Affiliates, (x) imposes liability on ElectronicsCo (or its Affiliates) for a share of the Relevant Legacy Liability that is greater than the Applicable ElectronicsCo Percentage of such Relevant Legacy Liability, (y) amends, modifies or supplements this Agreement or any Corteva Third Party Beneficiary Right or (z)

------

would impose any joint or several direct liability on ElectronicsCo (and/or its Affiliates) with respect to any Relevant Legacy Liability or other Liability where no such joint or several direct liability already exists (as opposed to liability pursuant to ElectronicsCo's indemnification obligations under this Agreement and the 2025 SDA), and for the avoidance of doubt, excluding any amendment, modification or supplement to the allocation of, including the Specialty Products Shared Historical DuPont Percentage and Agriculture Shared Historical DuPont Percentage (each as defined in the 2019 SDA) of, any applicable DWDP Legacy Liabilities under the 2019 SDA, the 2019 Letter Agreement or the MOU)) on behalf of ElectronicsCo in respect of the Relevant Legacy Liability); <u>provided</u>, <u>however</u>, that Corteva shall not be entitled to assume the defense of any such Third Party Claim to the extent such Third Party Claim (x) is an allegation of a criminal violation by ElectronicsCo, (y) seeks injunctive, equitable or other relief other than monetary damages against ElectronicsCo (provided that ElectronicsCo shall reasonably cooperate with Corteva, at the request of Corteva, in seeking to separate any such claims from any related claim for monetary damages if this <u>clause (y)</u> is the sole reason that such Third Party Claim is a Non-Assumable Third Party Claim) or (z) is made by a Governmental Entity against ElectronicsCo (<u>clauses (x)</u>, <u>(y)</u> and <u>(z)</u>, the "<u>Non-Assumable Third Party Claims</u>"). ElectronicsCo shall have the right to employ separate counsel and to participate in (but not control) the defense, compromise or settlement thereof, at its own expense and, in any event, shall cooperate with Corteva in such defense and omit from taking any action that would be reasonably likely to interfere with or adversely affect the rights and powers of Corteva to so manage and control such defense and make available to Corteva and its representatives all witnesses, employees, officers, directors, agents, properties, pertinent information and materials in ElectronicsCo's possession or control relating thereto as are reasonably required by Corteva and relating to the Relevant Legacy Liability, subject to appropriate restrictions for classified, privileged or confidential information; <u>provided</u>, <u>however</u>, that in the event a conflict of interest exists, or is reasonably likely to exist, that would make it inappropriate in the reasonable judgment of ElectronicsCo for the same counsel to represent both Corteva and ElectronicsCo, ElectronicsCo shall be entitled to retain separate counsel as required by the applicable rules of professional conduct with respect to such matter. With respect to the defense of a Third Party Claim as provided above, (A) Corteva shall keep ElectronicsCo apprised of all material developments in such defense, (B) Corteva shall not withdraw from the defense of such Third Party Claim without providing advance notice to ElectronicsCo reasonably sufficient to allow ElectronicsCo to prepare to assume the defense of such Third Party Claim, (C) Corteva shall conduct the defense of the Third Party Claim actively and diligently, (D) ElectronicsCo shall not admit any liability with respect to, consent to entry of any judgment of, or settle, compromise or discharge, the Third Party Claim without the prior written consent of Corteva (which consent shall not be unreasonably withheld, conditioned or delayed), (E) ElectronicsCo's cooperation and provision of access to Corteva shall be at no additional cost or expense to Corteva (other than for actual out-of-pocket costs and expenses which shall be allocated in the same manner as the Relevant Legacy Liability), (F) any amounts owed by either Corteva or ElectronicsCo in respect of any Relevant Legacy Liability (including reimbursement for their out-of-pocket costs and expenses of defending or, in the case of ElectronicsCo, providing assistance to Corteva with respect to, any Third Party Claim that is a Relevant Legacy Liability, which shall include any out-of-pocket amounts with respect to a bond, prepayment or similar security or obligation required (or determined to be advisable by the Corteva) to be posted by Corteva in respect of any claim) shall be included in the calculation of the amount of the applicable Relevant Legacy Liability in determining the reimbursement obligations of Corteva and ElectronicsCo with respect thereto (provided that any release or refund thereof in the future shall be refunded back to

------

ElectronicsCo to the extent funded by ElectronicsCo), and (G) it shall not be a defense to any obligation by ElectronicsCo to pay any amounts in respect of any Relevant Legacy Liability that that ElectronicsCo does not approve of the quality or manner of the defense thereof or that such Relevant Legacy Liability was incurred by reason of a settlement rather than by a judgment or other determination of liability (even if, subject to the immediately succeeding sentence, such settlement was effected without the consent or over the objection of ElectronicsCo (unless such settlement was a Non-Assumable Third Party Claim)). Corteva shall not admit any liability with respect to, consent to entry of any judgment of, or settle, compromise or discharge, the Third Party Claim without the prior written consent of ElectronicsCo (which consent shall not be unreasonably withheld, conditioned or delayed) unless such settlement or judgment (1) completely and unconditionally releases ElectronicsCo in connection with such matter, (2) provides relief consisting solely of money damages borne by ElectronicsCo and (3) does not involve any admission by ElectronicsCo of any wrongdoing or violation of Law. Notwithstanding anything in this <u>Section 1.01(b)</u> to the contrary, (i) the provisions of Section 8.11(b)-(g) of the 2019 SDA shall apply *mutatis mutandis* to any claim related to, arising out of or resulting from the Relevant ElectronicsCo Indemnity/Payment Obligations and relating to remediation of contaminated environmental media, where the owner or primary tenant of the impacted property is not the Party (or a Subsidiary thereof) to which such liability for remediation has been allocated, and (ii) the provisions of Section 8.12 of the 2019 SDA will apply *mutatis mutandis* to any liabilities to the extent arising from required actions to execute demolition and removal of any buildings, improvements, facilities, equipment or other fixtures that constitute Relevant ElectronicsCo Indemnity/Payment Obligations related to the Discontinued Buildings and Related Improvements (as defined in the 2019 SDA). In the event that Corteva and ElectronicsCo disagree on whether a claim, obligation or Liability is a DWDP Legacy Liability or a Relevant Legacy Liability or whether such claim, obligation or Liability constitutes a Liability allocated to one of the Parties (or its Group) pursuant to the 2019 SDA or the 2025 SDA, as applicable, then such matter shall be resolved pursuant to and in accordance with the dispute resolution provisions set forth in Article X of the 2019 SDA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Each of ElectronicsCo and Corteva acknowledges and agrees that, in the event that the conditions set forth under <u>Section 1.01(a)(ii)(B)(1)</u> or <u>(2)</u> are satisfied, it shall be bound, in respect of any matter for which Corteva (or any other Corteva Third Party Beneficiary) or RemainCo (or a member of its Group) has sought indemnity or payment from the other for a DWDP Legacy Liability under the 2019 SDA or the 2019 Letter Agreement, by (x) the terms and conditions of any agreement in writing in respect of such matter between Corteva (or any other Corteva Third Party Beneficiary) or RemainCo (or a member of its Group) or (y) any final, binding and non-appealable arbitration award in respect of such matter issued by an Arbitral Tribunal (as defined in the 2019 SDA), pursuant to the dispute resolution provisions set forth in Article X of the 2019 SDA or the Corteva Letter Agreement, in each case of clauses (x) and (y) whether entered into or issued before, on or after the date of this Agreement, but prior to the satisfaction of the conditions set forth under <u>Section 1.01(a)(ii)(B)(1)</u> or <u>(2)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;With reference to Section 7.1, Section 8.3 and Section 12.15(d) of the 2025 SDA and Section 1(b) and Section 6 of the Partial Assignment Agreement (the "<u>Relevant Sections</u>"), RemainCo and ElectronicsCo confirm and agree that none of the Relevant Sections are modified or limited in respect of DWDP Legacy Liabilities by (i) the Exhibits or Schedules to the 2025 SDA, or the tax matters agreement, transition services agreements, employee matters agreement or the intellectual property cross-license agreement, each dated as

------

of November 1, 2025, by and between RemainCo and ElectronicsCo, or their respective subsidiaries (collectively, the "<u>Form 10 Ancillary Agreements</u>"), (ii) any Ancillary Agreement (other than this Agreement and the Form 10 Ancillary Agreements) or (iii) any Conveyancing and Assumption Instrument (other than the Partial Assignment Agreement).

Section 1.02&nbsp;&nbsp;&nbsp;&nbsp;<u>No Amendments of Corteva Third Party Beneficiary Rights Without Corteva Consent.</u> Each of RemainCo and ElectronicsCo agrees that, except with the prior written consent of Corteva, it shall not waive, modify, supplement or amend (a) Section 7.1, Section 8.3 or Section 12.15(d) of the 2025 SDA or (b) Section 1(b) or Section 6 of the Partial Assignment Agreement, in each case (clauses (a) and (b)), in any manner or respect (including by waiving, modifying, supplementing or amending any other provision or schedule of the 2025 SDA, including any definitions included and used directly or indirectly in such sections) that adversely affects in any material respect the Corteva Third Party Beneficiary Rights. The Parties expressly agree that any such purported waiver, modification, supplement or amendment without Corteva's prior written consent (if such consent is required) shall not affect in any manner or respect the rights of any Corteva Third Party Beneficiary, or the obligations of RemainCo or ElectronicsCo (or any member of their respective Groups), with respect to the Corteva Third Party Beneficiary Rights.

**ARTICLE II**

**<u>MISCELLANEOUS</u>**

Section 2.01&nbsp;&nbsp;&nbsp;&nbsp;<u>No Modification</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise expressly set forth herein, nothing contained in this Agreement is intended to or shall be deemed to modify, alter, amend or otherwise change any of the rights or obligations of the parties and their respective Affiliates under the 2019 SDA, the 2025 SDA, the 2019 Letter Agreement and the MOU, including, for the avoidance of doubt, any allocation thereunder of liabilities among the parties thereto or any right or obligation thereunder of a party thereto or their affiliates in respect of indemnification for such liabilities. The representations, warranties, covenants, agreements and indemnities contained in the 2019 SDA, the 2025 SDA, the 2019 Letter Agreement and the MOU shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein, where applicable. The Parties hereto agree that, in the event of any discrepancy or inconsistency between the terms of this Agreement, on the one hand, and the terms of the 2019 SDA, the 2025 SDA, the 2019 Letter Agreement and the MOU, on the other hand, the terms of this Agreement shall prevail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;RemainCo agrees that none of the Partial Assignment Agreement, the 2025 SDA or this Agreement constitutes, or purports to constitute, a novation of any obligation of RemainCo to Corteva under the 2019 SDA, the 2019 Letter Agreement or the MOU, and this Agreement does not constitute in any respect Corteva's consent to any such novation.

Section 2.02&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. This Agreement, the Partial Assignment Agreement, 2019 SDA, the 2025 SDA, the 2019 Letter Agreement and the MOU, including the exhibits and schedules thereto, shall constitute the entire agreement between the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments, course of dealings and writings with respect to such subject matter.

------

Section 2.03&nbsp;&nbsp;&nbsp;&nbsp;<u>Third Party Beneficiaries</u>. Except as otherwise expressly provided herein, this Agreement is solely for the benefit of, and is only enforceable by, the Parties and their permitted successors and assigns and should not be deemed to confer upon third parties any remedy, benefit, claim, liability, reimbursement, claim of Action or other right of any nature whatsoever in excess of those existing without reference to this Agreement.

Section 2.04&nbsp;&nbsp;&nbsp;&nbsp;<u>Incorporation of Certain Provisions of the SDA by Reference</u>. The provisions of Article X (Dispute Resolution), Sections 1.2 (References; Interpretation) (except for the last sentence thereof), 12.3 (Counterparts), 12.7 (Waivers), 12.8 (Amendments), 12.9 (Assignment), 12.10 (Successors and Assigns), 12.13 (No Circumvention), 12.14 (Subsidiaries), 12.16 (Title and Headings), 12.18 (Governing Law), 12.19 (Specific Performance), 12.20 (Severability), and 12.21 (No Duplication, No Double Recovery) of the 2019 SDA shall apply *mutatis mutandis* as if such provisions were set forth in full herein, <u>provided</u>, <u>however</u>, that any reference to "Parties" in such provisions, shall mean, when applied to this Agreement, the Parties.

*[Remainder of this page intentionally left blank.]* 

------

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.

DUPONT DE NEMOURS, INC.

By:

Name: Erik T. Hoover

Title: Senior Vice President and General

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counsel

QNITY ELECTRONICS, INC.

By:

Name: Jon D. Kemp

Title: Chief Executive Officer

CORTEVA, INC.

By:

Name: Cornel B. Fuerer

Title: Senior Vice President, Strategic

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advisor and Corporate Secretary

## Ex-19

**Exhibit 19**

**Insider Trading Policy**

**Policy Statement**

**Purpose:** One of the principal purposes of the federal securities laws is to prohibit "insider trading." Simply stated, insider trading occurs when a person uses material non-public information obtained through involvement with the Company to make decisions to purchase, sell, give away or otherwise trade the Company's securities or provides material non-public information to others outside the Company who may trade on the basis of that information.

This Policy applies to all transactions in the Company's securities, including common stock, options and any other securities that the Company may issue, such as preferred stock, notes, bonds and convertible securities, as well as to derivative securities relating to any of the Company's securities, whether or not issued by the Company.

Each individual is responsible for making sure that he or she complies with this Policy, and that any family member or entity whose transactions are subject to this Policy, as discussed below, also comply with this Policy. **In all cases, the responsibility for determining whether an individual is in possession of material non-public information rests with that individual, and any action on the part of the Company, the Corporate Secretary or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws.** You could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described below in more detail under the heading "Violations of Insider Trading Laws."

All amendments, pre-clearance decisions, guidance and interpretations of this Policy are the sole decision of the Corporate Secretary or their applicable designees in the Corporate Secretary's office. Reference to the Corporate Secretary in this Insider Trading Policy also refer to any Corporate Secretary designee.

**Scope:** This Insider Trading Policy provides the standards of Corteva, Inc. (the "Company") on trading the Company's securities, or securities of its subsidiaries or other publicly-traded companies, while in possession of confidential information. This Policy is divided into three parts as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Part I** prohibits trading in certain circumstances and applies to all directors, officers and employees of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Part II** imposes blackout periods on trading and applies to all directors and officers subject to reporting under Section 16 of the Securities Exchange Act of 1934 ("Section 16 Persons") and Covered Persons (as defined below); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Part III**, which applies to Section 16 Persons and officers (as defined below) only, prohibits certain types of transactions in the Company's securities and requires the pre-clearance of all others.

**Definitions & Acronyms**

(a)<u>Covered Persons.</u> Those individuals designated as such from time to time by the Corporate Secretary based on factors determined by the Corporate Secretary to be relevant to the intent of this policy, including such individuals' respective position or responsibilities and/or actual or potential access to material, non-public information. A list of Covered Persons is maintained by the Corporate Secretary.

(b)<u>Materiality.</u> Information is considered "material" if a reasonable investor would consider that information important in making a decision to buy, hold or sell securities or if such information would otherwise be deemed material under applicable federal securities laws. Any information that could be expected to affect the Company's stock price, whether it is positive or negative, should be considered material. There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances and is often evaluated by enforcement authorities with the benefit of hindsight.

While it is not possible to define all categories of material information, some examples of information that ordinarily would be regarded as material are:

(i)A pending or proposed merger, acquisition, disposition, or joint venture;

(ii)A change in dividend policy or the declaration of a stock split;

------

(iii)The establishment of a repurchase program for the Company's securities;

(iv)A change in executive management;

(v)A change in auditors or notification that the auditor's reports may no longer be relied upon;

(vi)Pending or threatened significant litigation, or the resolution of such litigation;

(vii)Changes in earnings estimates or unusual gains or losses;

(vii)A major change in accounting methods or policies;

(viii) Impending bankruptcy or the existence of severe liquidity problems;

(ix)The gain or loss of a significant customer or supplier;

(x)Changes in debt ratings; and

(xi)A cybersecurity event exposing the Company to significant operational disruption, reputational harm, and/or material losses;

Material information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as a merger, acquisition or introduction of a new product, the point at which negotiations or product development are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company's operations or stock price should it occur. Thus, information concerning an event that would have a large effect on stock price (such as a merger) may be material even if the possibility that the event will occur is relatively small. When in doubt about whether particular non-public information is material, presume it is material. **If you are unsure whether information is material, you should consult the Corporate Secretary before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates.**

(c)<u>Non-Public Information.</u> Information that has not been disclosed to the public is generally considered to be "non-public information." In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated (for example, through the issuance of a press release). Once information is widely disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information. As a general rule, information should not be considered fully absorbed by the marketplace until one (1) full trading day has elapsed since the information was released. If, for example, the Company were to make an announcement before the market opens on Monday morning, you should not trade in the Company's securities until Tuesday. Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release of specific material non-public information.

**As with questions of materiality, if you are not sure whether information is considered public, you should either consult with the Corporate Secretary or assume that the information is "non- public" and treat it as confidential.**

(d)<u>Officer.</u> The term "officer" means an employee at Senior Vice President level and above.

**Policy Guidance**

**<u>PART I</u>**

**1. General Policy**: No Trading or Causing Trading While in Possession of Material Non-Public Information

(a)Except as otherwise specified in this Policy under the headings "Transactions Under Company Plans" and "Rule 10b5-1 Plans," the Company, nor any director, officer or employee may purchase or sell any security, whether or not issued by the Company, while in possession of material non- public information about the applicable company. This includes material non-public information about our Company, its subsidiaries or another company you obtain through your involvement with our Company, including all significant collaborators, customers, partners, suppliers, or competitors of the Company. No

------

director, officer or employee who knows of any such material non-public information may communicate that information to any other person, including family members and friends.

(b)In addition, neither the Company, nor any director, officer or employee may purchase or sell any security of any other company, whether or not issued by the Company, while in possession of material non-public information about that company that was obtained in the course of his or her involvement with the Company. No director, officer or employee who knows of any such material non-public information may communicate that information to any other person, including family members and friends.

(c)Never trade, tip or recommend securities (or otherwise cause the purchase or sale of securities) while in possession of information that you have reason to believe is material and non-public unless you first consult with, and obtain the advance approval of, the Corporate Secretary.

(d)There are no exceptions to this Policy, except as specifically noted herein. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure), or small transactions, are not exempt from this Policy. The securities laws do not recognize any mitigating circumstances.

**2. Violations of Insider Trading Laws**

In addition to severe civil and/or criminal penalties, employees who violate this Policy may be subject to disciplinary action by the Company, including dismissal for cause. Any exceptions to the Policy, if permitted, may only be granted by the Corporate Secretary and must be provided before any activity contrary to the above requirements takes place.

**3. Transactions by Family Members and Others**

This Policy applies to your family members who reside with you (including a spouse, a child, a child away at college, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws), anyone else who lives in your household, and any family members who do not live in your household but whose transactions in the Company's securities are directed by you or are subject to your influence or control, such as parents or children who consult with you before they trade in the Company's securities (collectively referred to as "family members").

**4. Transactions by Entities that You Influence or Control**

This Policy applies to any entities that you influence or control, including any corporations, partnerships or trusts (collectively referred to as "Controlled Entities"), and transactions by these Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for your own account.

**5. Transactions Under Company Plans**

This Policy only applies to the following transactions as specifically noted below:

(a)<u>Stock Option Exercises.</u> This Policy applies to any sale of stock as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option. The Policy does not, however, apply to a simple exercise and hold transaction.

(b)<u>Restricted Stock Units.</u> This Policy does not apply to the vesting of restricted stock units. The Policy does apply, however, to any open market sale of the underlying stock.

(c)<u>401(k) Plan.</u> This Policy does not apply to purchases of the Company's securities in the Company's 401(k) plan resulting from your periodic contribution of money to the plan pursuant to your payroll deduction election. This Policy does apply, however, to certain elections you may make under the 401(k) plan, including: (a) an election to increase or decrease the percentage of your periodic contributions that will be allocated to the Company stock fund; (b) an election to make an intra-plan transfer of an existing account balance into or out of the Company stock fund; (c) an election to borrow money against your 401(k) plan account if the loan will result in a liquidation of some or all of your Company stock fund balance; and (d) an election to pre-pay a plan loan if the pre-payment will result in allocation of loan proceeds to the Company stock fund.

(d)<u>Employee Stock Purchase Plan (ESPP)</u>. This policy does not apply to purchases of the Company's securities from the ESPP resulting from your periodic payroll deductions. This Policy does apply, to certain elections you make under the

------

ESPP, including a decision to enroll, leave or increase or decrease your periodic contributions under the ESPP, as well the subsequent sale of any securities purchased under the ESPP.

(e)<u>Deferred Compensation Plans.</u> This Policy does not apply to the allocation of Company stock units to your account under a deferred compensation plan resulting from your periodic deferrals under the plan pursuant to your deferral election. This Policy does apply, however, to certain elections you may make under a deferred compensation plan, including: (a) an election to increase or decrease the percentage of your deferral that will be allocated to Company stock units; and (b) an election to make an intra-plan transfer of an existing account balance into or out of the Company stock units.

**6. Other Transactions**

The Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions. It therefore is strongly recommended that any persons subject to this Policy not engage in any of the following transactions or otherwise consider the Company's preferences as described below:

(a)<u>Short-Term Trading.</u> Short-term trading of the Company's securities (an open market purchase within six months of a sale and vice versa) may be distracting and unduly focus the person's attention on the Company's short-term stock market performance instead of the Company's long- term business objectives.

(b) <u>Short Sales.</u> Short sales of the Company's securities (i.e., the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have the potential to signal to the market that the seller lacks confidence in the Company's prospects. In addition, short sales may reduce a seller's incentive to seek to improve the Company's performance.

(c)<u>Publicly-Traded Options.</u> Given the relatively short term of publicly-traded options, transactions in options may create the appearance that a director, officer or employee is trading based on material non-public information and focus a director's, officer's or other employee's attention on short-term performance at the expense of the Company's long-term objectives.

(d)<u>Hedging Transactions.</u> Hedging transactions (such as prepaid variable forwards, equity swaps, collars and exchange funds) may permit a director, officer or employee to continue to own the Company's securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the director, officer or employee may no longer have the same objectives as the Company's other shareholders.

(e)<u>Margin Accounts and Pledged Securities.</u> Securities held in a margin account or pledged as collateral for a loan may be sold without the customer's consent if the customer fails to meet a margin call or defaults on the loan. Such sale may occur at a time when the pledgor is aware of material non-public information.

**NOTE: Section 16 Persons and officers are subject to certain additional restrictions relative to these types of transactions. See Section 2 of Part III.**

**<u>PART II</u>**

**Blackout Periods**

The Company and all Section 16 Persons, officers, and Covered Persons are prohibited from trading in the Company's securities during blackout periods.

(a)<u>Quarterly Blackout Periods.</u> In addition to the general policy in Section 1 of Part I, trading in the Company's securities is prohibited during the period beginning at the close of the market on the fifteenth (15th) day of the third month of each fiscal quarter and ending at the close of business on the first full trading day after the Company's quarterly earnings are publicly disclosed. The Company may extend these blackout periods at any time by notice to Covered Persons.

(b)<u>Other Blackout Periods.</u> From time to time, other types of material non-public information regarding the Company (such as negotiation of mergers, acquisitions or dispositions or new product developments) may be pending and not be publicly disclosed. While such material non- public information is pending, the Company may impose special blackout periods

------

during which Covered Persons are prohibited from trading in the Company's securities. If the Company imposes a special blackout period, it will notify the Covered Persons affected.

(c)<u>Exception.</u> These trading restrictions do not apply to transactions under a pre-existing written plan, contract, instruction, or arrangement which provides a defense from insider trading liability under the securities laws (a "Rule 10b5-1 Plan"). To comply with the Policy, a Rule 10b5-1 Plan must be adopted during an open trading window, approved by the Corporate Secretary, and meet the requirements of Rule 10b5-1, including, but not limited to, the execution of all certifications, cooling-off period requirements, and limitations related to overlapping or single-trade plans and any additional guidelines that may be established by the Corporate Secretary.

**<u>PART III</u>**

**1. Pre-clearance of Securities Transactions**

Because the Company, Section 16 Persons, officers, and Covered Persons are likely to obtain material non-public information on a regular basis, the Company requires all such persons and the Company a to refrain from engaging in any transaction in the Company's securities, even during an open trading window, without first obtaining pre-clearance of the transaction from the Corporate Secretary. The Corporate Secretary is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in the Company's securities, and should not inform any other person of the restriction.

Unless otherwise specified by the Corporate Secretary, pre-cleared trades must be effected within five business days of receipt of pre-clearance, subject to such person not actually being in possession of material, non-public information. Transactions not effected within the five-day time limit would be subject to pre-clearance again. Company trading activities require daily preclearance unless covered by a Rule 10b5-1 plan.

**2. Restricted Transactions**

(a)<u>Short-Term Trading.</u> The securities laws impose liability for "short-swing profits" by Section 16 Persons and require the Company to recover those profits. Any profit realized from the open market purchase and sale or sale and purchase of the Company's securities, within any period of less than six months may be recovered in a court action brought by the Company or any stockholder on behalf of the Company. For this reason, Section 16 Persons and officers are prohibited from engaging in transactions that would generate "short-swing" profits.

(b)<u>Short Sales.</u> The securities laws also prohibit short sales by Section 16 Persons. Officers are also prohibited by this Policy from engaging in short sales of the Company's securities.

(c)<u>Hedging Transactions</u>. For the reasons described in Section 7 of Part I, Section 16 Persons and officers are prohibited from engaging in hedging transactions.

(d)<u>Margin Accounts and Pledged Securities.</u> For the reasons described in Section 7 of Part I, Section 16 Persons and officers are prohibited from holding the Company's securities in a margin account or otherwise pledging the Company's securities as collateral for a loan. The Corporate Secretary may grant exceptions to this prohibition when a Section 16 Person wishes to pledge the Company's securities as collateral for a loan (not including margin debt) and clearly demonstrates the financial capacity to repay the loan without resorting to the pledged securities. Any Section 16 Person or officer seeking an exception must submit a request for approval to the Corporate Secretary at least two weeks prior to the transaction.

------

**INSIDER TRADING FREQUENTLY ASKED QUESTIONS (FAQ)**

*This FAQ is designed to be illustrative and respond to the most frequent inquiries we receive regarding insider trading, the company's blackout periods, and the misuse of information.*

*Therefore, it is a supplement to, not a replacement for, reading Corteva's Insider Trading Policy.*

<u>Insider Trading Information Applicable to All Employees</u>

**1. What conduct is prohibited by insider trading laws?**

U.S. securities laws prohibit you from buying or sell securities while in possession of material non-public information. These laws also prohibit you from providing others with material non- public information which they trade on, or making recommendations to others to buy or sell securities based on material non-public information.

**2. Do these laws apply to me even if I'm not a resident or citizen of the United States?** 

Yes. The laws are applicable to non-U.S. residents and citizens as U.S. regulators can assert jurisdiction over individuals trading in securities of companies, like Corteva, listed on U.S. exchanges. Additionally, our policy on Insider Trading Policy applies to employees globally.

**3. Why is Insider trading illegal?**

Insider trading laws are intended to promote fairness among investors and maintain the integrity of our financial markets. It is ultimately unfair to the investment community at large to allow insiders and other individuals who find themselves in possession of material non-public information to benefit from access to this information that has not been made broadly available to the investing public at large.

**4. Who is an "*insider*"?**

ANYONE who possesses material non-public information is an insider, including a company's officers, directors, employees, contractors, consultants, financial advisors, legal counsel, and their respective family members (including spouse, children at home or at college, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws), anyone else who resides in the employee's household, and any entity, business, fund or trust in the insider's influence or control.

**5. What is "*material*" information?**

Material, can be defined as the information any investor considers important or relevant in deciding to <u>buy</u>, <u>sell</u> or <u>hold</u> a stock given the "total mix" of information available in the market. Material information would affect the market price of the stock or would otherwise be relevant to an investor's investment decision either on its own or when added to the information currently available publicly. Some examples: earnings information or other significant forecasts or financial results; mergers, acquisitions, divestitures and joint ventures; dividend changes, bankruptcy; new product introductions or product recalls, significant contracts or contract terminations; changes in credit ratings; management or control changes; labor disputes; significant cybersecurity breaches or disruptions, or litigation developments.

**6. What is "*non-public*" information?**

Non-public information is any information that <u>has not been publicly disclosed</u>. Non-public information becomes public when it is broadly disseminated, and investors have a chance to react to it. We generally consider that information ceases to be non-public after the second business day following the date on which the information was disclosed to the public.

**7. What is "*Tipping*"?**

Tipping is when an insider provides material non-public information (a "tip") to another person without a duty of confidentiality (a "tippee") and the tippee trades on the information. Under current securities laws, both the tipper and the tippee are deemed to have engaged in insider trading. Even if the tipper did not directly financially benefit from the trading transaction, the tipper may be held responsible for disgorging the profits from the transaction since the tipper is generally deemed to have benefitted in some other manner by providing this information to the tippee (i.e., generating goodwill, returning a favor, etc.).

**8. Is it still *Tipping* when I share information with my family?**

Yes, it is also illegal to tip family members. Therefore, this is why is important maintain confidentiality of Corteva information, even from family members, so as to avoid possible violations of the law and our policies.

------

**9. What is consider "*Misappropriation*" of the non-public information?**

In executing our job duties we are required to maintain confidences of our customers and suppliers, including material non-public information you receive about other companies, such as our customers or vendors while conducting business with them. When someone who is not an insider trades on information when they had a duty to maintain confidences around this information, they have engaged in "misappropriation" of this information (or as may be referred to in some regions, "outsider trading"). Misappropriation, like insider trading, is also considered illegal. Additionally, it is illegal for our vendor or customers to misappropriate our non-public information where they have a duty to maintain confidentiality around this information.

Suspected misappropriation activity should be reported to the Compliance Department.

**10.&nbsp;&nbsp;&nbsp;&nbsp; Is there any type of transactions or trade operations restricted or conditioned for Corteva employees?**

Our policy strongly discourages all employees from engaging in the following transactions with respect to Corteva securities,

which heighten the risk of improper conduct:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Short-term trading (i.e., a sale of Corteva securities within six months of buying Corteva securities or vice versa);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Short sales (i.e. sales of Corteva securities that you don't own);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Publicly-traded options;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hedging transactions (such as prepaid variable forwards, equity swaps, collars and exchange funds);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Margin accounts with Corteva securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pledges of Corteva securities.

If you are a "Covered Person" as defined below, you may be prohibited by our policies from engaging in the above activities with respect to Corteva securities all together. Therefore, it's important for Covered Persons to follow the Company's trade preclearance policies described in more below.

In certain circumstances, such as a highly confidential project or due to your participation in our earnings reporting process, you may be told by the Legal Department to refrain from trading in Corteva securities, even if you're not a Covered Person.

**11. What are the consequences of insider trading?**

Insider trading undermines the reputation of our Company as well as your individual reputation. In addition to resulting in Company discipline up to the termination of your employment, insider trading may result in criminal and civil penalties, imprisonment, disgorgement (the repayment of illicitly made profits); the freezing of your personal assets; and temporary or permanent bars from serving as a director, officer, compliance officer, attorney or accountant for a public company.

<u>Insider Trading Information Applicable to "Covered Persons" and Others</u>

**12. How do I know if I'm a "Covered Person" under the Company's Insider Trading Policy?** 

We post a list on the Compliance website of our current insiders. This list is updated periodically and you will be notified by the Legal Department if you're going to be added to or removed from the Covered Person list. Covered Persons are our directors, officers and other individuals who have been deemed by the Legal Department to have regular access to material non-public information.

**13. What are my obligations as a Covered Person?**

If you're a Covered Person, you have two key obligations regarding your trading activity: (i) preclearing your trading activity (and those of your family members and entities owned or managed by you or them) with Cornel Fuerer, SVP and General Counsel or his designee, Dana Eddis, Associate General Counsel, Corporate; and (ii) abiding by the Company's periodic blackout periods. The Company, Section 16 officers, and other officers are also subject to these same trading restrictions.

**14. When are Covered Persons prevented from trading (i.e. subject to a trading blackout)?**

Corteva has regularly quarterly blackouts beginning on the 15<sup>th</sup> calendar day of the last month of each quarter (i.e., March, June, September, and December) and ending on the first full business day after earnings are announced. However, the Legal Department may extend these blackouts or add additional blackouts to some or all Covered Persons at any time. The Legal Department may impose electronic barriers with Merrill Lynch, our service provider for our equity plans, to prevent Covered Persons, Section 16 Officers, and other officers from trading during a blackout. The Company, Section 16 officers, and other officers are also subject to these same trading restrictions.

**15. What information do I provide when I preclear a trade?**

Typically, we want to know the type of intended transaction (i.e., buy, sell, cashless exercise) and the size of the transaction. If you're an officer, we may also require verification that you're in compliance with your stock ownership guidelines. Section 16 officers are subject to additional procedures post-trade requiring the price specifics of their trades for reporting with the SEC, generally within two business days of the execution of their trade.

------

**16. My options are expiring during the trading blackout can I still engage in a cashless exercise and sell of those options during the blackout?**

Generally no, therefore you should consider carefully how blackouts may impact your ability to exercise these options before their expiration. Additionally, options must be "in the money" (i.e., the current trading price must exceed the option award's exercise price) in order to exercise.

During an open window, you may enter into a Rule 10b5-1 trading plan to exercise and sell these options during a closed window at your preferred price. Trading plans can be used to execute other types of transactions during a blackout as well. However, trading plans must be precleared with the Legal Department and entered into during an open window and are otherwise in possession of material non-public information. Trading plans must be precleared and are subject to certain parameters. Please contact Dana Eddis, Associate General Counsel, Corporate to discuss how to set up and preclear a trading plan.

**17. What transactions are prohibited in Corteva securities in a 401(k) plan or Employee Stock Purchase Plan (ESPP)?**

At the time you make an election to have contributions used to purchase shares under a 401(k) plan or ESPP, or make a decision to increase or decrease these contributions, Covered Persons should not be in a blackout when making these investment decisions and plan participants generally should not be in possession of any material non-public information at the time of their investment decision.

Acquisitions or dispositions of Corteva securities under it 401(k) and ESPP may be made during a blackout if the acquisitions or dispositions of Corteva securities are made pursuant to instructions entered into while the participant was not in possession of material nonpublic information and, if a Covered Person, while not subject to a trading blackout.

## Ex-21

**Exhibit 21**

**SUBSIDIARIES OF THE REGISTRANT**

Set forth below are certain subsidiaries of

Corteva, Inc. and EIDP, Inc.

---

| | |
|:---|:---|
| **<br>Name** | **Organized Under<br>Laws Of** |
| AG (Shanghai) Agriculture Technology Co., Ltd. | Shanghai |
| Agrigenetics, Inc. | Delaware |
| Agro Corteva Chile S.A. | Chile |
| Agro Corteva Colombia, S.A. | Colombia |
| Agro Cultivos Corteva Chile S.A. | Chile |
| AgroStollerec S.A. | Ecuador |
| AgSurf Corporation | Delaware |
| AgVenture, Inc. | Indiana |
| Christiana Insurance LLC | Delaware |
| Corteva (China) Investment Co., Ltd. | Shanghai |
| Corteva (China), LLC | Delaware |
| Corteva Agriscience (Cambodia) Co., Ltd. | Cambodia |
| Corteva Agriscience (Malaysia) Sdn. Bhd. | Malaysia |
| Corteva Agriscience (Myanmar) Company Limited | Myanmar |
| Corteva Agriscience (Nantong) Co., Ltd. | Jiangsu |
| Corteva Agriscience (Singapore) Pte. Ltd. | Singapore |
| Corteva Agriscience (Thailand) Co., Ltd. | Thailand |
| Corteva Agriscience AB | Sweden |
| Corteva Agriscience Argentina S.R.L. | Argentina |
| Corteva Agriscience Australia PTY Ltd | Australia |
| Corteva Agriscience Austria GmbH | Austria |
| Corteva Agriscience Bangladesh Limited | Bangladesh |
| Corteva Agriscience Belgium B.V. | Belgium |
| Corteva Agriscience Bolivia S.A. | Bolivia |
| Corteva Agriscience Bulgaria EOOD | Bulgaria |
| Corteva Agriscience Canada Company | Nova Scotia |
| Corteva Agriscience Chile Limitada | Chile |
| Corteva Agriscience Costa Rica S.A. | Costa Rica |
| Corteva Agriscience Cote d'Ivoire SASU | Ivory Coast |
| Corteva Agriscience Croatia LLC | Croatia |
| Corteva Agriscience Czech s.r.o. | Czech Republic |
| Corteva Agriscience de Colombia S.A.S. | Colombia |
| Corteva Agriscience de Ecuador S.A. | Ecuador |
| Corteva Agriscience Denmark A/S | Denmark |
| Corteva Agriscience do Brasil Ltda. | Brazil |
| Corteva Agriscience Egypt LLC | Egypt |
| Corteva Agriscience Ethiopia PLC | Ethiopia |
| Corteva Agriscience Finland OY | Finland |
| Corteva Agriscience Foundation | Iowa |

---

------

---

| | |
|:---|:---|
| Corteva Agriscience France S.A.S. | France |
| Corteva Agriscience Germany GmbH | Germany |
| Corteva Agriscience Guatemala S.A. | Guatemala |
| Corteva Agriscience Hellas S.A. | Greece |
| Corteva Agriscience Holding LLC | Delaware |
| Corteva Agriscience Holding Sàrl | Switzerland |
| Corteva Agriscience Holding Spain, S.L. | Spain |
| Corteva Agriscience Hungary Zrt. | Hungary |
| Corteva Agriscience India Private Limited | India |
| Corteva Agriscience International Sàrl | Switzerland |
| Corteva Agriscience Italia S.r.l. | Italy |
| Corteva Agriscience Japan Limited | Japan |
| Corteva Agriscience Kazakhstan Limited Liability Partnership | Kazakhstan |
| Corteva Agriscience Kenya Limited | Kenya |
| Corteva Agriscience Korea Ltd. | Korea |
| Corteva Agriscience Lithuania UAB | Lithuania |
| Corteva Agriscience LLC | Delaware |
| Corteva Agriscience Maroc SARL | Morocco |
| Corteva Agriscience MCS LLC | Iowa |
| Corteva Agriscience Mexico S. de R. L. de C. V. | México |
| Corteva Agriscience MW Limited | Malawi |
| Corteva Agriscience Netherlands B.V. | Netherlands |
| Corteva Agriscience New Zealand Ltd | New Zealand |
| Corteva Agriscience Nigeria Limited | Nigeria |
| Corteva Agriscience Pacific Limited | Hong Kong |
| Corteva Agriscience Pakistan Limited | Pakistan |
| Corteva Agriscience Paraguay S.A. | Paraguay |
| Corteva Agriscience Perú SAC | Peru |
| Corteva Agriscience Philippines, Inc. | Philippines |
| Corteva Agriscience Poland Sp. z o.o. | Poland |
| Corteva Agriscience Portugal, S.A. | Portugal |
| Corteva Agriscience Puerto Rico, Inc. | Iowa |
| Corteva Agriscience Romania S.R.L. | Romania |
| Corteva Agriscience RSA Proprietary Limited | Delaware |
| Corteva Agriscience RSA Proprietary Limited | South Africa |
| Corteva Agriscience S. de R.L. de C.V. | México |
| Corteva Agriscience Seeds Private Limited | India |
| Corteva Agriscience Services India Private Limited | India |
| Corteva Agriscience SLO d.o.o. | Slovenia |
| Corteva Agriscience Slovakia s.r.o. | Slovakia |
| Corteva Agriscience Spain, S.L.U. | Spain |
| Corteva Agriscience SRB d.o.o. | Serbia |
| Corteva Agriscience Tanzania Limited | Tanzania |
| Corteva Agriscience UK Limited | United Kingdom |
| Corteva Agriscience Ukraine LLC | Ukraine |
| Corteva Agriscience Uruguay S.A. | Uruguay |

---

------

---

| | |
|:---|:---|
| Corteva Agriscience Vietnam Co., Ltd. | Vietnam |
| Corteva Agriscience Worldwide, LLC | Delaware |
| Corteva Agriscience Zambia Limited | Zambia |
| Corteva Agriscience Zimbabwe (Private) Limited | Zimbabwe |
| Corteva Asia Pacific Inc. | Delaware |
| Corteva Biologicals International, LLC | Delaware |
| Corteva Biologics US, LLC | Delaware |
| Corteva Bolivia S.R.L. | Bolivia |
| Corteva CP Products SA (Pty) Ltd | South Africa |
| Corteva Crop India Private Limited | India |
| Corteva Crop Pakistan (Private) Limited | Pakistan |
| Corteva Crop Slovakia s.r.o | Slovakia |
| Corteva Crop Solutions HUN Kft. | Hungary |
| Corteva Crop Solutions Rom S.R.L. | Romania |
| Corteva Crop Solutions SA (Pty) Ltd | South Africa |
| Corteva Crop Taiwan Ltd. | Taiwan |
| Corteva Crop Ukraine LLC | Ukraine |
| Corteva Finance Company B.V. | Netherlands |
| Corteva Global Holding II Inc. | Delaware |
| Corteva Global Holding Inc. | Delaware |
| Corteva Holding France S.A.S. | France |
| Corteva Holding Mauritius Limited | Mauritius |
| Corteva Holding Netherlands 1 B.V. | Netherlands |
| Corteva Holding Netherlands 2 B.V. | Netherlands |
| Corteva Holding Netherlands 3 B.V. | Netherlands |
| Corteva Holding Netherlands 4 B.V. | Netherlands |
| Corteva Holding SA (Pty) Ltd | South Africa |
| Corteva Holding Switzerland Sàrl | Switzerland |
| Corteva Holding Zimbabwe (Private) Limited | Zimbabwe |
| Corteva Holdings NZ Limited | New Zealand |
| Corteva India Limited, LLC | Delaware |
| Corteva International Holding Corporation | Delaware |
| Corteva Investment Switzerland Sàrl | Switzerland |
| Corteva Japan Ltd. | Japan |
| Corteva MX S.A. de C.V. | México |
| Corteva Seeds Argentina S.R.L. | Argentina |
| Corteva Seeds Paraguay S.R.L. | Paraguay |
| Corteva Seeds RSA Proprietary Limited | South Africa |
| Corteva Services Sàrl | Switzerland |
| Corteva Turkey Tarim A.S. | Turkey |
| Corteva Turkey Tohumculuk A.S. | Turkey |
| Corteva US Feedstocks Company, LLC | Delaware |
| CTVA Proteção de Cultivos Ltda. | Brazil |
| DDP AgroSciences Kenya Limited | Kenya |
| DDP AgroSciences US DCOMCO, LLC | Delaware |
| Dikanka Nasinnia LLC | Ukraine |
| Dow AgroSciences Vertriebsgesellschaft m.b.H. | Austria |

---

------

---

| | |
|:---|:---|
| DuPont Capital Management Corporation | Delaware |
| DuPont Pioneer Investment Co., Ltd. | Beijing |
| Eyal S.A. | Uruguay |
| Granular Canada Company | Nova Scotia |
| Griffin L.L.C. Valdosta, Georgia | Delaware |
| Hoegemeyer Hybrids, Inc. | Nebraska |
| Organic Symbiosis, S. de | Mexico |
| Orion Mexico, LLC | Delaware |
| Pannar Properties Zambia Limited | Zambia |
| Pannar Seed (Pty) Ltd. | South Africa |
| Pannar Seed (Zimbabwe) Private Limited | Zimbabwe |
| Pannar Seed Kenya Ltd. | Kenya |
| Pannar Seed Lda | Mozambique |
| PHI Financial Services Canada Limited | Canada |
| PHI Financial Services, Inc. | Iowa |
| PHI Mexico, S.A. de C.V. | México |
| PhPhilippines Holdings Inc. | Philippines |
| Pioneer DuPont Zambia Limited | Zambia |
| Pioneer Génétique Sàrl | France |
| Pioneer Hi-Bred (Switzerland) S.A. | Switzerland |
| Pioneer Hi-Bred (Thailand) Co. Limited | Thailand |
| Pioneer Hi-Bred Australia, Pty Ltd. | Australia |
| Pioneer Hi-Bred Canada Company | Nova Scotia |
| Pioneer Hi-Bred International, Inc. | Iowa |
| Pioneer Hi-Bred Italia S.r.l. | Italy |
| Pioneer Hi-Bred Italia Sementi S.r.l. | Italy |
| Pioneer Hi-Bred Italia Servizi Agronomici S.r.l. | Italy |
| Pioneer Hi-Bred Magyarorszag Kft | Hungary |
| Pioneer Hi-Bred Northern Europe Sales Division GmbH | Germany |
| Pioneer Hi-Bred Northern Europe Service Division GmbH | Germany |
| Pioneer Hi-Bred Poland Sp z.o.o. | Poland |
| Pioneer HI-Bred Private Limited | India |
| Pioneer Hi-Bred Production Company | Nova Scotia |
| Pioneer Hi-Bred Romania S.R.L. | Romania |
| Pioneer Hi-Bred Spain, S.L. | Spain |
| Pioneer Mexico Holdings LLC | Iowa |
| Pioneer Overseas Corporation | Iowa |
| Pioneer Overseas Corporation (Singapore) Pte Ltd | Singapore |
| Pioneer Seeds, LLC | Iowa |
| Pioneer Semences S.A.S | France |
| Pioneer Tohumculuk Distribution and Marketing | Turkey |
| Pitt-Consol Chemical Company | New Jersey |
| Prochrom Internacional S.A. | Uruguay |
| Production Agriscience (Australia) Pty Ltd | Australia |
| PT Corteva Agriscience Indonesia | Indonesia |
| PT Corteva Agriscience Manufacturing Indonesia | Indonesia |
| PT Corteva Agriscience Seeds Indonesia | Indonesia |

---

------

---

| | |
|:---|:---|
| Quimicas Stoller de Centro America Sociedad Anonima | Guatemala |
| Quorum Vital Investments, S.L.U. | Spain |
| Seed Consultants Inc. | Ohio |
| Sporting Goods Properties, Inc. | Delaware |
| Stasi Nasinnia LLC | Ukraine |
| Stoller (Qingdao) Agricultural Technology Co., Ltd. | Qingdao |
| Stoller Argentina S.A.U. | Argentina |
| Stoller Australia Pty. Limited | Australia |
| Stoller Bio Science India Private Limited | India |
| Stoller Biociencias SRL | Argentina |
| Stoller Bolivia SRL | Bolivia |
| Stoller Colombia S.A. | Columbia |
| Stoller Costa Rica S.A. | Costa Rica |
| Stoller de Chile SpA | Chile |
| Stoller do Brasil Ltda. | Brazil |
| Stoller Enterprises, Inc. | Texas |
| Stoller Enterprises, Ltd. | Canada |
| Stoller Europe, S.L.U. | Spain |
| Stoller Group, Inc. | Delaware |
| Stoller International, Inc. | Texas |
| Stoller México S.A. de C.V | Mexico |
| Stoller Paraguay S.R.L. | Paraguay |
| Stoller Peru S.A. | Peru |
| Stoller Philippines, Inc. | Philippines |
| Stoller South Africa (Pty) Ltd | South Africa |
| Stoller Turkey Organik Tarim Sanayi Ticaret A.S. | Turkey |
| Stoller Uruguay SA | Uruguay |
| Symborg (Shanghai) Trading Co, Ltd. | Shanghai |
| Symborg Business Development, S.L.U. | Spain |
| Symborg Chile, SPA | Chile |
| Symborg Corporate, S.L.U. | Spain |
| Symborg Participacoes Ltda. | Brazil |
| Symborg Peru S.A.C. | Peru |
| Symborg Turkey Tarim A.S. | Turkey |
| Symborg, Inc. | California |
| Tieling Pioneer Seed Research Co., Ltd. | Liaoning |

---

## Exhibit 23.1

**Exhibit 23.1**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>** 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-287099) and Form S-8 (Nos. 333-249887 and 333-231869) of Corteva, Inc. of our report dated February 12, 2026 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting of Corteva, Inc., which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania

February 12, 2026

## Exhibit 23.2

**Exhibit 23.2**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>** 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-287099-01) of EIDP, Inc. of our report dated February 12, 2026 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting of EIDP, Inc., which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania

February 12, 2026

## Exhibit 31.1

**Exhibit 31.1**

**SECTION 302 CERTIFICATIONS**

I, Charles V. Magro, certify that:

1. I have reviewed this Annual Report on Form 10-K of Corteva, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | February 12, 2026 |
| By: | /s/ Charles V. Magro |
|  | Charles V. Magro |
|  | *Chief Executive Officer* |

---

------

I, Charles V. Magro, certify that:

1. I have reviewed this Annual Report on Form 10-K of EIDP, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | February 12, 2026 |
| By: | /s/ Charles V. Magro |
|  | Charles V. Magro |
|  | *Chief Executive Officer* |

---

## Exhibit 31.2

**Exhibit 31.2**

**SECTION 302 CERTIFICATIONS**

I, David P. Johnson, certify that:

1. I have reviewed this Annual Report on Form 10-K of Corteva, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | February 12, 2026 |
| By: | /s/ David P. Johnson |
|  | David P. Johnson |
|  | *Executive Vice President and<br>Chief Financial Officer* |

---

------

I, David P. Johnson, certify that:

1. I have reviewed this Annual Report on Form 10-K of EIDP, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | February 12, 2026 |
| By: | /s/ David P. Johnson |
|  | David P. Johnson |
|  | *Executive Vice President and<br>Chief Financial Officer* |

---

## Exhibit 32.1

**Exhibit 32.1**

**Certification of CEO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Annual Report of Corteva, Inc. (the "Company") on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Charles V. Magro, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Charles V. Magro |
| Charles V. Magro |
| Chief Executive Officer |
| February 12, 2026 |

---

------

**Certification of CEO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Annual Report of EIDP, Inc. on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Charles V. Magro, as Chief Executive Officer of EIDP, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of EIDP, Inc.

---

| |
|:---|
| /s/ Charles V. Magro |
| Charles V. Magro |
| Chief Executive Officer |
| February 12, 2026 |

---

## Exhibit 32.2

**Exhibit 32.2** 

**Certification of CFO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Annual Report of Corteva, Inc. (the "Company") on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David P. Johnson, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ David P. Johnson |
| David P. Johnson |
| Executive Vice President and <br>Chief Financial Officer |
| February 12, 2026 |

---

------

**Certification of CFO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Annual Report of EIDP, Inc. on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David P. Johnson, as Chief Financial Officer of EIDP, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of EIDP, Inc.

---

| |
|:---|
| /s/ David P. Johnson |
| David P. Johnson |
| Executive Vice President and <br>Chief Financial Officer |
| February 12, 2026 |

---

<br>